
<html lang="en"     class="pb-page"  data-request-id="a35b90c1-38cc-4fa5-8ac6-b66ba33b1c84"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.9b00167;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2019.62.issue-7;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton’s Tyrosine Kinase (BTK)" /></meta><meta name="dc.Creator" content="Scott H.  Watterson" /></meta><meta name="dc.Creator" content="Qingjie  Liu" /></meta><meta name="dc.Creator" content="Myra  Beaudoin Bertrand" /></meta><meta name="dc.Creator" content="Douglas G.  Batt" /></meta><meta name="dc.Creator" content="Ling  Li" /></meta><meta name="dc.Creator" content="Mark A.  Pattoli" /></meta><meta name="dc.Creator" content="Stacey  Skala" /></meta><meta name="dc.Creator" content="Lihong  Cheng" /></meta><meta name="dc.Creator" content="Mary T.  Obermeier" /></meta><meta name="dc.Creator" content="Robin  Moore" /></meta><meta name="dc.Creator" content="Zheng  Yang" /></meta><meta name="dc.Creator" content="Rodney  Vickery" /></meta><meta name="dc.Creator" content="Paul A.  Elzinga" /></meta><meta name="dc.Creator" content="Lorell  Discenza" /></meta><meta name="dc.Creator" content="Celia  D’Arienzo" /></meta><meta name="dc.Creator" content="Kathleen M.  Gillooly" /></meta><meta name="dc.Creator" content="Tracy L.  Taylor" /></meta><meta name="dc.Creator" content="Claudine  Pulicicchio" /></meta><meta name="dc.Creator" content="Yifan  Zhang" /></meta><meta name="dc.Creator" content="Elizabeth  Heimrich" /></meta><meta name="dc.Creator" content="Kim W.  McIntyre" /></meta><meta name="dc.Creator" content="Qian  Ruan" /></meta><meta name="dc.Creator" content="Richard A.  Westhouse" /></meta><meta name="dc.Creator" content="Ian M.  Catlett" /></meta><meta name="dc.Creator" content="Naiyu  Zheng" /></meta><meta name="dc.Creator" content="Charu  Chaudhry" /></meta><meta name="dc.Creator" content="Jun  Dai" /></meta><meta name="dc.Creator" content="Michael A.  Galella" /></meta><meta name="dc.Creator" content="Andrew J.  Tebben" /></meta><meta name="dc.Creator" content="Matt  Pokross" /></meta><meta name="dc.Creator" content="Jianqing  Li" /></meta><meta name="dc.Creator" content="Rulin  Zhao" /></meta><meta name="dc.Creator" content="Daniel  Smith" /></meta><meta name="dc.Creator" content="Richard  Rampulla" /></meta><meta name="dc.Creator" content="Alban  Allentoff" /></meta><meta name="dc.Creator" content="Michael A.  Wallace" /></meta><meta name="dc.Creator" content="Arvind  Mathur" /></meta><meta name="dc.Creator" content="Luisa  Salter-Cid" /></meta><meta name="dc.Creator" content="John E.  Macor" /></meta><meta name="dc.Creator" content="Percy H.  Carter" /></meta><meta name="dc.Creator" content="Aberra  Fura" /></meta><meta name="dc.Creator" content="James R.  Burke" /></meta><meta name="dc.Creator" content="Joseph A.  Tino" /></meta><meta name="dc.Description" content="Bruton’s tyrosine kinase (BTK), a non-receptor tyrosine kinase, is a member of the Tec family of kinases and is essential for B cell receptor (BCR) mediated signaling. BTK also plays a critical rol..." /></meta><meta name="Description" content="Bruton’s tyrosine kinase (BTK), a non-receptor tyrosine kinase, is a member of the Tec family of kinases and is essential for B cell receptor (BCR) mediated signaling. BTK also plays a critical rol..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 20, 2019" /></meta><meta name="dc.Type" content="news" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b00167" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00167" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b00167" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00167" /></link>
        
    
    

<title>Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton’s Tyrosine Kinase (BTK) | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b00167" /></meta><meta property="og:title" content="Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton’s Tyrosine Kinase (BTK)" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0027.jpeg" /></meta><meta property="og:description" content="Bruton’s tyrosine kinase (BTK), a non-receptor tyrosine kinase, is a member of the Tec family of kinases and is essential for B cell receptor (BCR) mediated signaling. BTK also plays a critical role in the downstream signaling pathways for the Fcγ receptor in monocytes, the Fcε receptor in granulocytes, and the RANK receptor in osteoclasts. As a result, pharmacological inhibition of BTK is anticipated to provide an effective strategy for the clinical treatment of autoimmune diseases such as rheumatoid arthritis and lupus. This article will outline the evolution of our strategy to identify a covalent, irreversible inhibitor of BTK that has the intrinsic potency, selectivity, and pharmacokinetic properties necessary to provide a rapid rate of inactivation systemically following a very low dose. With excellent in vivo efficacy and a very desirable tolerability profile, 5a (branebrutinib, BMS-986195) has advanced into clinical studies." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b00167"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00167">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b00167&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b00167&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b00167&amp;href=/doi/10.1021/acs.jmedchem.9b00167" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 7</span><span class="cit-fg-pageRange">, 3228-3250</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/7" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b01361" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Drug Annotation</span><a href="/doi/10.1021/acs.jmedchem.9b00415" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton’s Tyrosine Kinase (BTK)</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Scott H. Watterson</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Scott H. Watterson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: 609-252-6778. E-mail: <a href="/cdn-cgi/l/email-protection#7506161a01015b021401011007061a1b351718065b161a18"><span class="__cf_email__" data-cfemail="285b4b475c5c065f495c5c4d5a5b4746684a455b064b4745">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Scott+H.++Watterson">Scott H. Watterson</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9315-177X" title="Orcid link">http://orcid.org/0000-0001-9315-177X</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Qingjie Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Qingjie Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Qingjie++Liu">Qingjie Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Myra Beaudoin Bertrand</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Myra Beaudoin Bertrand</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Myra++Beaudoin+Bertrand">Myra Beaudoin Bertrand</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Douglas G. Batt</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Douglas G. Batt</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Douglas+G.++Batt">Douglas G. Batt</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ling Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ling Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ling++Li">Ling Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mark A. Pattoli</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mark A. Pattoli</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mark+A.++Pattoli">Mark A. Pattoli</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Stacey Skala</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stacey Skala</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stacey++Skala">Stacey Skala</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lihong Cheng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lihong Cheng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lihong++Cheng">Lihong Cheng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mary T. Obermeier</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mary T. Obermeier</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mary+T.++Obermeier">Mary T. Obermeier</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Robin Moore</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Robin Moore</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Robin++Moore">Robin Moore</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zheng Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zheng Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zheng++Yang">Zheng Yang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rodney Vickery</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rodney Vickery</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rodney++Vickery">Rodney Vickery</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Paul A. Elzinga</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paul A. Elzinga</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paul+A.++Elzinga">Paul A. Elzinga</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lorell Discenza</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lorell Discenza</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lorell++Discenza">Lorell Discenza</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Celia D’Arienzo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Celia D’Arienzo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Celia++D%E2%80%99Arienzo">Celia D’Arienzo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kathleen M. Gillooly</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kathleen M. Gillooly</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kathleen+M.++Gillooly">Kathleen M. Gillooly</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tracy L. Taylor</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tracy L. Taylor</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tracy+L.++Taylor">Tracy L. Taylor</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Claudine Pulicicchio</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Claudine Pulicicchio</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Claudine++Pulicicchio">Claudine Pulicicchio</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yifan Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yifan Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yifan++Zhang">Yifan Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Elizabeth Heimrich</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Elizabeth Heimrich</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Elizabeth++Heimrich">Elizabeth Heimrich</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kim W. McIntyre</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kim W. McIntyre</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kim+W.++McIntyre">Kim W. McIntyre</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Qian Ruan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Qian Ruan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Qian++Ruan">Qian Ruan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Richard A. Westhouse</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Richard A. Westhouse</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Richard+A.++Westhouse">Richard A. Westhouse</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ian M. Catlett</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ian M. Catlett</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ian+M.++Catlett">Ian M. Catlett</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Naiyu Zheng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Naiyu Zheng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Naiyu++Zheng">Naiyu Zheng</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5121-9024" title="Orcid link">http://orcid.org/0000-0002-5121-9024</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Charu Chaudhry</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Charu Chaudhry</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Charu++Chaudhry">Charu Chaudhry</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jun Dai</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jun Dai</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jun++Dai">Jun Dai</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7333-3899" title="Orcid link">http://orcid.org/0000-0002-7333-3899</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael A. Galella</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael A. Galella</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael+A.++Galella">Michael A. Galella</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Andrew J. Tebben</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andrew J. Tebben</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andrew+J.++Tebben">Andrew J. Tebben</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Matt Pokross</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Matt Pokross</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Matt++Pokross">Matt Pokross</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jianqing Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jianqing Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jianqing++Li">Jianqing Li</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8445-9796" title="Orcid link">http://orcid.org/0000-0002-8445-9796</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rulin Zhao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rulin Zhao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rulin++Zhao">Rulin Zhao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Daniel Smith</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Daniel Smith</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Daniel++Smith">Daniel Smith</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Richard Rampulla</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Richard Rampulla</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Richard++Rampulla">Richard Rampulla</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Alban Allentoff</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alban Allentoff</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alban++Allentoff">Alban Allentoff</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael A. Wallace</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael A. Wallace</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael+A.++Wallace">Michael A. Wallace</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Arvind Mathur</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Arvind Mathur</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Arvind++Mathur">Arvind Mathur</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Luisa Salter-Cid</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Luisa Salter-Cid</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Luisa++Salter-Cid">Luisa Salter-Cid</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">John E. Macor</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">John E. Macor</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=John+E.++Macor">John E. Macor</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Percy H. Carter</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Percy H. Carter</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Percy+H.++Carter">Percy H. Carter</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5880-1164" title="Orcid link">http://orcid.org/0000-0002-5880-1164</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Aberra Fura</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Aberra Fura</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Aberra++Fura">Aberra Fura</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">James R. Burke</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">James R. Burke</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=James+R.++Burke">James R. Burke</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Joseph A. Tino</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Joseph A. Tino</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Joseph+A.++Tino">Joseph A. Tino</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00167&amp;href=/doi/10.1021%2Facs.jmedchem.9b00167" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 7</span><span class="cit-pageRange">, 3228–3250</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 20, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>27 January 2019</li><li><span class="item_label"><b>Published</b> online</span>20 March 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 11 April 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b00167" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00167</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D3228%26pageCount%3D23%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DScott%2BH.%2BWatterson%252C%2BQingjie%2BLiu%252C%2BMyra%2BBeaudoin%2BBertrand%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D7%26contentID%3Dacs.jmedchem.9b00167%26title%3DDiscovery%2Bof%2BBranebrutinib%2B%2528BMS-986195%2529%253A%2BA%2BStrategy%2Bfor%2BIdentifying%2Ba%2BHighly%2BPotent%2Band%2BSelective%2BCovalent%2BInhibitor%2BProviding%2BRapid%2Bin%2BVivo%2BInactivation%2Bof%2BBruton%25E2%2580%2599s%2BTyrosine%2BKinase%2B%2528BTK%2529%26numPages%3D23%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D3250%26publicationDate%3DApril%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b00167"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">12055</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">33</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b00167" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton’s Tyrosine Kinase (BTK)&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Scott&quot;,&quot;last_name&quot;:&quot;H. Watterson&quot;},{&quot;first_name&quot;:&quot;Qingjie&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Myra&quot;,&quot;last_name&quot;:&quot;Beaudoin Bertrand&quot;},{&quot;first_name&quot;:&quot;Douglas&quot;,&quot;last_name&quot;:&quot;G. Batt&quot;},{&quot;first_name&quot;:&quot;Ling&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;A. Pattoli&quot;},{&quot;first_name&quot;:&quot;Stacey&quot;,&quot;last_name&quot;:&quot;Skala&quot;},{&quot;first_name&quot;:&quot;Lihong&quot;,&quot;last_name&quot;:&quot;Cheng&quot;},{&quot;first_name&quot;:&quot;Mary&quot;,&quot;last_name&quot;:&quot;T. Obermeier&quot;},{&quot;first_name&quot;:&quot;Robin&quot;,&quot;last_name&quot;:&quot;Moore&quot;},{&quot;first_name&quot;:&quot;Zheng&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Rodney&quot;,&quot;last_name&quot;:&quot;Vickery&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;A. Elzinga&quot;},{&quot;first_name&quot;:&quot;Lorell&quot;,&quot;last_name&quot;:&quot;Discenza&quot;},{&quot;first_name&quot;:&quot;Celia&quot;,&quot;last_name&quot;:&quot;D’Arienzo&quot;},{&quot;first_name&quot;:&quot;Kathleen&quot;,&quot;last_name&quot;:&quot;M. Gillooly&quot;},{&quot;first_name&quot;:&quot;Tracy&quot;,&quot;last_name&quot;:&quot;L. Taylor&quot;},{&quot;first_name&quot;:&quot;Claudine&quot;,&quot;last_name&quot;:&quot;Pulicicchio&quot;},{&quot;first_name&quot;:&quot;Yifan&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Elizabeth&quot;,&quot;last_name&quot;:&quot;Heimrich&quot;},{&quot;first_name&quot;:&quot;Kim&quot;,&quot;last_name&quot;:&quot;W. McIntyre&quot;},{&quot;first_name&quot;:&quot;Qian&quot;,&quot;last_name&quot;:&quot;Ruan&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;A. Westhouse&quot;},{&quot;first_name&quot;:&quot;Ian&quot;,&quot;last_name&quot;:&quot;M. Catlett&quot;},{&quot;first_name&quot;:&quot;Naiyu&quot;,&quot;last_name&quot;:&quot;Zheng&quot;},{&quot;first_name&quot;:&quot;Charu&quot;,&quot;last_name&quot;:&quot;Chaudhry&quot;},{&quot;first_name&quot;:&quot;Jun&quot;,&quot;last_name&quot;:&quot;Dai&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;A. Galella&quot;},{&quot;first_name&quot;:&quot;Andrew&quot;,&quot;last_name&quot;:&quot;J. Tebben&quot;},{&quot;first_name&quot;:&quot;Matt&quot;,&quot;last_name&quot;:&quot;Pokross&quot;},{&quot;first_name&quot;:&quot;Jianqing&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Rulin&quot;,&quot;last_name&quot;:&quot;Zhao&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;Smith&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;Rampulla&quot;},{&quot;first_name&quot;:&quot;Alban&quot;,&quot;last_name&quot;:&quot;Allentoff&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;A. Wallace&quot;},{&quot;first_name&quot;:&quot;Arvind&quot;,&quot;last_name&quot;:&quot;Mathur&quot;},{&quot;first_name&quot;:&quot;Luisa&quot;,&quot;last_name&quot;:&quot;Salter-Cid&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;E. Macor&quot;},{&quot;first_name&quot;:&quot;Percy&quot;,&quot;last_name&quot;:&quot;H. Carter&quot;},{&quot;first_name&quot;:&quot;Aberra&quot;,&quot;last_name&quot;:&quot;Fura&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;R. Burke&quot;},{&quot;first_name&quot;:&quot;Joseph&quot;,&quot;last_name&quot;:&quot;A. Tino&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;20&quot;,&quot;issue&quot;:&quot;7&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;3228-3250&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b00167&quot;},&quot;abstract&quot;:&quot;Bruton’s tyrosine kinase (BTK), a non-receptor tyrosine kinase, is a member of the Tec family of kinases and is essential for B cell receptor (BCR) mediated signaling. BTK also plays a critical role in the downstream signaling pathways for the Fcγ receptor in monocytes, the Fcε receptor in granulocytes, and the RANK receptor in osteoclasts. As a result, pharmacological inhibition of BTK is anticipated to provide an effective strategy for the clinical treatment of autoimmune diseases such as rheumatoid arthritis and lupus. This article will outline the evolution of our strategy to identify a covalent, irreversible inhibitor of BTK that has the intrinsic potency, selectivity, and pharmacokinetic properties necessary to provide a rapid rate of inactivation systemically following a very low dose. With excellent in vivo efficacy and a very desirable tolerability profile, 5a (branebrutinib, BMS-986195) has advanced into clinical studies.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00167&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00167" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00167&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00167" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00167&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00167" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00167&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00167&amp;href=/doi/10.1021/acs.jmedchem.9b00167" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b00167" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b00167" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b00167%26sid%3Dliteratum%253Aachs%26pmid%3D30893553%26genre%3Darticle%26aulast%3DWatterson%26date%3D2019%26atitle%3DDiscovery%2Bof%2BBranebrutinib%2B%2528BMS-986195%2529%253A%2BA%2BStrategy%2Bfor%2BIdentifying%2Ba%2BHighly%2BPotent%2Band%2BSelective%2BCovalent%2BInhibitor%2BProviding%2BRapid%2Bin%2BVivo%2BInactivation%2Bof%2BBruton%25E2%2580%2599s%2BTyrosine%2BKinase%2B%2528BTK%2529%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D7%26spage%3D3228%26epage%3D3250%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/7" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/jmcmar.2019.62.issue-7/20190411/jmcmar.2019.62.issue-7.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0027.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00167&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Bruton’s tyrosine kinase (BTK), a non-receptor tyrosine kinase, is a member of the Tec family of kinases and is essential for B cell receptor (BCR) mediated signaling. BTK also plays a critical role in the downstream signaling pathways for the Fcγ receptor in monocytes, the Fcε receptor in granulocytes, and the RANK receptor in osteoclasts. As a result, pharmacological inhibition of BTK is anticipated to provide an effective strategy for the clinical treatment of autoimmune diseases such as rheumatoid arthritis and lupus. This article will outline the evolution of our strategy to identify a covalent, irreversible inhibitor of BTK that has the intrinsic potency, selectivity, and pharmacokinetic properties necessary to provide a rapid rate of inactivation systemically following a very low dose. With excellent in vivo efficacy and a very desirable tolerability profile, <b>5a</b> (branebrutinib, BMS-986195) has advanced into clinical studies.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52156" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52156" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Bruton’s tyrosine kinase (BTK) is a member of the Tec family of non-receptor tyrosine kinases and is expressed in all hematopoietic cells, with the exception of T cells and terminally differentiated plasma cells. The underlying pathophysiology of autoimmune diseases such as rheumatoid arthritis (RA) and lupus relies on many of the pathways regulated by BTK, including B cell and myeloid cellular functions.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1−3)</a> In B cells, BTK kinase activity is essential in B cell receptor (BCR) mediated activation, resulting in cell proliferation, antibody and cytokine production, and co-stimulatory molecule expression (e.g., CD80, CD86, and CD69).<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> In myeloid cells, BTK is a critical component in the signaling pathway of low-affinity activating-Fcγ receptors (e.g., FcγRIIa and FcγRIIIa) for the immunoglobulin G (IgG) containing immune complexes in monocytic cells and Fcε receptor signaling in mast cells and basophils, triggering the expression of proinflammatory cytokines, chemokines, and cell adhesion molecules.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Of particular interest for the clinical treatment of RA, BTK-dependent signaling is required for RANK-L controlled osteoclastogenesis in monocytic precursors.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Overall, with its impact on both BCR signaling and Fcγ and Fcε receptor signaling, inhibition of the kinase activity of BTK<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7,8)</a> is expected to provide an effective strategy for the clinical treatment of autoimmune diseases such as lupus and RA, without depleting B cells.</div><div class="NLM_p">As a result of strong preclinical validation, there has been an intense effort to identify orally active small molecule inhibitors of BTK as clinical therapeutic agents for the treatment of both oncological and autoimmune diseases. With an appropriately positioned noncatalytic cysteine residue (Cys481) in the kinase domain,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> there has been particular interest in identifying inhibitors that covalently bind to Cys481. Ibrutinib (<b>1a</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), a covalent, irreversible inhibitor of BTK, is approved for the clinical treatment of chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom’s macroglobulinemia, and chronic graft versus host disease.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> In spite of significant clinical efficacy in otherwise difficult to treat diseases, administration of <b>1a</b> has led to undesirable clinical side effects including rash and diarrhea, attributed to the drug’s potent off-target inhibition of the epidermal growth factor receptors (EGFR), as well as bleeding and atrial fibrillation.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Additionally, as a result of high clearance and a slow rate of inactivation, <b>1a</b> requires high doses for clinical efficacy (420–560 mg q.d.), which when combined with the side effect profile would likely limit its use to oncological diseases. In an effort to improve upon the overall profile of <b>1a</b>, several additional covalent inhibitors,<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a> as well reversible inhibitors,<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14,15)</a> have advanced into clinical trials for the treatment of both oncological and autoimmune disorders. One such drug, acalabrutinib (<b>1b</b>), was recently approved for the treatment of mantle cell lymphoma.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0001.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Approved covalent, irreversible inhibitors of BTK.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00167&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We have previously reported on our efforts to identify reversible inhibitors of BTK.<a onclick="showRef(event, 'cit15c cit15d'); return false;" href="javascript:void(0);" class="ref cit15c cit15d">(15c,d)</a> This effort led to the discovery of BMS-986142 (<b>2</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), as a single, stable atropisomer, which is currently being evaluated clinically for the treatment of rheumatoid arthritis.<a onclick="showRef(event, 'cit15a cit15b'); return false;" href="javascript:void(0);" class="ref cit15a cit15b">(15a,b)</a> Dosing was designed to provide continuous coverage of the IC<sub>50</sub> throughout the dosing interval, as supported by preclinical animal studies.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Recognizing that coverage as high as IC<sub>90</sub> might be required for clinical efficacy, we initiated a covalent, irreversible discovery effort. It has been reported in the literature<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> that covalent, irreversible inhibition can provide advantages over traditional reversible inhibition such as increased biochemical efficiency for target disruption and a prolonged pharmacodynamic (PD) effect that outlasts the pharmacokinetics (PK) of the compound, both improving the potential for lower concentrations and subsequent improved therapeutic margins. However, covalent, irreversible inhibition also enhances the risk of off-target reactivity to biomolecules, potentially leading to hepatotoxicity, immunotoxicity, and mutagenicity.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> As a result of their covalent nature, off-target interaction would be expected to be more significant with the potential for prolonged recovery. Of particular concern with covalent inhibition is the potential for idiosyncratic adverse drug reactions (IADRs), which are characterized as immunogenicity of a protein adduct (haptenization) leading to an allergic response or drug hypersensitivity reaction.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0002.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Compound <b>2</b> is a potent reversible BTK inhibitor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00167&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In considering this strategy to develop a selective covalent, irreversible inhibitor for the treatment of autoimmune diseases, a low human dose of ≤10 mg was desired to significantly reduce the potential for off-target reactivity. Drugs with a dose of ≤10 mg are unlikely to cause IADRs, including those that form reactive metabolites.<a onclick="showRef(event, 'cit17a'); return false;" href="javascript:void(0);" class="ref cit17a">(17a)</a> We reasoned that a low human dose would require that a covalent, irreversible inhibitor have both a rapid rate of enzyme inactivation and PK properties amenable to rapid target engagement in vivo. As shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, covalent bonding requires a two-step process. The first step involves noncovalent, reversible binding to the active site of BTK to establish [E·I], as measured by <i>K</i><sub>i</sub>. The second step involves covalent, irreversible bonding of an electrophilic center on the inhibitor with the nucleophilic Cys481 residue in the active site, resulting in complete enzyme inactivation [EI], as measured by <i>k</i><sub>inact</sub>. The apparent second order rate of inactivation provided by a covalent, irreversible inhibitor (<i>k</i><sub>obs</sub>) is represented by <i>k</i><sub>inact</sub>/<i>K</i><sub>i</sub>. With this in mind, our strategy to attain a rapid rate of inactivation was to start with a high affinity, highly selective scaffold with reversible binding to the target in the absence of covalent bonding, where the electrophilic acceptor enhances but does not drive potency or selectivity. A high affinity compound (optimized <i>K</i><sub>i</sub>) would be expected to provide high concentrations of [E·I], which would be essential for a rapid rate of inactivation and enhanced selectivity. Additionally, a covalent, irreversible inhibitor with an appended acceptor with low intrinsic reactivity would be desirable to mitigate any off-target interactions. This would require an optimal scaffold, linker, and acceptor geometry to allow for precise positioning of the acceptor in close proximity to Cys481 to drive rapid inactivation (<i>k</i><sub>inact</sub>) while maintaining high affinity binding (<i>K</i><sub>i</sub>) to the hinge region of the kinase domain.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0003.jpeg" id="gr7" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00167&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To achieve a low human dose, a covalent, irreversible inhibitor would be expected to require PK properties that provide a balance between clearance and the rate of target engagement and ultimate enzymatic inactivation. In particular, the rate of target inactivation would need to occur at a rate faster than that of drug elimination, but remaining compound would need to be cleared rapidly to mitigate any off-target interactions (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). We expected that a compact, low molecular weight inhibitor with an acceptor with low intrinsic reactivity would offer the best chance for success. Overall, this strategy was anticipated to provide a rapid rate of inactivation of BTK, as well as minimal reactivity to small molecule thiols, proteins, and DNA to mitigate any off-target interactions.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0004.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. The rate of target inactivation must be faster than the rate of drug elimination.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00167&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As we began to focus on a covalent inhibition startegy, our deep understanding of noncovalent, reversible inhibition of BTK played a key role.<a onclick="showRef(event, 'cit15d ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref cit15d ref18 ref19 ref20">(15d,18−20)</a> As the X-ray cocrystal structure of our highly potent and selective clinical asset <b>2</b><a onclick="showRef(event, 'cit15d'); return false;" href="javascript:void(0);" class="ref cit15d">(15d)</a> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> and <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>; BTK IC<sub>50</sub> = 0.50 nM; hWB IC<sub>50</sub> = 90 nM; 1.5 Å, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5T18">5T18</a>) bound to the kinase domain of BTK revealed, the tetrahydrocarbazole motif provides strong hydrogen bonding interactions with the hinge region. Specifically, the tetrahydrocarbazole NH and the carboxamide carbonyl engaged in hydrogen bonding interactions with Met477 in the hinge region of the active site, while the NH<sub>2</sub> of the carboxamide formed hydrogen bonding interactions with Glu475 and a conserved water, providing a bridging interaction with the gatekeeper Leu408 residue. In addition, a weak hydrogen bonding interaction of the quinazolinedione to the Cys481 residue through a conserved water was observed, highlighting the compound’s close proximity. As a result, our initial strategy, as recently reported,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> involved replacing the quinazolinedione with a simple acrylamide, as shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>. Encouragingly, this provided compound <b>3a</b> with highly potent, covalent inhibition. As recently disclosed,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> a truncated dimethylindole scaffold, as represented by <b>3b</b> and <b>3c</b>, retained the activity seen with <b>3a</b>. Unfortunately, oral dosing of carbazole <b>3a</b> in a mouse PK study resulted in low plasma concentrations with an aniline metabolite, resulting from acrylamide hydrolysis, as the predominant drug-related compound in circulation. Alternative acceptors did not resolve the PK issue while sustaining desirable potency, so as a consequence, our revised strategy focused on replacing the aniline linker. Although we explored covalent, irreversibility across the full range of our reversible scaffolds, this article will focus on the SAR development of the dimethylindole carboxamide series since it provided a desirable balance between potency/selectivity and PK properties, as well as overall favorable pharmaceutical properties.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> This effort ultimately led to our covalent, irreversible clinical compound, branebrutinib (<b>5a</b>, BMS-986195).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0005.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. X-ray crystal structure of <b>2</b> bound to the kinase domain of BTK (1.5 Å structure) (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5T18">5T18</a>).<a onclick="showRef(event, 'cit15d'); return false;" href="javascript:void(0);" class="ref cit15d">(15d)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00167&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0006.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Initial design strategy for covalent, irreversible inhibition.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00167&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Biological Evaluation</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76137" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76137" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">The covalent, irreversible compounds presented in this article were evaluated in a human recombinant BTK enzyme assay to determine their intrinsic activity against BTK. It should be noted that the potency of a compound with a BTK IC<sub>50</sub> significantly below 1 nM may be underestimated since this approaches the lower limit of potency that can be measured in the enzyme assay (limited by enzyme concentration). Given the intrinsic potency of the parent scaffold, significant potency resulting from the addition of an electrophilic acceptor suggests but does not prove covalent, irreversible inhibition. As a result, a dialysis assay was used to determine whether or not a compound was irreversibly bound. In this assay, the compound was incubated with BTK for 90 min at concentrations approximately 25-fold higher than the IC<sub>50</sub> to ensure saturation of the active site, followed by overnight dialysis against assay buffer with two buffer exchanges. If BTK activity did not return, the compound was regarded as a likely covalent inhibitor (later confirmed by active site occupancy, mass spectrometry, and crystallographic analysis of select compounds). In this assay, a reversible BTK inhibitor showed almost complete recovery of activity. A BCR stimulated calcium flux assay in Ramos B cells was used to establish activity in a cellular environment. In light of the fact that IC<sub>50</sub> determinations are dependent on both preincubation time and the rate of covalent bonding, the intrinsic potency of a covalent, irreversible inhibitor would need to be evaluated in a time-dependent manner. As a result, the rate of BTK engagement and inactivation of selected analogues was determined in an active site probe-based assay using a biotinylated covalent inactivator<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> to quantify unmodified active sites following incubation with the compound in human whole blood, as well as the kinetics and dose relationships of in vivo inactivation of BTK in mice and cynomolgus monkeys after oral administration. In parallel with the in vitro potency assays, in vitro liability profiling data were assessed to prioritize compounds. Selected compounds were evaluated in multispecies PK studies and ultimately rodent efficacy models of human lupus and RA.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67614" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67614" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">As seen in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, replacing the tolyl or phenyl linker in <b>3b</b> and <b>3c</b>, respectively, with a 3-aminopiperidine ring appended with an acrylamide afforded <b>4a</b> (racemic) which resulted in a 20-fold loss in activity. Replacing the acrylamide acceptor with a more reactive vinyl sulfonamide (<b>4b</b>) resulted in a ∼3-fold increase in activity relative to <b>4a</b>. Enantiomerically pure derivatives <b>4c</b> and <b>4d</b> were subsequently prepared and evaluated, with <b>4d</b> providing similar intrinsic potency as both <b>3b</b> and <b>3c</b> in both the biochemical BTK assay and the Ramos cellular assay. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, <b>4d</b> had substantially improved stability in human liver microsomes when compared to <b>1a</b> (90% remaining; <i>T</i><sub>1/2</sub> of 50 min vs 1% remaining; <i>T</i><sub>1/2</sub> of 1.5 min, respectively). However, in spite of the increased metabolic stability relative to <b>1a</b>, plasma concentrations for <b>4d</b> in a mouse coarse PK study were low (<i>C</i><sub>max</sub> = 127 nM; AUC = 0.35 μM·h). Unfortunately, metabolite identification studies in human liver microsomes (10 μM incubation, 30 min.) revealed that the primary route of metabolism of <b>4d</b> was through direct glutathione addition not mediated through glutathione-<i>S</i>-transferase (GST), which would be undesirable for a covalent, irreversible inhibitor. This suggested that the vinyl sulfonamide acceptor is too reactive and is likely driving the observed potency. Interestingly, in spite of having a highly reactive acceptor, <b>4d</b> provided a slower rate of inactivation relative to <b>1a</b> in a time-dependent, concentration-dependent BTK inactivation assay in human whole blood, as shown in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>. This clearly suggested that compound <b>4d</b> has a less than optimal linker/acceptor geometry to provide both high affinity binding to the hinge region of the kinase domain active site (<i>K</i><sub>i</sub>) and optimal positioning of the acceptor for rapid inactivation (<i>k</i><sub>inact</sub>).</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0007.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. BTK inactivation rate comparison between <b>4d</b> and <b>1a</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00167&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. In Vitro Potency of Dimethylindole Analogues <b>4</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0020.gif" alt="" id="fx3fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0021.gif" alt="" id="GRAPHIC-d7e869-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values are shown as mean values of at least three determinations unless specified otherwise.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">HLM = human liver microsomes. Human liver microsomal stability (% remaining): 0.5 μM substrate, 1 mg/mL protein, 10 min at 37 °C. Human liver microsomal <i>t</i><sub>1/2</sub> (min): 0.5 μM substrate, 1 mg/mL protein, 1 mM NAPDH, 37 °C.</p></div></div><div></div></div><div class="NLM_p">As a result, our strategy evolved into the optimization of the linker and acceptor trajectory. Saturated linkers with varying sizes, points of attachment, and chirality were paired with less reactive acceptors to fine-tune the geometry (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>), with a primary focus on optimizing <i>k</i><sub>inact</sub> while maintaining the intrinsic high affinity (<i>K</i><sub>i</sub>) for the target. The SARs representing our effort to improve both potency and pharmacokinetic properties are outlined in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. This effort resulted in two interesting leads, compounds <b>4k</b> and <b>4f</b>, both providing less than 10 nM cellular potency. Further evaluation showed that <b>4k</b> inactivated BTK in the human whole blood assay at a rate similar to <b>1a</b> (apparent second order rate = 1.0 × 10<sup>–4</sup> nM<sup>–1</sup>·min<sup>–1</sup> vs 1.2 × 10<sup>–4</sup> nM<sup>–1</sup>·min<sup>–1</sup>, respectively). On a more intriguing note, compound <b>4f</b>, with a propiolamide acceptor, provided 1.8 nM activity in the cellular assay and inactivated BTK in the human whole blood assay at a rate >10-fold faster than <b>1a</b> (>10 × 10<sup>–4</sup> nM<sup>–1</sup>·min<sup>–1</sup> vs 1.2 × 10<sup>–4</sup> nM<sup>–1</sup>·min<sup>–1</sup>). Unfortunately, low plasma concentrations were observed in a mouse PK study. In both human and mouse liver microsomes, the primary metabolic pathway identified corresponded to direct glutathione addition, likely contributing to the poor in vivo exposure, once again suggesting that the acceptor is too reactive. In an effort to mitigate the reactivity, the corresponding but-2-ynamide acceptor <b>4g</b> was investigated. Intriguingly, <b>4g</b> was no longer a substrate for direct GSH addition and provided acceptable plasma concentrations in vivo; however, <b>4g</b> was ∼20-fold less potent than <b>4f</b> in the cellular assay, with an rate of inactivation similar to that of <b>1a</b>.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0008.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Optimizing linker and acceptor geometry to improve intrinsic covalent potency.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00167&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. In Vitro Potency of Dimethylindole Analogues <b>4</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0022.gif" alt="" id="fx5fx6" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0023.gif" alt="" id="GRAPHIC-d7e998-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values are shown as mean values of at least three determinations unless specified otherwise.</p></div></div><div></div></div><div class="NLM_p">Encouraged by the balance between potency and reactivity as well as PK and stability attained with the but-2-ynamide acceptor paired with the (<i>S</i>)-3-aminopiperadine linker, we directed our attention toward improving both the intrinsic potency and PK through core modifications. Consistent with our observations in the reversible effort,<a onclick="showRef(event, 'cit15d'); return false;" href="javascript:void(0);" class="ref cit15d">(15d)</a> addition of a fluoro substituent at C5 of the indole core, to give <b>5a</b>, provided significant enhancements in potency, with 0.1 nM inhibition of BTK and 7 nM inhibition in the cellular assay (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Additionally, <b>5a</b> provided significantly higher plasma concentrations in a mouse PK study relative to <b>4g</b> (<i>C</i><sub>max</sub> = 42 μM; AUC = 52 μM·h vs <i>C</i><sub>max</sub> = 0.49 uM; AUC = 1.1 μM·h, respectively). As shown in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>, <b>5a</b> inactivated BTK in the human whole blood assay at a rate 3-fold faster than <b>1a</b> (3.5 × 10<sup>−4</sup> nM<sup>−1</sup>·min<sup>−1</sup> vs 1.2 × 10<sup>−4</sup> nM<sup>−1</sup>·min<sup>−1</sup>, respectively). Adding further support, biochemical kinetic evaluation of <b>5a</b> demonstrated a rate of BTK inactivation 4-fold faster than <b>1a</b> (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). This clearly illustrated that we had optimized the geometry of the compound to allow for both high affinity binding (<i>K</i><sub>i</sub>) and rapid inactivation through covalent bonding with Cys 481 (<i>k</i><sub>inact</sub>). As expected, the des-methyl derivative <b>5b</b> was shown, when biochemically evaluated, to inactivate BTK at a rate 7-fold faster than <b>5a</b> and consequently would be expected to be too reactive in vivo.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0009.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Time- and dose-dependent inactivation of BTK with <b>5a</b> (A) vs <b>1a</b> (B). Either <b>5a</b> or <b>1a</b> at various concentrations was added to human whole blood, and the kinetics of BTK inactivation were measured. The solid line represents the fit of the data to a second order rate constant of 3.5 × 10<sup>–4</sup> nM<sup>–1</sup>·min<sup>–1</sup> (<b>5a</b>) vs 1.2 × 10<sup>–4</sup> nM<sup>–1</sup>·min<sup>–1</sup> (<b>1a</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00167&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. In Vitro Potency of C5-F-Dimethylindole Analogues <b>5</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0024.gif" alt="" id="fx7fx8" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0025.gif" alt="" id="GRAPHIC-d7e1150-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values are shown as mean values of at least three determinations unless specified otherwise.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Biochemical Kinetic Evaluation of the Rate of Inactivation of <b>5a</b> vs <b>1a</b> (<i>k</i><sub>inact</sub>/<i>K</i><sub>i,app</sub>)</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">compound</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center"><b>5a</b></th><th class="colsep0 rowsep0" align="center"><b>1a</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>K</i><sub>i,app</sub> (nM)</td><td class="colsep0 rowsep0" align="left">116</td><td class="colsep0 rowsep0" align="left">425</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>k</i><sub>inact</sub> (1/s)</td><td class="colsep0 rowsep0" align="left">0.11</td><td class="colsep0 rowsep0" align="left">0.09</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>k</i><sub>inact</sub>/<i>K</i><sub>i,app</sub> (1/(mM·s))</td><td class="colsep0 rowsep0" align="left">0.97</td><td class="colsep0 rowsep0" align="left">0.23</td></tr></tbody></table></div></div><div class="NLM_p">An expanded view of the in vitro activity profile of <b>5a</b> is outlined in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>. In B cells stimulated through the B cell receptor (BCR), <b>5a</b> potently inhibited signaling and functional end points, including calcium flux (IC<sub>50</sub> = 7 nM), production of cytokines, proliferation, and surface expression of the costimulatory molecule CD86 (IC<sub>50</sub> values of <1 nM). As expected, CD69 expression in peripheral B cells, when stimulated through CD40, was not impacted by <b>5a</b> since this pathway is not dependent on the kinase activity of BTK to mediate downstream signaling, thus demonstrating the compound’s functional selectivity. When evaluated against IgG-containing immune complex low affinity activating Fcγ (FcγRIIa and FcγRIII) receptor end points in peripheral blood mononuclear cells (PBMC), <b>5a</b> was highly effective at inhibiting TNFα production with equivalent potency to those measured for the BCR-dependent end points in B cells. In human whole blood assays, <b>5a</b> potently inhibited BCR-stimulated expression of CD69 on B cells with an IC<sub>50</sub> of 11 nM. Measurements of BTK inactivation in these assays showed a similar IC<sub>50</sub> of 5 nM. Since the concentration of BTK in human whole blood is approximately 10 nM, the compound effectively titrated the amount of BTK present in these assays. As previously mentioned, <b>5a</b> rapidly inactivated BTK in a time- and concentration-dependent manner when added to human whole blood, providing a second order rate of inactivation of 3.5 × 10<sup>–4</sup> nM<sup>–1</sup>·min<sup>–1</sup>.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Partial in Vitro Cell Activity Data and Whole Blood Data for <b>5a</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0026.gif" alt="" id="fx9" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">assay</th><th class="colsep0 rowsep0" align="center">receptor/stimulation</th><th class="colsep0 rowsep0" align="center"><b>5a</b> IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cellular assay</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">calcium flux in Ramos B cells</td><td class="colsep0 rowsep0" align="left">BCR/anti-IgM</td><td class="colsep0 rowsep0" align="left">7.2 ± 2.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">proliferation of human peripheral B cells</td><td class="colsep0 rowsep0" align="left">BCR/anti-IgM/IgG</td><td class="colsep0 rowsep0" align="left">0.04 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CD86 surface expression in peripheral B cells</td><td class="colsep0 rowsep0" align="left">BCR/anti-IgM/IgG</td><td class="colsep0 rowsep0" align="left">0.3<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CD86 surface expression in memory B cells (peripheral blood)</td><td class="colsep0 rowsep0" align="left">IL-6</td><td class="colsep0 rowsep0" align="left">0.9<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CD69 surface expression in peripheral B cells</td><td class="colsep0 rowsep0" align="left">CD40/CD40L</td><td class="colsep0 rowsep0" align="left">>300<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TNFα from human PBMCs<a class="ref internalNav" href="#tbl5-fn1" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">FCγR/immune complex</td><td class="colsep0 rowsep0" align="left">0.3<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human whole blood assay</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human whole blood CD69 surface expression in peripheral B cells</td><td class="colsep0 rowsep0" align="left">BCR/anti-IgM</td><td class="colsep0 rowsep0" align="left">11 ± 8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BTK inacivation</td><td class="colsep0 rowsep0" align="left">second order rate of inactivation</td><td class="colsep0 rowsep0" align="left">3.5 × 10<sup>–4</sup> nM<sup>–1</sup><sub>·</sub>min<sup>–1</sup></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values are shown as mean values of at least three determinations unless specified otherwise.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">IC<sub>50</sub> values as single determinations.</p></div><div class="footnote" id="tbl5-fn1"><sup><sup>c</sup></sup><p class="last">PBMC = peripheral blood mononuclear cell.</p></div></div></div><div class="NLM_p">In order to gain an understanding of the overall kinase selectivity, <b>5a</b> was evaluated against a panel of 245 kinases (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>). A partial list of kinase selectivity data is summarized in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>. Dimethylindole <b>5a</b> was highly selective, providing >5000-fold selectivity for BTK over 240 kinases with only the four related Tec family kinases demonstrating less than 5000-fold selectivity (9- to 1000-fold), as shown in <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>. Interestingly, 10 kinases have a comparable cysteine residue in the active site, the Tec family, the EGFR family, and JAK3. Out of these 10 kinases, <b>5a</b> demonstrated activity of less than 5000-fold relative to BTK for only the four other members of the Tec family. Overall, when compared to reversible inhibitor <b>2</b>,<a onclick="showRef(event, 'cit15d'); return false;" href="javascript:void(0);" class="ref cit15d">(15d)</a> covalent inhibition with <b>5a</b> resulted in significant improvement in the overall magnitude of selectivity, with the exception of Tec family kinases TEC, BMX, and TXK. On the other hand, the selectivity of <b>5a</b> against Tec family kinase ITK was significantly enhanced relative to <b>2</b> (1000× vs 30×, respectively). The improved selectivity against ITK observed with <b>5a</b> is likely attributed to both the intrinsic structural selectivity of the compound and the impact of the unique cysteine microenvironment of ITK on covalent bonding, compared to the other four Tec family kinases, BTK, TEC, BMX, and TXK, which all share a similar microenvironment.<a onclick="showRef(event, 'cit13c'); return false;" href="javascript:void(0);" class="ref cit13c">(13c)</a> Of particular note, <b>5a</b> was >10 000-fold selective for BTK over members of the EGFR family (HER1 and HER4). Since a kinase assay does not fully capture the time-dependent nature of a covalent inhibitor, compound <b>5a</b> was evaluated against an EGFR-dependent AU565 breast cancer cell line to assess functional EGFR kinase activity over a 3 day period. Compound <b>5a</b> failed to show inhibition at concentrations up to 25 000 nM in this assay. Compound <b>1a</b>, on the other hand, inhibited this assay with an IC<sub>50</sub> of 30 nM.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0010.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Compound <b>5a</b> is highly selective for BTK. Illustration reproduced courtesy of Cell Signaling Technology, Inc.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00167&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Partial in Vitro Selectivity Data for <b>5a</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center">biochemical IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">kinase/BTK fold selectivity</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BTK (Tec family)</td><td class="colsep0 rowsep0" align="left">0.10</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TEC (Tec family)</td><td class="colsep0 rowsep0" align="left">0.90</td><td class="colsep0 rowsep0" align="left">9×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BMX (Tec family)</td><td class="colsep0 rowsep0" align="left">1.5</td><td class="colsep0 rowsep0" align="left">15×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TXK (Tec family)</td><td class="colsep0 rowsep0" align="left">5.0</td><td class="colsep0 rowsep0" align="left">50×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ITK (Tec family)</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">1000×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HER1 and -4 (EGFR family)</td><td class="colsep0 rowsep0" align="left">2000/1040</td><td class="colsep0 rowsep0" align="left">>10000×</td></tr></tbody></table></div></div><div class="NLM_p">The X-ray cocrystal structure of <b>5a</b> bound to the kinase domain of BTK (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O8I">6O8I</a>) clearly highlighted that the compact nature of <b>5a</b> binds tightly in the active site to facilitate the rapid rate of BTK inactivation that is observed. Consistent with our reversible clinical inhibitor <b>2</b>,<a onclick="showRef(event, 'cit15d'); return false;" href="javascript:void(0);" class="ref cit15d">(15d)</a> the cocrystal structure revealed that the tetrahydrocarbazole NH and the carboxamide carbonyl are engaged in a hydrogen bonding interaction with Met477 in the hinge region of the active site. The NH<sub>2</sub> of the carboxamide is forming a hydrogen bonding interaction not only with Glu475 but also with a conserved water, providing a bridging interaction with the gatekeeper Leu408 residue. Most importantly, the structure confirmed the covalent nature of the inhibitor through a clearly defined, albeit stereochemically nonselective, covalent bond with the sulfur of Cys481. As shown in <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>, the overlay of the single crystal X-ray structure with the cocrystal structure of <b>5a</b> bound with BTK clearly illustrates that we have designed a covalent, irreversible inhibitor that maintains both the high affinity binding of our reversible compounds while orienting the acceptor in close proximity to the cysteine nucleophile for rapid inactivation.</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0011.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. X-ray crystal structure of <b>5a</b> covalently bound to the kinase domain of BTK (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O8I">6O8I</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00167&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0012.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Overlay of the single crystal X-ray structure (pink) with the X-ray crystal structure of <b>5a</b> bound to the active site of BTK (gold).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00167&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">With a highly desirable activity and selectivity profile, a rapid rate of BTK inactivation, a favorable liability profile (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>) particularly for a covalent inhibitor, and desirable compound plasma concentrations in mice, <b>5a</b> was further evaluated in vivo.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> In multispecies pharmacokinetic studies (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>), the absolute oral bioavailability of <b>5a</b> was 100% in mice, 74% in rats, 46% in cynomolgus monkeys, and 81% in dogs. The total body plasma clearance of <b>5a</b> was low in all species. The steady-state volume of distribution observed was greater than the plasma volume but less than the total body water, indicative of extravascular distribution, in spite of the high protein binding (free fraction: 0.2–1.2%, <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). However, brain penetration was very low in mice, rats, and dogs (<5% of plasma concentration). Of particular interest, both the plasma <i>T</i><sub>1/2</sub> (iv) and <i>T</i><sub>max</sub> (po) values were short across species (0.46–4.3 h and 0.58–1.0 h, respectively, <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>). We viewed this as important for a covalent inhibitor since the compound would need to have adequate intrinsic stability to facilitate rapid enzymatic inactivation in vivo, but remaining inhibitor would need to be cleared quickly to mitigate any off-target interaction.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Partial in Vitro Profiling Data for <b>5a</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center">result</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">protein binding (bound)</td><td class="colsep0 rowsep0" align="left">98.8% human</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">99.6% mouse</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">99.8% rat</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">99.8% dog</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">99.6% monkey</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mutagenicity</td><td class="colsep0 rowsep0" align="left">Ames negative</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">in vitro micronucleus assay</td><td class="colsep0 rowsep0" align="left">negative</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hERG (patch clamp)</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> = 11 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Na<sup>+</sup> (patch clamp)</td><td class="colsep0 rowsep0" align="left">3.1% at 10 μM (1 and 4 Hz)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ca<sup>+</sup> (patch clamp)</td><td class="colsep0 rowsep0" align="left">23% at 10 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PAMPA permeability</td><td class="colsep0 rowsep0" align="left">859/978 nm/s (pH 5.5/7.4)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Caco2 permeability</td><td class="colsep0 rowsep0" align="left">177–422 nm/s (A to B)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(2.1–35 μM)</td><td class="colsep0 rowsep0" align="left">127 to 250 nm/s (B to A)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">aqueous solubility</td><td class="colsep0 rowsep0" align="left">0.002–0.003 mg/mL (pH 1–7.4)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FaSSIF<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a> solubility</td><td class="colsep0 rowsep0" align="left">0.009 mg/mL</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FeSSIF<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a> solubility</td><td class="colsep0 rowsep0" align="left">0.145 mg/mL</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">log <i>D</i> at pH 7.0 (HPLC)</td><td class="colsep0 rowsep0" align="left">3.18</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">FaSSIF = fasted state simulated intestinal fluid.</p></div><div class="footnote" id="t7fn2"><sup><sup>b</sup></sup><p class="last">FeSSIF = fed state simulated intestinal fluid.</p></div></div></div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Pharmacokinetic Parameters for <b>5a</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center">mouse<a class="ref internalNav" href="#t8fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">rat<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">monkey<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">dog<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">po dose (mg/kg)</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">iv dose (mg/kg)</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (μM), po</td><td class="colsep0 rowsep0" align="left">7.7</td><td class="colsep0 rowsep0" align="left">9.6 ± 1.0</td><td class="colsep0 rowsep0" align="left">2.3 ± 1.5</td><td class="colsep0 rowsep0" align="left">19 ± 2.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (μM), po</td><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="left">0.58 ± 0.4</td><td class="colsep0 rowsep0" align="left">1.0 ± 0.3</td><td class="colsep0 rowsep0" align="left">0.67 ± 0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC (μM·h), po</td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left">18 ± 0.8</td><td class="colsep0 rowsep0" align="left">4.9 ± 3.1</td><td class="colsep0 rowsep0" align="left">78 ± 3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h), iv</td><td class="colsep0 rowsep0" align="left">0.46</td><td class="colsep0 rowsep0" align="left">4.3 ± 0.5</td><td class="colsep0 rowsep0" align="left">3.2 ± 2.5</td><td class="colsep0 rowsep0" align="left">3.0 ± 0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MRT (h), iv</td><td class="colsep0 rowsep0" align="left">0.57</td><td class="colsep0 rowsep0" align="left">0.80 ± 0.20</td><td class="colsep0 rowsep0" align="left">1.0 ± 0.4</td><td class="colsep0 rowsep0" align="left">4.1 ± 0.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL (mL min<sup>–1</sup> kg<sup>–1</sup>), iv</td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left">8.7 ± 0.4</td><td class="colsep0 rowsep0" align="left">9.4 ± 3.7</td><td class="colsep0 rowsep0" align="left">0.94 ± 0.25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>ss</sub> (L/kg), iv</td><td class="colsep0 rowsep0" align="left">0.48</td><td class="colsep0 rowsep0" align="left">0.40 ± 0.10</td><td class="colsep0 rowsep0" align="left">0.45 ± 0.1</td><td class="colsep0 rowsep0" align="left">0.24 ± 0.11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i><sub>po</sub> (%)</td><td class="colsep0 rowsep0" align="left">106</td><td class="colsep0 rowsep0" align="left">74 ± 3</td><td class="colsep0 rowsep0" align="left">46 ± 18</td><td class="colsep0 rowsep0" align="left">81 ± 18</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup><sup>a</sup></sup><p class="last">Average of three animals.</p></div><div class="footnote" id="t8fn2"><sup><sup>b</sup></sup><p class="last">Cynomolgus monkey.</p></div><div class="footnote" id="t8fn3"><sup><sup>c</sup></sup><p class="last">Average of two animals; vehicle, PEG400/water (80/20).</p></div></div></div><div class="NLM_p">When administered orally to BALB/c mice, <b>5a</b> dose-dependently inactivated BTK in peripheral blood with a single dose of 0.5 mg/kg, providing 90% inactivation 4 h after dosing (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>A). Consistent with a slow rate of BTK resynthesis, inactivation was sustained at this dose with 86% inactivation remaining at 24 h postdose. Evaluation of <b>5a</b> in BALB/C mice (0.5–2.5 mg/kg po) for 48 h indicated that approximately 25% of BTK active sites were resynthesized over 24 h. In cynomolgus monkeys, when administered orally with a single 0.5 mg/kg dose, 100% inactivation was achieved at the 4 h time point with 74% inactivation remaining at 72 h (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>B). The drop in inactivation over 72 h is reflective of the slow resynthesis rate of BTK. Interestingly, the compound was largely cleared within 4–6 h after dosing in both studies, clearly highlighting one of the key advantages of covalent inhibition. When compared with <b>1a</b>, <b>5a</b> was ∼30-fold more potent at inactivating BTK in mice after a single dose (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>C).</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0013.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. A single, low dose of <b>5a</b> (0.5 mg/kg orally, once daily) resulted in >90% BTK inactivation in mice (A) and 100% inactivation in cynomolgus monkey (B). (c) Compound <b>5a</b> inactivated BTK in mice significantly faster than <b>1a</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00167&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Dimethylindole <b>5a</b> was evaluated in vivo in a mouse collagen-induced arthritis (CIA) model of human RA, which is both B-cell- and FcγR-dependent. Once daily oral dosing of <b>5a</b>, started at the time of the initial collagen immunization and continued throughout the duration of the study (38 days), resulted in dose-dependent inhibition of clinically evident disease with 21%, 83%, and 92% inhibition observed at the end of the study at doses of 0.1, 0.5, and 2.5 mg/kg po, q.d., respectively (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>). Of particular note, the 0.5 mg/kg and 2.5 mg/kg dose levels provided robust protection from clinically evident disease (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>A and <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>B). Measurements of BTK inactivation in blood samples collected 24 h after the last dose showed high levels of inactivation (0.1 mg/kg, 64%; 0.5 mg/kg, 97%; and 2.5 mg/kg, 99%; <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>B). Histological evaluation of the right hind paws, evaluating bone resorption and inflammation, was consistent with the clinical scores (data not shown). Microcomputed tomography of the hind limbs (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>C) illustrated that <b>5a</b> provided a dose-dependent protection against pitting, loss of bone mass, woven porous bone, and fusion of the small bones evident in the mice receiving only vehicle. The animals receiving 0.5 mg/kg showed essentially complete protection, as illustrated by the presence of a smooth bone surface and easily recognizable small individual bones of the foot and ankle. The compound was also effective at 0.5 mg/kg po, q.d. in blocking disease progression when dosed in a pseudoestablished dosing mode (data not shown).<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0014.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Potent and robust activity against collagen-induced arthritis in vivo was observed with <b>5a</b> (fully preventative dosing). Error bars represent the mean ± SEM: *<i>P</i> < 0.05, **<i>P</i> < 0.01 versus vehicle control group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00167&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Additionally, <b>5a</b> was evaluated in vivo in a NZB/W lupus-prone mouse model, in which the mice develop a disease closely resembling human systemic lupus erythematosus and lupus nephritis (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>). Mice were dosed by once daily oral gavage for 14 weeks with either <b>5a</b> (0.2, 0.5, and 1.5 mg/kg), prednisolone (10 mg/kg), or vehicle (80:20 PEG400/water). In this study, treatment with <b>5a</b> provided complete protection from disease-related death over the course of treatment (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>A). Additionally, compound <b>5a</b> was shown to dose-dependently inhibit the increase in severe proteinuria (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>B), a measure of the underlying nephritis. Serum anti-double-stranded DNA (anti-dsDNA) titers, which progressively increased over the course of the study in vehicle control mice, were also inhibited in a dose-dependent manner (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>C) with 40%, 51%, and 61% reductions at the end of the study at the 0.2, 0.5, and 1.5 mg/kg doses, respectively. Histological evaluation of the kidneys confirmed that treatment with <b>5a</b> at all doses provided robust protection against tubulo-interstitial and glomerular nephritis, as well as inflammatory infiltration, at levels equivalent to those seen with prednisolone (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>D). IgG immune complex deposition, critical in driving disease pathobiology in both this murine model and human lupus nephritis, was prominent in the capillaries of the glomeruli of vehicle control mice. As seen in <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>E, histological evaluation revealed that <b>5a</b> reduced the level of immune complex deposits as effectively as prednisolone. Measurements of BTK inactivation in blood samples collected 24 h after the last dose showed high levels of inactivation at all three doses (0.2 mg/kg, 92%; 0.5 mg/kg, 99%; and 1.5 mg/kg, 100%; <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>F).</div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0015.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Protection against lupus nephritis by <b>5a</b> in NZB/W mice vs vehicle and prednisolone. Error bars represent the mean ± SEM: *<i>P</i> < 0.05, **<i>P</i> < 0.01 versus vehicle control group. ds-DNA = double-stranded DNA; Ig = I mmunoglobulin; Pred = prednisolone.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00167&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In evaluating the in vivo efficacy results, achieving >90% inactivation was associated with a very robust response, with near complete protection from disease. On the basis of these results, we felt that a projected human dose targeting BTK inactivation of ≥95% was desirable. Considering the rapid rate of inactivation in human whole blood, the hepatocyte metabolism in human and other species, and the in vivo PK results in multiple species, the human dose to achieve ≥95% inactivation was projected to be <10 mg, po, q.d.</div><div class="NLM_p">With highly desirable pharmacology favoring a low projected human dose, we concentrated our efforts on assessing the off-target reactivity and overall toxicity. As previously mentioned, the concern with covalent, irreversible inhibition is the potential for off-target reactivity to biomolecules. To assess the risk for <b>5a</b>, several studies were undertaken to evaluate intrinsic reactivity to thiols, proteins, and DNA and to evaluate nonspecific protein covalent binding both in vitro and in vivo. Evaluation of covalent binding in vitro in human hepatocytes incubated for 2 h at a concentration of 10 μM using <sup>14</sup>C-labeled <b>5a</b>, incorporated in the carbonyl of the acetylene acceptor (see <a class="ref internalNav" href="#sec6" aria-label="Experimental Section">Experimental Section</a>), revealed very low levels of protein covalent binding (1.0%, 131 ± 2 pmol/mg of protein). In addition, no covalent binding was observed with off-target cysteine residues in protein mixtures containing BTK (10 cysteine residues), human hemoglobin, or human serum albumin, up to 10 μM concentrations of <b>5a</b>. In fact, only <10% protein binding in human hemoglobin was observed at a concentration of 100 μM. When incubated with GSH in enzyme free phosphate buffer, no GSH addition was observed, indicating a low intrinsic chemical reactivity to thiol containing nucleophiles. This is consistent with the previously reported GSH reactivity data for acalabrutinib, which benefits from the same but-2-ynamide acceptor.<a onclick="showRef(event, 'cit13c'); return false;" href="javascript:void(0);" class="ref cit13c">(13c)</a></div><div class="NLM_p">In a rat quantitative whole body autoradiography study (10 mg/kg, po) evaluating tissue distribution and retention, the majority of the compound was cleared within 24 h with only minor radioactivity remaining in the liver, kidneys, and skin after 48–96 h, indicating low tissue binding. Consistent with this finding, a mass balance study with <sup>14</sup>C-labeled <b>5a</b> (10 mg/kg, po) in intact rats (<i>n</i> = 3) showed complete recovery of the total radioactivity in urine and feces over 72 h with only 0.7% (±0.2) of the radioactivity remaining in the carcass. Furthermore, very low covalent binding was observed in the organs studied, including liver (≤0.03% of dose), spleen (≤0.007% of dose), and pancreas (≤0.002% of dose) in rats over a 7–24 h time point with a single, oral dose of <b>5a</b> (1 and 10 mg/kg). Additionally, no significant increase in covalent binding was observed in these tissues after 5 days of daily, oral dosing (1 and 10 mg/kg) in rats.</div><div class="NLM_p last">A recent report outlined a strategy to predict the in vivo daily covalent binding burden (DCBB) for covalent, irreversible inhibitors derived from an analysis of several marketed covalent drugs that have established safe clinical profiles, as well as compounds that did not.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> The authors concluded that if a compound has an estimated DCBB of ≤10 mg/day, it is more likely to be clinically safe. When applying this strategy to <b>5a</b> considering the low projected human dose of <10 mg q.d., po and the assessment of both in vitro protein covalent binding (<1%) in human hepatocytes and in vivo rat studies, <b>5a</b> was determined to have a DCBB of <0.10 mg/day. This value is significantly lower than the literature reported upper limit of 10 mg/day for clinically safe drugs. While this does not guarantee that <b>5a</b> will be safe in humans, it does instill a sense of confidence as the compound proceeds clinically. In evaluating genotoxicity, <b>5a</b> was negative in both Ames and in vitro micronucleus (CHO cells) assessments (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). With an extremely low DCBB and a very desirable tolerability in toxicity studies in both rat and dog, compound <b>5a</b> was advanced into clinical development.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46738" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46738" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The synthetic pathways utilized in the preparation of the compounds presented in this article are provided in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a> and <a class="ref internalNav" href="#sch2" aria-label="2">2</a>.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Analogues <b>4</b> were prepared as outlined in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. The desired commercially available primary and secondary amines were coupled with <b>6</b> under Buchwald–Hartwig amination conditions<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> to provide intermediates <b>7a</b> and <b>7b</b>. Attempts to perform the amination step on carboxamide intermediate <b>13</b> failed to provide any appreciable product. Heating a mixture of either <b>7a</b> or <b>7b</b> in sulfuric acid at 60 °C for 1 h resulted in concurrent hydrolysis of the carbonitrile to the carboxamide and deprotection of the protecting group. The final covalent, irreversible analogues <b>4a</b>–<b>q</b> were prepared by an acylation step using chloromethanesulfonyl chloride, acryloyl chloride, propiolic acid, or but-2-ynoic acid, as indicated in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. C5 Fluoro substituted derivatives <b>5a</b> and <b>5b</b> were prepared in a similar fashion as analogues <b>4</b> starting from compound <b>9</b>, as outlined in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. The absolute structure of <b>5a</b> was determined by single crystal X-ray structure analysis (CCDC no. 1901788) (see <a class="ref internalNav" href="#sec6" aria-label="Experimental Section">Experimental Section</a> for more detail). As previously reported,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> dimethylindoles <b>3b</b> and <b>3c</b> were prepared as depicted in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>.</div><figure id="sch1" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0016.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of Dimethylindoles <b>4</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00167&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) R<sup>1</sup>R<sup>2</sup>NH, Pd<sub>2</sub>(dba)<sub>3</sub>, BINAP, Cs<sub>2</sub>CO<sub>3</sub>; (b) H<sub>2</sub>SO<sub>4</sub>, 60 °C; (c) chloroethanesulfonyl chloride, THF/CH<sub>2</sub>Cl<sub>2</sub>; (d) acryloyl chloride, Hunig’s base, THF/CH<sub>2</sub>Cl<sub>2</sub>; (e) propiolic acid or but-2-ynoic acid, HATU, Hunig’s base.</p></p></figure><figure id="sch2" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0017.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of Dimethylindoles <b>5a</b> and <b>5b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00167&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (<i>S</i>)-<i>tert</i>-butyl piperidin-3-ylcarbamate, Pd<sub>2</sub>(dba)<sub>3</sub>, BINAP, Cs<sub>2</sub>CO<sub>3</sub>, 86%; (b) H<sub>2</sub>SO<sub>4</sub>, 60 °C, 82–95%; (c) but-2-ynoic acid, HATU, Hunig’s base, 75–85%; (d) propiolic acid, HATU, Hunig’s base, 45%.</p></p></figure><figure id="sch3" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0018.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of Dimethylindoles <b>3b</b> and <b>3c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00167&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (Ph<sub>3</sub>P)<sub>4</sub>Pd, 2 M Na<sub>2</sub>CO<sub>3</sub>, toluene/EtOH, 90 °C, 16 h.</p></p></figure><div class="NLM_p">The dimethylindole core intermediates <b>6</b> and <b>9</b> in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a> and <a class="ref internalNav" href="#sch2" aria-label="2">2</a>, respectively, were prepared as outlined in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. Both the C5 hydrogen and the C5 fluoro substituted cores, utilized in the preparation of analogues <b>4</b> and <b>5</b>, were prepared through a Fischer indole cyclization between hydrazines <b>12</b><a onclick="showRef(event, 'cit15d ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref cit15d ref19 ref20 ref21">(15d,19−21)</a> and 2-butanone in the presence of acetic acid to afford dimethylindoles <b>13</b> in good yield. The acids (<b>13</b>) were then activated with EDCI and HOBt and treated with ammonium hydroxide to afford dimethylindole amides <b>14</b>. The carbonitrile intermediates <b>6</b> (R = H) and <b>9</b> (R = F) utilized in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a> and <a class="ref internalNav" href="#sch2" aria-label="2">2</a> were prepared in high yield when the corresponding amines were stirred with POCl<sub>3</sub> in tetrahydrofuran at room temperature overnight.</div><figure id="sch4" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0019.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Preparation of Intermediates <b>6</b> and <b>9</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00167&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 2-butanone, AcOH, toluene, 50–90%; (b) NH<sub>4</sub>OH, EDC, HOBt, THF, CH<sub>2</sub>Cl<sub>2</sub>, 75–90%; (c) POCl<sub>3</sub>, THF, 89%; (d) POCl<sub>3</sub>, pyridine, CH<sub>2</sub>Cl<sub>2</sub>, 92%.</p></p></figure></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17572" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17572" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, we have outlined a strategy to identify a covalent, irreversible inhibitor of BTK which provides both a rapid in vivo enzymatic inactivation and a low projected human dose. The strategy involved starting with a scaffold with high intrinsic affinity (<i>K</i><sub>i</sub>) for both binding and selectivity, in the absence of covalent inhibition, where the acceptor only enhances but does not drive potency and selectivity. Electrophilic acceptors were explored to bond with Cys481 with low intrinsic reactivity to mitigate off-target interactions. This required optimizing the linker and acceptor geometry to enhance <i>k</i><sub>inact</sub> while maintaining the overall binding affinity (<i>K</i><sub>i</sub>). In addition, this strategy focused on identifying a compound with PK/ADME properties amenable for rapid target engagement but would allow for excess compound to be rapidly cleared. This effort resulted in the identification of branebrutinib, <b>5a</b>, (<i>S</i>)-4-(3-(but-2-ynamido)piperidin-1-yl)-5-fluoro-2,3-dimethyl-1<i>H</i>-indole-7-carboxamide, as a highly selective covalent, irreversible inhibitor of BTK with rapid target inactivation in vivo, supporting a low projected oral human dose of <10 mg po, q.d. With a very low off-target/nonspecific daily covalent binding burden of <0.10 mg/day and a desirable safety and tolerability profile, <b>5a</b> was advanced for clinical evaluation. In phase I randomized, placebo-controlled multiple-ascending dose studies in healthy participants, <b>5a</b> was well tolerated providing >99% BTK occupancy (inactivation) at doses of  ≥3 mg dosed orally, once daily.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> These data are consistent with our preclinical dose projection and highly support the continued clinical investigation of this novel agent.</div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32305" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32305" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Proton magnetic resonance (<sup>1</sup>H) spectra were recorded on either a Bruker Avance 400 (400 MHz), a Bruker Avance III 500 (500 MHz), or a JEOL Eclipse 500 (500 MHz) spectrometer and are reported in ppm relative to the reference solvent of the sample in which they were run. LCMS analyses were conducted using a Shimadzu SCL-10A liquid chromatograph and a SPD UV–vis detector at 220 or 254 nm with the MS detection performed on a Waters Micromass ZQ spectrometer or a Waters Acquity UPLC with a MS detection performed on a Waters SQ spectrometer. Preparative, reverse-phase HPLC purifications were performed using one of the following conditions: (1) Analogues <b>4a</b>–<b>d</b>,<b>g</b>–<b>j</b>,<b>m</b>–<b>q</b> were purified via preparative LCMS with the following conditions. Column: Waters XBridge C18, 19 mm × 250 mm, 5 μm particles. Mobile phase A: 5:95 acetonitrile/water with 10 mM ammonium acetate. Mobile phase B: 95:5 acetonitrile/water with 10 mM ammonium acetate. Gradient: 5–100% or 15–55% B over 25 min, then a 5 min hold at 100% B. Flow: 20 mL/min. Fractions containing the desired product were combined and dried via centrifugal evaporation. (2) Analogue <b>4e</b> was purified via preparative LCMS with the following conditions. Column: Waters XBridge C18, 19 mm × 250 mm, 5 μm particles. Mobile phase A: 5:95 acetonitrile/water with 0.05% TFA. Mobile phase B: 95:5 acetonitrile/water with 0.05% TFA. Gradient: 0–100% B over 25 min, then a 5 min hold at 100% B. Flow: 20 mL/min. Fractions containing the desired product were combined and dried via centrifugal evaporation, or (3) analogue <b>4l</b> was purified via preparative HPLC with the following conditions. Columns: Phenomenex Axia C<sub>18</sub> column with a binary solvent system where solvent A = 5% acetonitrile, 95% water, 0.05% trifluoroacetic acid and solvent B = 95% acetonitrile, 5% water, and 0.05% trifluoroacetic acid and eluting with a gradient of increasing concentration of acetonitrile suitable to the column size and separation to be achieved. Fractions containing the product were neutralized with an aqueous solution of sodium bicarbonate and concentrated under reduced pressure. The residue was dissolved in an organic solvent, washed with water, dried over anhydrous sodium sulfate or magnesium sulfate, and concentrated under reduced pressure. All flash column chromatography was performed on EM Science silica gel 60 (particle size of 40–60 μm) or with an ISCO column. All reagents were purchased from commercial sources and used without further purification unless otherwise noted. All reactions were performed under an inert atmosphere.</div><div class="NLM_p">Research involving animals was performed in accordance with institutional guidelines as defined in the U.S. by the Institutional Animal Care and Use Committee.</div><div class="NLM_p">HPLC analyses were performed using the following conditions. All final compounds had an HPLC purity of ≥95%.</div><div id="sec6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Method A</h3><div class="NLM_p last">A linear gradient using 5% acetonitrile, 95% water, and 0.05% trifluoroacetic acid (solvent A) and 95% acetonitrile, 5% water, and 0.05% trifluoroacetic acid (solvent B), <i>t</i> = 0 min, 10% B, <i>t</i> = 12 min, 100% B (15 min), was employed on a SunFire C18 3.5 μm, 3.0 mm × 150 mm column. Flow rate was 1.0 mL/min, and UV detection was set to 220/254 nm. The LC column was maintained at ambient temperature.</div></div><div id="sec6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Method B</h3><div class="NLM_p last">A linear gradient using 5% acetonitrile, 95% water, and 0.05% trifluoroacetic (solvent A) and 95% acetonitrile, 5% water, and 0.05% trifluoroacetic (solvent B), <i>t</i> = 0 min, 10% B, <i>t</i> = 12 min, 100% B (15 min), was employed on a XBridge Ph 3.5 μm, 3.5 mm × 150 mm column. Flow rate was 1.0 mL/min, and UV detection was set to 220/254 nm. The LC column was maintained at ambient temperature.</div></div><div id="sec6_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Method C</h3><div class="NLM_p last">Column: Waters Acquity UPLC BEH C18, 2.1 mm × 50 mm, 1.7 μm particles. Mobile phase A: 5:95 acetonitrile/water with 10 mM ammonium acetate. Mobile phase B: 95:5 acetonitrile/water with 10 mM ammonium acetate. Temperature: 50 °C. Gradient: 0–100% B over 3 min, then a 0.75 min hold at 100% B. Flow: 1.11 mL/min. Detection: UV at 220 nm.</div></div><div id="sec6_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Method D</h3><div class="NLM_p last">Column: Waters Acquity UPLC BEH C18, 2.1 mm × 50 mm, 1.7 μm particles. Mobile phase A: 5:95 acetonitrile/water with 0.1% trifluoroacetic acid. Mobile phase B: 95:5 acetonitrile/water with 0.1% trifluoroacetic acid. Temperature: 50 °C. Gradient: 0–100% B over 3 min, then a 0.75 min hold at 100% B. Flow: 1.11 mL/min. Detection: UV at 220 nm.</div></div><div id="sec6_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Method E</h3><div class="NLM_p last">A linear gradient using 10% methanol, 90% water, and 0.2% phosphoric acid (solvent A) and 90% methanol, 10% water, and 0.2% phosphoric acid (solvent B), <i>t</i> = 0 min, 0% B, <i>t</i> = 9 min, 100% B (8 min), was employed on a YMC ProC18 S5 ODS 4.6 mm × 50 mm column (oven temperature, 40 °C). Flow rate was 2.5 mL/min, and UV detection was set to 220 nm. The LC column was maintained at ambient temperature.</div></div><div id="sec6_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Method F</h3><div class="NLM_p last">Waters UPLC. Column: Waters Acquity BEH C18 1.7 μm, 2.1 mm × 150 mm at 40 °C. Flow rate: 0.4 mL/min. Mobile phase: A, 0.05% trifuoroacetic acid in water; B, acetonitrile. Gradient: 0 min (10% B), 15 min. (95% B), 17 min (95% B), and 17.1 min (10% B). Detection: UV 220–400 nm.</div></div><div id="sec6_6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> 4-(3-Acrylamido-2-methylphenyl)-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide (<b>3a</b>)</h3><div class="NLM_p">A mixture of 3-bromo-2-methylaniline (6.20 g, 33.3 mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (9.31 g, 36.7 mmol), and potassium acetate (6.54 g, 66.6 mmol) in 1,4-dioxane (83 mL) was purged with nitrogen for 10 min. The PdCl<sub>2</sub>(dppf)–CH<sub>2</sub>Cl<sub>2</sub> adduct catalyst (0.653 g, 0.800 mmol) was added, and the mixture was purged for another 5 min and then heated at reflux (110 °C) for 2.75 h. The reaction mixture was cooled and filtered through Celite, and the pad was washed with ethyl acetate. The filtrate was washed with water, washed with brine, and dried over anhydrous sodium sulfate. Concentration under reduced pressure followed by purification by silica gel chromatography (ISCO 120 g column, 10–20% ethyl acetate in hexane) afforded 2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (7.09 g, 30.4 mmol, 91% yield) as a light yellow solid. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>13</sub>H<sub>20</sub>BNO<sub>2</sub> [M + H]<sup>+</sup> 234.2. Found: 234.1. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.23 (dd, <i>J</i> = 7.3, 1.1 Hz, 1H), 7.04 (t, <i>J</i> = 7.6 Hz, 1H), 6.77 (dd, <i>J</i> = 7.9, 1.1 Hz, 1H), 3.61 (br s, 2H), 2.39 (s, 3H), and 1.35 (s, 12H).</div><div class="NLM_p">To a solution of 2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (0.525 g, 2.25 mmol) and Hunig’s base (0.433 mL, 2.48 mmol) in dichloromethane (11.3 mL) was added acryloyl chloride (0.192 mL, 2.37 mmol). The reaction mixture was stirred at room temperature for 2 h, partitioned between brine and dichloromethane, and the organic phase was collected and dried over sodium sulfate. Concentration under reduced pressure followed by purification by silica gel chromatography (ISCO 40 g column; 5–20% ethyl acetate in hexane) gave <i>N</i>-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acrylamide as a pale yellow solid. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>22</sub>BNO<sub>3</sub> [M + H]<sup>+</sup> 288.2. Found: 288.3. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.01 (br s, 1H), 7.64 (d, <i>J</i> = 5.9 Hz, 1H), 7.23 (t, <i>J</i> = 7.7 Hz, 1H), 7.07 (br s, 1H), 6.48–6.40 (m, 1H), 6.32 (br s, 1H), 5.78 (d, <i>J</i> = 9.5 Hz, 1H), 2.49 (s, 3H), and 1.36 (s, 12H).</div><div class="NLM_p last">A mixture of 4-bromo-7-(2-hydroxypropan-2-yl)-9<i>H</i>-carbazole-1-carboxamide<a onclick="showRef(event, 'cit15d cit19b'); return false;" href="javascript:void(0);" class="ref cit15d cit19b">(15d,19b)</a> (40 mg, 0.115 mmol), <i>N</i>-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acrylamide (36.4 mg, 0.127 mmol), and tetrakis(triphenylphosphine)palladium (6.66 mg, 5.76 μmol) in toluene (2.2 mL) and ethanol (720 mL) was degassed with argon for 2–5 min. To the mixture was added 2 M aqueous sodium carbonate (146 μL, 0.291 mmol), followed by purging with argon. The reaction mixture was heated at 90 °C overnight, concentrated under reduced pressure, and purified by reverse-phase, preparative HPLC to give <b>3a</b> (12 mg, 0.028 mmol, 24%) as a pale yellow solid. HPLC purity: 99% (<i>t</i><sub>R</sub> = 1.29 min, method C; <i>t</i><sub>R</sub> = 1.28 min, method D); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>25</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup> 428.2. Found: 428.2. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.42 (s, 1H), 9.69 (s, 1H), 8.16 (br s, 1H), 7.95 (s, 1H), 7.86 (d, <i>J</i> = 1.0 Hz, 1H), 7.64 (d, <i>J</i> = 7.9 Hz, 1H), 7.47 (br s, 1H), 7.36 (t, <i>J</i> = 7.7 Hz, 1H), 7.12 (d, <i>J</i> = 7.4 Hz, 1H), 6.99 (dd, <i>J</i> = 8.4, 1.5 Hz, 1H), 6.94 (d, <i>J</i> = 7.4 Hz, 1H), 6.73 (d, <i>J</i> = 8.4 Hz, 1H), 6.56 (dd, <i>J</i> = 17.1, 10.2 Hz, 1H), 6.27 (dd, <i>J</i> = 16.8, 2.0 Hz, 1H), 5.78–5.74 (m, 1H), 4.98 (s, 1H), 1.88 (s, 3H), and 1.44 (s, 6H).</div></div><div id="sec6_6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 4-(3-Acrylamido-2-methylphenyl)-2,3-dimethyl-1<i>H</i>-indole-7-carboxamide (<b>3b</b>)<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></h3><div class="NLM_p">Following the procedure used to prepare <b>3a</b>, 2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (see procedure for <b>3a</b>) was converted into <i>N</i>-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acrylamide in 80% yield. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.01 (br s, 1H), 7.64 (d, <i>J</i> = 5.9 Hz, 1H), 7.23 (t, <i>J</i> = 7.7 Hz, 1H), 7.07 (br s, 1H), 6.48–6.40 (m, 1H), 6.32 (br s, 1H), 5.78 (d, <i>J</i> = 9.5 Hz, 1H), 2.49 (s, 3H), and 1.36 (s, 12H).</div><div class="NLM_p last">A mixture of 4-bromo-2,3-dimethyl-1<i>H</i>-indole-7-carboxamide (50 mg, 0.112 mmol), <i>N</i>-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acrylamide (35.5 mg, 0.124 mmol), and tetrakis(triphenylphosphine)palladium (6.49 mg, 5.62 μmol) in a mixture of toluene (2.1 mL) and ethanol (0.70 mL) was degassed under argon for 2–5 min. To the mixture was added 2 M aqueous sodium carbonate (140 μL, 0.281 mmol), followed by purging with argon. The reaction mixture was heated at 90 °C overnight, concentrated under reduced pressure, and purified by reverse-phase, preparative HPLC to provide <b>3b</b> (10.8 mg, 0.031 mmol, 28%). HPLC purity: 97%; <i>t</i><sub>R</sub> = 1.41 min (method C); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>21</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup> 348.2. Found: 348.2. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.74 (s, 1H), 9.60 (s, 1H), 8.00 (br s, 1H), 7.58 (d, <i>J</i> = 7.9 Hz, 1H), 7.48 (d, <i>J</i> = 7.9 Hz, 1H), 7.32 (br s, 1H), 7.23 (t, <i>J</i> = 7.7 Hz, 1H), 7.01 (d, <i>J</i> = 7.4 Hz, 1H), 6.69 (d, <i>J</i> = 7.4 Hz, 1H), 6.53 (dd, <i>J</i> = 17.1, 10.2 Hz, 1H), 6.24 (dd, <i>J</i> = 17.3, 2.0 Hz, 1H), 5.74 (dd, <i>J</i> = 10.4, 2.0 Hz, 1H), 2.29 (s, 3H), 1.83 (s, 3H), and 1.50 (s, 3H).</div></div><div id="sec6_6_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 4-(3-Acrylamidophenyl)-2,3-dimethyl-1<i>H</i>-indole-7-carboxamide (<b>3c</b>)<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></h3><div class="NLM_p">A mixture of 3-bromoaniline (1.00 g, 5.81 mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (1.55 g, 6.10 mmol), and potassium acetate (1.14 g, 11.6 mmol) in 1,4-dioxane (14.5 mL) was purged with nitrogen for 10 min. The mixture was treated with PdCl<sub>2</sub>(dppf) dichloromethane adduct (0.114 g, 0.140 mmol) and bubbled with nitrogen for an additional 5 min. The mixture was heated at reflux for 2.75 h and then cooled to room temperature and filtered through Celite. The pad was washed with ethyl acetate and tetrahydrofuran, and the filtrate was concentrated under reduced pressure and purified by silica gel chromatography (ISCO 40 g, 10–25% ethyl acetate in hexanes) to provide 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline as an off-white solid (1.27 g, >99%). LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>12</sub>H<sub>18</sub>BNO<sub>2</sub> [M + H]<sup>+</sup> 220.2. Found: 220. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.24–7.13 (m, 3H), 6.82–6.77 (m, 1H), 3.64 (br s, 2H), and 1.35 (s, 12H).</div><div class="NLM_p">A solution of 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (0.300 g, 1.37 mmol) and Hunig’s base (0.311 mL, 1.78 mmol) in dichloromethane (9.1 mL) was cooled in an ice-bath and treated with acryloyl chloride (0.117 mL, 1.44 mmol). The mixture was stirred at room temperature for 40 min, concentrated under reduced pressure, and purified by silica gel chromatography (ISCO 24 g, 15–40% ethyl acetate in hexanes) to provide <i>N</i>-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl) acrylamide as a white solid (0.292 g, 78% yield). LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>15</sub>H<sub>20</sub>BNO<sub>3</sub> [M + H]<sup>+</sup> 274.2. Found: 274.0.</div><div class="NLM_p last">A mixture of 4-bromo-2,3-dimethyl-1<i>H</i>-indole-7-carboxamide (30 mg, 0.112 mmol), <i>N</i>-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acrylamide (32.2 mg, 0.118 mmol), and tetrakis(triphenylphosphine)palladium (6.49 mg, 5.62 μmol) in toluene (2.1 mL) and ethanol (0.7 mL) was degassed for 2–5 min. The mixture was treated with a 2 M aqueous sodium carbonate (142 μL, 0.284 mmol), degassed again, and the reaction mixture was heated at 90 °C overnight, concentrated under reduced pressure, and purified by reverse-phase, preparative HPLC to give <b>3c</b> (10.2 mg, 0.030 mmol, 27% yield). HPLC purity: 98% (<i>t</i><sub>R</sub> = 1.41 min, method C; <i>t</i><sub>R</sub> = 1.40 min, method D); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>19</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup> 334.2. Found: 334.1. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.82 (br s, 1H), 10.23 (br s, 1H), 8.02 (br s, 1H), 7.73 (br s, 1H), 7.68 (d, <i>J</i> = 7.9 Hz, 1H), 7.59 (dd, <i>J</i> = 7.4, 4.0 Hz, 1H), 7.42–7.31 (m, 2H), 7.11–7.05 (m, 1H), 6.80 (dd, <i>J</i> = 7.7, 4.2 Hz, 1H), 6.49–6.39 (m, 1H), 6.25 (d, <i>J</i> = 17.3 Hz, 1H), 5.76 (d, <i>J</i> = 9.9 Hz, 1H), 2.33 (d, <i>J</i> = 4.0 Hz, 3H), and 1.71 (d, <i>J</i> = 3.5 Hz, 3H).</div></div><div id="sec6_6_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> (<i>RS</i>)-4-(3-Acrylamidopiperidin-1-yl)-2,3-dimethyl-1<i>H</i>-indole-7-carboxamide (<b>4a</b>)<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></h3><div class="NLM_p">Following the procedures used for the preparation of <b>4d</b> but substituting (<i>RS</i>)-benzyl piperidin-3-ylcarbamate for (<i>S</i>)-benzyl piperidin-3-ylcarbamate, 4-bromo-2,3-dimethyl-1<i>H</i>-indole-7-carbonitrile (<b>6</b>) was converted into (<i>RS</i>)-4-(3-aminopiperidin-1-yl)-2,3-dimethyl-1<i>H</i>-indole-7-carboxamide. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>22</sub>N<sub>4</sub>O [M + H]<sup>+</sup> 287.2. Found: 287<sup><b>+</b></sup>.</div><div class="NLM_p last">To a solution of 4-(3-aminopiperidin-1-yl)-2,3-dimethyl-1<i>H</i>-indole-7-carboxamide (35 mg, 0.092 mmol) and Hunig’s base (21 μL, 0.119 mmol) in a 1:1 mixture of dichloromethane and tetrahydrofuran (1.8 mL), cooled in an ice-bath, was added acryloyl chloride (8.19 μL, 0.101 mmol). The resulting reaction mixture was stirred at room temperature for 1 h. Concentrated under reduce pressure followed by purification by reverse-phase, preparative HPLC gave <b>4a</b> (10 mg, 0.029 mmol, 32% yield). HPLC purity: 99% (<i>t</i><sub>R</sub> = 1.29 min, method C; <i>t</i><sub>R</sub> = 1.21 min, method D); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>24</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 341.2. Found: 341.1. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.60 (br s, 1H), 8.13–8.01 (m, 1H), 7.82 (br s, 1H), 7.46 (dd, <i>J</i> = 7.9, 4.0 Hz, 1H), 7.12 (br s, 1H), 6.53 (dd, <i>J</i> = 8.2, 3.7 Hz, 1H), 6.28–6.16 (m, 1H), 6.13–6.02 (m, 1H), 5.58 (dd, <i>J</i> = 10.2, 2.2 Hz, 1H), 4.02 (br s, 1H), 3.39 (br s, 1H), 3.17 (br s, 1H), 2.63 (br s, 1H), 2.43–2.26 (m, 7H), 1.99–1.67 (m, 3H), and 1.36 (d, <i>J</i> = 11.4 Hz, 1H).</div></div><div id="sec6_6_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> (<i>RS</i>)-2,3-Dimethyl-4-(3-(vinylsulfonamido)piperidin-1-yl)-1<i>H</i>-indole-7-carboxamide (<b>4b</b>)<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></h3><div class="NLM_p last">To a solution of 4-(3-aminopiperidin-1-yl)-2,3-dimethyl-1<i>H</i>-indole-7-carboxamide (30 mg, 0.105 mmol) (see procedure for <b>4a</b>) and Hunig’s base (46 μL, 0.262 mmol) in dichloromethane (1.3 mL), cooled at 0 °C, was added 2-chloroethanesulfonyl chloride (22 μL, 0.210 mmol) dropwise. The resulting reaction mixture was stirred at room temperature for 3 h. Concentration under reduce pressure followed by purification by reverse-phase, preparative HPLC provided <b>4b</b> (7.2 mg, 0.105 mmol, 18% yield). HPLC purity: 97% (<i>t</i><sub>R</sub> = 1.43 min, method C; <i>t</i><sub>R</sub> = 1.43 min, method D); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>24</sub>N<sub>4</sub>O<sub>3</sub>S [M + H]<sup>+</sup> 377.2. Found: 377.1. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.40 (d, <i>J</i> = 7.9 Hz, 1H), 6.63–6.54 (m, 2H), 6.20 (d, <i>J</i> = 16.8 Hz, 1H), 5.90 (d, <i>J</i> = 9.9 Hz, 1H), 3.52 (br s, 2H), 3.21 (br s, 1H), 2.75–2.50 (m, 2H), 2.41 (s, 3H), 2.34 (s, 3H), 2.09–2.00 (m, 1H), 1.90–1.77 (m, 2H), and 1.43 (br s, 1H).</div></div><div id="sec6_6_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> (<i>R</i>)-2,3-Dimethyl-4-(3-(vinylsulfonamido)piperidin-1-yl)-1<i>H</i>-indole-7-carboxamide (<b>4c</b>)<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></h3><div class="NLM_p">Following the procedures used to prepare <b>4d</b> but substituting (<i>R</i>)-benzyl piperidin-3-ylcarbamate for (<i>S</i>)-benzyl piperidin-3-ylcarbamate, 4-bromo-2,3-dimethyl-1<i>H</i>-indole-7-carbonitrile (<b>6</b>) was converted into (<i>R</i>)-4-(3-aminopiperidin-1-yl)-2,3-dimethyl-1<i>H</i>-indole-7-carboxamide. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>24</sub>N<sub>4</sub>O<sub>3</sub>S [M + H]<sup>+</sup> 287.2. Found: 287<sup>+</sup>.</div><div class="NLM_p last">To a solution of (<i>R</i>)-4-(3-aminopiperidin-1-yl)-2,3-dimethyl-1<i>H</i>-indole-7-carboxamide (50 mg, 0.105 mmol) and Hunig’s base (37 μL, 0.210 mmol) in a 1:1 mixture of dichloromethane and tetrahydrofuran (1.9 mL), cooled in an ice–acetone–dry ice bath, was added a solution of 2-chloroethanesulfonyl chloride (20 μL, 0.189 mmol) in dichloromethane (273 μL). The resulting reaction mixture was stirred at 0 °C for 1 h. Concentration under reduced pressure followed by purification by reverse-phase, preparative HPLC afforded <b>4c</b> (5.8 mg, 0.015 mmol, 15% yield). HPLC purity: 99% (<i>t</i><sub>R</sub> = 1.32 min, method C; <i>t</i><sub>R</sub> = 1.29 min, method D); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>24</sub>N<sub>4</sub>O<sub>3</sub>S [M + H]<sup>+</sup> 377.2. Found: 377.2. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.61 (s, 1H), 7.82 (br s, 1H), 7.47 (d, <i>J</i> = 7.9 Hz, 2H), 7.13 (br s, 1H), 6.76 (dd, <i>J</i> = 16.5, 9.8 Hz, 1H), 6.52 (d, <i>J</i> = 7.9 Hz, 1H), 6.05 (d, <i>J</i> = 16.5 Hz, 1H), 5.94 (d, <i>J</i> = 9.8 Hz, 1H), 3.39 (br s, 2H), 3.13 (br s, 1H), 2.56 (br s, 1H), 2.42 (d, <i>J</i> = 11.0 Hz, 1H), 2.32 (d, <i>J</i> = 10.4 Hz, 6H), 1.97 (d, <i>J</i> = 11.0 Hz, 1H), 1.78 (br s, 1H), 1.68 (d, <i>J</i> = 13.4 Hz, 1H), and 1.32 (d, <i>J</i> = 13.4 Hz, 1H).</div></div><div id="sec6_6_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> (<i>S</i>)-2,3-Dimethyl-4-(3-(vinylsulfonamido)piperidin-1-yl)-1<i>H</i>-indole-7-carboxamide (<b>4d</b>)<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></h3><div class="NLM_p">A mixture of 4-bromo-2,3-dimethyl-1<i>H</i>-indole-7-carbonitrile (<b>6</b>) (2.50 g, 10.0 mmol), (<i>S</i>)-benzyl piperidin-3-ylcarbamate (2.47 g, 10.5 mmol), 2,2′-bis(diphenylphosphino)-1,1′-binaphthalene (0.312 g, 0.502 mmol), tris(dibenzylideneacetone)dipalladium (0.460 g, 0.502 mmol), and cesium carbonate (4.58 g, 14.1 mmol) in 1,4-dioxane (143 mL) was purged with nitrogen and then heated at 100 °C for 16 h. The reaction mixture was cooled to room temperature, diluted with tetrahydrofuran, filtered through Celite, and the solids were washed with tetrahydrofuran. The filtrate was concentrated under reduced pressure and purified by silica gel chromatography (ISCO 80 g column, 15–30% ethyl acetate in hexanes) to provide (<i>S</i>)-benzyl (1-(7-cyano-2,3-dimethyl-1<i>H</i>-indol-4-yl)piperidin-3-yl)carbamate as a light yellow solid (2.13 g, 53% yield). LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>26</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 403.2. Found: 403<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.43 (s, 1H), 7.40–7.26 (m, 7H), 6.62 (d, <i>J</i> = 8.1 Hz, 1H), 5.08–4.94 (m, 2H), 3.79–3.65 (m, 1H), 3.41 (d, <i>J</i> = 10.1 Hz, 1H), 3.20 (d, <i>J</i> = 11.0 Hz, 1H), 2.60 (t, <i>J</i> = 10.7 Hz, 1H), 2.43–2.16 (m, 7H), 1.92 (d, <i>J</i> = 9.5 Hz, 1H), 1.86–1.78 (m, 1H), 1.71 (d, <i>J</i> = 11.2 Hz, 1H), and 1.40–1.26 (m, 1H).</div><div class="NLM_p">A suspension of (<i>S</i>)-benzyl (1-(7-cyano-2,3-dimethyl-1<i>H</i>-indol-4-yl)piperidin-3-yl)carbamate (1.69 g, 3.44 mmol) in 80% aqueous sulfuric acid (11 mL, 172 mmol) was heated at 60 °C for 2.5 h. The mixture was cooled to room temperature and then poured over ice. The pH of the mixture was adjusted to about 9–10 with concentrated aqueous potassium hydroxide, and the resulting mixture was extracted with a 3:1 mixture of chloroform and isopropanol. The organic phase was dried over anhydrous sodium sulfate and concentrated to provide (<i>S</i>)-4-(3-aminopiperidin-1-yl)-2,3-dimethyl-1<i>H</i>-indole-7-carboxamide as a brown solid (1.66 g, 99% yield), which was used without further purification. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>22</sub>N<sub>4</sub>O [M + H]<sup>+</sup> 287.2. Found: 287<sup>+</sup>.</div><div class="NLM_p">To a solution of (<i>S</i>)-4-(3-aminopiperidin-1-yl)-2,3-dimethyl-1<i>H</i>-indole-7-carboxamide (40 mg, 0.095 mmol) and Hunig’s base (58 μL, 0.332 mmol) in dichloromethane (1.9 mL), cooled at 0 °C, was slowly added 2-chloroethanesulfonyl chloride (30 μL, 0.285 mmol) dropwise. The resulting reaction mixture was stirred at room temperature for 3 h, concentrated under reduced pressure, and purified by reverse-phase, preparative HPLC to give <b>4d</b> (13 mg, 0.033 mmol, 35%). HPLC purity: 99% (<i>t</i><sub>R</sub> = 1.36 min, method C; <i>t</i><sub>R</sub> = 1.31 min, method D); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>24</sub>N4O<sub>3</sub>S [M + H]<sup>+</sup> 377.2. Found: 376.9. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.62 (s, 1H), 7.83 (br s, 1H), 7.52–7.40 (m, 2H), 7.14 (br s, 1H), 6.76 (dd, <i>J</i> = 16.3, 9.9 Hz, 1H), 6.58–6.46 (m, 1H), 6.06 (d, <i>J</i> = 16.8 Hz, 1H), 5.94 (d, <i>J</i> = 9.9 Hz, 1H), 3.42–3.36 (m, 2H), 3.14 (d, <i>J</i> = 9.9 Hz, 1H), 2.61–2.53 (m, 1H), 2.42 (d, <i>J</i> = 10.9 Hz, 1H), 2.32 (d, <i>J</i> = 10.9 Hz, 6H), 1.97 (d, <i>J</i> = 10.9 Hz, 1H), 1.83–1.76 (m, 1H), 1.74–1.60 (m, 1H), and 1.40–1.26 (m, 1H).</div><div id="sec6_6_7_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> Alternative Procedure</h4><div class="NLM_p last">To a solution of (<i>S</i>)-4-(3-aminopiperidin-1-yl)-2,3-dimethyl-1<i>H</i>-indole-7-carboxamide (2.2 g, 4.23 mmol) and Hunig’s base (1.26 mL, 7.18 mmol) in a 2:1 mixture of dichloromethane and tetrahydrofuran (63 mL), cooled in ice–acetone–dry ice at −20 °C, was slowly added a solution of 2-chloroethaneulfonyl chloride (0.71 mL, 6.76 mmol) in dichloromethane (9.0 mL). The resulting brown suspension was stirred at 0 °C for 1 h. The reaction was filtered under reduce pressure, and the brown solid was washed with tetrahydrofuran and ethyl acetate. The filtrates were concentrated under reduced pressure and purified by silica gel chromatography (ISCO 80 g column, 50–70%/15 min, 70%/13 min, 70–80%/12 min, 80%/8 min, 80–90/5 min, 90%/15 min, ethyl acetate in hexane) to afford <b>4d</b> (0.519, 1.34 mmol, 32% yield) as a pale yellow solid. HPLC purity: 97.1%; <i>t</i><sub>R</sub> = 7.73 min (method A); 96.1%; <i>t</i><sub>R</sub> = 7.36 min (method B); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>24</sub>N4O<sub>3</sub>S [M + H]<sup>+</sup> 377.2. Found: 377.2. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.60 (s, 1H), 7.80 (br s, 1H), 7.51–7.39 (m, 2H), 7.11 (br s, 1H), 6.76 (dd, <i>J</i> = 16.5, 9.9 Hz, 1H), 6.53 (d, <i>J</i> = 8.1 Hz, 1H), 6.06 (d, <i>J</i> = 16.5 Hz, 1H), 5.94 (d, <i>J</i> = 9.9 Hz, 1H), 3.39 (d, <i>J</i> = 9.9 Hz, 2H), 3.14 (d, <i>J</i> = 11.0 Hz, 1H), 2.62–2.55 (m, 1H), 2.46–2.38 (m, 1H), 2.32 (d, <i>J</i> = 8.6 Hz, 6H), 1.97 (d, <i>J</i> = 12.1 Hz, 1H), 1.85–1.76 (m, 1H), 1.75–1.63 (m, 1H), and 1.39–1.27 (m, 1H).</div></div></div><div id="sec6_6_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> (<i>R</i>)-2,3-Dimethyl-4-(3-propiolamidopiperidin-1-yl)-1<i>H</i>-indole-7-carboxamide (<b>4e</b>)<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></h3><div class="NLM_p last">A solution of (<i>R</i>)-4-(3-aminopiperidin-1-yl)-2,3-dimethyl-1<i>H</i>-indole-7-carboxamide (50 mg, 0.105 mmol) (see procedure for <b>4c</b>), HATU (80 mg, 0.210 mmol), Hunig’s base (55 μL, 0.314 mmol), and propiolic acid (8.07 mg, 0.115 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (1.7 mL) was stirred at room temperature for 2.5 h. The reaction mixture was filtered, and the filtrate was concentrated and purified by reverse-phase, preparative HPLC to provide <b>4e</b> (21 mg, 0.062 mmol, 59% yield). HPLC purity: 96% (<i>t</i><sub>R</sub> = 1.34 min, method C; <i>t</i><sub>R</sub> = 1.30 min, method D); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>22</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 339.2. Found: 339.2. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.62 (s, 1H), 8.83–8.72 (m, 1H), 7.48 (d, <i>J</i> = 8.1 Hz, 1H), 6.54 (d, <i>J</i> = 8.4 Hz, 1H), 3.99 (br s, 1H), 2.65–2.55 (m, 1H), 2.36 (s, 3H), 2.30 (s, 3H), 1.93–1.65 (m, 3H), and 1.37 (br s, 1H). Some alkyl and exchangable carboxamide protons were not observed due to water suppression.</div></div><div id="sec6_6_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> (<i>S</i>)-2,3-Dimethyl-4-(3-propiolamidopiperidin-1-yl)-1<i>H</i>-indole-7-carboxamide (<b>4f</b>)<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></h3><div class="NLM_p last">A mixture of (<i>S</i>)-4-(3-aminopiperidin-1-yl)-2,3-dimethyl-1<i>H</i>-indole-7-carboxamide (0.077 g, 0.269 mmol) (see procedure for <b>4d</b>), propiolic acid (0.020 mL, 0.323 mmol), HATU (0.143 g, 0.376 mmol), and Hunig’s base (0.164 mL, 0.941 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (2.0 mL) was stirred at room temperature for 40 min. The mixture was diluted with ethyl acetate, washed with 10% aqueous lithium chloride (2×), and washed with brine. The organic layer was collected, and the aqueous layers were sequentially extracted with ethyl acetate (2×). The combined organic layers were dried over anhydrous sodium sulfate and concentrated. Purification by silica gel chromatography (ISCO 12 g column, 0–5% methanol in dichloromethane) afforded (<i>S</i>)-2,3-dimethyl-4-(3-propiolamidopiperidin-1-yl)-1<i>H</i>-indole-7-carboxamide (0.061 g, 0.177 mmol, 66% yield) as a pale yellow solid. HPLC purity: 98.1%; <i>t</i><sub>R</sub> = 7.82 min (method A); 98.4%; <i>t</i><sub>R</sub> = 7.43 min (method B); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>22</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 339.2. Found: 339.2. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.61 (s, 1H), 8.74 (d, <i>J</i> = 7.8 Hz, 1H), 7.91–7.73 (m, 1H), 7.48 (d, <i>J</i> = 8.1 Hz, 1H), 7.19–7.04 (m, 1H), 6.54 (d, <i>J</i> = 8.1 Hz, 1H), 4.05–3.93 (m, 1H), 3.36–3.33 (m, 1H), 3.30–3.28 (m, 1H), 3.25–3.14 (m, 1H), 2.67–2.55 (m, 1H), 2.44–2.39 (m, 1H), 2.38–2.36 (m, 3H), 2.34–2.30 (m, 3H), 1.95–1.67 (m, 3H), and 1.45–1.31 (m, 1H).</div></div><div id="sec6_6_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> (<i>S</i>)-4-(3-(But-2-ynamido)piperidin-1-yl)-2,3-dimethyl-1<i>H</i>-indole-7-carboxamide (<b>4g</b>)<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></h3><div class="NLM_p last">To a mixture of (<i>S</i>)-4-(3-aminopiperidin-1-yl)-2,3-dimethyl-1<i>H</i>-indole-7-carboxamide (60 mg, 0.210 mmol) (see procedure for <b>4d</b>), HATU (159 mg, 0.419 mmol), and Hunig’s base (110 μL, 0.629 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (3.1 mL) at room temperature was added but-2-ynoic acid (18.5 mg, 0.220 mmol). The reaction mixture was stirred at room temperature for 2 h. Concentration under reduce pressure followed by purification by silica gel flash chromatography (ISCO 12 g column, 30–65% ethyl acetate in hexane) afforded <b>4g</b> (37 mg, 0.102 mmol, 49% yield) as a pale yellow solid. HPLC purity: 97.0%; <i>t</i><sub>R</sub> = 8.74 min (method A); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>24</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 353.2. Found: 353.2. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.58 (s, 1H), 8.46 (d, <i>J</i> = 7.9 Hz, 1H), 7.79 (br s, 1H), 7.46 (d, <i>J</i> = 7.9 Hz, 1H), 7.09 (br s, 1H), 6.51 (d, <i>J</i> = 8.1 Hz, 1H), 3.97 (br s, 1H), 3.60 (t, <i>J</i> = 6.4 Hz, 2H), 3.17 (d, <i>J</i> = 11.9 Hz, 1H), 2.57 (d, <i>J</i> = 10.6 Hz, 1H), 2.37–2.29 (m, 6H), 1.94 (s, 3H), 1.91–1.77 (m, 3H), and 1.34–1.28 (m, 1H).</div></div><div id="sec6_6_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> (<i>RS</i>)-4-(3-Acrylamidopyrrolidin-1-yl)-2,3-dimethyl-1<i>H</i>-indole-7-carboxamide (<b>4h</b>)<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></h3><div class="NLM_p">Following the procedures used to prepare <b>4d</b> but substituting (<i>RS</i>)-benzyl pyrrolidin-3-ylcarbamate for (<i>S</i>)-benzyl piperidin-3-ylcarbamate, 4-bromo-2,3-dimethyl-1<i>H</i>-indole-7-carbonitrile (<b>6</b>) was converted into (<i>RS</i>)-4-(3-aminopyrrolidin-1-yl)-2,3-dimethyl-1<i>H</i>-indole-7-carboxamide. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>15</sub>H<sub>20</sub>N<sub>4</sub>O [M + H]<sup>+</sup> 273.2. Found: 273<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.60 (s, 1H), 7.73 (dd, <i>J</i> = 8.7, 5.6 Hz, 1H), 7.44 (d, <i>J</i> = 8.1 Hz, 1H), 6.96 (br s, 3H), 6.44 (d, <i>J</i> = 8.1 Hz, 1H), 3.56–3.46 (m, 1H), 3.26–3.08 (m, 3H), 2.82 (dd, <i>J</i> = 9.5, 5.3 Hz, 1H), 2.33 (s, 3H), 2.30 (s, 3H), 2.19–2.11 (m, 1H), 1.61–1.50 (m, 1H).</div><div class="NLM_p last">To a solution of 4-(3-aminopyrrolidin-1-yl)-2,3-dimethyl-1<i>H</i>-indole-7-carboxamide (35 mg, 0.129 mmol) and Hunig’s base (29 μL, 0.167 mmol) in a 1:1 mixture of dichloromethane and tetrahydrofuran (2.6 mL), cooled in an ice-bath, was added acryloyl chloride (12 μL, 0.141 mmol). The reaction mixture was stirred at room temperature for 3 h, concentrated under reduced pressure, and purified by reverse-phase, preparative HPLC to give <b>4h</b> (12 mg, 0.037 mmol, 29% yield). HPLC purity: 99% (<i>t</i><sub>R</sub> = 1.15 min, method C); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>22</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 327.2. Found: 327.1. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.63 (s, 1H), 8.39 (d, J = 6.4 Hz, 1H), 7.78 (br s, 1H), 7.45 (d, J = 7.9 Hz, 1H), 7.07 (br s, 1H), 6.48 (d, J = 8.4 Hz, 1H), 6.33–6.20 (m, 1H), 6.14–6.04 (m, 1H), 5.59 (dd, J = 9.9, 2.0 Hz, 1H), 4.45–4.30 (m, 1H), 3.30–3.23 (m, 2H), 3.14–2.98 (m, 2H), 2.38–2.22 (m, 7H), and 1.85–1.77 (m, 1H).</div></div><div id="sec6_6_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> (<i>RS</i>)-2,3-Dimethyl-4-(3-(vinylsulfonamido)pyrrolidin-1-yl)-1<i>H</i>-indole-7-carboxamide (<b>4i</b>)<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></h3><div class="NLM_p last">To a solution of 4-(3-aminopyrrolidin-1-yl)-2,3-dimethyl-1<i>H</i>-indole-7-carboxamide (30 mg, 0.088 mmol) (see procedure for <b>4h</b>) and Hunig’s base (39 μL, 0.220 mmol) in dichloromethane (1.1 mL), cooled at 0 °C, was added 2-chloroethanesulfonyl chloride (18 μL, 0.176 mmol) dropwise. The reaction mixture was stirred at room temperature for 3 h, concentrated under reduce pressure, and purified by reverse-phase, preparative HPLC to give <b>4i</b> (9.8 mg, 0.029 mmol, 36% yield). HPLC purity: 99% (<i>t</i><sub>R</sub> = 1.30 min, method C; <i>t</i><sub>R</sub> = 1.22 min, method D); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>22</sub>N<sub>4</sub>O<sub>3</sub>S [M + H]<sup>+</sup> 363.2. Found: 363.1. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.64 (s, 1H), 7.77 (d, <i>J</i> = 14.9 Hz, 1H), 7.69 (br s, 1H), 7.45 (d, <i>J</i> = 7.9 Hz, 1H), 7.08 (br s, 1H), 6.78 (dd, <i>J</i> = 16.3, 9.9 Hz, 1H), 6.46 (d, <i>J</i> = 7.9 Hz, 1H), 6.08 (d, <i>J</i> = 16.3 Hz, 1H), 5.99 (d, <i>J</i> = 9.9 Hz, 1H), 3.83 (br s, 1H), 3.42–3.38 (m, 1H), 3.21–3.09 (m, 2H), 3.00 (dd, <i>J</i> = 9.7, 6.2 Hz, 1H), 2.35–2.21 (m, 7H), and 1.88–1.78 (m, 1H).</div></div><div id="sec6_6_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> (<i>R</i>)-2,3-Dimethyl-4-(3-propiolamidopyrrolidin-1-yl)-1<i>H</i>-indole-7-carboxamide (<b>4j</b>)<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></h3><div class="NLM_p">Following the procedures used to prepare <b>4d</b> but substituting (<i>R</i>)-benzyl pyrrolidin-3-ylcarbamate for (<i>S</i>)-benzyl piperidin-3-ylcarbamate, 4-bromo-2,3-dimethyl-1<i>H</i>-indole-7-carbonitrile (<b>6</b>) was converted into (<i>R</i>)-4-(3-aminopyrrolidin-1-yl)-2,3-dimethyl-1<i>H</i>-indole-7-carboxamide. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>15</sub>H<sub>20</sub>N<sub>4</sub>O [M + H]<sup>+</sup> 373.2. Found: 273<sup>+</sup>.</div><div class="NLM_p last">A solution of (<i>R</i>)-4-(3-aminopyrrolidin-1-yl)-2,3-dimethyl-1<i>H</i>-indole-7-carboxamide (30 mg, 0.094 mmol), HATU (71 mg, 0.187 mmol), Hunig’s base (49 μL, 0.281 mmol), and propiolic acid (7.2 mg, 0.103 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (1.3 mL) was stirred at room temperature for 4 h, concentrated under reduced pressure, and purified by reverse-phase, preparative HPLC to provide <b>4j</b> (4.0 mg, 0.024 mmol, 13% yield). HPLC purity: 96% (<i>t</i><sub>R</sub> = 1.20 min, method C; <i>t</i><sub>R</sub> = 1.08 min, method D); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>20</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 325.2. Found: 325.2. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.63 (s, 1H), 9.08 (d, <i>J</i> = 6.1 Hz, 1H), 7.79 (br s, 1H), 7.45 (d, <i>J</i> = 7.9 Hz, 1H), 7.07 (br s, 1H), 6.47 (d, <i>J</i> = 7.9 Hz, 1H), 4.32 (br s, 1H), 4.14 (s, 1H), 3.26–3.13 (m, 2H), 3.12–2.98 (m, 2H), 2.31 (d, <i>J</i> = 13.4 Hz, 6H), 2.24 (dd, <i>J</i> = 13.7, 5.8 Hz, 1H), and 1.85 (dd, <i>J</i> = 12.8, 6.1 Hz, 1H).</div></div><div id="sec6_6_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> (<i>S</i>)-4-((1-Acryloylpyrrolidin-3-yl)amino)-2,3-dimethyl-1<i>H</i>-indole-7-carboxamide (<b>4k</b>)<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></h3><div class="NLM_p">A mixture of 4-bromo-2,3-dimethyl-1<i>H</i>-indole-7-carbonitrile (<b>6</b>) (0.400 g, 1.61 mmol) and (<i>S</i>)-<i>tert</i>-butyl 3-aminopyrrolidine-1-carboxylate (0.336 g, 1.80 mmol) in 1,4-dioxane (15 mL) was purged with nitrogen for 5 min. To the mixture was added 2,2′-bis(diphenylphosphino)-1,1′-binaphthalene (0.050 g, 0.080 mmol), tris(dibenzylideneacetone)dipalladium (0.074 g, 0.080 mmol), and cesium carbonate (0.732 g, 2.25 mmol), and the reaction mixture was sealed under nitrogen and heated at 100 °C for 19 h. After cooling to room temperature, the mixture was diluted with ethyl acetate (50 mL), washed with water (50 mL), and washed with brine. The organic layer was collected, and the aqueous layers were sequentially washed with ethyl acetate (3 × 50 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel chromatography, eluting with ethyl acetate and hexanes, to provide (<i>S</i>)-<i>tert</i>-butyl 3-((7-cyano-2,3-dimethyl-1<i>H</i>-indol-4-yl)amino)pyrrolidine-1-carboxylate as a pale yellow solid (0.47 g, 79% yield). LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>26</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 355.2. Found: 355<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.16 (s, 1H), 7.24 (d, <i>J</i> = 8.1 Hz, 1H), 6.23 (d, <i>J</i> = 8.4 Hz, 1H), 5.36 (br s, 1H), 4.25–4.08 (m, 1H), 3.69–3.57 (m, 1H), 3.48–3.37 (m, 1H), 3.38–3.31 (m, 1H), 3.27–3.16 (m, 1H), 2.34 (s, 3H), 2.24 (s, 3H), 2.22–2.13 (m, 1H), 1.97–1.86 (m, 1H), and 1.49–1.31 (m, 9H).</div><div class="NLM_p">A mixture of (<i>S</i>)-<i>tert</i>-butyl 3-((7-cyano-2,3-dimethyl-1<i>H</i>-indol-4-yl)amino)pyrrolidine-1-carboxylate (0.470 g, 1.33 mmol) and dichloromethane (5 mL) was cooled to 0 °C, treated with trifluoroacetic acid (5 mL), and stirred for 1 h. The mixture was concentrated under reduced pressure to provide (<i>S</i>)-2,3-dimethyl-4-(pyrrolidin-3-ylamino)-1<i>H</i>-indole-7-carbonitrile as a trifluoroacetic acid salt. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>15</sub>H<sub>18</sub>N<sub>4</sub> [M + H]<sup>+</sup> 255.2. Found: 255<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.23 (s, 1H), 8.93–8.72 (m, 1H), 7.27 (d, <i>J</i> = 8.1 Hz, 1H), 6.21 (d, <i>J</i> = 8.6 Hz, 1H), 5.48 (br s, 1H), 4.27 (br s, 1H), 3.54–3.44 (m, 1H), 3.42–3.33 (m, 1H), 3.31–3.17 (m, 2H), 2.38 (s, 3H), 2.36–2.28 (m, 1H), 2.26 (s, 3H), and 2.09–2.00 (m, 1H).</div><div class="NLM_p">A mixture of (<i>S</i>)-2,3-dimethyl-4-(pyrrolidin-3-ylamino)-1<i>H</i>-indole-7-carbonitrile, TFA salt (488 mg, 1.33 mmol) and 80% aqueous sulfuric acid (3 mL) was heated at 60 °C for 2 h. The mixture was cooled to room temperature and was then slowly added to a 10 M aqueous solution of sodium hydroxide at 0 °C. The aqueous layer was removed from the resulting sticky brown solid by decantation. Water was added to the solid, and the mixture was extracted with ethyl acetate (4 × 50 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and concentrated to provide (<i>S</i>)-2,3-dimethyl-4-(pyrrolidin-3-ylamino)-1<i>H</i>-indole-7-carboxamide (270 mg, 75% yield) as an orange solid. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>15</sub>H<sub>20</sub>N<sub>4</sub>O [M + H]<sup>+</sup> 273.2. Found: 273<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.40 (s, 1H), 7.59 (br s, 1H), 7.42 (d, <i>J</i> = 8.4 Hz, 1H), 6.85 (br s, 1H), 6.05 (d, <i>J</i> = 8.4 Hz, 1H), 5.07 (d, <i>J</i> = 6.8 Hz, 1H), 3.99–3.89 (m, 1H), 3.30 (br s, 1H), 3.04 (dd, J = 11.1, 6.1 Hz, 1H), 2.98–2.88 (m, 1H), 2.82–2.67 (m, 2H), 2.36 (s, 3H), 2.26 (s, 3H), 2.10 (td, J = 13.4, 7.5 Hz, 1H), and 1.68–1.53 (m, 1H).</div><div class="NLM_p last">To a mixture of (<i>S</i>)-2,3-dimethyl-4-(pyrrolidin-3-ylamino)-1<i>H</i>-indole-7-carboxamide (80 mg, 0.294 mmol) and Hunig’s base (0.154 mL, 0.881 mmol) in a mixture of tetrahydrofuran (7 mL) and dichloromethane (1 mL), cooled to 0 °C, was added a solution of acryloyl chloride (0.14 mL, 1.76 mmol) in 1.3 mL of tetrahydrofuran dropwise over 3 min. The reaction mixture was stirred at 0 °C for 1.5 h and then concentrated and purified by silica gel chromatography (ISCO, 0–10% methanol in dichloromethane) to provide <b>4k</b> (78 mg, 0.234 mmol, 80% yield) as a pale yellow solid. HPLC purity: 98.2%; <i>t</i><sub>R</sub> = 6.10 min (method A); 98.6%; <i>t</i><sub>R</sub> = 9.07 min (method B); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>22</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 327.2. Found: 327.1. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.43 (s, 1H), 7.59 (br s, 1H), 7.45 (d, J = 7.0 Hz, 1H), 6.88 (br s, 1H), 6.68–6.45 (m, 1H), 6.24–6.05 (m, 2H), 5.73–5.59 (m, 1H), 5.16 (dd, J = 9.7, 6.6 Hz, 1H), 4.34–4.22 (m, 0.5H), 4.20–4.10 (m, 0.5H), 3.99 (dd, J = 10.1, 6.2 Hz, 0.5H), 3.84–3.71 (m, 1H), 3.67- 3.64 (m, 0.5H), 3.62–3.55 (m, 0.5H), 3.53–3.40 (m, 1.5H), 2.34 (s, 3H), 2.33–2.31 (m, 0.5H), 2.26 (s, 3H), 2.24–2.18 (m, 0.5H), 2.14–2.03 (m, 0.5H), and 2.02–1.94 (m, 0.5H).</div></div><div id="sec6_6_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> (<i>R</i>)-4-((1-Acryloylpyrrolidin-3-yl)amino)-2,3-dimethyl-1<i>H</i>-indole-7-carboxamide (<b>4l</b>)<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></h3><div class="NLM_p">Following the procedures used to prepare <b>4k</b> but substituting (<i>R</i>)-<i>tert</i>-butyl 3-aminopyrrolidine-1-carboxylate for (<i>S</i>)-<i>tert</i>-butyl 3-aminopyrrolidine-1-carboxylate, 4-bromo-2,3-dimethyl-1<i>H</i>-indole-7-carbonitrile (<b>6</b>) was converted into (<i>R</i>)-2,3-dimethyl-4-(pyrrolidin-3-ylamino)-1<i>H</i>-indole-7-carboxamide. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>15</sub>H<sub>20</sub>N<sub>4</sub>O [M + H]<sup>+</sup> 273.2. Found: 273<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.40 (s, 1H), 7.59 (br s, 1H), 7.42 (d, <i>J</i> = 8.4 Hz, 1H), 6.85 (br s, 1H), 6.05 (d, <i>J</i> = 8.4 Hz, 1H), 5.07 (d, <i>J</i> = 6.8 Hz, 1H), 3.99–3.89 (m, 1H), 3.30 (br s, 1H), 3.04 (dd, J = 11.1, 6.1 Hz, 1H), 2.98–2.88 (m, 1H), 2.82–2.67 (m, 2H), 2.36 (s, 3H), 2.26 (s, 3H), 2.10 (td, J = 13.4, 7.5 Hz, 1H), and 1.68–1.53 (m, 1H).</div><div class="NLM_p last">To a mixture of (<i>R</i>)-2,3-dimethyl-4-(pyrrolidin-3-ylamino)-1<i>H</i>-indole-7-carboxamide (50 mg, 0.184 mmol) and Hunig’s base (0.096 mL, 0.551 mmol) in a mixture of tetrahydrofuran (6 mL) and dichloromethane (1 mL), cooled to 0 °C, was added a solution of acryloyl chloride (0.012 mL, 0.147 mmol) in tetrahydrofuran (0.5 mL) slowly over 3 min. The reaction mixture was stirred at 0 °C for 1 h, concentrated under reduced pressure, and purified by reverse-phase, preparative HPLC to afford <b>4l</b> (8.0 mg, 0.024 mmol, 13% yield) as an off-white solid. HPLC purity: 99% (<i>t</i><sub>R</sub> = 4.19 min, method E); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>22</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 327.2. Found: 327.3. <sup>1</sup>H NMR (400 MHz, methanol-d<sub>4</sub>) δ 7.44 (d, <i>J</i> = 8.3 Hz, 1H), 6.70–6.53 (m, 1H), 6.33–6.22 (m, 2H), 5.74 (ddd, <i>J</i> = 15.2, 10.5, 2.0 Hz, 1H), 4.40–4.32 (m, 1H), 4.32–4.23 (m, 1H), 3.90 (dd, <i>J</i> = 12.8, 5.9 Hz, 1H), 3.86–3.58 (m, 3H), 2.47–2.33 (s, 3H), 2.30 (s, 3H), 2.24–2.14 (m, 1H), and 2.14–2.02 (m, 1H).</div></div><div id="sec6_6_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> (<i>S</i>)-2,3-Dimethyl-4-((1-propioloylpyrrolidin-3-yl)amino)-1<i>H</i>-indole-7-carboxamide (<b>4m</b>)<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></h3><div class="NLM_p last">A solution of 2,3-dimethyl-4-(pyrrolidin-3-ylamino)-1<i>H</i>-indole-7-carboxamide (35 mg, 0.096 mmol) (see procedure for <b>4k</b>), HATU (73 mg, 0.193 mmol), Hunig’s base (51 μL, 0.289 mmol), and propiolic acid (7.4 mg, 0.106 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (1.4 mL) was stirred at room temperature for 4 h, concentrated under reduced pressure, and purified by reverse-phase, preparative HPLC to provide <b>4m</b> (7.1 mg, 0.022 mmol, 28% yield). HPLC purity: 95% (<i>t</i><sub>R</sub> = 1.03 min, method C; <i>t</i><sub>R</sub> = 1.02 min, method D); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>20</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 325.2. Found: 325.2. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.44 (s, 1H), 7.64 (br s, 1H), 7.44 (d, <i>J</i> = 8.5 Hz, 1H), 6.88 (br s, 1H), 6.15 (dd, <i>J</i> = 18.9, 7.9 Hz, 1H), 5.20 (br s, 1H), 4.52–4.40 (m, 1H), 4.29–4.17 (m, 1H), 4.11 (br s, 1H), 3.83–3.51 (m, 3H), 2.38–2.19 (m, 7H), and 2.12–1.98 (m, 1H).</div></div><div id="sec6_6_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> 4-((1-Acryloylpiperidin-4-yl)amino)-2,3-dimethyl-1<i>H</i>-indole-7-carboxamide (<b>4n</b>)<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></h3><div class="NLM_p">Following the procedures used to prepare <b>4d</b> but substituting benzyl 4-aminopiperidine-1-carboxylate for (<i>S</i>)-benzyl piperidin-3-ylcarbamate, 4-bromo-2,3-dimethyl-1<i>H</i>-indole-7-carbonitrile (<b>6</b>) was converted into 2,3-dimethyl-4-(piperidin-4-ylamino)-1<i>H</i>-indole-7-carboxamide. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>22</sub>N<sub>4</sub>O [M + H]<sup>+</sup> 287.2. Found: 287<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.40 (s, 1H), 7.40 (d, <i>J</i> = 8.1 Hz, 1H), 7.21–6.95 (m, 2H), 6.08 (d, <i>J</i> = 8.4 Hz, 1H), 4.87 (d, <i>J</i> = 7.9 Hz, 1H), 3.89–3.76 (m, 1H), 3.46 (br s, 1H), 3.00–2.85 (m, 2H), 2.67–2.54 (m, 2H), 2.37 (s, 3H), 2.26 (s, 3H), 1.94 (d, <i>J</i> = 9.5 Hz, 2H), and 1.36 (d, <i>J</i> = 9.0 Hz, 2H).</div><div class="NLM_p last">To a solution of 2,3-dimethyl-4-(piperidin-4-ylamino)-1<i>H</i>-indole-7-carboxamide (50 mg, 0.122 mmol) and Hunig’s base (0.085 mL, 0.489 mmol) in tetrahydrofuran (3 mL), cooled at 0 °C, was slowly added a solution of acryloyl chloride (9 μL, 0.110 mmol) (0.09 mL of a solution of 0.09 mL of acryloyl chloride in 0.9 mL of tetrahydrofuran). The reaction mixture was stirred at 0 °C for 1 h. The mixture was concentrated under reduced pressure, and the residue was purified by reverse-phase, preparative HPLC to give <b>4n</b> (0.007 g, 0.020 mmol, 16% yield). HPLC purity: 96% (<i>t</i><sub>R</sub> = 1.18 min, method C; <i>t</i><sub>R</sub> = 1.09 min, method D); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>24</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 341.2. Found: 341.2. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.40 (s, 1H), 7.59 (br s, 1H), 7.42 (d, <i>J</i> = 7.9 Hz, 1H), 6.83 (dd, <i>J</i> = 16.5, 10.4 Hz, 2H), 6.16 (d, <i>J</i> = 8.5 Hz, 1H), 6.10 (d, <i>J</i> = 16.5 Hz, 1H), 5.67 (d, <i>J</i> = 10.4 Hz, 1H), 4.95 (d, <i>J</i> = 7.9 Hz, 1H), 4.32 (d, <i>J</i> = 6.1 Hz, 1H), 4.02 (d, <i>J</i> = 13.4 Hz, 1H), 3.79–3.65 (m, 1H), 3.31–3.22 (m, 1H), 3.00–2.90 (m, 1H), 2.35 (s, 3H), 2.25 (s, 3H), 2.08–1.98 (m, 2H), and 1.50–1.40 (m, 2H).</div></div><div id="sec6_6_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> 2,3-Dimethyl-4-((1-propioloylpiperidin-4-yl)amino)-1<i>H</i>-indole-7-carboxamide (<b>4o</b>)<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></h3><div class="NLM_p last">A mixture of 2,3-dimethyl-4-(piperidin-4-ylamino)-1<i>H</i>-indole-7-carboxamide (35 mg, 0.122 mmol) (see procedure for <b>4n</b>), propiolic acid (25.7 mg, 0.367 mmol), HATU (139 mg, 0.367 mmol), and Hunig’s base (0.085 mL, 0.489 mmol) in dimethylfomamide (1 mL) was stirred at room temperature for 1.5 h, concentrated under reduced pressure, and purified by reverse-phase, preparative HPLC to give <b>4o</b> (6.2 mg; 0.018, 15% yield). HPLC purity: 97% (<i>t</i><sub>R</sub> = 1.19 min, method C; <i>t</i><sub>R</sub> = 1.13 min, method D); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>22</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 339.2. Found: 339.2. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.41 (s, 1H), 7.59 (br s, 1H), 7.42 (d, <i>J</i> = 8.5 Hz, 1H), 6.85 (br s, 1H), 6.16 (d, <i>J</i> = 8.5 Hz, 1H), 4.96 (d, <i>J</i> = 8.5 Hz, 1H), 4.53 (s, 1H), 4.26–4.11 (m, 2H), 3.73 (q, <i>J</i> = 9.0 Hz, 1H), 3.48–3.42 (m, 1H), 2.98 (t, <i>J</i> = 11.0 Hz, 1H), 2.35 (s, 3H), 2.25 (s, 3H), 2.08 (d, <i>J</i> = 11.6 Hz, 1H), 2.01 (d, <i>J</i> = 9.8 Hz, 1H), 1.61–1.49 (m, 1H), and 1.47–1.34 (m, 1H).</div></div><div id="sec6_6_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> (<i>RS</i>)-4-((1-Acryloylpiperidin-3-yl)amino)-2,3-dimethyl-1<i>H</i>-indole-7-carboxamide (<b>4p</b>)<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></h3><div class="NLM_p">Following the procedures used to prepare <b>4d</b> but substituting (<i>RS</i>)-benzyl 3-aminopiperidine-1-carboxylate for (<i>S</i>)-benzyl piperidin-3-ylcarbamate, 4-bromo-2,3-dimethyl-1<i>H</i>-indole-7-carbonitrile (<b>6</b>) was converted into (<i>RS</i>)-2,3-dimethyl-4-(piperidin-3-ylamino)-1<i>H</i>-indole-7-carboxamide. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>22</sub>N<sub>4</sub>O [M + H]<sup>+</sup> 287.2. Found: 287<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.40 (s, 1H), 7.94 (s, 1H), 7.56 (br s, 1H), 7.41 (d, <i>J</i> = 7.9 Hz, 1H), 6.81 (br s, 1H), 6.08 (d, <i>J</i> = 8.5 Hz, 1H), 5.40–5.23 (m, 1H), 3.77–3.56 (m, 2H), 3.06 (d, <i>J</i> = 12.2 Hz, 1H), 2.78 (br s, 1H), 2.70–2.61 (m, 2H), 2.38 (s, 3H), 2.26 (s, 3H), 1.86–1.78 (m, 1H), 1.69–1.60 (m, 1H), and 1.52–1.41 (m, 1H).</div><div class="NLM_p last">To a solution of 2,3-dimethyl-4-(piperidin-3-ylamino)-1<i>H</i>-indole-7-carboxamide (42.7 mg, 0.149 mmol) and Hunig’s base (0.078 mL, 0.447 mmol) in tetrahydrofuran (2 mL), cooled at 0 °C, was slowly added a solution of acryloyl chloride (11 μL, 0.134 mmol) (0.1 mL of a solution of 0.1 mL of acryloyl chloride in 1 mL of tetrahydrofuran). The reaction mixture was stirred at 0 °C for 1 h, concentrated under reduced pressure, and purified by reverse-phase, preparative HPLC to afford <b>4p</b> (3.0 mg, 0.007 mmol, 5% yield). HPLC purity: 97% (<i>t</i><sub>R</sub> = 1.36 min, method C; <i>t</i><sub>R</sub> = 1.01 min, method D); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>24</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 341.2. Found: 341.2. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.42 (br s, 1H), 7.61 (br s, 1H), 7.43 (d, <i>J</i> = 7.9 Hz, 1H), 6.85 (dd, <i>J</i> = 16.5, 11.0 Hz, 1H), 6.67–6.52 (m, 0.5H), 6.14 (d, <i>J</i> = 17.7 Hz, 2H), 6.08–5.95 (m, 0.5H), 5.75–5.66 (m, 0.5H), 5.62–5.51 (m, 0.5H), 5.04–4.90 (m, 1H), 4.27–4.17 (m, 1H), 3.88–3.81 (m, 1H), 3.79–3.72 (m, 1H), 3.70- 3.62 (m, 1H), 3.56–3.49 (m, 1H), 2.89 (s, 3H), 2.73 (s, 3H), 2.03–1.93 (m, 1H), 1.80–1.69 (m, 1H), 1.58–1.49 (m, 1H), and 1.30–1.20 (m, 1H).</div></div><div id="sec6_6_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> (<i>RS</i>)-2,3-Dimethyl-4-((1-propioloylpiperidin-3-yl)amino)-1<i>H</i>-indole-7-carboxamide (<b>4q</b>)<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></h3><div class="NLM_p last">A mixture of 2,3-dimethyl-4-(piperidin-3-ylamino)-1<i>H</i>-indole-7-carboxamide (28.4 mg, 0.099 mmol) (see procedure for <b>4p</b>), propiolic acid (13.87 mg, 0.198 mmol), HATU (83 mg, 0.218 mmol), and Hunig’s base (0.086 mL, 0.495 mmol) in dimethylformamide (1 mL) was stirred at room temperature for 1.5 h. The crude material was purified by reverse-phase, preparative HPLC to provide <b>4q</b> (6.2 mg, 0.017, 18% yield). HPLC purity: 95% (<i>t</i><sub>R</sub> = 1.36 min, method C; <i>t</i><sub>R</sub> = 1.36 min, method D); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>22</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 339.2. Found: 339.2. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.43 (s, 1H), 7.59 (br s, 1H), 7.43 (dd, <i>J</i> = 8.1, 4.4 Hz, 1H), 6.85 (br s, 1H), 6.29–6.08 (m, 1H), 4.98 (t, <i>J</i> = 7.9 Hz, 1H), 4.18 (d, <i>J</i> = 11.4 Hz, 1H), 3.94 (d, <i>J</i> = 13.5 Hz, 0.5H), 3.76 (d, <i>J</i> = 12.5 Hz, 0.5H), 3.64 (d, <i>J</i> = 3.7 Hz, 0.5H), 3.58–3.43 (m, 0.5H), 3.41–3.34 (m, 1H), 3.29–3.22 (m, 0.5H), 3.12 (dd, <i>J</i> = 12.5, 8.4 Hz, 0.5H), 2.35 (s, 3H), 2.26 (s, 3H), 1.99–1.90 (m, 1H), 1.83–1.65 (m, 2H), 1.62–1.48 (m, 1H), and 1.28–1.22 (m, 1H).</div></div><div id="sec6_6_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> (<i>S</i>)-4-(3-(But-2-ynamido)piperidin-1-yl)-5-fluoro-2,3-dimethyl-1<i>H</i>-indole-7-carboxamide (<b>5a</b>)<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></h3><div class="NLM_p">A mixture of (<i>S</i>)-<i>tert</i>-butyl piperidin-3-ylcarbamate (33.9 g, 169 mmol), 4-bromo-5-fluoro-2,3-dimethyl-1<i>H</i>-indole-7-carbonitrile (<b>9</b>, 41.1 g, 154 mmol), cesium carbonate (100 g, 308 mmol), and BINAP (9.59 g, 15.4 mmol) in 1,4-dioxane (1,380 mL) was degassed by bubbling nitrogen for 5 min. To the mixture was added Pd<sub>2</sub>(dba)<sub>3</sub> (7.05 g, 7.70 mmol), and the reaction mixture was stirred at reflux for 24 h. The reaction mixture was diluted with ethyl acetate (750 mL), washed with water (1000 mL), washed with brine (100 mL), and dried over anhydrous sodium sulfate. Concentration under reduced pressure afforded the crude product as a brown solid, which was passed through a pad of silica gel with ethyl acetate (900 mL) to remove any inorganics. The reddish crude product was then purified by recrystallization from acetonitrile to give two crops of (<i>S</i>)-<i>tert</i>-butyl (1-(7-cyano-5-fluoro-2,3-dimethyl-1<i>H</i>-indol-4-yl)piperidin-3-yl)carbamate (53 g, 108 mmol, 86% yield). LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>22</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 387.2. Found: 387.3.</div><div class="NLM_p">To a 100 mL three-neck flask was added sulfuric acid (90 g). The solution was heated to 60 °C, and (<i>S</i>)-<i>tert</i>-butyl (1-(7-cyano-5-fluoro-2,3-dimethyl-1<i>H</i>-indol-4-yl)piperidin-3-yl)carbamate (21 g, 54.3 mmol) was added portionwise over a period of 1.5 h. After 1 h at 60 °C, the reaction mixture was added to ice and warmed to room temperature with stirring. The aqueous phase was extracted with dichloromethane (3×) to remove organic impurities. The pH of the aqueous phase was adjusted to 8, and the solution was extracted with ethyl acetate (2×). The combined organic layers were washed with brine (500 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give (<i>S</i>)-4-(3-aminopiperidin-1-yl)-5-fluoro-2,3-dimethyl-1<i>H</i>-indole-7-carboxamide (13.6 g, 44.7 mmol, 82% yield) as a yellow solid. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>21</sub>FN<sub>4</sub>O [M + H]<sup>+</sup> 305.2. Found: 305.2.</div><div class="NLM_p last">To a 500 mL three-neck flask was added (<i>S</i>)-4-(3-aminopiperidin-1-yl)-5-fluoro-2,3-dimethyl-1<i>H</i>-indole-7-carboxamide (33.2 g, 109 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (364 mL), but-2-ynoic acid (11.9 g, 142 mmol), HATU (62.2 g, 164 mmol), and Hunig’s base (38 mL, 218 mmol) (temperature rose to 35 °C). The resulting solution was stirred at room temperature for 1.5 h. The mixture was diluted with ethyl acetate (250 mL) and washed with water (500 mL). The organic phase was separated, and the aqueous layer was extracted with ethyl acetate (2 × 250 mL) (layer separation was faciliated with a small amount of NaCl). The combined organic extracts were washed with water (with small amount of NaCl) (4 × 500 mL), washed with brine (500 mL), and dried over anhydrous sodium sulfate. Concentration under reduced pressure afforded the crude product, which was purified by recrystallization from ethyl acetate to give (<i>S</i>)-4-(3-(but-2-ynamido)piperidin-1-yl)-5-fluoro-2,3-dimethyl-1<i>H</i>-indole-7-carboxamide (31 g, 83 mmol, 76% yield) as a white solid. HPLC purity: >99.5%; <i>t</i><sub>R</sub> = 9.18 min (method A); >99.5%; <i>t</i><sub>R</sub> = 7.90 min (method B); 99.7%; <i>t</i><sub>R</sub> = 7.44 min (method F). Chiral purity: 99.8% ee; LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>23</sub>FN<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 371.2. Found: 371.1. Anal. Calcd for C<sub>20</sub>H<sub>23</sub>FN<sub>4</sub>O<sub>2</sub>, 0.36% H<sub>2</sub>O: C 64.85, H 6.26, N 15.13. Found: C 64.95, H 6.05, N 15.15. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.61 (s, 1H), 8.46 (br d, <i>J</i> = 5.6 Hz, 1H), 7.91 (br s, 1H), 7.40 (d, <i>J</i> = 14.2 Hz, 1H), 7.32 (br s, 1H), 3.99–3.81 (m, 1H), 3.19–3.07 (m, 1H), 3.06–2.89 (m, 1H), 3.06–2.89 (m, 1H), 2.80 (br s, 1H), 2.37 (s, 3H), 2.31 (s, 3H), 1.94 (s, 3H), 1.91–1.80 (m, 1H), 1.72 (br s, 2H), and 1.33 (br s, 1H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.7 (d, <i>J</i> = 1.8 Hz, 1C), 153.8 (d, <i>J</i> = 233.4 Hz, 1C), 152.4, 134.8, 133.7 (d, <i>J</i> = 9.1 Hz, 1C), 132.6, 127.0 (dd, <i>J</i> = 5.4, 1.0 Hz, 1C), 112.8 (d, <i>J</i> = 7.3 Hz, 1C), 108.9 (d, <i>J</i> = 26.3 Hz, 1C), 106.5 (d, <i>J</i> = 5.5 Hz, 1C), 82.8, 76.2, 57.4, 52.4, 46.8, 30.2, 24.9, 11.6, 10.7, and 3.5.</div></div><div id="sec6_6_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> (<i>S</i>)-4-(3-(But-2-ynamido-1-<sup>14</sup>C)piperidin-1-yl)-5-fluoro-2,3-dimethyl-1<i>H</i>-indole-7-carboxamide (<sup>14</sup>C-<b>5a</b>)</h3><div class="NLM_p">Ba[<sup>14</sup>C]CO<sub>3</sub> (105 mg, 0.497 mmol, 25 mCi, 1 equiv) was weighed into a 100 mL two-neck flask equipped with a septa, and the flask was attached to a vacuum line. A solution of propynl magnesium bromide (0.5 M in tetrahydrofuran, 1.24 mL, 0.621 mmol, 1.25 equiv) was transferred by syringe to a 50 mL round-bottom flask which was then placed on the vacuum line and frozen with liquid nitrogen. The system was evacuated and isolated. Concentrated sulfuric acid (2 mL, 0.497 mmol) was added to the Ba[<sup>14</sup>C]CO<sub>3</sub> through the septa to generate [<sup>14</sup>C]CO<sub>2</sub> which was allowed to condense into the frozen flask containing propynlmagnesium bromide for 40 min. The frozen propynlmagnesium bromide containing condensed [<sup>14</sup>C]CO<sub>2</sub> was then sealed and allowed to warm to room temperature with stirring for an additional hour. After addition of 1 N HCl (2 mL), the aqueous solution was extracted with ether (4 × 4 mL). The combined ether phases were washed with 2 mL of brine and dried over MgSO<sub>4</sub>. After filtration, the solvent was removed, and the resulting residue was redissolved in 4 mL of <i>N</i>,<i>N</i>-dimethylformamide. Scintillation counting of the solution showed that it contained 22.6 mCi (90% radiochemical yield) of [1-<sup>14</sup>C]butynoic acid. HPLC analysis of the solution with radioactivity detection (mobile phase A = 0.1% TFA in water, mobile phase B = acetonitrile, column = Zorbax SBC18, 4.6 mm × 250 mm, linear gradient from 5% to 50% over 20 min, rt = 6.9 min) showed radiochemical purity = 99.2%.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0029.gif" alt="" id="fx1" /></img></div><div class="NLM_p last">To a solution of (S)-4-(3-aminopiperidin-1-yl)-5-fluoro-2,3-dimethyl-1<i>H</i>-indole-7-carboxamide (30 mg, 0.099 mmol) dissolved in 1 mL of <i>N</i>,<i>N</i>-dimethylformamide was added a 1.2 mL portion of the above <i>N</i>,<i>N</i>-dimethylformamide solution of [<sup>14</sup>C]butynoic acid (6.8 mCi, 0.118 mmol). To the stirred solution was added Hunig’s base (34 μL, 0.20 mmol, and the resulting solution was stirred for 5 min. HATU (45.0 mg, 0.118 mmol, 1.2 equiv) was dissolved in approximately 200 μL of <i>N</i>,<i>N</i>-dimethylformamide and then added dropwise to the solution. The resulting mixture was stirred for 30 min at room temperature and then quenched by addition of 2.5 mL of water. This solution was subjected to semipreparative HPLC (mobile phase A = 0.1% trifluoroacetic acid in water, mobile phase B = acetonitrile, column = Luna C18(2) 25 mm × 250 mm, linear gradient 30% to 95% B over 20 min). Fractions containing pure product were collected and combined. After removal of the majority of the acetonitrile, the solution was neutralized with aqueous bicarbonate solution and then loaded onto an Oasis 500 mg solid phase extraction cartridge. Pure amide product (3.3 mCi, 49% radiochemical yield) was eluted from the Sep-Pak with acetonitrile: LC/MS (positive ion, mobile phase A of 0.1% formic acid in water, mobile phase B of 0.1% formic acid in acetonitrile, linear gradient from 20% B to 90% B over 5.5 min, column Luna C18(2), 3 μm, 50 mm × 100 mm, <i>t</i><sub>R</sub> = 3.3 min) <i>m</i>/<i>z</i> = 371 (unlabeled) 373, 374; HPLC analysis with UV and radioactivity detection (mobile phase A = 0.1% TFA in water, mobile phase B = 0.1% formic acid in acetonitrile, column = Luna C18(2) 3 μm, 50 mm × 100 mm, isocratic gradient 30% B for 2 min, then linear gradient 30% B to 60% B over 14 min, <i>t</i><sub>R</sub> = 12.9 min) showed radiochemical purity = 98.4% with an identical retention time to a standard of unlabeled <b>5a</b>; LCMS analysis of labeled <b>5a</b> versus unlabeled <b>5a</b> determined specific activity = 60.1 mCi/mmol (162 μCi/mg).</div></div><div id="sec6_6_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> (<i>S</i>)-5-Fluoro-2,3-dimethyl-4-(3-propiolamidopiperidin-1-yl)-1<i>H</i>-indole-7-carboxamide (<b>5b</b>)<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></h3><div class="NLM_p last">A mixture of (<i>S</i>)-4-(3-aminopiperidin-1-yl)-5-fluoro-2,3-dimethyl-1<i>H</i>-indole-7-carboxamide (see procedure for <b>5a</b>, 0.255 g, 0.838 mmol), propiolic acid (0.070 g, 1.005 mmol), HATU (0.446 g, 1.173 mmol), and Hunig’s base (0.512 mL, 2.93 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (4 mL) was stirred at room temperature for 40 min. The mixture was diluted with ethyl acetate, washed with 10% aqueous lithium chloride (2×), and washed with brine. The organic layer was collected, and the aqueous layers were sequentially extracted with ethyl acetate (2×). The combined organic layers were dried over anhydrous sodium sulfate and concentrated. Purification by silica gel chromatography (ISCO 24 g column; 0–5% methanol in dichloromethane) afforded <b>5b</b> (0.136 g, 0.374 mmol, 45% yield) as a pale yellow solid. HPLC purity: 98.2%; <i>t</i><sub>R</sub> = 8.86 min (method A); 98.3%; <i>t</i><sub>R</sub> = 8.27 min (method B); LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>21</sub>FN<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 357.2. Found: 357.3. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.69–10.55 (m, 1H), 8.82–8.63 (m, 1H), 8.00–7.82 (m, 1H), 7.41 (d, <i>J</i> = 14.2 Hz, 1H), 7.33 (br s, 1H), 4.00–3.85 (m, 1H), 3.23–3.10 (m, 2H), 3.07–2.90 (m, 2H), 2.89–2.75 (m, 1H), 2.43–2.35 (m, 3H), 2.32 (s, 3H), 1.96–1.84 (m, 1H), 1.81–1.63 (m, 2H), and 1.46–1.30 (m, 1H).</div></div><div id="sec6_6_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> 4-Bromo-2,3-dimethyl-1<i>H</i>-indole-7-carbonitrile (<b>6</b>)<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></h3><div class="NLM_p last">A suspension of 4-bromo-2,3-dimethyl-1<i>H</i>-indole-7-carboxamide (<b>14a</b>) (5.65 g, 21.2 mmol) in tetrahydrofuran (151 mL) was treated slowly with phosphorus oxychloride (13.8 mL, 148 mmol). The resulting mixture was stirred at room temperature for 23 h and was then concentrated under reduced pressure. The residue was suspended in ethyl acetate, and the precipitate was collected by filtration, and the solid was washed sequentially with water, saturated aqueous sodium bicarbonate, and water. The organic filtrate was concentrated, and the residue was suspended in water. The resulting precipitate was collected by filtration, washed sequentially with water, saturated aqueous sodium bicarbonate, and water. The combined precipitates were dried well to give 4-bromo-2,3-dimethyl-1<i>H</i>-indole-7-carbonitrile as a yellow solid (4.68 g, 89% yield). LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>9</sub>BrN<sub>2</sub> [M + H]<sup>+</sup> 249.0. Found: 249<sup>+</sup> and 251<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.89 (br s, 1H), 7.35 (d, <i>J</i> = 7.9 Hz, 1H), 7.26 (d, <i>J</i> = 7.9 Hz, 1H), 2.39 (s, 3H), and 2.34 (s, 3H).</div></div><div id="sec6_6_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> 4-Bromo-5-fluoro-2,3-dimethyl-1<i>H</i>-indole-7-carbonitrile (<b>9</b>)<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></h3><div class="NLM_p last">To a solution of 4-bromo-5-fluoro-2,3-dimethyl-1<i>H</i>-indole-7-carboxamide (<b>14b</b>, 40.4 g, 142 mmol) in dichloromethane (810 mL) was added pyridine (50 g, 2.5 equiv) followed by phosphoryl trichloride (19.8 mL, 213 mmol) dropwise at room temperature over 2 min. The reaction mixture was stirred for 20 min, and the solvent was removed under reduced pressure. To the residue was added water, and the mixture was stirred for 30 min. The precipitate was collected by filtration and dried to give 4-bromo-5-fluoro-2,3-dimethyl-1<i>H</i>-indole-7-carbonitrile (35 g, 131 mmol, 92% yield) as a tan solid. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>8</sub>BrFN<sub>2</sub> [M + H]<sup>+</sup> 266.0. Found: 266.2 and 268.2.</div></div><div id="sec6_6_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> 4-Bromo-2,3-dimethyl-1<i>H</i>-indole-7-carboxamide (<b>14a</b>)<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></h3><div class="NLM_p">A suspension of 4-bromo-2-hydrazinylbenzoic acid hydrochloride<a onclick="showRef(event, 'cit19b ref20'); return false;" href="javascript:void(0);" class="ref cit19b ref20">(19b,20)</a> (<b>12a</b>, 5.87 g, 21.9 mmol) in acetic acid (73 mL) at 75 °C was treated with 2-butanone (9.8 mL, 110 mmol). The mixture was heated on an oil bath at 110 °C. After 18 h, the mixture was concentrated under vacuum to provide a dark brown solid. The residue was suspended in ethyl acetate, and the insoluble material was collected by filtration, washed with ethyl acetate, and dried. The filtrate was concentrated, and the residue was again suspended in ethyl acetate. Additional solid was collected by filtration, washed with ethyl acetate, and dried. The combined solids were dried well to provide 4-bromo-2,3-dimethyl-1<i>H</i>-indole-7-carboxylic acid as a brown solid (<b>13a</b>, 4.63 g, 79% yield). LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>10</sub>BrNO<sub>2</sub> [M + H]<sup>+</sup> 268.0. Found: 268<sup>+</sup> and 270<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.29–12.97 (m, 1H), 10.87 (br s, 1H), 7.48 (d, <i>J</i> = 7.9 Hz, 1H), 7.20 (d, <i>J</i> = 8.1 Hz, 1H), 2.40 (s, 3H), and 2.36 (s, 3H).</div><div class="NLM_p last">A mixture of 4-bromo-2,3-dimethyl-1<i>H</i>-indole-7-carboxylic acid (<b>13a</b>, 4.63 g, 17.3 mmol), EDC (4.97 g, 25.9 mmol) and HOBT (3.44 g, 22.5 mmol) in a mixture of tetrahydrofuran (276 mL) and dichloromethane (69 mL) was stirred at room temperature for 1 h, then treated with 28% aqueous ammonium hydroxide (5.38 mL, 138 mmol). The resulting suspension was stirred at room temperature for 4 days. The mixture was concentrated under reduced pressure, and the residue was partitioned between water and ethyl acetate. The organic layer was collected, and the aqueous phase was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and concentrated to provide 4-bromo-2,3-dimethyl-1<i>H</i>-indole-7-carboxamide as a yellow solid (<b>14a</b>, 3.34 g, 72% yield). LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>11</sub>BrN<sub>2</sub>O [M + H]<sup>+</sup> 267.0. Found: 267<sup>+</sup> and 269<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.92 (s, 1H), 8.01 (br s, 1H), 7.48–7.31 (m, 2H), 7.14 (d, J = 7.9 Hz, 1H), 2.39 (d, J = 0.4 Hz, 3H), and 2.34 (s, 3H).</div></div><div id="sec6_6_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> 4-Bromo-5-fluoro-2,3-dimethyl-1<i>H</i>-indole-7-carboxamide (<b>14b</b>)<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></h3><div class="NLM_p">A stirred suspension of 4-bromo-5-fluoro-2-hydrazinylbenzoic acid hydrochloride (<b>12b</b>, 1.00 g, 3.50 mmol)<a onclick="showRef(event, 'cit15c ref20 ref24'); return false;" href="javascript:void(0);" class="ref cit15c ref20 ref24">(15c,20,24)</a> in acetic acid (11.7 mL) was treated with 2-butanone (1.26 mL, 14.0 mmol) at room temperature. The mixture was heated at 75 °C for 30 min, forming a brown solution, and then at 110 °C for 16 h. The reaction mixture was concentrated, and the residue was suspended in ethyl acetate. The precipitate was collected by filtration, washed with ethyl acetate, and dried. The filtrates were concentrated, and the residue was suspended in ethyl acetate, forming additional precipitate which was collected by filtration, washed with ethyl acetate, and air-dried. The combined solids were dried well to provide 4-bromo-5-fluoro-2,3-dimethyl-1<i>H</i>-indole-7-carboxylic acid as a brown solid (<b>13b</b>, 0.515 g, 51% yield). LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>9</sub>BrFNO<sub>2</sub> [M + H]<sup>+</sup> 286.0. Found: 286<sup>+</sup> and 288<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.84–12.75 (m, 1H), 10.96 (s, 1H), 7.45 (d, <i>J</i> = 9.7 Hz, 1H), 2.40 (s, 3H), and 2.37 (s, 3H).</div><div class="NLM_p last">Following the procedure used in the final step of the preparation of <b>14a</b>, 4-bromo-5-fluoro-2,3-dimethyl-1<i>H</i>-indole-7-carboxylic acid (<b>13b</b>) was converted into 4-bromo-5-fluoro-2,3-dimethyl-1<i>H</i>-indole-7-carboxamide in 75% yield. LCMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>11</sub>H<sub>10</sub>BrFN<sub>2</sub>O [M + H]<sup>+</sup> 285.0. Found: 285<sup>+</sup> and 287<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.98 (s, 1H), 8.08 (br s, 1H), 7.62–7.44 (m, 2H), 2.39 (s, 3H), and 2.35 (s, 3H).</div></div><div id="sec6_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> Human Recombinant BTK Enzyme Assay</h3><div class="NLM_p last">To V-bottom 384-well plates were added test compounds, human recombinant BTK (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), ATP (20 μM), and assay buffer (20 mM HEPES, pH 7.4, 10 mM MgCl<sub>2</sub>, 0.015% Brij 35 surfactant, and 4 mM DTT in 1.6% DMSO), with a final volume of 30 μL. After incubating at room temperature for 60 min, the reaction was terminated by adding 45 μL of 35 mM EDTA to each sample. The reaction mixture was analyzed on the Caliper LabChip 3000 (Caliper, Hopkinton, MA) by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data were calculated by comparison to control reactions with no enzyme (for 100% inhibition) and controls with no inhibitor (for 0% inhibition). Dose–response curves were generated to determine the concentration required for inhibiting 50% of BTK activity (IC<sub>50</sub>). Compounds were dissolved at 10 mM in DMSO and evaluated at 11 concentrations.</div></div><div id="sec6_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> BCR-Stimulated Calcium Flux in Ramos B Cells</h3><div class="NLM_p last">Human Ramos (RA1) B cells (ATCC CRL-1596) at a density of 2 × 10<sup>6</sup> cells/mL in RPMI minus phenol red (Invitrogen 11835-030) and 50 mM HEPES (Invitrogen 15630-130) containing 0.1% BSA (Sigma A8577) were added to one-half volume of calcium loading buffer (BD bulk kit for probenecid sensitive assays, no. 640177) and incubated at room temperature in the dark for 1 h. Dye-loaded cells were pelleted (Beckmann GS-CKR, 1200 rpm, room temperature, 5 min) and resuspended at room temperature in RPMI minus phenol red with 50 mM HEPES and 10% FBS to a density of 1 × 106 cells/mL. 150 μL aliquots (150 000 cells/well) were plated into 96 well poly-<span class="smallcaps smallerCapital">d</span>-lysine coated assay plates (BD 35 4640) and briefly centrifuged (Beckmann GS-CKR 800 rpm, 5 min, without brake). Next, 50 μL compound dilutions in 0.4% DMSO/RPMI minus phenol red + 50 mM HEPES + 10% FBS were added to the wells and the plate was incubated at room temperature in the dark for 1 h. The assay plate was briefly centrifuged as above prior to measuring calcium levels. Using the FLIPR1 (Molecular Devices), cells were stimulated by adding goat anti-human IgM (Invitrogen AHI0601) to 2.5 μg/mL. Changes in intracellular calcium concentrations were measured for 180 s, and percent inhibition was determined relative to peak calcium levels seen in the presence of stimulation only.</div></div><div id="sec6_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> BTK Inactivation Determination in Human Whole Blood</h3><div class="NLM_p last">The rate of inactivation of BTK in human whole blood was measured by adding the compound at various concentrations to blood and incubated at 37°C. At various time points, aliquots were removed and lysed with lysis buffer (Cell Signaling, 9803) containing protease inhibitor (Calbiochem, 539134) and 120 nM of a biotinylated inactivator of BTK. After agitation for 1 h at room temperature, the lysate was transferred to a streptavidin-coated plate and incubated for 1 h at room temperature. After washing 3 times with PBS containing 0.05% Tween20) 100 μL of anti-BTK antibody (Cell Signaling, catalog no. 8547) in PBS containing 0.05% Tween20 and 0.5% BSA was added and incubated with continuous agitation for 1 h at room temperature. After washing 3 times, goat anti-rabbit horseradish peroxidase secondary antibody was added, incubated for 1 h at room temperature, then washed 3 times as above. The ELISA was developed with the addition of 100 μL of tetramethylbenzidine (Sigma, T0440) and allowed to develop for 20 min before quenching with the addition of 100 μL of 2 N sulfuric acid. The absorbance at 450 nm was measured, and the relative percentage of free active sites were calculated from a standard curve of samples containing different ratios of lysates from normal blood mixed with lysates from blood pretreated with 2 μM of a rapid inactivator. A global fit of the data to an integrated rate equation defining second order kinetics (enzyme and compound being the two reactants) was used to determine a second order rate constant of the inactivation in whole blood.</div></div><div id="sec6_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> Determining <i>k</i><sub>inact</sub>/<i>K</i><sub>i</sub> for Irreversible Inhibitors Using Time Resolved Fluorescence (HTRF)</h3><div class="NLM_p last">His tagged kinase (1 nM) was preincubated with anti-6xHis-terbium labeled antibody (0.2 nM; Cis-bio) and an ATP competitive fluorescent probe at <i>K</i><sub>d</sub> for 1.5 h to perform the kinase-antibody-probe FRET complex. Test compound was 3× serially diluted in DMSO for 11 concentrations, and an assay plate was prepared with 1000× inhibitor. Reactions were initiated by adding kinase-antibody-probe FRET complex to wells of the assay plate, and fluorescence decrease was monitored kinetically over time. Assays were performed in black, flat-bottom, 384-well plates, and the final reaction volume was 20 μL in assay buffer consisting of 20 mM Hepes, pH 7.5, 150 mM NaCl, 10 mM MgCl<sub>2</sub>, 2 mM DTT, 50 μg/mL BSA, 0.015% Brij 35. The HTRF signal, a ratio of fluorescence intensities at emission wavelengths for fluorescein acceptor (520 nm) and terbium donor (495 nm), generated by the reaction was measured on the Envision plate reader. Progress curve data were fit to a single exponential decay function to determine <i>k</i><sub>obs</sub>, and <i>k</i><sub>inact</sub> and <i>K</i><sub>I</sub> were determined by plotting <i>k</i><sub>obs</sub> versus inhibitor concentration and fitting to the following equation using GraphPad Prism software: <i>k</i><sub>obs</sub> = <i>k</i><sub>inact</sub>/(1+ <i>K</i><sub>I</sub>/[I]).</div></div><div id="sec6_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> Collagen-Induced Arthritis in Mice</h3><div class="NLM_p">DBA/1 male mice (8–10 weeks of age; Harlan) were immunized subcutaneously at the base of the tail on day 0 and again on day 21 with 200 μg of bovine type II collagen admixed with reconstituted Sigma Adjuvant System (SAS; Sigma-Aldrich). For “preventative” dosing, mice were dosed daily (beginning on day 0) by oral gavage with vehicle (EtOH/TPGS/PEG300, 5:5:90) or compound <b>5a</b>. For “pseudo-established” dosing, the start of dosing was delayed until the day 21 booster immunization. Following the booster immunization, mice were monitored 3 times per week for the development and severity of paw inflammation. Each paw was visually scored by the following scheme: +0 = normal. +1 = one (or more) joints inflamed on digits. +2 = mild–moderate inflammation of plantar surface of paw and paw thickness modestly increased. +3 = moderate–severe inflammation of plantar surface of paw and paw thickness significantly increased. +4 = ankylosis of ankle joint (significantly reduced hock joint motion on flexion/extension). Unblinded clinical paw scores for all four paws were summed for each mouse, and mean ± SEM was calculated for each treatment group.</div><div class="NLM_p last">For histological evaluation, rear paws were fixed, decalcified, and embedded in paraffin. Sections were cut in the sagittal plane, stained in H&E, and evaluated microscopically without knowledge of treatment group. Lesions were scored on a severity scale of 0 (normal) to 4 in two separate categories, inflammation (cellular infiltration and pannus formation) and bone resorption. Bone morphology and bone mineral density of hind paws excised post-mortem were analyzed by microcomputed tomography (micro-CT) after fixation in 10% neutral buffered formalin. Age-matched naïve (disease-free) paws were used as a control for comparative micro-CT analysis. The analysis was conducted in a blinded format.</div></div><div id="sec6_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> Microcomputed Tomography Imaging and Histopathology</h3><div class="NLM_p last">Bone morphology was evaluated by micro-CT using the Scanco VivaCT40 (Scanco Medical AG, Zurich, Switzerland). Imaging parameters included approximately 500 slices (21 μm thick) acquired with 250 projections, 500 ms integration time, 55 kVp photon energy, and 145 μA of current. Region of interest focused on the hind/mid-foot sections (talus to proximal end of the first metatarsal bone). Threshold settings were optimized using histomorphometric methods. Bone mineral density and bone surface area were evaluated using a hydroxylapatite calibration phantom and Scanco proprietary software. The analysis was conducted in a blinded format.</div></div><div id="sec6_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> NZB/W Lupus-Prone Mice</h3><div class="NLM_p last">Baseline body weight, proteinuria, and serum dsDNA titers were determined for female NZB/WF1 mice (Jackson Laboratories) at 24 weeks of age prior to their randomization into treatment groups, each with <i>n</i> = 12. Mice were dosed by oral gavage, q.d., for 16 weeks and included the following treatment groups: <b>5a</b> at 30 mg/kg in vehicle (80:20 PEG400/water) and prednisolone (Sigma P6004) at 10 mg/kg. Mice were routinely monitored for overall health, and body weight, proteinuria, and dsDNA titers were measured every 3 weeks. Proteinuria was measured using a colorimetric assay for albumin (Siemens Albustix reagent strips for urinalysis). Anti-dsDNA antibody titers were measured by applying serial dilutions of serum samples to DNA-coated ELISA plates. Bound antibody was detected with HRP-conjugated polyclonal goat-anti-mouse IgG. The individual titers were expressed as relative to that of a pooled serum standard. At the end of the study, final body weight and proteinuria were measured. Terminal blood samples were drawn for PK and anti-dsDNA titers. The amount of BTK inactivation in blood from these mice, 24 h after their last dose, was determined as described above. At the end of the study, kidneys (<i>n</i> = 5–6 per group) were collected in 10% neutral buffered formalin for histological evaluation. Fixed kidney tissues were routinely processed and paraffin embedded. Kidney sections were stained with periodic acid Schiff and hematoxylin and hematoxylin and eosin for the evaluation of nephritis severity. Blinded to treatment group, severity of nephritis was evaluated using the following criteria. For glomerular damage: 1, mesangial matrix thickening and/or mesangial cell proliferation; 2, crescent formation, cellular deposits/casts in Bowman’s space; 3, cellular infiltration, composed of mononuclear cells in glomerular tufts; 4, fbrosis of Bowman’s capsule. For tubular damage: 1, infiltration of mononuclear cells; 2, severity of tubular epithelial cell damage; 3, protein casts. For tubule-interstitial damage: 1, fibrosis; 2, infiltration of mononuclear cells. Each subcategory was assigned a score from 0 to 4. The total score for each mouse was the sum of the above nine subcategories with the highest possible score of 36. To evaluate IC deposition in the glomeruli, immunohistochemistry was performed using biotinylated goat anti-mouse IgG (Vector Laboratories, Burlingame, CA) with 45 μg/mL normal goat serum (Jackson Immunoresearch Laboratories, Inc.) as the negative control. Sections were conjugated to horseradish peroxidase using Vectastain ABC ELITE reagent (Vector Laboratories) and developed with Deep Space Black chromogen (Biocare Medical) for visualization of IgG. IC deposition was evaluated under 100× magnification by dividing the kidney into three sections and randomly selecting 10 glomeruli from each section. Each glomerulus was subdivided into four quadrants, and each quadrant was assigned a score from 0 to 4 based on severity of IgG deposition, defined as the following: 0, unremarkable; 1, minimal linear deposition and/or focal lesion; 2, mild linear deposition or multifocal lesions; 3, moderate/segmental lesions; 4, marked/global or diffuse deposition. The total score of each glomerulus was calculated, as was the total score of each kidney, and the group average score was determined. Statistical analysis was performed using a one-way ANOVA model after a square root transformation of the data to establish significant overall difference in the mean score of treatment groups with <i>P</i> < 0.0001. One-sided Dunnett’s test was used to determine significance of inhibition of each treatment group compared to the vehicle control group.</div></div><div id="sec6_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> Single Crystal X-ray Diffraction Data for <b>5a</b></h3><div class="NLM_p">Compound <b>5a</b> acetone solvate crystals were obtained from an acetone/<i>n</i>-heptane (v/v = 1/1) solution after 1 day of slow evaporation of the mother liquor at room temperature. A colorless plate shaped single crystal of dimensions 0.32 mm × 0.20 mm × 0.01 mm was used to collect single crystal X-ray diffraction (XRD) data. The XRD data collection was carried out using a Bruker-AXS Microstar rotating anode equipped with Cu Kα radiation (λ = 1.541 78 Å), a Kappa2000 diffractometer and APEX II detector. The crystal was kept at −70 °C (203 K) and the XRD data were acquired using sets of ω and φ scans, each at a frame width of 1.2°. Indexing and processing of the measured intensity data were performed using the BrukerSAINT-APEX2 software package/program suite [Bruker (2012); BrukerSAINT-APEX2; Bruker AXS Inc., Madison, WI, USA]. A direct methods solution was calculated using SHELXS-97 [<contrib-group><span class="NLM_string-name">Sheldrick, G. M.</span></contrib-group>  <cite><i>SHELXS97 and SHELXL97; Program for Crystal Structure Solution and Refinement</i></cite>; University of Göttingen: Göttingen, Germany, <span class="NLM_year">1997</span>], which provided the atomic positions from the E-map. Full-matrix least-squares refinement and difference Fourier cycles were performed using SHELXL-2014/6 [<contrib-group><span class="NLM_string-name">Sheldrick, G. M.</span></contrib-group> SHELX version 2014/6.   <cite><i>Acta Crystallogr.</i></cite> <span class="NLM_year">2008</span>, <em>A64</em>, 112−122]. The non-hydrogen atoms for compound <b>5a</b> were refined with anisotropic displacement parameters. Due to partial desolvation, the non-hydrogen atoms for the acetone molecule were refined isotropically and with geometric constraints. Hydrogen atoms were placed in ideal positions and refined as riding atoms with relative isotropic displacement parameters.</div><div class="NLM_p last">Single crystal X-ray data for compound <b>5a</b>. Crystal data (CCDC 1901788): C<sub>13</sub>H<sub>9</sub>N<sub>3</sub>OS<sub>2</sub>, FW = 287.36, orthorhombic <i>P</i>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub>, <i>a</i> = 9.5112(4) Å, <i>b</i> = 20.9712(7) Å, <i>c</i> = 26.3443(12) Å, <i>V</i> = 5254.7(4) Å<sup>3</sup>, <i>T</i> = 203 K, Cu Kα, 88 907 reflections, 6619 unique (<i>R</i><sub>int</sub> = 0.0818), R1 = 0.0953, wR2 = 0.2817 (for 5730 observed reflections with <i>I</i> > 2σ(<i>I</i>) and 513 parameters), Flack(<i>x</i>) = 0.00(9), Hooft(<i>y</i>) = −0.06(8), P3True = 1.000.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0028.gif" alt="" id="fx2" /></img></div></div><div id="sec6_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> X-ray Crystallography of <b>5a</b> Bound to the Kinase Domain of BTK</h3><div class="NLM_p last">Purification, crystallization, X-ray data collection, and first maps were performed by Proteros Biostructures GmbH. The final refinement was carried out with BUSTER/TNT (<contrib-group><span class="NLM_string-name">Blanc, E.</span>; <span class="NLM_string-name">Roversi, P.</span>; <span class="NLM_string-name">Vonrhein, C.</span>; <span class="NLM_string-name">Flensburg, C.</span>; <span class="NLM_string-name">Lea, S. M.</span>; <span class="NLM_string-name">Bricogne, G.</span></contrib-group>  <cite><i>Acta Crystallogr.</i></cite> <span class="NLM_year">2004</span>, <em>D60</em>, 2210−2221) (GlobalPhasing, Ltd., Cambridge, U.K.), GRADE (GlobalPhasing, Ltd., Cambridge, U.K.) for restraint dictionary generation, and COOT (<contrib-group><span class="NLM_string-name">Emsley, P.</span>; <span class="NLM_string-name">Lohkamp, B.</span>; <span class="NLM_string-name">Scott, W. G.</span>; <span class="NLM_string-name">Cowtan, K.</span></contrib-group>  <cite><i>Acta Crystallogr.</i></cite> <span class="NLM_year">2010</span>, <em>D66</em>, 486−501) for modeling building into electron density. The structure of hBTK + compound <b>5a</b> has been deposited to RCSB with PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O8I">6O8I</a>.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i63"><a href="/doi/suppl/10.1021/acs.jmedchem.9b00167" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50436" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50436" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.9b00167" class="ext-link">10.1021/acs.jmedchem.9b00167</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula strings and some data (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00167/suppl_file/jm9b00167_si_001.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00167/suppl_file/jm9b00167_si_001.csv">jm9b00167_si_001.csv (1.68 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB code for <b>5a</b> is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O8I">6O8I</a>. Authors will release the atomic coordinates upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.9b00167" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37107" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37107" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Scott H. Watterson</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9315-177X" title="Orcid link">http://orcid.org/0000-0001-9315-177X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#4f3c2c203b3b61382e3b3b2a3d3c20210f2d223c612c2022"><span class="__cf_email__" data-cfemail="5526363a21217b223421213027263a3b153738267b363a38">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qingjie Liu</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Myra Beaudoin Bertrand</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Douglas G. Batt</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ling Li</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark A. Pattoli</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stacey Skala</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lihong Cheng</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mary T. Obermeier</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robin Moore</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zheng Yang</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rodney Vickery</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul A. Elzinga</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lorell Discenza</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Celia D’Arienzo</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kathleen M. Gillooly</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tracy L. Taylor</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Claudine Pulicicchio</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yifan Zhang</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elizabeth Heimrich</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kim W. McIntyre</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qian Ruan</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard A. Westhouse</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ian M. Catlett</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Naiyu Zheng</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5121-9024" title="Orcid link">http://orcid.org/0000-0002-5121-9024</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Charu Chaudhry</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jun Dai</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7333-3899" title="Orcid link">http://orcid.org/0000-0002-7333-3899</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael A. Galella</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew J. Tebben</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matt Pokross</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jianqing Li</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8445-9796" title="Orcid link">http://orcid.org/0000-0002-8445-9796</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rulin Zhao</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel Smith</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard Rampulla</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alban Allentoff</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael A. Wallace</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Arvind Mathur</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Luisa Salter-Cid</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John E. Macor</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Percy H. Carter</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5880-1164" title="Orcid link">http://orcid.org/0000-0002-5880-1164</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aberra Fura</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James R. Burke</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joseph A. Tino</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research
and Development, P.O. Box 4000, Princeton, New Jersey 08543, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e6544-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i65">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45050" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45050" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Proteros Biostructures GmbH is acknowledged for the purification, crystallization, X-ray data collection, and first maps of the X-ray cocrystal structure of <b>5a</b> bound to the active site of BTK.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">BTK</td><td class="NLM_def"><p class="first last">Bruton’s tyrosine kinase</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-a-go-go-related gene.</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i67">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25218" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25218" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 27 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Jansson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmdahl, R.</span></span> <span> </span><span class="NLM_article-title">Genes on the X chromosome affect development of collagen-induced arthritis in mice</span>. <i>Clin. Exp. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">465</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2249.1993.tb08218.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1111%2Fj.1365-2249.1993.tb08218.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=8252807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADyaK2cXhtVCksL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1993&pages=459-465&author=L.+Janssonauthor=R.+Holmdahl&title=Genes+on+the+X+chromosome+affect+development+of+collagen-induced+arthritis+in+mice&doi=10.1111%2Fj.1365-2249.1993.tb08218.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">Genes on the X chromosome affect development of collagen-induced arthritis in mice</span></div><div class="casAuthors">Jansson, Liselotte; Holmdahl, R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Experimental Immunology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">459-65</span>CODEN:
                <span class="NLM_cas:coden">CEXIAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-9104</span>.
    </div><div class="casAbstract">Susceptibility to collagen-induced arthritis (CIA) in mice is assocd. with a class II gene in MHC (Aq) but also with unknown genes outside MHC.  Investigated here is the influence of genes on the X chromosome as well as the role of the X-linked immunodeficiency (xid) mutation.  Reciprocal male F1 hybrids, bred to be heterozygous or homozygous for Aq, showed a genetic influence in their susceptibility to develop CIA.  Crosses were made between B10.G, B10.Q, DBA/1, SWR/J, C3H.Q and CBA/Ca, and all F1 mice were castrated to avoid sex hormone modulation of the susceptibility.  A differential timing of arthritis onset and severity were seen in the reciprocal F1 males.  An exception was the reciprocal F1 male offspring from SWR/J and DBA/1 crosses which differed only in disease severity late in the course of the disease.  The female F1 crosses did not show the same pattern of differential susceptibility to CIA as the F1 males.  To exclude the possible influence of the Y chromosome, F1 males of reciprocal crosses were back-crossed to the parental strains creating offspring with equal X chromosomes but divergent Y chromosomes.  No difference in development of arthritis was obsd. in these.  The influence of the xid mutation was investigated next.  The xid loci from the CBA/N mouse was bred into DBA/1 strain which is highly susceptible to CIA.  The resulting congenic DBA/1-xid strain was resistant to induction of CIA and did not develop an antibody response to type II collagen.  The authors concluded that polymorphic genes on the X chromosome modulate susceptibility to CIA.  The results from the expts. with mice carrying xid mutations confirm that such immune modulating genes exist on the sex chromosomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXuu6ocKN6h7Vg90H21EOLACvtfcHk0ljYGl66IsBIWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhtVCksL0%253D&md5=77777b6215fb6c1e839b5a68d555df3c</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2249.1993.tb08218.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2249.1993.tb08218.x%26sid%3Dliteratum%253Aachs%26aulast%3DJansson%26aufirst%3DL.%26aulast%3DHolmdahl%26aufirst%3DR.%26atitle%3DGenes%2520on%2520the%2520X%2520chromosome%2520affect%2520development%2520of%2520collagen-induced%2520arthritis%2520in%2520mice%26jtitle%3DClin.%2520Exp.%2520Immunol.%26date%3D1993%26volume%3D94%26spage%3D459%26epage%3D465%26doi%3D10.1111%2Fj.1365-2249.1993.tb08218.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit1b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Steinberg, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smathers, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederiksen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinberg, A. D.</span></span> <span> </span><span class="NLM_article-title">Ability of the <i>xid</i> gene to prevent autoimmunity in (NZBXNZW)F1 mice during the course of their natural history, after polyclonal stimulation, or following immunization with DNA</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">587</span>– <span class="NLM_lpage">597</span>, <span class="refDoi"> DOI: 10.1172/JCI110651</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1172%2FJCI110651" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=6980900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A280%3ADyaL383ms1ejtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=1982&pages=587-597&author=B.+J.+Steinbergauthor=P.+A.+Smathersauthor=K.+Frederiksenauthor=A.+D.+Steinberg&title=Ability+of+the+xid+gene+to+prevent+autoimmunity+in+%28NZBXNZW%29F1+mice+during+the+course+of+their+natural+history%2C+after+polyclonal+stimulation%2C+or+following+immunization+with+DNA&doi=10.1172%2FJCI110651"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">Ability of the xid gene to prevent autoimmunity in (NZB X NZW)F1 mice during the course of their natural history, after polyclonal stimulation, or following immunization with DNA</span></div><div class="casAuthors">Steinberg B J; Smathers P A; Frederiksen K; Steinberg A D</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">587-97</span>
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    </div><div class="casAbstract">F1 hybrid offspring of New Zealand Black mothers and New Zealand White fathers [(NZB X NZW)F1] female mice develop antibodies to single-stranded (ss) and native DNA, immune complex glomerulonephritis, massive proteinuria, and premature death with renal failure.  By a series of matings, congenic (NZB X NZW)F1 . xid/xid mice were prepared.  These mice were different from (NZB X NZW)F1 mice in having the X chromosome-linked immune deficiency gene, xid, in homozygous form.  Such congenic (NZB X NZW)F1 . xid/xid females failed to develop antibodies to single-stranded or native DNA.  They also failed to develop fatal renal disease as measured by proteinuria, glomerular histology, glomerular immunofluorescence, and survival.  To control for unknown genetic factors, studies were performed with littermates that were derived by mating NZB . xid/+ females with NZW . xid/Y males such that the resulting offspring were either (NZB X NZW)F1 . xid/xid (and therefore "defective") or (NZB X NZW)F1 . xid/+ [phenotypically like (NZB X NZW)F1].  In these and in additional studies, mice were housed in the same cages and identified by ear tagging so as to avoid possible environmental variations from cage to cage.  In these studies, xid/xid mice failed to develop the characteristic signs of autoimmunity, whereas the controls did.  Similar results were also obtained with (NZW X NZB)F1 xid/xid mice compared with (NZW X NZB)F1 xid/+ mice.  The effect of xid/xid upon (NZB X NZW)F1 mice was further investigated by assessing responses to immunization and polyclonal B cell activation in vivo.  The xid/xid mice failed to produce anti-ssDNA following immunization with ssDNA complexed to a protein carrier in fluid form or even emulsified in adjuvant.  Finally, the xid/xid mice failed to produce antiDNA in response to multiple injections of the polyclonal activator, bacterial lipopolysaccharide (LPS), or the polyclonal activator, polyribose inosinic acid . polyribose cytidylic acid.  However, the xid/xid mice were neither generally hyporesponsive nor unable to recognize LPS because they made normal antibody responses following immunization with LPS to which multiple trinitrophenyl groups were chemically attached.  We conclude from these studies that xid/xid, which is known to cause the deletion of a B cell subset, has a profound affect upon (NZB X NZW)F1 mice, rendering them insusceptible to the naturally occurring autoimmune disease characteristic of (NZB X NZW)F1 mice, and preventing them from producing antibodies to DNA despite purposeful immunization and polyclonal B cell activation.  These results force a reevaluation of previous concepts regarding the mechanisms by which xid/xid might interfere with the development of autoimmunity, and a consideration of therapeutic implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcThDLn7032pYRBrI9DTGjC0fW6udTcc2eZy4sUmFp7r4bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL383ms1ejtg%253D%253D&md5=8608a4617f65a1c46ef46a6e5388f7a6</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1172%2FJCI110651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI110651%26sid%3Dliteratum%253Aachs%26aulast%3DSteinberg%26aufirst%3DB.%2BJ.%26aulast%3DSmathers%26aufirst%3DP.%2BA.%26aulast%3DFrederiksen%26aufirst%3DK.%26aulast%3DSteinberg%26aufirst%3DA.%2BD.%26atitle%3DAbility%2520of%2520the%2520xid%2520gene%2520to%2520prevent%2520autoimmunity%2520in%2520%2528NZBXNZW%2529F1%2520mice%2520during%2520the%2520course%2520of%2520their%2520natural%2520history%252C%2520after%2520polyclonal%2520stimulation%252C%2520or%2520following%2520immunization%2520with%2520DNA%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1982%26volume%3D70%26spage%3D587%26epage%3D597%26doi%3D10.1172%2FJCI110651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postelnek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vu, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, D.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pashine, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Mahony, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narula, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMartino, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fine, J. S.</span></span> <span> </span><span class="NLM_article-title">RN486, a selective Bruton’s tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>341</i></span>,  <span class="NLM_fpage">90</span>– <span class="NLM_lpage">103</span>, <span class="refDoi"> DOI: 10.1124/jpet.111.187740</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1124%2Fjpet.111.187740" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=22228807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC38XltVagt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=2012&pages=90-103&author=D.+Xuauthor=Y.+Kimauthor=J.+Postelnekauthor=M.+D.+Vuauthor=D.-Q.+Huauthor=C.+Liaoauthor=M.+Bradshawauthor=J.+Hsuauthor=J.+Zhangauthor=A.+Pashineauthor=D.+Srinivasanauthor=J.+Woodsauthor=A.+Levinauthor=A.+O%E2%80%99Mahonyauthor=T.+D.+Owensauthor=Y.+Louauthor=R.+J.+Hillauthor=S.+Narulaauthor=J.+DeMartinoauthor=J.+S.+Fine&title=RN486%2C+a+selective+Bruton%E2%80%99s+tyrosine+kinase+inhibitor%2C+abrogates+immune+hypersensitivity+responses+and+arthritis+in+rodents&doi=10.1124%2Fjpet.111.187740"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents</span></div><div class="casAuthors">Xu, Daigen; Kim, Yong; Postelnek, Jennifer; Vu, Minh Diem; Hu, Dong-Qing; Liao, Cheng; Bradshaw, Mike; Hsu, Jonathan; Zhang, Jun; Pashine, Achal; Srinivasan, Dinesh; Woods, John; Levin, Anita; O'Mahony, Alison; Owens, Timothy D.; Lou, Yan; Hill, Ronald J.; Narula, Satwant; DeMartino, Julie; Fine, Jay S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">90-103</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Genetic mutation and pharmacol. inhibition of Bruton's tyrosine kinase (Btk) both have been shown to prevent the development of collagen-induced arthritis (CIA) in mice, providing a rationale for the development of Btk inhibitors for treating rheumatoid arthritis (RA).  In the present study, we characterized a novel Btk inhibitor, 6-cyclopropyl-8-fluoro-2-(2-hydroxymethyl-3-{1-methyl-5-[5-(4-methyl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-2H-isoquinolin-1-one (RN486), in vitro and in rodent models of immune hypersensitivity and arthritis.  We demonstrated that RN486 not only potently and selectively inhibited the Btk enzyme, but also displayed functional activities in human cell-based assays in multiple cell types, blocking Fcε receptor crosslinking-induced degranulation in mast cells (IC50 = 2.9 nM), Fcγ receptor engagement-mediated tumor necrosis factor α prodn. in monocytes (IC50 = 7.0 nM), and B cell antigen receptor-induced expression of an activation marker, CD69, in B cells in whole blood (IC50 = 21.0 nM).  RN486 displayed similar functional activities in rodent models, effectively preventing type I and type III hypersensitivity responses.  More importantly, RN486 produced robust anti-inflammatory and bone-protective effects in mouse CIA and rat adjuvant-induced arthritis (AIA) models.  In the AIA model, RN486 inhibited both joint and systemic inflammation either alone or in combination with methotrexate, reducing both paw swelling and inflammatory markers in the blood.  Together, our findings not only demonstrate that Btk plays an essential and conserved role in regulating immunoreceptor-mediated immune responses in both humans and rodents, but also provide evidence and mechanistic insights to support the development of selective Btk inhibitors as small-mol. disease-modifying drugs for RA and potentially other autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXBTQENfl5RbVg90H21EOLACvtfcHk0lgQHp9beelQHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltVagt7g%253D&md5=06be56a47afd2eb09e0871710c1d2b47</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.187740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.187740%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DPostelnek%26aufirst%3DJ.%26aulast%3DVu%26aufirst%3DM.%2BD.%26aulast%3DHu%26aufirst%3DD.-Q.%26aulast%3DLiao%26aufirst%3DC.%26aulast%3DBradshaw%26aufirst%3DM.%26aulast%3DHsu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DPashine%26aufirst%3DA.%26aulast%3DSrinivasan%26aufirst%3DD.%26aulast%3DWoods%26aufirst%3DJ.%26aulast%3DLevin%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Mahony%26aufirst%3DA.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DLou%26aufirst%3DY.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DNarula%26aufirst%3DS.%26aulast%3DDeMartino%26aufirst%3DJ.%26aulast%3DFine%26aufirst%3DJ.%2BS.%26atitle%3DRN486%252C%2520a%2520selective%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitor%252C%2520abrogates%2520immune%2520hypersensitivity%2520responses%2520and%2520arthritis%2520in%2520rodents%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D341%26spage%3D90%26epage%3D103%26doi%3D10.1124%2Fjpet.111.187740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balazs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barck, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carano, R. A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darrow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeForge, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrando, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallion, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannetti, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gribling, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropf, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciejewski, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staker, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span> <span> </span><span class="NLM_article-title">Specific Btk inhibition suppresses B cell and myeloid cell-mediated arthritis</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1038/nchembio.481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1038%2Fnchembio.481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=21113169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=41-50&author=J.+A.+Di+Paoloauthor=T.+Huangauthor=M.+Balazsauthor=J.+Barbosaauthor=K.+H.+Barckauthor=B.+J.+Bravoauthor=R.+A.+D.+Caranoauthor=J.+Darrowauthor=D.+R.+Daviesauthor=L.+E.+DeForgeauthor=L.+Diehlauthor=R.+Ferrandoauthor=S.+L.+Gallionauthor=A.+M.+Giannettiauthor=P.+P.+Griblingauthor=V.+Hurezauthor=S.+G.+Hymowitzauthor=R.+Jonesauthor=J.+E.+Kropfauthor=W.+P.+Leeauthor=P.+M.+Maciejewskiauthor=S.+A.+Mitchellauthor=H.+Rongauthor=B.+L.+Stakerauthor=J.+A.+Whitneyauthor=S.+Yehauthor=W.+B.+Youngauthor=C.+Yuauthor=J.+Zhangauthor=K.+Reifauthor=K.+S.+Currie&title=Specific+Btk+inhibition+suppresses+B+cell+and+myeloid+cell-mediated+arthritis&doi=10.1038%2Fnchembio.481"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis</span></div><div class="casAuthors">Di Paolo, Julie A.; Huang, Tao; Balazs, Mercedesz; Barbosa, James; Barck, Kai H.; Bravo, Brandon J.; Carano, Richard A. D.; Darrow, James; Davies, Douglas R.; DeForge, Laura E.; Diehl, Lauri; Ferrando, Ronald; Gallion, Steven L.; Giannetti, Anthony M.; Gribling, Peter; Hurez, Vincent; Hymowitz, Sarah G.; Jones, Randall; Kropf, Jeffrey E.; Lee, Wyne P.; Maciejewski, Patricia M.; Mitchell, Scott A.; Rong, Hong; Staker, Bart L.; Whitney, J. Andrew; Yeh, Sherry; Young, Wendy B.; Yu, Christine; Zhang, Juan; Reif, Karin; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-50</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a therapeutic target for rheumatoid arthritis, but the cellular and mol. mechanisms by which Btk mediates inflammation are poorly understood.  Here we describe the discovery of CGI1746, a small-mol. Btk inhibitor chemotype with a new binding mode that stabilizes an inactive nonphosphorylated enzyme conformation.  CGI1746 has exquisite selectivity for Btk and inhibits both auto- and transphosphorylation steps necessary for enzyme activation.  Using CGI1746, we demonstrate that Btk regulates inflammatory arthritis by two distinct mechanisms.  CGI1746 blocks B cell receptor-dependent B cell proliferation and in prophylactic regimens reduces autoantibody levels in collagen-induced arthritis.  In macrophages, Btk inhibition abolishes FcγRIII-induced TNFα, IL-1β and IL-6 prodn.  Accordingly, in myeloid- and FcγR-dependent autoantibody-induced arthritis, CGI1746 decreases cytokine levels within joints and ameliorates disease.  These results provide new understanding of the function of Btk in both B cell- or myeloid cell-driven disease processes and provide a compelling rationale for targeting Btk in rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoegiZYoitP57Vg90H21EOLACvtfcHk0lj6rbRj-qryRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP&md5=99d925c71bc1b201191ebde0f1c0b50f</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.481%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%2BA.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBarck%26aufirst%3DK.%2BH.%26aulast%3DBravo%26aufirst%3DB.%2BJ.%26aulast%3DCarano%26aufirst%3DR.%2BA.%2BD.%26aulast%3DDarrow%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DD.%2BR.%26aulast%3DDeForge%26aufirst%3DL.%2BE.%26aulast%3DDiehl%26aufirst%3DL.%26aulast%3DFerrando%26aufirst%3DR.%26aulast%3DGallion%26aufirst%3DS.%2BL.%26aulast%3DGiannetti%26aufirst%3DA.%2BM.%26aulast%3DGribling%26aufirst%3DP.%2BP.%26aulast%3DHurez%26aufirst%3DV.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DMaciejewski%26aufirst%3DP.%2BM.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DStaker%26aufirst%3DB.%2BL.%26aulast%3DWhitney%26aufirst%3DJ.%2BA.%26aulast%3DYeh%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DSpecific%2520Btk%2520inhibition%2520suppresses%2520B%2520cell%2520and%2520myeloid%2520cell-mediated%2520arthritis%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D41%26epage%3D50%26doi%3D10.1038%2Fnchembio.481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rankin, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seth, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreyeva, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmonds, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathialagan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benoit, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyashiro, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peeva, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramaiah, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messing, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homer, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunussi-Joannopoulos, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickerson-Nutter, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnute, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douhan, J.,  III.</span></span> <span> </span><span class="NLM_article-title">Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>191</i></span>,  <span class="NLM_fpage">4540</span>– <span class="NLM_lpage">4550</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1301553</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.4049%2Fjimmunol.1301553" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=24068666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1eqs7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2013&pages=4540-4550&author=A.+L.+Rankinauthor=N.+Sethauthor=S.+Keeganauthor=T.+Andreyevaauthor=T.+A.+Cookauthor=J.+Edmondsauthor=N.+Mathialaganauthor=M.+J.+Bensonauthor=J.+Syedauthor=Y.+Zhanauthor=S.+E.+Benoitauthor=J.+S.+Miyashiroauthor=N.+Woodauthor=S.+Mohanauthor=E.+Peevaauthor=S.+K.+Ramaiahauthor=D.+Messingauthor=B.+L.+Homerauthor=K.+Dunussi-Joannopoulosauthor=C.+L.+Nickerson-Nutterauthor=M.+E.+Schnuteauthor=J.+Douhan&title=Selective+inhibition+of+BTK+prevents+murine+lupus+and+antibody-mediated+glomerulonephritis&doi=10.4049%2Fjimmunol.1301553"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2cR"><div class="casContent"><span class="casTitleNuber">2c</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of BTK Prevents Murine Lupus and Antibody-Mediated Glomerulonephritis</span></div><div class="casAuthors">Rankin, Andrew L.; Seth, Nilufer; Keegan, Sean; Andreyeva, Tatyana; Cook, Tim A.; Edmonds, Jason; Mathialagan, Nagappan; Benson, Micah J.; Syed, Jameel; Zhan, Yutian; Benoit, Stephen E.; Miyashiro, Joy S.; Wood, Nancy; Mohan, Shashi; Peeva, Elena; Ramaiah, Shashi K.; Messing, Dean; Homer, Bruce L.; Dunussi-Joannopoulos, Kyri; Nickerson-Nutter, Cheryl L.; Schnute, Mark E.; Douhan, John, III</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4540-4550</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Autoantibody prodn. and immune complex deposition within the kidney promote renal disease in patients with lupus nephritis.  Thus, therapeutics that inhibit these pathways may be efficacious in the treatment of systemic lupus erythematosus.  Bruton's tyrosine kinase (BTK) is a crit. signaling component of both BCR and FcR signaling.  We sought to assess the efficacy of inhibiting BTK in the development of lupus-like disease, and in this article describe (R)-5-amino-1-(1-cyanopiperidin-3-yl)-3-(4-[2,4-difluorophenoxy]phenyl)-1H-pyrazole-4-carboxamide (PF-06250112), a novel highly selective and potent BTK inhibitor.  We demonstrate in vitro that PF-06250112 inhibits both BCR-mediated signaling and proliferation, as well as FcR-mediated activation.  To assess the therapeutic impact of BTK inhibition, we treated aged NZBxWF1 mice with PF-06250112 and demonstrate that PF-06250112 significantly limits the spontaneous accumulation of splenic germinal center B cells and plasma cells.  Correspondingly, anti-dsDNA and autoantibody levels were reduced in a dose-dependent manner.  Moreover, administration of PF-06250112 prevented the development of proteinuria and improved glomerular pathol. scores in all treatment groups.  Strikingly, this therapeutic effect could occur with only a modest redn. obsd. in anti-dsDNA titers, implying a crit. role for BTK signaling in disease pathogenesis beyond inhibition of autoantibody prodn.  We subsequently demonstrate that PF-06250112 prevents proteinuria in an FcR-dependent, Ab-mediated model of glomerulonephritis.  Importantly, these results highlight that BTK inhibition potently limits the development of glomerulonephritis by impacting both cell- and effector mol.-mediated pathways.  These data provide support for evaluating the efficacy of BTK inhibition in systemic lupus erythematosus patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBldekay4INLVg90H21EOLACvtfcHk0lj6rbRj-qryRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1eqs7zE&md5=7abfb074bf422aa3fb63aa0bc3d8cf58</span></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1301553&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1301553%26sid%3Dliteratum%253Aachs%26aulast%3DRankin%26aufirst%3DA.%2BL.%26aulast%3DSeth%26aufirst%3DN.%26aulast%3DKeegan%26aufirst%3DS.%26aulast%3DAndreyeva%26aufirst%3DT.%26aulast%3DCook%26aufirst%3DT.%2BA.%26aulast%3DEdmonds%26aufirst%3DJ.%26aulast%3DMathialagan%26aufirst%3DN.%26aulast%3DBenson%26aufirst%3DM.%2BJ.%26aulast%3DSyed%26aufirst%3DJ.%26aulast%3DZhan%26aufirst%3DY.%26aulast%3DBenoit%26aufirst%3DS.%2BE.%26aulast%3DMiyashiro%26aufirst%3DJ.%2BS.%26aulast%3DWood%26aufirst%3DN.%26aulast%3DMohan%26aufirst%3DS.%26aulast%3DPeeva%26aufirst%3DE.%26aulast%3DRamaiah%26aufirst%3DS.%2BK.%26aulast%3DMessing%26aufirst%3DD.%26aulast%3DHomer%26aufirst%3DB.%2BL.%26aulast%3DDunussi-Joannopoulos%26aufirst%3DK.%26aulast%3DNickerson-Nutter%26aufirst%3DC.%2BL.%26aulast%3DSchnute%26aufirst%3DM.%2BE.%26aulast%3DDouhan%26aufirst%3DJ.%26atitle%3DSelective%2520inhibition%2520of%2520BTK%2520prevents%2520murine%2520lupus%2520and%2520antibody-mediated%2520glomerulonephritis%26jtitle%3DJ.%2520Immunol.%26date%3D2013%26volume%3D191%26spage%3D4540%26epage%3D4550%26doi%3D10.4049%2Fjimmunol.1301553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mease, P. J.</span></span> <span> </span><span class="NLM_article-title">B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application</span>. <i>J. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">1245</span>– <span class="NLM_lpage">1255</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=18609733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpslajtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2008&pages=1245-1255&author=P.+J.+Mease&title=B+cell-targeted+therapy+in+autoimmune+disease%3A+rationale%2C+mechanisms%2C+and+clinical+application"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application</span></div><div class="casAuthors">Mease, Philip J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Rheumatology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1245-1255</span>CODEN:
                <span class="NLM_cas:coden">JRHUA9</span>;
        ISSN:<span class="NLM_cas:issn">0315-162X</span>.
    
            (<span class="NLM_cas:orgname">Journal of Rheumatology Publishing Co. Ltd.</span>)
        </div><div class="casAbstract">A review.  B cells play a crit. role in the pathogenesis of rheumatoid arthritis (RA) and other autoimmune diseases.  Recently, a no. of biol. agents that target B cells have been tested as therapies for these conditions.  These agents either deplete B cells, by targeting cell-surface antigens such as CD20, or block B cell function, for example by inhibiting the activity of B cell survival factors such as BLyS.  Of this group of agents, the first in clin. use has been rituximab, a chimeric monoclonal antibody that depletes B cells by binding to the CD20 cell-surface antigen.  Initially introduced as a treatment for non-Hodgkin's lymphoma, rituximab is now approved for the treatment of RA.  In this review we explore the rationale behind B cell-targeted therapy, highlight the results of clin. trials with rituximab in RA and other autoimmune diseases, and describe other emerging therapies directed at B cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEpprn0Fq_lLVg90H21EOLACvtfcHk0lj0dMtoAsYfgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpslajtro%253D&md5=1e31bd50b6afae7e8273a1da7a06f828</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMease%26aufirst%3DP.%2BJ.%26atitle%3DB%2520cell-targeted%2520therapy%2520in%2520autoimmune%2520disease%253A%2520rationale%252C%2520mechanisms%252C%2520and%2520clinical%2520application%26jtitle%3DJ.%2520Rheumatol.%26date%3D2008%26volume%3D35%26spage%3D1245%26epage%3D1255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Mohamed, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bäckesjö, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vargas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faryal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aints, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berglöf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vihinen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nore, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. I. E.</span></span> <span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain</span>. <i>Immunol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>228</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.1111/j.1600-065X.2008.00741.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1111%2Fj.1600-065X.2008.00741.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=19290921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=2009&pages=58-73&author=A.+J.+Mohamedauthor=L.+Yuauthor=C.-M.+B%C3%A4ckesj%C3%B6author=L.+Vargasauthor=R.+Faryalauthor=A.+Aintsauthor=B.+Christenssonauthor=A.+Bergl%C3%B6fauthor=M.+Vihinenauthor=B.+F.+Noreauthor=C.+I.+E.+Smith&title=Bruton%E2%80%99s+tyrosine+kinase+%28Btk%29%3A+function%2C+regulation%2C+and+transformation+with+special+emphasis+on+the+PH+domain&doi=10.1111%2Fj.1600-065X.2008.00741.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain</span></div><div class="casAuthors">Mohamed, Abdalla J.; Yu, Liang; Backesjo, Carl-Magnus; Vargas, Leonardo; Faryal, Rani; Aints, Alar; Christensson, Birger; Berglof, Anna; Vihinen, Mauno; Nore, Beston F.; Smith, C. I. Edvard</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">228</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-73</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Bruton's agammaglobulinemia tyrosine kinase (Btk) is a cytoplasmic tyrosine kinase important in B-lymphocyte development, differentiation, and signaling.  Btk is a member of the Tec family of kinases.  Mutations in the Elk gene lead to X-linked agammaglobulinemia (XLA) in humans and X-linked immunodeficiency (Xid) in mice.  Activation of Btk triggers a cascade of signaling events that culminates in the generation of calcium mobilization and fluxes, cytoskeletal rearrangements, and transcriptional regulation involving nuclear factor-κB (NF-κB) and nuclear factor of activated T cells (NFAT).  In B cells, NF-κB was shown to bind to the Btk promoter and induce transcription, whereas the B-cell receptor-dependent NF-κB signaling pathway requires functional Btk.  Moreover, Btk activation is tightly regulated by a plethora of other signaling proteins including protein kinase C (PKC), Sab/SH3BP5, and caveolin-1.  For example, the prolyl isomerase Pin1 neg. regulates Btk by decreasing tyrosine phosphorylation and steady state levels of Btk.  It is intriguing that PKC and Pin1, both of which are neg. regulators, bind to the pleckstrin homol. domain of Btk.  To this end, we describe here novel mutations in the pleckstrin homol. domain investigated for their transforming capacity.  In particular, we show that the mutant D43R behaves similar to E41K, already known to possess such activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpo1L-Ch4HjNLVg90H21EOLACvtfcHk0lj0dMtoAsYfgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7rO&md5=7a84f2b3604d67bcc1490fadcbfea234</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00741.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00741.x%26sid%3Dliteratum%253Aachs%26aulast%3DMohamed%26aufirst%3DA.%2BJ.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DB%25C3%25A4ckesj%25C3%25B6%26aufirst%3DC.-M.%26aulast%3DVargas%26aufirst%3DL.%26aulast%3DFaryal%26aufirst%3DR.%26aulast%3DAints%26aufirst%3DA.%26aulast%3DChristensson%26aufirst%3DB.%26aulast%3DBergl%25C3%25B6f%26aufirst%3DA.%26aulast%3DVihinen%26aufirst%3DM.%26aulast%3DNore%26aufirst%3DB.%2BF.%26aulast%3DSmith%26aufirst%3DC.%2BI.%2BE.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528Btk%2529%253A%2520function%252C%2520regulation%252C%2520and%2520transformation%2520with%2520special%2520emphasis%2520on%2520the%2520PH%2520domain%26jtitle%3DImmunol.%2520Rev.%26date%3D2009%26volume%3D228%26spage%3D58%26epage%3D73%26doi%3D10.1111%2Fj.1600-065X.2008.00741.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit4b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Mohamed, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nore, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. I. E.</span></span> <span> </span><span class="NLM_article-title">Signaling of Bruton’s tyrosine kinase, Btk</span>. <i>Scand. J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">118</span>, <span class="refDoi"> DOI: 10.1046/j.1365-3083.1999.00504.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1046%2Fj.1365-3083.1999.00504.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10075013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADyaK1MXhslSisr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1999&pages=113-118&author=A.+J.+Mohamedauthor=B.+F.+Noreauthor=B.+Christenssonauthor=C.+I.+E.+Smith&title=Signaling+of+Bruton%E2%80%99s+tyrosine+kinase%2C+Btk&doi=10.1046%2Fj.1365-3083.1999.00504.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">Signalling of Bruton's tyrosine kinase, Btk</span></div><div class="casAuthors">Mohamed, A. J.; Nore, B. F.; Christensson, B.; Smith, C. I. E.</div><div class="citationInfo"><span class="NLM_cas:title">Scandinavian Journal of Immunology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">113-118</span>CODEN:
                <span class="NLM_cas:coden">SJIMAX</span>;
        ISSN:<span class="NLM_cas:issn">0300-9475</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">A review with 63 refs.  Bruton's tyrosine kinase, which is encoded by the BTK gene, is a cytoplasmic protein tyrosine kinase (PTK) crucial for B-cell development and differentiation.  It belongs to the Tec family of PTKs contg. several domains that are characteristic of signalling mols.  In humans, mutations that disrupt the function of this gene lead to the classical XLA syndrome (X-linked agammaglobulinemia), a primary immunodeficiency mainly characterized by lack of mature B cells as well as low levels of Igs.  In contrast, animal models of this disease such as the xid mice display profoundly milder XLA phenotype.  BTK phosphorylation and activation in response to engagement of the B-cell receptor (BCR) by antigen is a dynamic process whereby a variety of proteins interact with each other and recruit signalling mols. resulting in a physiol. response such as B-cell proliferation and antibody prodn.  The main players, however, that participate in the intracellular downstream cascade have not yet been identified and are therefore under intense scrutiny in several labs.  This review discusses certain aspects of BTK activation following receptor stimulation by agonists and how this event is translated into the biochem. signals within the cell that eventually lead to nuclear responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphmZBDkpS1ubVg90H21EOLACvtfcHk0lgS5PnVOrvgow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhslSisr0%253D&md5=a3842c00d3cd4e45458c050941026476</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-3083.1999.00504.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-3083.1999.00504.x%26sid%3Dliteratum%253Aachs%26aulast%3DMohamed%26aufirst%3DA.%2BJ.%26aulast%3DNore%26aufirst%3DB.%2BF.%26aulast%3DChristensson%26aufirst%3DB.%26aulast%3DSmith%26aufirst%3DC.%2BI.%2BE.%26atitle%3DSignaling%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%252C%2520Btk%26jtitle%3DScand.%2520J.%2520Immunol.%26date%3D1999%26volume%3D49%26spage%3D113%26epage%3D118%26doi%3D10.1046%2Fj.1365-3083.1999.00504.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit4c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Takata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurosaki, T.</span></span> <span> </span><span class="NLM_article-title">A role for Bruton’s tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-γ2</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>184</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">40</span>, <span class="refDoi"> DOI: 10.1084/jem.184.1.31</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1084%2Fjem.184.1.31" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=8691147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADyaK28Xkt1ajs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=1996&pages=31-40&author=M.+Takataauthor=T.+Kurosaki&title=A+role+for+Bruton%E2%80%99s+tyrosine+kinase+in+B+cell+antigen+receptor-mediated+activation+of+phospholipase+C-%CE%B32&doi=10.1084%2Fjem.184.1.31"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4cR"><div class="casContent"><span class="casTitleNuber">4c</span><div class="casTitle"><span class="NLM_cas:atitle">A role for Bruton's tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-γ2</span></div><div class="casAuthors">Takata, Minoru; Kurosaki, Tomohiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-40</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Defects in the gene encoding Bruton's tyrosine kinase (Btk) result in a disease called X-linked agammaglobulinemia, in which there is a profound decrease of mature B cells due to a block in B cell development.  Recent studies have shown that Btk is tyrosine phosphorylated and activated upon B cell antigen receptor (BCR) stimulation.  To elucidate the functions of this kinase, we examd. BCR signaling of DT40 B cells deficient in Btk.  Tyrosine phosphorylation of phospholipase C (PLC)-γ2 upon receptor stimulation was significantly reduced in the mutant cells, leading to the loss of both BCR-coupled phosphatidylinositol hydrolysis and calcium mobilization.  Pleckstrin homol. and Src-homol. 2 domains of Btk were required for PLC-γ2 activation.  Since Syk is also required for the BCR-induced PLC-γ2 activation, our findings indicate that PLC-γ2 activation is regulated by Btk and Syk through their concerted actions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrvJR6GCfI7rVg90H21EOLACvtfcHk0lgS5PnVOrvgow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xkt1ajs74%253D&md5=7244a36ac8298ccde274e05016ec68ba</span></div><a href="/servlet/linkout?suffix=cit4c&amp;dbid=16384&amp;doi=10.1084%2Fjem.184.1.31&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.184.1.31%26sid%3Dliteratum%253Aachs%26aulast%3DTakata%26aufirst%3DM.%26aulast%3DKurosaki%26aufirst%3DT.%26atitle%3DA%2520role%2520for%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520in%2520B%2520cell%2520antigen%2520receptor-mediated%2520activation%2520of%2520phospholipase%2520C-%25CE%25B32%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D1996%26volume%3D184%26spage%3D31%26epage%3D40%26doi%3D10.1084%2Fjem.184.1.31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Jongstra-Bilen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puig Cano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasija, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cybulsky, M. I.</span></span> <span> </span><span class="NLM_article-title">Dual functions of Bruton’s tyrosine kinase and Tec kinase during Fcγ receptor-induced signaling and phagocytosis</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">288</span>– <span class="NLM_lpage">298</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.181.1.288</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.4049%2Fjimmunol.181.1.288" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2008&pages=288-298&author=J.+Jongstra-Bilenauthor=A.+Puig+Canoauthor=M.+Hasijaauthor=H.+Xiaoauthor=C.+I.+Smithauthor=M.+I.+Cybulsky&title=Dual+functions+of+Bruton%E2%80%99s+tyrosine+kinase+and+Tec+kinase+during+Fc%CE%B3+receptor-induced+signaling+and+phagocytosis&doi=10.4049%2Fjimmunol.181.1.288"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.181.1.288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.181.1.288%26sid%3Dliteratum%253Aachs%26aulast%3DJongstra-Bilen%26aufirst%3DJ.%26aulast%3DPuig%2BCano%26aufirst%3DA.%26aulast%3DHasija%26aufirst%3DM.%26aulast%3DXiao%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DC.%2BI.%26aulast%3DCybulsky%26aufirst%3DM.%2BI.%26atitle%3DDual%2520functions%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520and%2520Tec%2520kinase%2520during%2520Fc%25CE%25B3%2520receptor-induced%2520signaling%2520and%2520phagocytosis%26jtitle%3DJ.%2520Immunol.%26date%3D2008%26volume%3D181%26spage%3D288%26epage%3D298%26doi%3D10.4049%2Fjimmunol.181.1.288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit5b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kuehn, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radinger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanhaesebroeck, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaven, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalfe, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilfillan, A. M.</span></span> <span> </span><span class="NLM_article-title">Btk-dependent Rac activation and actin rearrangement following FcεRI aggregation promotes enhanced chemotactic responses of mast cells</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">2576</span>– <span class="NLM_lpage">2585</span>, <span class="refDoi"> DOI: 10.1242/jcs.071043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1242%2Fjcs.071043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=20587594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtF2mtL7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2010&pages=2576-2585&author=H.+S.+Kuehnauthor=M.+Radingerauthor=J.+M.+Brownauthor=K.+Aliauthor=B.+Vanhaesebroeckauthor=M.+A.+Beavenauthor=D.+D.+Metcalfeauthor=A.+M.+Gilfillan&title=Btk-dependent+Rac+activation+and+actin+rearrangement+following+Fc%CE%B5RI+aggregation+promotes+enhanced+chemotactic+responses+of+mast+cells&doi=10.1242%2Fjcs.071043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">Btk-dependent Rac activation and actin rearrangement following FcεRI aggregation promotes enhanced chemotactic responses of mast cells</span></div><div class="casAuthors">Kuehn, Hye Sun; Radinger, Madeleine; Brown, Jared M.; Ali, Khaled; Vanhaesebroeck, Bart; Beaven, Michael A.; Metcalfe, Dean D.; Gilfillan, Alasdair M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2576-2585</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">Mast cells infiltrate the sites of inflammation assocd. with chronic atopic disease and during helminth and bacterial infection.  This process requires receptor-mediated cell chemotaxis across a concn. gradient of their chemotactic ligands.  In vivo, mast cells are likely to be exposed to several such agents, which can cooperate in a synergistic manner to regulate mast cell homing.  Here, we report that chemotaxis of mouse bone-marrow-derived mast cells (BMMCs) in response to the chemoattractants stem-cell factor (SCF) and prostaglandin (PG)E2, is substantially enhanced following antigen-dependent ligation of the high-affinity receptor for IgE (FcεRI).  These responses were assocd. with enhanced activation of phosphoinositide 3-kinase (PI3K), and downstream activation of the tyrosine protein kinase Btk, with subsequent enhanced phospholipase (PL)Cγ-mediated Ca2+ mobilization, Rac activation and F-actin rearrangement.  Antigen-induced chemotaxis, and the ability of antigen to amplify responses mediated by SCF, adenosine and PGE2 were suppressed following inhibition of PI3K, and were impaired in BMMCs derived from Btk-/- mice.  There were corresponding decreases in the PLCγ-mediated Ca2+ signal, Rac activation and F-actin rearrangement, which, as they are essential for BMMC chemotaxis, accounts for the impaired migration of Btk-deficient cells.  Taken together, these data demonstrate that, by regulating signaling pathways that control F-actin rearrangement, Btk is crucial for the ability of antigen to amplify mast-cell chemotactic responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx05z-3Sv-D7Vg90H21EOLACvtfcHk0lhmvHuRfVZo_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtF2mtL7O&md5=2a02fc66a2b3994eb6c983a8c3b91f63</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1242%2Fjcs.071043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.071043%26sid%3Dliteratum%253Aachs%26aulast%3DKuehn%26aufirst%3DH.%2BS.%26aulast%3DRadinger%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DJ.%2BM.%26aulast%3DAli%26aufirst%3DK.%26aulast%3DVanhaesebroeck%26aufirst%3DB.%26aulast%3DBeaven%26aufirst%3DM.%2BA.%26aulast%3DMetcalfe%26aufirst%3DD.%2BD.%26aulast%3DGilfillan%26aufirst%3DA.%2BM.%26atitle%3DBtk-dependent%2520Rac%2520activation%2520and%2520actin%2520rearrangement%2520following%2520Fc%25CE%25B5RI%2520aggregation%2520promotes%2520enhanced%2520chemotactic%2520responses%2520of%2520mast%2520cells%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2010%26volume%3D123%26spage%3D2576%26epage%3D2585%26doi%3D10.1242%2Fjcs.071043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit5c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawlings, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, O. N.</span></span> <span> </span><span class="NLM_article-title">Role of Bruton’s tyrosine kinase in immunodeficiency</span>. <i>Curr. Opin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">623</span>– <span class="NLM_lpage">630</span>, <span class="refDoi"> DOI: 10.1016/0952-7915(94)90151-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1016%2F0952-7915%2894%2990151-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=7946052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADyaK2cXlsFCqur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1994&pages=623-630&author=S.+Tsukadaauthor=D.+J.+Rawlingsauthor=O.+N.+Witte&title=Role+of+Bruton%E2%80%99s+tyrosine+kinase+in+immunodeficiency&doi=10.1016%2F0952-7915%2894%2990151-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5cR"><div class="casContent"><span class="casTitleNuber">5c</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Bruton's tyrosine kinase in immunodeficiency</span></div><div class="casAuthors">Tsukada, Satoshi; Rawlings, David J.; Witte, Owen N.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Immunology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">623-30</span>CODEN:
                <span class="NLM_cas:coden">COPIEL</span>;
        ISSN:<span class="NLM_cas:issn">0952-7915</span>.
    </div><div class="casAbstract">A review, with 71 refs.  The genetic defect assocd. with human X-linked agammaglobulinemia and murine X-linked immunodeficiency was recently shown to result from lack of function of a new cytoplasmic tyrosine kinase, called Bruton's tyrosine kinase (Btk).  The phenotypes assocd. with these immunodeficiencies indicate that Btk plays a crit. role in B lymphocyte development.  The distinctive protein structure of Btk and preliminary functional studies suggest that Btk may act in a novel manner in a variety of signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAyW0bZjSS3rVg90H21EOLACvtfcHk0lhmvHuRfVZo_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXlsFCqur8%253D&md5=d9932cf5d56f7a77723a46cae519cbeb</span></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=10.1016%2F0952-7915%2894%2990151-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0952-7915%252894%252990151-1%26sid%3Dliteratum%253Aachs%26aulast%3DTsukada%26aufirst%3DS.%26aulast%3DRawlings%26aufirst%3DD.%2BJ.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26atitle%3DRole%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520in%2520immunodeficiency%26jtitle%3DCurr.%2520Opin.%2520Immunol.%26date%3D1994%26volume%3D6%26spage%3D623%26epage%3D630%26doi%3D10.1016%2F0952-7915%2894%2990151-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y.</span></span> <span> </span><span class="NLM_article-title">The Tec family tyrosine kinase Btk regulates RANKL-induced osteoclast maturation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">11526</span>– <span class="NLM_lpage">11534</span>, <span class="refDoi"> DOI: 10.1074/jbc.M708935200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1074%2Fjbc.M708935200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=11526-11534&author=S.+H.+Leeauthor=T.+Kimauthor=D.+Jeongauthor=N.+Kimauthor=Y.+Choi&title=The+Tec+family+tyrosine+kinase+Btk+regulates+RANKL-induced+osteoclast+maturation&doi=10.1074%2Fjbc.M708935200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M708935200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M708935200%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DT.%26aulast%3DJeong%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DN.%26aulast%3DChoi%26aufirst%3DY.%26atitle%3DThe%2520Tec%2520family%2520tyrosine%2520kinase%2520Btk%2520regulates%2520RANKL-induced%2520osteoclast%2520maturation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26spage%3D11526%26epage%3D11534%26doi%3D10.1074%2Fjbc.M708935200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Middendorp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dingjan, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlenborg, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendriks, R. W.</span></span> <span> </span><span class="NLM_article-title">Function of Bruton’s tyrosine kinase during B cell development is partially independent of its catalytic activity</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>171</i></span>,  <span class="NLM_fpage">5988</span>– <span class="NLM_lpage">5996</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.171.11.5988</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.4049%2Fjimmunol.171.11.5988" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2003&pages=5988-5996&author=S.+Middendorpauthor=G.+M.+Dingjanauthor=A.+Maasauthor=K.+Dahlenborgauthor=R.+W.+Hendriks&title=Function+of+Bruton%E2%80%99s+tyrosine+kinase+during+B+cell+development+is+partially+independent+of+its+catalytic+activity&doi=10.4049%2Fjimmunol.171.11.5988"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.171.11.5988&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.171.11.5988%26sid%3Dliteratum%253Aachs%26aulast%3DMiddendorp%26aufirst%3DS.%26aulast%3DDingjan%26aufirst%3DG.%2BM.%26aulast%3DMaas%26aufirst%3DA.%26aulast%3DDahlenborg%26aufirst%3DK.%26aulast%3DHendriks%26aufirst%3DR.%2BW.%26atitle%3DFunction%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520during%2520B%2520cell%2520development%2520is%2520partially%2520independent%2520of%2520its%2520catalytic%2520activity%26jtitle%3DJ.%2520Immunol.%26date%3D2003%26volume%3D171%26spage%3D5988%26epage%3D5996%26doi%3D10.4049%2Fjimmunol.171.11.5988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Petro, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, S. M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, W. N.</span></span> <span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase is required for activation of IκB kinase and nuclear factor κB in response to B cell receptor engagement</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>191</i></span>,  <span class="NLM_fpage">1745</span>– <span class="NLM_lpage">1753</span>, <span class="refDoi"> DOI: 10.1084/jem.191.10.1745</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1084%2Fjem.191.10.1745" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2000&pages=1745-1753&author=J.+B.+Petroauthor=S.+M.+J.+Rahmanauthor=D.+W.+Ballardauthor=W.+N.+Khan&title=Bruton%E2%80%99s+tyrosine+kinase+is+required+for+activation+of+I%CE%BAB+kinase+and+nuclear+factor+%CE%BAB+in+response+to+B+cell+receptor+engagement&doi=10.1084%2Fjem.191.10.1745"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1084%2Fjem.191.10.1745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.191.10.1745%26sid%3Dliteratum%253Aachs%26aulast%3DPetro%26aufirst%3DJ.%2BB.%26aulast%3DRahman%26aufirst%3DS.%2BM.%2BJ.%26aulast%3DBallard%26aufirst%3DD.%2BW.%26aulast%3DKhan%26aufirst%3DW.%2BN.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520is%2520required%2520for%2520activation%2520of%2520I%25CE%25BAB%2520kinase%2520and%2520nuclear%2520factor%2520%25CE%25BAB%2520in%2520response%2520to%2520B%2520cell%2520receptor%2520engagement%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2000%26volume%3D191%26spage%3D1745%26epage%3D1753%26doi%3D10.1084%2Fjem.191.10.1745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whyburn, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halcomb, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contreras, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, O. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satterthwaite, A. B.</span></span> <span> </span><span class="NLM_article-title">Haploinsufficiency of B cell linker protein enhanced B cell signaling defects in mice expressing a limiting dosage of Bruton’s tyrosine kinase</span>. <i>Int. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">383</span>– <span class="NLM_lpage">392</span>, <span class="refDoi"> DOI: 10.1093/intimm/dxg034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1093%2Fintimm%2Fdxg034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=12618482" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitFKlsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2003&pages=383-392&author=L.+R.+Whyburnauthor=K.+E.+Halcombauthor=C.+M.+Contrerasauthor=R.+Pappuauthor=O.+N.+Witteauthor=A.+C.+Chanauthor=A.+B.+Satterthwaite&title=Haploinsufficiency+of+B+cell+linker+protein+enhanced+B+cell+signaling+defects+in+mice+expressing+a+limiting+dosage+of+Bruton%E2%80%99s+tyrosine+kinase&doi=10.1093%2Fintimm%2Fdxg034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Haploinsufficiency of B cell linker protein enhances B cell signaling defects in mice expressing a limiting dosage of Bruton's tyrosine kinase</span></div><div class="casAuthors">Whyburn, Lindsey R.; Halcomb, Kristina E.; Contreras, Cristina M.; Pappu, Rajita; Witte, Owen N.; Chan, Andrew C.; Satterthwaite, Anne B.</div><div class="citationInfo"><span class="NLM_cas:title">International Immunology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">383-392</span>CODEN:
                <span class="NLM_cas:coden">INIMEN</span>;
        ISSN:<span class="NLM_cas:issn">0953-8178</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Current models of lymphocyte activation suggest that formation of a signaling complex, or signalosome', composed of Syk, Bruton's tyrosine kinase (Btk), phospholipase γ2 and the adaptor protein B cell linker protein (BLNK) is crit. for transmission of signals from the BCR.  However, impaired B cell development in mice lacking each individual signalosome component has made it difficult to study the functional consequences of the formation of this complex in mature B cells.  Sensitized genetic systems, commonly used in Drosophila, define signaling pathways by combining partial loss of function mutations in the components of interest.  This allows genetic interactions to be obsd. in the absence of pleiotropic or lethal effects of complete deficiency of either gene.  We used this approach to demonstrate that Btk and BLNK are limiting components of a common signaling pathway that mediates the mitogenic response of mature B cells to antigen.  B cells from transgenic mice expressing a limiting dosage of Btk (Btklo) have normal nos. of mature B cells that have reduced, but measurable, responses to BCR crosslinking.  Haploinsufficiency of BLNK did not affect the development of Btklo B cells.  However, it exacerbated their defects in BCR-induced Ca2+ flux, IκB degrdn., and up-regulation of cyclin D2, bcl-xL and A1 leading to dramatic impairment of B cell mitogenic responses.  In contrast, no effect of reduced Btk and BLNK dosage was obsd. on extracellular signal-regulated kinase activation.  These results suggest that the signals regulating the maintenance and activation of mature B cells are differentially sensitive to the strength of the signal emanating from the signalosome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrowqlQ3xDitLVg90H21EOLACvtfcHk0ljcT9cpi2hEgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitFKlsL4%253D&md5=8d56f66c8b68159d61a86322e174c81f</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1093%2Fintimm%2Fdxg034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fintimm%252Fdxg034%26sid%3Dliteratum%253Aachs%26aulast%3DWhyburn%26aufirst%3DL.%2BR.%26aulast%3DHalcomb%26aufirst%3DK.%2BE.%26aulast%3DContreras%26aufirst%3DC.%2BM.%26aulast%3DPappu%26aufirst%3DR.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26aulast%3DChan%26aufirst%3DA.%2BC.%26aulast%3DSatterthwaite%26aufirst%3DA.%2BB.%26atitle%3DHaploinsufficiency%2520of%2520B%2520cell%2520linker%2520protein%2520enhanced%2520B%2520cell%2520signaling%2520defects%2520in%2520mice%2520expressing%2520a%2520limiting%2520dosage%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DInt.%2520Immunol.%26date%3D2003%26volume%3D15%26spage%3D383%26epage%3D392%26doi%3D10.1093%2Fintimm%2Fdxg034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taunton, J.</span></span> <span> </span><span class="NLM_article-title">Structural bioinformatics-based design of selective, irreversible kinase inhibitors</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>308</i></span>,  <span class="NLM_fpage">1318</span>– <span class="NLM_lpage">1321</span>, <span class="refDoi"> DOI: 10.1126/science1108367</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1126%2Fscience1108367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=15919995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1Ciurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=308&publication_year=2005&pages=1318-1321&author=M.+S.+Cohenauthor=C.+Zhangauthor=K.+M.+Shokatauthor=J.+Taunton&title=Structural+bioinformatics-based+design+of+selective%2C+irreversible+kinase+inhibitors&doi=10.1126%2Fscience1108367"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9a</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors</span></div><div class="casAuthors">Cohen, Michael S.; Zhang, Chao; Shokat, Kevan M.; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">308</span>
        (<span class="NLM_cas:issue">5726</span>),
    <span class="NLM_cas:pages">1318-1321</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The active sites of 491 human protein kinase domains are highly conserved, which makes the design of selective inhibitors a formidable challenge.  We used a structural bioinformatics approach to identify two selectivity filters, a threonine and a cysteine, at defined positions in the active site of p90 ribosomal protein S6 kinase (RSK).  A fluoromethylketone inhibitor, designed to exploit both selectivity filters, potently and selectively inactivated RSK1 and RSK2 in mammalian cells.  Kinases with only one selectivity filter were resistant to the inhibitor, yet they became sensitized after genetic introduction of the second selectivity filter.  Thus, two amino acids that distinguish RSK from other protein kinases are sufficient to confer inhibitor sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovfUrzVFth_bVg90H21EOLACvtfcHk0ljExk46eQgxTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1Ciurs%253D&md5=1364444dada4d1d46510aa0212428952</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1126%2Fscience1108367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience1108367%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DM.%2BS.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DStructural%2520bioinformatics-based%2520design%2520of%2520selective%252C%2520irreversible%2520kinase%2520inhibitors%26jtitle%3DScience%26date%3D2005%26volume%3D308%26spage%3D1318%26epage%3D1321%26doi%3D10.1126%2Fscience1108367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit9b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Leproult, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barluenga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moras, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurtz, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winssinger, N.</span></span> <span> </span><span class="NLM_article-title">Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1347</span>– <span class="NLM_lpage">1355</span>, <span class="refDoi"> DOI: 10.1021/jm101396q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101396q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvFeis70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1347-1355&author=E.+Leproultauthor=S.+Barluengaauthor=D.+Morasauthor=J.-M.+Wurtzauthor=N.+Winssinger&title=Cysteine+mapping+in+conformationally+distinct+kinase+nucleotide+binding+sites%3A+application+to+the+design+of+selective+covalent+inhibitors&doi=10.1021%2Fjm101396q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors</span></div><div class="casAuthors">Leproult, Emeline; Barluenga, Sofia; Moras, Dino; Wurtz, Jean-Marie; Winssinger, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1347-1355</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Kinases have emerged as one of the most prolific therapeutic targets.  An important criterion in the therapeutic success of inhibitors targeting the nucleotide binding pocket of kinases is the inhibitor residence time.  Recently, covalent kinase inhibitors have attracted attention since they confer terminal inhibition and should thus be more effective than reversible inhibitors with transient inhibition.  The most robust approach to design irreversible inhibitors is to capitalize on the nucleophilicity of a cysteine thiol group present in the target protein.  Herein, the authors report a systematic anal. of cysteine residues present in the nucleotide binding site of kinases, which could be harnessed for irreversible inhibition, taking into consideration the different kinase conformations.  The authors demonstrate the predictive power of this anal. with the design and validation of an irreversible inhibitor of KIT/PDGFR kinases.  This is the first example of a covalent kinase inhibitor that combines a pharmacophore addressing the DFG-out conformation with a covalent trap.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkzqt0gMrz3rVg90H21EOLACvtfcHk0ljExk46eQgxTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvFeis70%253D&md5=329ae5eaa6102b6dd34a0d1274631247</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1021%2Fjm101396q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101396q%26sid%3Dliteratum%253Aachs%26aulast%3DLeproult%26aufirst%3DE.%26aulast%3DBarluenga%26aufirst%3DS.%26aulast%3DMoras%26aufirst%3DD.%26aulast%3DWurtz%26aufirst%3DJ.-M.%26aulast%3DWinssinger%26aufirst%3DN.%26atitle%3DCysteine%2520mapping%2520in%2520conformationally%2520distinct%2520kinase%2520nucleotide%2520binding%2520sites%253A%2520application%2520to%2520the%2520design%2520of%2520selective%2520covalent%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1347%26epage%3D1355%26doi%3D10.1021%2Fjm101396q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulligan, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaeger, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devereux, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barr, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kipps, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cymbalista, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pocock, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thornton, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caligaris-Cappio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robak, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delgado, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuster, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montillo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dearden, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fardis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGreivy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clow, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmen, P.</span></span> <span> </span><span class="NLM_article-title">Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>371</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1400376</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1056%2FNEJMoa1400376" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=24881631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1egsbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=213-223&author=J.+C.+Byrdauthor=J.+R.+Brownauthor=S.+O%E2%80%99Brienauthor=J.+C.+Barrientosauthor=N.+E.+Kayauthor=N.+M.+Reddyauthor=S.+Coutreauthor=C.+S.+Tamauthor=S.+P.+Mulliganauthor=U.+Jaegerauthor=S.+Devereuxauthor=P.+M.+Barrauthor=R.+R.+Furmanauthor=T.+J.+Kippsauthor=F.+Cymbalistaauthor=C.+Pocockauthor=P.+Thorntonauthor=F.+Caligaris-Cappioauthor=T.+Robakauthor=J.+Delgadoauthor=S.+J.+Schusterauthor=M.+Montilloauthor=A.+Schuhauthor=S.+de+Vosauthor=D.+Gillauthor=A.+Bloorauthor=C.+Deardenauthor=C.+Morenoauthor=J.+J.+Jonesauthor=A.+D.+Chuauthor=M.+Fardisauthor=J.+McGreivyauthor=F.+Clowauthor=D.+F.+Jamesauthor=P.+Hillmen&title=Ibrutinib+versus+ofatumumab+in+previously+treated+chronic+lymphoid+leukemia&doi=10.1056%2FNEJMoa1400376"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia</span></div><div class="casAuthors">Byrd, J. C.; Brown, J. R.; O'Brien, S.; Barrientos, J. C.; Kay, N. E.; Reddy, N. M.; Coutre, S.; Tam, C. S.; Mulligan, S. P.; Jaeger, U.; Devereux, S.; Barr, P. M.; Furman, R. R.; Kipps, T. J.; Cymbalista, F.; Pocock, C.; Thornton, P.; Caligaris-Cappio, F.; Robak, T.; Delgado, J.; Schuster, S. J.; Montillo, M.; Schuh, A.; de Vos, S.; Gill, D.; Bloor, A.; Dearden, C.; Moreno, C.; Jones, J. J.; Chu, A. D.; Fardis, M.; McGreivy, J.; Clow, F.; James, D. F.; Hillmen, P.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">213-223, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: In patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response to therapy or adverse cytogenetic abnormalities are assocd. with a poor outcome.  We evaluated the efficacy of ibrutinib, a covalent inhibitor of Bruton's tyrosine kinase, in patients at risk for a poor outcome.  Methods: In this multicenter, open-label, phase 3 study, we randomly assigned 391 patients with relapsed or refractory CLL or SLL to receive daily ibrutinib or the anti-CD20 antibody ofatumumab.  The primary end point was the duration of progression-free survival, with the duration of overall survival and the overall response rate as secondary end points.  Results: At a median follow-up of 9.4 mo, ibrutinib significantly improved progression-free survival; the median duration was not reached in the ibrutinib group (with a rate of progression-free survival of 88% at 6 mo), as compared with a median of 8.1 mo in the ofatumumab group (hazard ratio for progression or death in the ibrutinib group, 0.22; P < 0.001).  Ibrutinib also significantly improved overall survival (hazard ratio for death, 0.43; P = 0.005).  At 12 mo, the overall survival rate was 90% in the ibrutinib group and 81% in the ofatumumab group.  The overall response rate was significantly higher in the ibrutinib group than in the ofatumumab group (42.6% vs. 4.1%, P < 0.001).  An addnl. 20% of ibrutinib-treated patients had a partial response with lymphocytosis.  Similar effects were obsd. regardless of whether patients had a chromosome 17p13.1 deletion or resistance to purine analogs.  The most frequent nonhematol. adverse events were diarrhea, fatigue, pyrexia, and nausea in the ibrutinib group and fatigue, infusion-related reactions, and cough in the ofatumumab group.  Conclusions: Ibrutinib, as compared with ofatumumab, significantly improved progression-free survival, overall survival, and response rate among patients with previously treated CLL or SLL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCuX1vrLZxQLVg90H21EOLACvtfcHk0li4I3q-viGqqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1egsbrN&md5=87b692d35faa0fb8666bb945746fb9b0</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1400376&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1400376%26sid%3Dliteratum%253Aachs%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DKay%26aufirst%3DN.%2BE.%26aulast%3DReddy%26aufirst%3DN.%2BM.%26aulast%3DCoutre%26aufirst%3DS.%26aulast%3DTam%26aufirst%3DC.%2BS.%26aulast%3DMulligan%26aufirst%3DS.%2BP.%26aulast%3DJaeger%26aufirst%3DU.%26aulast%3DDevereux%26aufirst%3DS.%26aulast%3DBarr%26aufirst%3DP.%2BM.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DKipps%26aufirst%3DT.%2BJ.%26aulast%3DCymbalista%26aufirst%3DF.%26aulast%3DPocock%26aufirst%3DC.%26aulast%3DThornton%26aufirst%3DP.%26aulast%3DCaligaris-Cappio%26aufirst%3DF.%26aulast%3DRobak%26aufirst%3DT.%26aulast%3DDelgado%26aufirst%3DJ.%26aulast%3DSchuster%26aufirst%3DS.%2BJ.%26aulast%3DMontillo%26aufirst%3DM.%26aulast%3DSchuh%26aufirst%3DA.%26aulast%3Dde%2BVos%26aufirst%3DS.%26aulast%3DGill%26aufirst%3DD.%26aulast%3DBloor%26aufirst%3DA.%26aulast%3DDearden%26aufirst%3DC.%26aulast%3DMoreno%26aufirst%3DC.%26aulast%3DJones%26aufirst%3DJ.%2BJ.%26aulast%3DChu%26aufirst%3DA.%2BD.%26aulast%3DFardis%26aufirst%3DM.%26aulast%3DMcGreivy%26aufirst%3DJ.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DJames%26aufirst%3DD.%2BF.%26aulast%3DHillmen%26aufirst%3DP.%26atitle%3DIbrutinib%2520versus%2520ofatumumab%2520in%2520previously%2520treated%2520chronic%2520lymphoid%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26spage%3D213%26epage%3D223%26doi%3D10.1056%2FNEJMoa1400376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit10b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rule, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahl, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurczak, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Advani, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romaguera, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielowska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stilgenbauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreyling, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jedrzejczak, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spurgeon, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newberry, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGreivy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clow, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaupre, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunkel, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, K. A.</span></span> <span> </span><span class="NLM_article-title">Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>369</i></span>,  <span class="NLM_fpage">507</span>– <span class="NLM_lpage">516</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1306220</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1056%2FNEJMoa1306220" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=23782157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1OgtL%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=507-516&author=M.+L.+Wangauthor=S.+Ruleauthor=P.+Martinauthor=A.+Goyauthor=R.+Auerauthor=B.+S.+Kahlauthor=W.+Jurczakauthor=R.+H.+Advaniauthor=J.+E.+Romagueraauthor=M.+E.+Williamsauthor=J.+C.+Barrientosauthor=E.+Chmielowskaauthor=J.+Radfordauthor=S.+Stilgenbauerauthor=M.+Dreylingauthor=W.+W.+Jedrzejczakauthor=P.+Johnsonauthor=S.+E.+Spurgeonauthor=L.+Liauthor=L.+Zhangauthor=K.+Newberryauthor=Z.+Ouauthor=N.+Chengauthor=B.+Fangauthor=J.+McGreivyauthor=F.+Clowauthor=J.+J.+Buggyauthor=B.+Y.+Changauthor=D.+M.+Beaupreauthor=L.+A.+Kunkelauthor=K.+A.+Blum&title=Targeting+BTK+with+ibrutinib+in+relapsed+or+refractory+mantle-cell+lymphoma&doi=10.1056%2FNEJMoa1306220"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma</span></div><div class="casAuthors">Wang, Michael L.; Rule, Simon; Martin, Peter; Goy, Andre; Auer, Rebecca; Kahl, Brad S.; Jurczak, Wojciech; Advani, Ranjana H.; Romaguera, Jorge E.; Williams, Michael E.; Barrientos, Jacqueline C.; Chmielowska, Ewa; Radford, John; Stilgenbauer, Stephan; Dreyling, Martin; Jedrzejczak, Wieslaw Wiktor; Johnson, Peter; Spurgeon, Stephen E.; Li, Lei; Zhang, Liang; Newberry, Kate; Ou, Zhishuo; Cheng, Nancy; Fang, Bingliang; McGreivy, Jesse; Clow, Fong; Buggy, Joseph J.; Chang, Betty Y.; Beaupre, Darrin M.; Kunkel, Lori A.; Blum, Kristie A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">507-516</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Bruton's tyrosine kinase (BTK) is a mediator of the B-cell-receptor signaling pathway implicated in the pathogenesis of B-cell cancers.  In a phase 1 study, ibrutinib, a BTK inhibitor, showed antitumor activity in several types of non-Hodgkin's lymphoma, including mantle-cell lymphoma.  METHODS: In this phase 2 study, we investigated oral ibrutinib, at a daily dose of 560 mg, in 111 patients with relapsed or refractory mantle-cell lymphoma.  Patients were enrolled into two groups: those who had previously received at least 2 cycles of bortezomib therapy and those who had received less than 2 complete cycles of bortezomib or had received no prior bortezomib therapy.  The primary end point was the overall response rate.  Secondary end points were duration of response, progression-free survival, overall survival, and safety.  RESULTS: The median age was 68 years, and 86% of patients had intermediate-risk or high-risk mantle-cell lymphoma according to clin. prognostic factors.  Patients had received a median of three prior therapies.  The most common treatment-related adverse events were mild or moderate diarrhea, fatigue, and nausea.  Grade 3 or higher hematol. events were infrequent and included neutropenia (in 16% of patients), thrombocytopenia (in 11%), and anemia (in 10%).  A response rate of 68% (75 patients) was obsd., with a complete response rate of 21% and a partial response rate of 47%; prior treatment with bortezomib had no effect on the response rate.  With an estd. median follow-up of 15.3 mo, the estd. median response duration was 17.5 mo (95% confidence interval [CI], 15.8 to not reached), the estd. median progression-free survival was 13.9 mo (95% CI, 7.0 to not reached), and the median overall survival was not reached.  The estd. rate of overall survival was 58% at 18 mo.  CONCLUSIONS: Ibrutinib shows durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovUuOKvHS0NrVg90H21EOLACvtfcHk0li4I3q-viGqqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1OgtL%252FF&md5=7a92bbd5acf86e614cea96f44503e12b</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1306220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1306220%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DM.%2BL.%26aulast%3DRule%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DP.%26aulast%3DGoy%26aufirst%3DA.%26aulast%3DAuer%26aufirst%3DR.%26aulast%3DKahl%26aufirst%3DB.%2BS.%26aulast%3DJurczak%26aufirst%3DW.%26aulast%3DAdvani%26aufirst%3DR.%2BH.%26aulast%3DRomaguera%26aufirst%3DJ.%2BE.%26aulast%3DWilliams%26aufirst%3DM.%2BE.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DChmielowska%26aufirst%3DE.%26aulast%3DRadford%26aufirst%3DJ.%26aulast%3DStilgenbauer%26aufirst%3DS.%26aulast%3DDreyling%26aufirst%3DM.%26aulast%3DJedrzejczak%26aufirst%3DW.%2BW.%26aulast%3DJohnson%26aufirst%3DP.%26aulast%3DSpurgeon%26aufirst%3DS.%2BE.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DNewberry%26aufirst%3DK.%26aulast%3DOu%26aufirst%3DZ.%26aulast%3DCheng%26aufirst%3DN.%26aulast%3DFang%26aufirst%3DB.%26aulast%3DMcGreivy%26aufirst%3DJ.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DBeaupre%26aufirst%3DD.%2BM.%26aulast%3DKunkel%26aufirst%3DL.%2BA.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26atitle%3DTargeting%2520BTK%2520with%2520ibrutinib%2520in%2520relapsed%2520or%2520refractory%2520mantle-cell%2520lymphoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D507%26epage%3D516%26doi%3D10.1056%2FNEJMoa1306220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit10c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Treon, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripsas, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meid, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varma, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argyropoulos, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zehnder, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aster, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghobrial, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castillo, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laubach, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, Z. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salman, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clow, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graef, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palomba, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Advani, R. H.</span></span> <span> </span><span class="NLM_article-title">Ibrutinib in previously treated waldenstrom’s macroglobulinemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">1430</span>– <span class="NLM_lpage">1440</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1501548</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1056%2FNEJMoa1501548" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=25853747" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC2MXns1Wrt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=1430-1440&author=S.+P.+Treonauthor=C.+K.+Tripsasauthor=K.+Meidauthor=D.+Warrenauthor=G.+Varmaauthor=R.+Greenauthor=K.+V.+Argyropoulosauthor=G.+Yangauthor=+Caoauthor=L.+Xuauthor=C.+J.+Pattersonauthor=S.+Rodigauthor=J.+L.+Zehnderauthor=J.+C.+Asterauthor=N.+L.+Harrisauthor=S.+Kananauthor=I.+Ghobrialauthor=J.+J.+Castilloauthor=J.+P.+Laubachauthor=Z.+R.+Hunterauthor=Z.+Salmanauthor=J.+Liauthor=M.+Chengauthor=F.+Clowauthor=T.+Graefauthor=M.+L.+Palombaauthor=R.+H.+Advani&title=Ibrutinib+in+previously+treated+waldenstrom%E2%80%99s+macroglobulinemia&doi=10.1056%2FNEJMoa1501548"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10cR"><div class="casContent"><span class="casTitleNuber">10c</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib in previously treated waldenstrom's macroglobulinemia</span></div><div class="casAuthors">Treon, Steven P.; Tripsas, Christina K.; Meid, Kirsten; Warren, Diane; Varma, Gaurav; Green, Rebecca; Argyropoulos, Kimon V.; Yang, Guang; Cao, Yang; Xu, Lian; Patterson, Christopher J.; Rodig, Scott; Zehnder, James L.; Aster, Jon C.; Harris, Nancy Lee; Kanan, Sandra; Ghobrial, Irene; Castillo, Jorge J.; Laubach, Jacob P.; Hunter, Zachary R.; Salman, Zeena; Li, Jianling; Cheng, Mei; Clow, Fong; Graef, Thorsten; Palomba, M. Lia; Advani, Ranjana H.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1430-1440</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">MYD88L265P and CXCR4WHIM mutations are highly prevalent in Waldenstrom's macroglobulinemia.  MYD88L265P triggers tumor-cell growth through Bruton's tyrosine kinase, a target of ibrutinib.  CXCR4WHIM mutations confer in vitro resistance to ibrutinib.  We performed a prospective study of ibrutinib in 63 symptomatic patients with Waldenstrom's macroglobulinemia who had received at least one previous treatment, and we investigated the effect of MYD88 and CXCR4 mutations on outcomes.  Ibrutinib at a daily dose of 420 mg was administered orally until disease progression or the development of unacceptable toxic effects.  After the patients received ibrutinib, median serum IgM levels decreased from 3520 mg per dL to 880 mg per dL, median Hb levels increased from 10.5 g per dL to 13.8 g per dL, and bone marrow involvement decreased from 60% to 25% (P<0.01 for all comparisons).  The median time to at least a minor response was 4 wk.  The overall response rate was 90.5%, and the major response rate was 73.0%; these rates were highest among patients with MYD88L265PCXCR4WT (with WT indicating wild-type) (100% overall response rate and 91.2% major response rate), followed by patients with MYD88L265PCXCR4WHIM (85.7% and 61.9%, resp.) and patients with MYD88WTCXCR4WT (71.4% and 28.6%).  The estd. 2-yr progression-free and overall survival rates among all patients were 69.1% and 95.2%, resp.  Treatment-related toxic effects of grade 2 or higher included neutropenia (in 22% of the patients) and thrombocytopenia (in 14%), which were more common in heavily pretreated patients; postprocedural bleeding (in 3%); epistaxis assocd. with the use of fish-oil supplements (in 3%); and atrial fibrillation assocd. with a history of arrhythmia (5%).  Ibrutinib was highly active, assocd. with durable responses, and safe in pretreated patients with Waldenstrom's macroglobulinemia.  MYD88 and CXCR4 mutation status affected responses to this drug. (Funded by Pharmacyclics and others; ClinicalTrials.gov no., NCT01614821.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoifbEcGkxnFrVg90H21EOLACvtfcHk0ljZJmupkiNKxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXns1Wrt7w%253D&md5=00d1d3dd9be87801725d8c161afa899c</span></div><a href="/servlet/linkout?suffix=cit10c&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1501548&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1501548%26sid%3Dliteratum%253Aachs%26aulast%3DTreon%26aufirst%3DS.%2BP.%26aulast%3DTripsas%26aufirst%3DC.%2BK.%26aulast%3DMeid%26aufirst%3DK.%26aulast%3DWarren%26aufirst%3DD.%26aulast%3DVarma%26aufirst%3DG.%26aulast%3DGreen%26aufirst%3DR.%26aulast%3DArgyropoulos%26aufirst%3DK.%2BV.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DCao%26aulast%3DXu%26aufirst%3DL.%26aulast%3DPatterson%26aufirst%3DC.%2BJ.%26aulast%3DRodig%26aufirst%3DS.%26aulast%3DZehnder%26aufirst%3DJ.%2BL.%26aulast%3DAster%26aufirst%3DJ.%2BC.%26aulast%3DHarris%26aufirst%3DN.%2BL.%26aulast%3DKanan%26aufirst%3DS.%26aulast%3DGhobrial%26aufirst%3DI.%26aulast%3DCastillo%26aufirst%3DJ.%2BJ.%26aulast%3DLaubach%26aufirst%3DJ.%2BP.%26aulast%3DHunter%26aufirst%3DZ.%2BR.%26aulast%3DSalman%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DGraef%26aufirst%3DT.%26aulast%3DPalomba%26aufirst%3DM.%2BL.%26aulast%3DAdvani%26aufirst%3DR.%2BH.%26atitle%3DIbrutinib%2520in%2520previously%2520treated%2520waldenstrom%25E2%2580%2599s%2520macroglobulinemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D1430%26epage%3D1440%26doi%3D10.1056%2FNEJMoa1501548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mauro, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caputo, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosati, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pepe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Benedittis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Luca, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foa, R.</span></span> <span> </span><span class="NLM_article-title">Balancing efficacy and toxicity of targeted agents currently used for the treatment of patients with chronic lymphocytic leukemia</span>. <i>Expert Rev. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">601</span>– <span class="NLM_lpage">611</span>, <span class="refDoi"> DOI: 10.1080/17474086.2018.1495557</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1080%2F17474086.2018.1495557" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=29969322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlClt73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=601-611&author=F.+R.+Mauroauthor=M.+D.+Caputoauthor=S.+Rosatiauthor=S.+Pepeauthor=D.+De+Benedittisauthor=M.+L.+De+Lucaauthor=R.+Foa&title=Balancing+efficacy+and+toxicity+of+targeted+agents+currently+used+for+the+treatment+of+patients+with+chronic+lymphocytic+leukemia&doi=10.1080%2F17474086.2018.1495557"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Balancing efficacy and toxicity of targeted agents currently used for the treatment of patients with chronic lymphocytic leukemia</span></div><div class="casAuthors">Mauro, Francesca R.; Caputo, Maria D.; Rosati, Serena; Pepe, Sara; De Benedittis, Daniela; De Luca, Maria L.; Foa, Robin</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Hematology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">601-611</span>CODEN:
                <span class="NLM_cas:coden">ERHXAV</span>;
        ISSN:<span class="NLM_cas:issn">1747-4094</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: In recent years, innovative mechanism-based drugs have enriched the therapeutic armamentarium for patients with chronic lymphocytic leukemia (CLL) and are widely used in the clin. practice.  These small mols. targeting the B-cell receptor signaling pathway and the BCL-2 anti-apoptotic protein offer new chemo-free options to both unfit patients and high-risk patients who show a poor response to chemoimmunotherapy.  Nonetheless, treatment with ibrutinib, idelalisib and venetoclax is assocd. with unique side effects.  Awareness, prevention and the appropriate management of these specific toxicities are of crucial importance for a successful treatment.: The purpose of this review is to discuss the most relevant studies on small mols. in CLL, with particular attention to the emerging toxicity profile of these agents and to the factors that should be considered to address the most appropriate treatment approach for each patient.: The increased knowledge on the biol. of CLL has translated into the development of targeted agents that are highly effective and produce deep responses.  Toxicities potentially assocd. with these agents should be known for an optimal management of CLL patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOEVNTkF_oYLVg90H21EOLACvtfcHk0ljZJmupkiNKxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlClt73O&md5=44f85d32375f1ac41227a37d75aebe9c</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1080%2F17474086.2018.1495557&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17474086.2018.1495557%26sid%3Dliteratum%253Aachs%26aulast%3DMauro%26aufirst%3DF.%2BR.%26aulast%3DCaputo%26aufirst%3DM.%2BD.%26aulast%3DRosati%26aufirst%3DS.%26aulast%3DPepe%26aufirst%3DS.%26aulast%3DDe%2BBenedittis%26aufirst%3DD.%26aulast%3DDe%2BLuca%26aufirst%3DM.%2BL.%26aulast%3DFoa%26aufirst%3DR.%26atitle%3DBalancing%2520efficacy%2520and%2520toxicity%2520of%2520targeted%2520agents%2520currently%2520used%2520for%2520the%2520treatment%2520of%2520patients%2520with%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DExpert%2520Rev.%2520Hematol.%26date%3D2018%26volume%3D11%26spage%3D601%26epage%3D611%26doi%3D10.1080%2F17474086.2018.1495557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, P.</span></span> <span> </span><span class="NLM_article-title">Investigational Bruton’s tyrosine kinase inhibitors for the treatment of rheumatoid arthritis</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">891</span>– <span class="NLM_lpage">899</span>, <span class="refDoi"> DOI: 10.1080/13543784.2016.1182499</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1080%2F13543784.2016.1182499" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=27148767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC28Xnslentb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2016&pages=891-899&author=P.+Norman&title=Investigational+Bruton%E2%80%99s+tyrosine+kinase+inhibitors+for+the+treatment+of+rheumatoid+arthritis&doi=10.1080%2F13543784.2016.1182499"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">Investigational Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis</span></div><div class="casAuthors">Norman, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">891-899</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The Tec family of non-receptor tyrosine kinases comprises five members.  The cellular expression and function of these kinases has implicated them as potential drug targets for the treatment of both malignant and autoimmune diseases.  Most attention has focused on inhibitors of BTK kinase with ibrutinib already approved for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia.  Multiple BTK inhibitors are being developed for both oncol. and autoimmune disease indications.  BTK inhibitors being evaluated in rheumatoid arthritis are considered.  Both inhibitors which have progressed to early clin. development, and those demonstrating activity in rodent models of arthritis are reviewed.  These include both reversible and irreversible inhibitors of the kinase, most of which target the cysteine-481 residue of BTK.  The selectivity of these inhibitors for Tec family kinases is considered.  Developing inhibitors of any kinase to treat of rheumatoid arthritis has proved problematic with regard to both efficacy and selectivity.  It is anticipated that the more selective BTK inhibitors may prove more useful in treating arthritis, with the use of reversible inhibitors possibly offering a better strategy.  Chronic dosing may exacerbate the emergence of drug resistance, with resistant mutations already obsd. in ibrutinib-treated patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQsRSjuYxYa7Vg90H21EOLACvtfcHk0ljHb1Yft5aI5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xnslentb0%253D&md5=037f60be680ad282725fe8f7619f1212</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1080%2F13543784.2016.1182499&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2016.1182499%26sid%3Dliteratum%253Aachs%26aulast%3DNorman%26aufirst%3DP.%26atitle%3DInvestigational%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2016%26volume%3D25%26spage%3D891%26epage%3D899%26doi%3D10.1080%2F13543784.2016.1182499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit12b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, J. A.</span></span> <span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase inhibitors: first and second generation agents for patients with chronic lymphocytic leukemia (CLL)</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1080/13543784.2018.1404027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1080%2F13543784.2018.1404027" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2018&pages=31-42&author=P.+A.+Thompsonauthor=J.+A.+Burger&title=Bruton%E2%80%99s+tyrosine+kinase+inhibitors%3A+first+and+second+generation+agents+for+patients+with+chronic+lymphocytic+leukemia+%28CLL%29&doi=10.1080%2F13543784.2018.1404027"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1080%2F13543784.2018.1404027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2018.1404027%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DP.%2BA.%26aulast%3DBurger%26aufirst%3DJ.%2BA.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitors%253A%2520first%2520and%2520second%2520generation%2520agents%2520for%2520patients%2520with%2520chronic%2520lymphocytic%2520leukemia%2520%2528CLL%2529%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2018%26volume%3D27%26spage%3D31%26epage%3D42%26doi%3D10.1080%2F13543784.2018.1404027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit12c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnarajah, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunn, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karr, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masjedizadeh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gourlay, S. G.</span></span> <span> </span><span class="NLM_article-title">A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton’s tyrosine kinase in healthy volunteers</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">2367</span>– <span class="NLM_lpage">2376</span>, <span class="refDoi"> DOI: 10.1111/bcp.13351</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1111%2Fbcp.13351" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=28636208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslWrsLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2017&pages=2367-2376&author=P.+F.+Smithauthor=J.+Krishnarajahauthor=P.+A.+Nunnauthor=R.+J.+Hillauthor=D.+Karrauthor=D.+Tamauthor=M.+Masjedizadehauthor=J.+O.+Funkauthor=S.+G.+Gourlay&title=A+phase+I+trial+of+PRN1008%2C+a+novel+reversible+covalent+inhibitor+of+Bruton%E2%80%99s+tyrosine+kinase+in+healthy+volunteers&doi=10.1111%2Fbcp.13351"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12cR"><div class="casContent"><span class="casTitleNuber">12c</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers</span></div><div class="casAuthors">Smith, Patrick F.; Krishnarajah, Janakan; Nunn, Philip A.; Hill, Ron J.; Karr, Dane; Tam, D.; Masjedizadeh, Mohammad; Funk, Jens O.; Gourlay, Steve G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2367-2376</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">To evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics of PRN1008, a novel Bruton's tyrosine kinase (BTK) inhibitor, in healthy volunteers, and thus det. the dose range for future clin. studies.  This was a two-part randomized, placebo controlled study in healthy volunteers using a liq. formulation.  Part I was a single ascending dose design with dose levels of 50-1200 mg (n = 6 active, two placebos per cohort); Part II was a multiple ascending dose design, with dose regimens ranging from 300 to 900 mg daily, either four times or twice daily for 10 days.  Plasma pharmacokinetics, adverse events, vital signs, electrocardiograms and lab. parameters were assessed.  BTK occupancy in peripheral blood mononuclear cells was evaluated as a marker of target engagement.  PRN1008 was rapidly absorbed following oral administration, and was safe and well tolerated in all dose regimens evaluated in both single and multiple doses.  PRN1008 demonstrated a large vol. of distribution, and a half-life of approx. 3-4 h.  BTK occupancy of >90% was obsd. within 4 h after dosing in both single and multiple dose regimens, and was closely linked to max. plasma concn.  BTK occupancy decay was slow (-1.6% h-1), and occupancy was sustained despite drug concns. being undetectable.  No severe or serious adverse events occurred, and the most common adverse events were gastrointestinal in nature.  PRN1008 was safe and well-tolerated following oral administration, and achieved high, sustained levels of BTK occupancy in peripheral blood mononuclear cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDCmAr26_VXLVg90H21EOLACvtfcHk0ljHb1Yft5aI5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslWrsLnE&md5=8da03545b8beec4c50cdd95854bcad8f</span></div><a href="/servlet/linkout?suffix=cit12c&amp;dbid=16384&amp;doi=10.1111%2Fbcp.13351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.13351%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DP.%2BF.%26aulast%3DKrishnarajah%26aufirst%3DJ.%26aulast%3DNunn%26aufirst%3DP.%2BA.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DKarr%26aufirst%3DD.%26aulast%3DTam%26aufirst%3DD.%26aulast%3DMasjedizadeh%26aufirst%3DM.%26aulast%3DFunk%26aufirst%3DJ.%2BO.%26aulast%3DGourlay%26aufirst%3DS.%2BG.%26atitle%3DA%2520phase%2520I%2520trial%2520of%2520PRN1008%252C%2520a%2520novel%2520reversible%2520covalent%2520inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520in%2520healthy%2520volunteers%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2017%26volume%3D83%26spage%3D2367%26epage%3D2376%26doi%3D10.1111%2Fbcp.13351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit12d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harb, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabrilove, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreeder, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barr, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foran, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahadevan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnett, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marine, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miranda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azaryan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nava-Parada, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kipps, T. J.</span></span> <span> </span><span class="NLM_article-title">Phase I study of single-agent CC-292, a highly selective Bruton’s tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">e295</span>– <span class="NLM_lpage">e298</span>, <span class="refDoi"> DOI: 10.3324/haematol.2015.140806</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.3324%2Fhaematol.2015.140806" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=27151992" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2016&pages=e295-e298&author=J.+R.+Brownauthor=W.+A.+Harbauthor=B.+T.+Hillauthor=J.+Gabriloveauthor=J.+P.+Sharmanauthor=M.+T.+Schreederauthor=P.+M.+Barrauthor=J.+M.+Foranauthor=T.+P.+Millerauthor=J.+A.+Burgerauthor=K.+R.+Kellyauthor=D.+Mahadevanauthor=S.+Maauthor=Y.+Liauthor=D.+W.+Pierceauthor=E.+Barnettauthor=J.+Marineauthor=M.+Mirandaauthor=A.+Azaryanauthor=X.+Yuauthor=P.+Nava-Paradaauthor=J.+Meiauthor=T.+J.+Kipps&title=Phase+I+study+of+single-agent+CC-292%2C+a+highly+selective+Bruton%E2%80%99s+tyrosine+kinase+inhibitor%2C+in+relapsed%2Frefractory+chronic+lymphocytic+leukemia&doi=10.3324%2Fhaematol.2015.140806"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12d&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2015.140806&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2015.140806%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DHarb%26aufirst%3DW.%2BA.%26aulast%3DHill%26aufirst%3DB.%2BT.%26aulast%3DGabrilove%26aufirst%3DJ.%26aulast%3DSharman%26aufirst%3DJ.%2BP.%26aulast%3DSchreeder%26aufirst%3DM.%2BT.%26aulast%3DBarr%26aufirst%3DP.%2BM.%26aulast%3DForan%26aufirst%3DJ.%2BM.%26aulast%3DMiller%26aufirst%3DT.%2BP.%26aulast%3DBurger%26aufirst%3DJ.%2BA.%26aulast%3DKelly%26aufirst%3DK.%2BR.%26aulast%3DMahadevan%26aufirst%3DD.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DPierce%26aufirst%3DD.%2BW.%26aulast%3DBarnett%26aufirst%3DE.%26aulast%3DMarine%26aufirst%3DJ.%26aulast%3DMiranda%26aufirst%3DM.%26aulast%3DAzaryan%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DNava-Parada%26aufirst%3DP.%26aulast%3DMei%26aufirst%3DJ.%26aulast%3DKipps%26aufirst%3DT.%2BJ.%26atitle%3DPhase%2520I%2520study%2520of%2520single-agent%2520CC-292%252C%2520a%2520highly%2520selective%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitor%252C%2520in%2520relapsed%252Frefractory%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DHaematologica%26date%3D2016%26volume%3D101%26spage%3De295%26epage%3De298%26doi%3D10.3324%2Fhaematol.2015.140806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit12e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Kivitz, A. J.</span>; <span class="NLM_string-name">Gupta, R.</span>; <span class="NLM_string-name">Valenzuela, G.</span>; <span class="NLM_string-name">Smith, E.</span>; <span class="NLM_string-name">Rehman, Q.</span>; <span class="NLM_string-name">El Kadi, H.</span>; <span class="NLM_string-name">Bretton, E.</span>; <span class="NLM_string-name">Aelion, J. A.</span>; <span class="NLM_string-name">Chadha, A.</span>; <span class="NLM_string-name">Tesser, J.</span>; <span class="NLM_string-name">Hough, D.</span>; <span class="NLM_string-name">Korish, S.</span>; <span class="NLM_string-name">Schafer, P. H.</span>; <span class="NLM_string-name">Ringheim, G.</span>; <span class="NLM_string-name">Sutherland, D.</span>; <span class="NLM_string-name">Li, L.</span></span> <span> </span><span class="NLM_article-title">A phase 2a, 4-week double-blind, proof of concept efficacy and safety study of CC-292 versus placebo as co-therapy with methotrexate in active rheumatoid arthritis (RA)</span>.  <i>Arthritis Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume">68</span>, (<span class="NLM_issue">Suppl. 10</span>), <a href="https://acrabstracts.org/abstract/a-phase-2a-4-week-double-blind-proof-of-concept-efficacy-and-safety-study-of-cc-292-versus-placebo-as-co-therapy-with-methotrexate-in-active-rheumatoid-arthritis-ra/." class="extLink">https://acrabstracts.org/abstract/a-phase-2a-4-week-double-blind-proof-of-concept-efficacy-and-safety-study-of-cc-292-versus-placebo-as-co-therapy-with-methotrexate-in-active-rheumatoid-arthritis-ra</a>/.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2016&issue=Suppl.+10&author=A.+J.+Kivitz&author=R.+Gupta&author=G.+Valenzuela&author=E.+Smith&author=Q.+Rehman&author=H.+El+Kadi&author=E.+Bretton&author=J.+A.+Aelion&author=A.+Chadha&author=J.+Tesser&author=D.+Hough&author=S.+Korish&author=P.+H.+Schafer&author=G.+Ringheim&author=D.+Sutherland&author=L.+Li&title=A+phase+2a%2C+4-week+double-blind%2C+proof+of+concept+efficacy+and+safety+study+of+CC-292+versus+placebo+as+co-therapy+with+methotrexate+in+active+rheumatoid+arthritis+%28RA%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKivitz%26aufirst%3DA.%2BJ.%26atitle%3DA%2520phase%25202a%252C%25204-week%2520double-blind%252C%2520proof%2520of%2520concept%2520efficacy%2520and%2520safety%2520study%2520of%2520CC-292%2520versus%2520placebo%2520as%2520co-therapy%2520with%2520methotrexate%2520in%2520active%2520rheumatoid%2520arthritis%2520%2528RA%2529%26jtitle%3DArthritis%2520Rheumatol.%26date%3D2016%26volume%3D68%26issue%3DSuppl.%252010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rule, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R. W.</span></span> <span> </span><span class="NLM_article-title">New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma – where do they fit in?</span>. <i>Expert Rev. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">749</span>– <span class="NLM_lpage">756</span>, <span class="refDoi"> DOI: 10.1080/17474086.2018.1506327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1080%2F17474086.2018.1506327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=30052472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVGjtrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=749-756&author=S.+Ruleauthor=R.+W.+Chen&title=New+and+emerging+Bruton+tyrosine+kinase+inhibitors+for+treating+mantle+cell+lymphoma+%E2%80%93+where+do+they+fit+in%3F&doi=10.1080%2F17474086.2018.1506327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?</span></div><div class="casAuthors">Rule, Simon; Chen, Robert W.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Hematology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">749-756</span>CODEN:
                <span class="NLM_cas:coden">ERHXAV</span>;
        ISSN:<span class="NLM_cas:issn">1747-4094</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: Despite recent prognostic improvements, mantle cell lymphoma (MCL) remains incurable.  Bruton tyrosine kinase (BTK) is a key receptor in B-cell tumorigenesis, and the benefits of the first BTK inhibitor, ibrutinib, are becoming clear in MCL.  However, off-target activities, which contribute to ibrutinib-related adverse events, suggest potential for further improvement of this drug class.: The authors systematically interrogated ClinicalTrials.gov for trials contg. keywords for BTK and MCL.  Published literature for new and emerging BTK inhibitors being investigated in MCL was then identified (PubMed and Embase), summarized, and placed in the context of treatment guidelines.: Reduced off-target effects of new and emerging covalent, irreversible BTK inhibitors under investigation in patients with MCL offer the potential of improved safety compared with ibrutinib.  Efficacy may also be favorable based on trial data for acalabrutinib, which has just been approved in the USA as second-line therapy for MCL.  The role of BTK inhibitors in treating MCL will evolve substantially over the coming years as results from a no. of trials become available, particularly in relation to potential upfront use and possible synergy with other targeted therapies such as B-cell lymphoma 2, phosphoinositide 3-kinase and checkpoint inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjnXtQxShPybVg90H21EOLACvtfcHk0ljdg6HIbrrisA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVGjtrrI&md5=59bf858c7cffaceff538b87366042739</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1080%2F17474086.2018.1506327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17474086.2018.1506327%26sid%3Dliteratum%253Aachs%26aulast%3DRule%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DR.%2BW.%26atitle%3DNew%2520and%2520emerging%2520Bruton%2520tyrosine%2520kinase%2520inhibitors%2520for%2520treating%2520mantle%2520cell%2520lymphoma%2520%25E2%2580%2593%2520where%2520do%2520they%2520fit%2520in%253F%26jtitle%3DExpert%2520Rev.%2520Hematol.%26date%3D2018%26volume%3D11%26spage%3D749%26epage%3D756%26doi%3D10.1080%2F17474086.2018.1506327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rule, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinzani, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casasnovas, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damaj, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doorduijn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamy, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morschhauser, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panizo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupuis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kater, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Gouill, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oberic, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robak, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dua, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamdy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothbaum, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slatter, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurczak, W.</span></span> <span> </span><span class="NLM_article-title">Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>391</i></span>,  <span class="NLM_fpage">659</span>– <span class="NLM_lpage">667</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(17)33108-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1016%2FS0140-6736%2817%2933108-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=29241979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFOhsb%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=391&publication_year=2018&pages=659-667&author=M.+Wangauthor=S.+Ruleauthor=P.+L.+Zinzaniauthor=A.+Goyauthor=O.+Casasnovasauthor=S.+D.+Smithauthor=G.+Damajauthor=J.+Doorduijnauthor=T.+Lamyauthor=F.+Morschhauserauthor=C.+Panizoauthor=B.+Shahauthor=A.+Daviesauthor=R.+Eekauthor=J.+Dupuisauthor=E.+Jacobsenauthor=A.+P.+Katerauthor=S.+Le+Gouillauthor=L.+Obericauthor=T.+Robakauthor=T.+Coveyauthor=R.+Duaauthor=A.+Hamdyauthor=X.+Huangauthor=R.+Izumiauthor=P.+Patelauthor=W.+Rothbaumauthor=J.+G.+Slatterauthor=W.+Jurczak&title=Acalabrutinib+in+relapsed+or+refractory+mantle+cell+lymphoma+%28ACE-LY-004%29%3A+a+single-arm%2C+multicentre%2C+phase+2+trial&doi=10.1016%2FS0140-6736%2817%2933108-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicenter, phase 2 trial</span></div><div class="casAuthors">Wang, Michael; Rule, Simon; Zinzani, Pier Luigi; Goy, Andre; Casasnovas, Olivier; Smith, Stephen D.; Damaj, Gandhi; Doorduijn, Jeanette; Lamy, Thierry; Morschhauser, Franck; Panizo, Carlos; Shah, Bijal; Davies, Andrew; Eek, Richard; Dupuis, Jehan; Jacobsen, Eric; Kater, Arnon P.; Le Gouill, Steven; Oberic, Lucie; Robak, Taduesz; Covey, Todd; Dua, Richa; Hamdy, Ahmed; Huang, Xin; Izumi, Raquel; Patel, Priti; Rothbaum, Wayne; Slatter, J. Greg; Jurczak, Wojciech</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">391</span>
        (<span class="NLM_cas:issue">10121</span>),
    <span class="NLM_cas:pages">659-667</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Bruton tyrosine kinase is a clin. validated target in mantle cell lymphoma.  Acalabrutinib (ACP-196) is a highly selective, potent Bruton tyrosine kinase inhibitor developed to minimize off-target activity.  In this open-label, phase 2 study, oral acalabrutinib (100 mg twice per day) was given to patients with relapsed or refractory mantle cell lymphoma, until disease progression or unacceptable toxicity.  The primary endpoint was overall response assessed according to the Lugano classification, and safety analyses were done in all participants.  This trial is registered with ClinicalTrials.gov, no. NCT02213926.  From March 12, 2015, to Jan 5, 2016, 124 patients with relapsed or refractory mantle cell lymphoma were enrolled and all patients received treatment; median age 68 years.  Patients received a median of two (IQR 1-2) previous therapies.  At a median follow-up of 15·2 mo, 100 (81%) patients achieved an overall response and 49 (40%) patients achieved a complete response.  The Kaplan-Meier estd. medians for duration of response, progression-free survival, and overall survival were not reached; the 12-mo rates were 72% (95% CI 62-80), 67% (58-75), and 87% (79-92%), resp.  The most common adverse events were primarily grade 1 or 2 and were headache (47 [38%]), diarrhea (38 [31%]), fatigue (34 [27%]), and myalgia (26 [21%]).  The most common grade 3 or worse adverse events were neutropenia (13 [10%]), anemia (11 [9%]), and pneumonia (six [5%]).  There were no cases of atrial fibrillation and one case of grade 3 or worse hemorrhage.  The median duration of treatment was 13·8 mo.  Treatment was discontinued in 54 (44%) patients, primarily due to progressive disease (39 [31%]) and adverse events (seven [6%]).  Acalabrutinib treatment provided a high rate of durable responses and a favorable safety profile in patients with relapsed or refractory mantle cell lymphoma.  These findings suggest an important role for acalabrutinib in the treatment of this disease population.  Acerta Pharma, a member of the AstraZeneca Group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpM5ii2D3nt7rVg90H21EOLACvtfcHk0ljdg6HIbrrisA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFOhsb%252FN&md5=5631617d6830e4f1f062a0531d8d36a0</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2817%2933108-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252817%252933108-2%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DM.%26aulast%3DRule%26aufirst%3DS.%26aulast%3DZinzani%26aufirst%3DP.%2BL.%26aulast%3DGoy%26aufirst%3DA.%26aulast%3DCasasnovas%26aufirst%3DO.%26aulast%3DSmith%26aufirst%3DS.%2BD.%26aulast%3DDamaj%26aufirst%3DG.%26aulast%3DDoorduijn%26aufirst%3DJ.%26aulast%3DLamy%26aufirst%3DT.%26aulast%3DMorschhauser%26aufirst%3DF.%26aulast%3DPanizo%26aufirst%3DC.%26aulast%3DShah%26aufirst%3DB.%26aulast%3DDavies%26aufirst%3DA.%26aulast%3DEek%26aufirst%3DR.%26aulast%3DDupuis%26aufirst%3DJ.%26aulast%3DJacobsen%26aufirst%3DE.%26aulast%3DKater%26aufirst%3DA.%2BP.%26aulast%3DLe%2BGouill%26aufirst%3DS.%26aulast%3DOberic%26aufirst%3DL.%26aulast%3DRobak%26aufirst%3DT.%26aulast%3DCovey%26aufirst%3DT.%26aulast%3DDua%26aufirst%3DR.%26aulast%3DHamdy%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DIzumi%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DP.%26aulast%3DRothbaum%26aufirst%3DW.%26aulast%3DSlatter%26aufirst%3DJ.%2BG.%26aulast%3DJurczak%26aufirst%3DW.%26atitle%3DAcalabrutinib%2520in%2520relapsed%2520or%2520refractory%2520mantle%2520cell%2520lymphoma%2520%2528ACE-LY-004%2529%253A%2520a%2520single-arm%252C%2520multicentre%252C%2520phase%25202%2520trial%26jtitle%3DLancet%26date%3D2018%26volume%3D391%26spage%3D659%26epage%3D667%26doi%3D10.1016%2FS0140-6736%2817%2933108-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit13c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Barf, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Kar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulrajani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Lith, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Hoek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Zwart, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittag, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demont, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verkaik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krantz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulrich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaptein, A.</span></span> <span> </span><span class="NLM_article-title">Acalabrutinib (ACP-196): a covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>363</i></span>,  <span class="NLM_fpage">240</span>– <span class="NLM_lpage">252</span>, <span class="refDoi"> DOI: 10.1124/jpet.117.242909</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1124%2Fjpet.117.242909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=28882879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtleltrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2017&pages=240-252&author=T.+Barfauthor=T.+Coveyauthor=R.+Izumiauthor=B.+van+de+Karauthor=M.+Gulrajaniauthor=B.+van+Lithauthor=M.+van+Hoekauthor=E.+de+Zwartauthor=D.+Mittagauthor=D.+Demontauthor=S.+Verkaikauthor=F.+Krantzauthor=P.+G.+Pearsonauthor=R.+Ulrichauthor=A.+Kaptein&title=Acalabrutinib+%28ACP-196%29%3A+a+covalent+Bruton+tyrosine+kinase+inhibitor+with+a+differentiated+selectivity+and+in+vivo+potency+profile&doi=10.1124%2Fjpet.117.242909"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13cR"><div class="casContent"><span class="casTitleNuber">13c</span><div class="casTitle"><span class="NLM_cas:atitle">Acalabrutinib (ACP-196): a covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile</span></div><div class="casAuthors">Barf, Tjeerd; Covey, Todd; Izumi, Raquel; van de Kar, Bas; Gulrajani, Michael; van Lith, Bart; van Hoek, Maaike; de Zwart, Edwin; Mittag, Diana; Demont, Dennis; Verkaik, Saskia; Krantz, Fanny; Pearson, Paul G.; Ulrich, Roger; Kaptein, Allard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">240-252</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Several small-mol. Bruton tyrosine kinase (BTK) inhibitors are in development for B cell malignancies and autoimmune disorders, each characterized by distinct potency and selectivity patterns.  Herein we describe the pharmacol. characterization of BTK inhibitor acalabrutinib [compd. 1, ACP-196 (4-[8- amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin1-yl]-N-(2-pyridyl)benzamide)].  Acalabrutinib possesses a reactive butynamide group that binds covalently to Cys481 in BTK.  Relative to the other BTK inhibitors described here, the reduced intrinsic reactivity of acalabrutinib helps to limit inhibition of off-target kinases having cysteine-mediated covalent binding potential.  Acalabrutinib demonstrated higher biochem. and cellular selectivity than ibrutinib and spebrutinib (compds. 2 and 3, resp.).  Importantly, off-target kinases, such as epidermal growth factor receptor (EGFR) and interleukin 2-inducible T cell kinase (ITK), were not inhibited.  Detn. of the inhibitory potential of anti-IgM-induced CD69 expression in human peripheral blood mononuclear cells and whole blood demonstrated that acalabrutinib is a potent functional BTK inhibitor.  In vivo evaluation in mice revealed that acalabrutinib is more potent than ibrutinib and spebrutinib.  Preclin. and clin. studies showed that the level and duration of BTK occupancy correlates with in vivo efficacy.  Evaluation of the pharmacokinetic properties of acalabrutinib in healthy adult volunteers demonstrated rapid absorption and fast elimination.  In these healthy individuals, a single oral dose of 100 mg showed approx. 99% median target coverage at 3 and 12 h and around 90% at 24 h in peripheral B cells.  In conclusion, acalabrutinib is a BTK inhibitor with key pharmacol. differentiators vs. ibrutinib and spebrutinib and is currently being evaluated in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol9xhDmwvup7Vg90H21EOLACvtfcHk0lieyqaf4Hncfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtleltrnO&md5=73cbd3a87396abbf8cb20e4361f96f64</span></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=10.1124%2Fjpet.117.242909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.117.242909%26sid%3Dliteratum%253Aachs%26aulast%3DBarf%26aufirst%3DT.%26aulast%3DCovey%26aufirst%3DT.%26aulast%3DIzumi%26aufirst%3DR.%26aulast%3Dvan%2Bde%2BKar%26aufirst%3DB.%26aulast%3DGulrajani%26aufirst%3DM.%26aulast%3Dvan%2BLith%26aufirst%3DB.%26aulast%3Dvan%2BHoek%26aufirst%3DM.%26aulast%3Dde%2BZwart%26aufirst%3DE.%26aulast%3DMittag%26aufirst%3DD.%26aulast%3DDemont%26aufirst%3DD.%26aulast%3DVerkaik%26aufirst%3DS.%26aulast%3DKrantz%26aufirst%3DF.%26aulast%3DPearson%26aufirst%3DP.%2BG.%26aulast%3DUlrich%26aufirst%3DR.%26aulast%3DKaptein%26aufirst%3DA.%26atitle%3DAcalabrutinib%2520%2528ACP-196%2529%253A%2520a%2520covalent%2520Bruton%2520tyrosine%2520kinase%2520inhibitor%2520with%2520a%2520differentiated%2520selectivity%2520and%2520in%2520vivo%2520potency%2520profile%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2017%26volume%3D363%26spage%3D240%26epage%3D252%26doi%3D10.1124%2Fjpet.117.242909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belmont, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanedo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coraggio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katewa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohli, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span> <span> </span><span class="NLM_article-title">Discovery of GDC-0853: A potent, selective, and noncovalent Bruton’s tyrosine kinase inhibitor in early clinical development</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2227</span>– <span class="NLM_lpage">2245</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01712</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01712" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFCnt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2227-2245&author=J.+J.+Crawfordauthor=A.+R.+Johnsonauthor=D.+L.+Misnerauthor=L.+D.+Belmontauthor=G.+Castanedoauthor=R.+Choyauthor=M.+Coraggioauthor=L.+Dongauthor=C.+Eigenbrotauthor=R.+Ericksonauthor=N.+Ghilardiauthor=J.+Hauauthor=A.+Katewaauthor=P.+B.+Kohliauthor=W.+Leeauthor=J.+W.+Lubachauthor=B.+S.+McKenzieauthor=D.+F.+Ortwineauthor=L.+Schuttauthor=S.+Tayauthor=B.+Weiauthor=K.+Reifauthor=L.+Liuauthor=H.+Wongauthor=W.+B.+Young&title=Discovery+of+GDC-0853%3A+A+potent%2C+selective%2C+and+noncovalent+Bruton%E2%80%99s+tyrosine+kinase+inhibitor+in+early+clinical+development&doi=10.1021%2Facs.jmedchem.7b01712"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development</span></div><div class="casAuthors">Crawford, James J.; Johnson, Adam R.; Misner, Dinah L.; Belmont, Lisa D.; Castanedo, Georgette; Choy, Regina; Coraggio, Melis; Dong, Liming; Eigenbrot, Charles; Erickson, Rebecca; Ghilardi, Nico; Hau, Jonathan; Katewa, Arna; Kohli, Pawan Bir; Lee, Wendy; Lubach, Joseph W.; McKenzie, Brent S.; Ortwine, Daniel F.; Schutt, Leah; Tay, Suzanne; Wei, BinQing; Reif, Karin; Liu, Lichuan; Wong, Harvey; Young, Wendy B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2227-2245</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a nonreceptor cytoplasmic tyrosine kinase involved in B-cell and myeloid cell activation, downstream of B-cell and Fcγ receptors, resp.  Preclin. studies have indicated that inhibition of Btk activity might offer a potential therapy in autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus.  Here we disclose the discovery and preclin. characterization of a potent, selective, and noncovalent Btk inhibitor currently in clin. development.  GDC-0853 (29) suppresses B cell- and myeloid cell-mediated components of disease and demonstrates dose-dependent activity in an in vivo rat model of inflammatory arthritis.  It demonstrates highly favorable safety, pharmacokinetic (PK), and pharmacodynamic (PD) profiles in preclin. and Phase 2 studies ongoing in patients with rheumatoid arthritis, lupus, and chronic spontaneous urticaria.  On the basis of its potency, selectivity, long target residence time, and noncovalent mode of inhibition, 29 has the potential to be a best-in-class Btk inhibitor for a wide range of immunol. indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOUJgTOFJ-o7Vg90H21EOLACvtfcHk0lieyqaf4Hncfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFCnt7c%253D&md5=eddbd31f387fe86827a7469e8be45430</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01712%26sid%3Dliteratum%253Aachs%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DMisner%26aufirst%3DD.%2BL.%26aulast%3DBelmont%26aufirst%3DL.%2BD.%26aulast%3DCastanedo%26aufirst%3DG.%26aulast%3DChoy%26aufirst%3DR.%26aulast%3DCoraggio%26aufirst%3DM.%26aulast%3DDong%26aufirst%3DL.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DErickson%26aufirst%3DR.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DHau%26aufirst%3DJ.%26aulast%3DKatewa%26aufirst%3DA.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DMcKenzie%26aufirst%3DB.%2BS.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DSchutt%26aufirst%3DL.%26aulast%3DTay%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26atitle%3DDiscovery%2520of%2520GDC-0853%253A%2520A%2520potent%252C%2520selective%252C%2520and%2520noncovalent%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitor%2520in%2520early%2520clinical%2520development%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D2227%26epage%3D2245%26doi%3D10.1021%2Facs.jmedchem.7b01712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15a"><span><span class="NLM_label">(a) </span> ClinicalTrials.gov
identifiers: phase II, NCT02638948; phase I, NCT02257151, NCT02880670,
NCT02762123, NCT02456844, NCT02832180..</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+ClinicalTrials.gov%0Aidentifiers%3A+phase+II%2C+NCT02638948%3B+phase+I%2C+NCT02257151%2C+NCT02880670%2C%0ANCT02762123%2C+NCT02456844%2C+NCT02832180.."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catlett, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamczyk, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffies, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murthy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, M.</span></span> <span> </span><span class="NLM_article-title">Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants</span>. <i>Eur. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">689</span>– <span class="NLM_lpage">698</span>, <span class="refDoi"> DOI: 10.1007/s00228-017-2226-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1007%2Fs00228-017-2226-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=28265691" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjvVahs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2017&pages=689-698&author=S.+K.+Leeauthor=J.+Xingauthor=I.+M.+Catlettauthor=R.+Adamczykauthor=A.+Griffiesauthor=A.+Liuauthor=B.+Murthyauthor=M.+Nowak&title=Safety%2C+pharmacokinetics%2C+and+pharmacodynamics+of+BMS-986142%2C+a+novel+reversible+BTK+inhibitor%2C+in+healthy+participants&doi=10.1007%2Fs00228-017-2226-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15bR"><div class="casContent"><span class="casTitleNuber">15b</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants</span></div><div class="casAuthors">Lee, Sun Ku; Xing, Jun; Catlett, Ian M.; Adamczyk, Robert; Griffies, Amber; Liu, Ang; Murthy, Bindu; Nowak, Miroslawa</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">689-698</span>CODEN:
                <span class="NLM_cas:coden">EJCPAS</span>;
        ISSN:<span class="NLM_cas:issn">0031-6970</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">BMS-986142 is an oral, small-mol. reversible inhibitor of Bruton's tyrosine kinase.  The main objectives of our phase I studies were to characterize the safety and tolerability, pharmacokinetics, and pharmacodynamics of BMS-986142 in healthy participants, and to investigate the potential for the effect of BMS-986142 on the PK of methotrexate (MTX) in combination.  In a combined single ascending dose and multiple ascending dose study, the safety, pharmacokinetics, and pharmacodynamics of BMS-986142 were assessed in healthy non-Japanese participants following administration of a single dose (5-900 mg) or multiple doses (25-350 mg, once daily for 14 days).  In a drug-drug interaction study, the effect of BMS-986142 (350 mg, once daily for 5 days) on the single-dose pharmacokinetics of MTX (7.5 mg) was assessed in healthy participants.  Results: BMS-986142 was generally well tolerated, alone and in combination with MTX.  BMS-986142 was rapidly absorbed with peak concns. occurring within 2 h, and was eliminated with a mean half-life ranging from 7 to 11 h.  Exposure of BMS-986142 appeared dose proportional within the dose ranges tested.  A dose- and concn.-dependent inhibition of CD69 expression was obsd. following administration of BMS-986142.  BMS-986142 did not affect the pharmacokinetics of MTX.  BMS-986142 was well tolerated at the doses tested, had pharmacokinetic and pharmacodynamic profiles which support once-daily dosing, and can be coadministered with MTX without the pharmacokinetic interaction of BMS-986142 on MTX.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkY5ZXpICJWrVg90H21EOLACvtfcHk0lj1pt3fbGA8ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjvVahs70%253D&md5=d1435ec2479d5a50d0a5b863cc98d803</span></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=10.1007%2Fs00228-017-2226-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00228-017-2226-2%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%2BK.%26aulast%3DXing%26aufirst%3DJ.%26aulast%3DCatlett%26aufirst%3DI.%2BM.%26aulast%3DAdamczyk%26aufirst%3DR.%26aulast%3DGriffies%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DA.%26aulast%3DMurthy%26aufirst%3DB.%26aulast%3DNowak%26aufirst%3DM.%26atitle%3DSafety%252C%2520pharmacokinetics%252C%2520and%2520pharmacodynamics%2520of%2520BMS-986142%252C%2520a%2520novel%2520reversible%2520BTK%2520inhibitor%252C%2520in%2520healthy%2520participants%26jtitle%3DEur.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2017%26volume%3D73%26spage%3D689%26epage%3D698%26doi%3D10.1007%2Fs00228-017-2226-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit15c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulicicchio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattoli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukral, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudhgaonkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span> <span> </span><span class="NLM_article-title">Bruton’s Tyrosine Kinase Inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">e0181782</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0181782</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1371%2Fjournal.pone.0181782" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=28742141" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVSntbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=e0181782&author=K.+M.+Gilloolyauthor=C.+Pulicicchioauthor=M.+A.+Pattoliauthor=L.+Chengauthor=S.+Skalaauthor=E.+M.+Heimrichauthor=K.+W.+McIntyreauthor=T.+L.+Taylorauthor=D.+W.+Kukralauthor=S.+Dudhgaonkarauthor=J.+Nagarauthor=D.+Banasauthor=S.+H.+Wattersonauthor=J.+A.+Tinoauthor=A.+Furaauthor=J.+R.+Burke&title=Bruton%E2%80%99s+Tyrosine+Kinase+Inhibitor+BMS-986142+in+experimental+models+of+rheumatoid+arthritis+enhances+efficacy+of+agents+representing+clinical+standard-of-care&doi=10.1371%2Fjournal.pone.0181782"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15cR"><div class="casContent"><span class="casTitleNuber">15c</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care</span></div><div class="casAuthors">Gillooly, Kathleen M.; Pulicicchio, Claudine; Pattoli, Mark A.; Cheng, Lihong; Skala, Stacey; Heimrich, Elizabeth M.; McIntyre, Kim W.; Taylor, Tracy L.; Kukral, Daniel W.; Dudhgaonkar, Shailesh; Nagar, Jignesh; Banas, Dana; Watterson, Scott H.; Tino, Joseph A.; Fura, Aberra; Burke, James R.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e0181782/1-e0181782/20</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) regulates crit. signal transduction pathways involved in the pathobiol. of rheumatoid arthritis (RA) and other autoimmune disorders.  BMS-986142 is a potent and highly selective reversible small mol. inhibitor of BTK currently being investigated in clin. trials for the treatment of both RA and primary Sj.ovrddot.ogren's syndrome.  In the present report, we detail the in vitro and in vivo pharmacol. of BMS-986142 and show this agent provides potent and selective inhibition of BTK (IC50 = 0.5 nM), blocks antigen receptor-dependent signaling and functional endpoints (cytokine prodn., co-stimulatory mol. expression, and proliferation) in human B cells (IC50 ≤ 5 nM), inhibits Fcγ receptor-dependent cytokine prodn. from peripheral blood mononuclear cells, and blocks RANK-L-induced osteoclastogenesis.  Through the benefits of impacting these important drivers of autoimmunity, BMS-986142 demonstrated robust efficacy in murine models of rheumatoid arthritis (RA), including collagen-induced arthritis (CIA) and collagen antibody-induced arthritis (CAIA).  In both models, robust efficacy was obsd. without continuous, complete inhibition of BTK.  When a suboptimal dose of BMS-986142 was combined with other agents representing the current std. of care for RA (e.g., methotrexate, the TNFα antagonist etanercept, or the murine form of CTLA4-Ig) in the CIA model, improved efficacy compared to either agent alone was obsd.  The results suggest BMS-986142 represents a potential therapeutic for clin. investigation in RA, as monotherapy or co-administered with agents with complementary mechanisms of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg22LhZ5lc9rVg90H21EOLACvtfcHk0lj1pt3fbGA8ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVSntbs%253D&md5=144039a2425c898869da3d9c263d7321</span></div><a href="/servlet/linkout?suffix=cit15c&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0181782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0181782%26sid%3Dliteratum%253Aachs%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DPulicicchio%26aufirst%3DC.%26aulast%3DPattoli%26aufirst%3DM.%2BA.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DHeimrich%26aufirst%3DE.%2BM.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DKukral%26aufirst%3DD.%2BW.%26aulast%3DDudhgaonkar%26aufirst%3DS.%26aulast%3DNagar%26aufirst%3DJ.%26aulast%3DBanas%26aufirst%3DD.%26aulast%3DWatterson%26aufirst%3DS.%2BH.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26atitle%3DBruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Inhibitor%2520BMS-986142%2520in%2520experimental%2520models%2520of%2520rheumatoid%2520arthritis%2520enhances%2520efficacy%2520of%2520agents%2520representing%2520clinical%2520standard-of-care%26jtitle%3DPLoS%2520One%26date%3D2017%26volume%3D12%26spage%3De0181782%26doi%3D10.1371%2Fjournal.pone.0181782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit15d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lucca, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langevine, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudoin
Bertrand, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traeger, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattoli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickery, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulicchio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampulla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of 6-fluoro-5-(<i>R</i>)-(3-(<i>S</i>)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-2-(<i>S</i>)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide (BMS-986142): A reversible inhibitor of bruton’s tyrosine kinase conformationally constrained by two locked atropisomers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9173</span>– <span class="NLM_lpage">9200</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01088</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01088" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9173-9200&author=S.+H.+Wattersonauthor=G.+V.+De+Luccaauthor=Q.+Shiauthor=C.+M.+Langevineauthor=Q.+Liuauthor=D.+G.+Battauthor=M.+Beaudoin%0ABertrandauthor=H.+Gongauthor=J.+Daiauthor=S.+Yipauthor=P.+Liauthor=D.+Sunauthor=D.-R.+Wuauthor=C.+Wangauthor=Y.+Zhangauthor=S.+C.+Traegerauthor=M.+A.+Pattoliauthor=S.+Skalaauthor=L.+Chengauthor=M.+T.+Obermeierauthor=R.+Vickeryauthor=L.+Discenzaauthor=C.+D%E2%80%99Arienzoauthor=Y.+Zhangauthor=E.+Heimrichauthor=K.+Gilloolyauthor=T.+L.+Taylorauthor=C.+Pulicchioauthor=K.+W.+McIntyreauthor=A.+J.+Tebbenauthor=J.+K.+Muckelbauerauthor=C.+Y.+Changauthor=R.+Rampullaauthor=A.+Mathurauthor=L.+Salter-Cidauthor=J.+C.+Barrishauthor=P.+H.+Carterauthor=A.+Furaauthor=J.+R.+Burkeauthor=J.+A.+Tino&title=Discovery+of+6-fluoro-5-%28R%29-%283-%28S%29-%288-fluoro-1-methyl-2%2C4-dioxo-1%2C2-dihydroquinazolin-3%284H%29-yl%29-2-methylphenyl%29-2-%28S%29-%282-hydroxypropan-2-yl%29-2%2C3%2C4%2C9-tetrahydro-1H-carbazole-8-carboxamide+%28BMS-986142%29%3A+A+reversible+inhibitor+of+bruton%E2%80%99s+tyrosine+kinase+conformationally+constrained+by+two+locked+atropisomers&doi=10.1021%2Facs.jmedchem.6b01088"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15d&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01088%26sid%3Dliteratum%253Aachs%26aulast%3DWatterson%26aufirst%3DS.%2BH.%26aulast%3DDe%2BLucca%26aufirst%3DG.%2BV.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DLangevine%26aufirst%3DC.%2BM.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DBeaudoin%2BBertrand%26aufirst%3DM.%26aulast%3DGong%26aufirst%3DH.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DYip%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DD.-R.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DTraeger%26aufirst%3DS.%2BC.%26aulast%3DPattoli%26aufirst%3DM.%2BA.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DObermeier%26aufirst%3DM.%2BT.%26aulast%3DVickery%26aufirst%3DR.%26aulast%3DDiscenza%26aufirst%3DL.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHeimrich%26aufirst%3DE.%26aulast%3DGillooly%26aufirst%3DK.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DPulicchio%26aufirst%3DC.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DRampulla%26aufirst%3DR.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%25206-fluoro-5-%2528R%2529-%25283-%2528S%2529-%25288-fluoro-1-methyl-2%252C4-dioxo-1%252C2-dihydroquinazolin-3%25284H%2529-yl%2529-2-methylphenyl%2529-2-%2528S%2529-%25282-hydroxypropan-2-yl%2529-2%252C3%252C4%252C9-tetrahydro-1H-carbazole-8-carboxamide%2520%2528BMS-986142%2529%253A%2520A%2520reversible%2520inhibitor%2520of%2520bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520conformationally%2520constrained%2520by%2520two%2520locked%2520atropisomers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9173%26epage%3D9200%26doi%3D10.1021%2Facs.jmedchem.6b01088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lonsdale, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. S.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of targeted covalent inhibitors</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">3816</span>– <span class="NLM_lpage">3830</span>, <span class="refDoi"> DOI: 10.1039/C7CS00220C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1039%2FC7CS00220C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=29620097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVGiurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2018&pages=3816-3830&author=R.+Lonsdaleauthor=R.+S.+Ward&title=Structure-based+design+of+targeted+covalent+inhibitors&doi=10.1039%2FC7CS00220C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16aR"><div class="casContent"><span class="casTitleNuber">16a</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design of targeted covalent inhibitors</span></div><div class="casAuthors">Lonsdale, Richard; Ward, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3816-3830</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Covalent inhibition is a rapidly growing discipline within drug discovery.  Many historical covalent inhibitors were discovered by serendipity, with such a mechanism of action often regarded as undesirable due to potential toxicity issues.  Recent progress has seen a major shift in this outlook, as covalent inhibition shows promise for targets where previous efforts to identify non-covalent small mol. inhibitors have failed.  Targeted covalent inhibitors (TCIs) can offer drug discovery scientists the ability to increase the potency and/or selectivity of small mol. inhibitors, by attachment of reactive functional groups designed to covalently bind to specific sites in a target.  In this tutorial review we introduce the broader concept of covalent inhibition, discuss the potential benefits and challenges of such an approach, and provide an overview of the current status of the field.  We also describe some strategies and computational tools to enable successful covalent drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnSIGMuS3vm7Vg90H21EOLACvtfcHk0lhBgbc3lj1Pgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVGiurs%253D&md5=a7e31b23cf8ecfcad1397ad10ea10b7b</span></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1039%2FC7CS00220C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7CS00220C%26sid%3Dliteratum%253Aachs%26aulast%3DLonsdale%26aufirst%3DR.%26aulast%3DWard%26aufirst%3DR.%2BS.%26atitle%3DStructure-based%2520design%2520of%2520targeted%2520covalent%2520inhibitors%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2018%26volume%3D47%26spage%3D3816%26epage%3D3830%26doi%3D10.1039%2FC7CS00220C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit16b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Bello, C.</span></span> <span> </span><span class="NLM_article-title">Designing irreversible inhibitors—Worth the effort?</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">22</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500469</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1002%2Fcmdc.201500469" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=26593241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVyhtLnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=22-30&author=C.+Gonzalez-Bello&title=Designing+irreversible+inhibitors%E2%80%94Worth+the+effort%3F&doi=10.1002%2Fcmdc.201500469"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16b</span><div class="casTitle"><span class="NLM_cas:atitle">Designing Irreversible Inhibitors-Worth the Effort?</span></div><div class="casAuthors">Gonzalez-Bello, Concepcion</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">22-30</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Despite the unquestionable success of numerous irreversible drugs that are currently in clin. use, such as acetylsalicylic acid (Aspirin) and penicillin, the no. of such approved drugs is much lower than that of noncovalent drugs.  Over the years, the potential off-target effects of these types of compds. have been the primary concern that has hampered their development.  However, their remarkable advantages over noncovalent drugs and a better anal. of the risks have decreased the widespread skepticism surrounding them.  The design of irreversible inhibitors is a challenge, particularly considering that in some cases their efficacy is due to complex and unexpected mechanisms of action.  In this review the main advantages of irreversible inhibition are summarized, and the complexity of certain covalent modification mechanisms is highlighted with selected examples.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpER985BdGxe7Vg90H21EOLACvtfcHk0lgBGPAPkxBIHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVyhtLnK&md5=a4686a10be608f23a1131023ff1594ad</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500469%26sid%3Dliteratum%253Aachs%26aulast%3DGonzalez-Bello%26aufirst%3DC.%26atitle%3DDesigning%2520irreversible%2520inhibitors%25E2%2580%2594Worth%2520the%2520effort%253F%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D22%26epage%3D30%26doi%3D10.1002%2Fcmdc.201500469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D.
S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weerapana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">Strategies for discovering and derisking covalent, irreversible enzyme inhibitors</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">949</span>– <span class="NLM_lpage">964</span>, <span class="refDoi"> DOI: 10.4155/fmc.10.21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.4155%2Ffmc.10.21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=20640225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsFakur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=949-964&author=D.%0AS.+Johnsonauthor=E.+Weerapanaauthor=B.+F.+Cravatt&title=Strategies+for+discovering+and+derisking+covalent%2C+irreversible+enzyme+inhibitors&doi=10.4155%2Ffmc.10.21"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies for discovering and derisking covalent, irreversible enzyme inhibitors</span></div><div class="casAuthors">Johnson, Douglas S.; Weerapana, Eranthie; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">949-964</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  This article presents several covalent inhibitors, including examples of successful drugs, as well as highly selective, irreversible inhibitors of emerging therapeutic targets, such as fatty acid amide hydolase.  Covalent inhibitors have many desirable features, including increased biochem. efficiency of target disruption, less sensitivity toward pharmacokinetic parameters and increased duration of action that outlasts the pharmacokinetics of the compd.  Safety concerns that must be mitigated include lack of specificity and the potential immunogenicity of protein-inhibitor adduct(s).  Particular attention will be given to recent technologies, such as activity-based protein profiling, which allow one to define the proteome-wide selectivity patterns for covalent inhibitors in vitro and in vivo.  For instance, any covalent inhibitor can, in principle, be modified with a 'clickable' tag to generate an activity probe that is almost indistinguishable from the original agent.  These probes can be applied to any living system across a broad dose range to fully inventory their on and off targets.  The substantial no. of drugs on the market today that act by a covalent mechanism belies historical prejudices against the development of irreversibly acting therapeutic small mols.  Emerging proteomic technologies offer a means to systematically discriminate safe (selective) vs. deleterious (nonselective) covalent inhibitors and thus should inspire their future design and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqm0whEybB-LVg90H21EOLACvtfcHk0lgBGPAPkxBIHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsFakur4%253D&md5=07e1f89418b168798ae5c1a9fa43e9c1</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.4155%2Ffmc.10.21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.10.21%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DD.%2BS.%26aulast%3DWeerapana%26aufirst%3DE.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DStrategies%2520for%2520discovering%2520and%2520derisking%2520covalent%252C%2520irreversible%2520enzyme%2520inhibitors%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2010%26volume%3D2%26spage%3D949%26epage%3D964%26doi%3D10.4155%2Ffmc.10.21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit17b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J.
P.</span></span> <span> </span><span class="NLM_article-title">New concepts in immunology relevant to idiosyncratic drug reactions: The “danger hypothesis” and innate immue system</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">395</span>, <span class="refDoi"> DOI: 10.1021/tx980249i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx980249i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1999&pages=387-395&author=J.%0AP.+Uetrecht&title=New+concepts+in+immunology+relevant+to+idiosyncratic+drug+reactions%3A+The+%E2%80%9Cdanger+hypothesis%E2%80%9D+and+innate+immue+system&doi=10.1021%2Ftx980249i"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1021%2Ftx980249i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx980249i%26sid%3Dliteratum%253Aachs%26aulast%3DUetrecht%26aufirst%3DJ.%2BP.%26atitle%3DNew%2520concepts%2520in%2520immunology%2520relevant%2520to%2520idiosyncratic%2520drug%2520reactions%253A%2520The%2520%25E2%2580%259Cdanger%2520hypothesis%25E2%2580%259D%2520and%2520innate%2520immue%2520system%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D1999%26volume%3D12%26spage%3D387%26epage%3D395%26doi%3D10.1021%2Ftx980249i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit17c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atsumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takakusa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurihara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okazaki, O.</span></span> <span> </span><span class="NLM_article-title">A zone classification system for risk assessemnt of idiosyncratic drug toxicity using daily dose and covalent binding</span>. <i>Drug Met. Distrib.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1970</span>– <span class="NLM_lpage">1977</span>, <span class="refDoi"> DOI: 10.1124/dmd.109.027797</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1124%2Fdmd.109.027797" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=19487250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVOrsrfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=1970-1977&author=S.+Nakayamaauthor=R.+Atsumiauthor=H.+Takakusaauthor=Y.+Kobayashiauthor=A.+Kuriharaauthor=Y.+Nagaiauthor=D.+Nakaiauthor=O.+Okazaki&title=A+zone+classification+system+for+risk+assessemnt+of+idiosyncratic+drug+toxicity+using+daily+dose+and+covalent+binding&doi=10.1124%2Fdmd.109.027797"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17cR"><div class="casContent"><span class="casTitleNuber">17c</span><div class="casTitle"><span class="NLM_cas:atitle">A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding</span></div><div class="casAuthors">Nakayama, Shintaro; Atsumi, Ryo; Takakusa, Hideo; Kobayashi, Yoshimasa; Kurihara, Atsushi; Nagai, Yoko; Nakai, Daisuke; Okazaki, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1970-1977</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The risk of idiosyncratic drug toxicity (IDT) is of great concern to the pharmaceutical industry.  Current hypotheses based on retrospective studies suggest that the occurrence of IDT is related to covalent binding and daily dose.  The authors detd. the covalent binding of 42 radiolabeled drugs in three test systems (human liver microsomes and hepatocytes in vitro and rat liver in vivo) to assess the risk of IDT.  On the basis of safety profiles given in official documentation, tested drugs were classified into the safety categories of safe, warning, black box warning, and withdrawn.  The covalent binding in each of the three test systems did not distinguish the safety categories clearly.  However, when the log-normalized covalent binding was plotted against the log-normalized daily dose, the distribution of the plot in the safety categories became clear.  An ordinal logistic regression anal. indicated that both covalent binding and daily dose were significantly correlated with safety category and that covalent binding in hepatocytes was the best predictor among the three systems.  When two sepn. lines were drawn on the correlation graph between covalent binding in human hepatocytes and daily dose by a regression anal. to create three zones, 30 of 37 tested drugs were located in zones corresponding to their resp. classified safety categories.  In conclusion, the authors established a zone classification system using covalent binding in human hepatocytes and daily dose for the risk assessment of IDTs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtahZPkNJ3JbVg90H21EOLACvtfcHk0lh5L8RaV4MsDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVOrsrfO&md5=425119e0451fc50ec6ca95d5e3fe5fd3</span></div><a href="/servlet/linkout?suffix=cit17c&amp;dbid=16384&amp;doi=10.1124%2Fdmd.109.027797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.109.027797%26sid%3Dliteratum%253Aachs%26aulast%3DNakayama%26aufirst%3DS.%26aulast%3DAtsumi%26aufirst%3DR.%26aulast%3DTakakusa%26aufirst%3DH.%26aulast%3DKobayashi%26aufirst%3DY.%26aulast%3DKurihara%26aufirst%3DA.%26aulast%3DNagai%26aufirst%3DY.%26aulast%3DNakai%26aufirst%3DD.%26aulast%3DOkazaki%26aufirst%3DO.%26atitle%3DA%2520zone%2520classification%2520system%2520for%2520risk%2520assessemnt%2520of%2520idiosyncratic%2520drug%2520toxicity%2520using%2520daily%2520dose%2520and%2520covalent%2520binding%26jtitle%3DDrug%2520Met.%2520Distrib.%26date%3D2009%26volume%3D37%26spage%3D1970%26epage%3D1977%26doi%3D10.1124%2Fdmd.109.027797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyckman, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spergel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olini, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strnad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surti, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leftheris, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lucca, G. V.</span></span> <span> </span><span class="NLM_article-title">Purine derivatives as potent Bruton’s tyrosine kinase (BTK) inhibitors for autoimmune diseases</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">2206</span>– <span class="NLM_lpage">2211</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.02.075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1016%2Fj.bmcl.2014.02.075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=24685542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFOgsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=2206-2211&author=Q.+Shiauthor=A.+Tebbenauthor=A.+J.+Dyckmanauthor=H.+Liauthor=C.+Liuauthor=J.+Linauthor=S.+Spergelauthor=J.+R.+Burkeauthor=K.+W.+McIntyreauthor=G.+C.+Oliniauthor=J.+Strnadauthor=N.+Surtiauthor=J.+K.+Muckelbauerauthor=C.+Changauthor=Y.+Anauthor=L.+Chengauthor=Q.+Ruanauthor=K.+Leftherisauthor=P.+H.+Carterauthor=J.+A.+Tinoauthor=G.+V.+De+Lucca&title=Purine+derivatives+as+potent+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+inhibitors+for+autoimmune+diseases&doi=10.1016%2Fj.bmcl.2014.02.075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases</span></div><div class="casAuthors">Shi, Qing; Tebben, Andrew; Dyckman, Alaric J.; Li, Hedy; Liu, Chunjian; Lin, James; Spergel, Steve; Burke, James R.; McIntyre, Kim W.; Olini, Gilbert C.; Strnad, Joann; Surti, Neha; Muckelbauer, Jodi K.; Chang, Chiehying; An, Yongmi; Cheng, Lin; Ruan, Qian; Leftheris, Katerina; Carter, Percy H.; Tino, Joseph; De Lucca, George V.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2206-2211</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Investigation of various heterocyclic core isosteres of imidazopyrazines 1 & 2 yielded purine derivs. 3 & 8 as potent and selective BTK inhibitors.  Subsequent SAR studies of the purine series led to the discovery of 20 as a leading compd.  Compd. 20 is very selective when screened against a panel of 400 kinases and is a potent inhibitor in cellular assays of human B cell function including B-Cell proliferation and CD86 cell surface expression and exhibited in vivo efficacy in a mouse PCA model.  Its X-ray co-crystal structure with BTK shows that the high selectivity is gained from filling a BTK specific lipophilic pocket.  However, phys. and ADME properties leading to low oral exposure hindered further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobsHsC5Hi6lbVg90H21EOLACvtfcHk0lh5L8RaV4MsDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFOgsL8%253D&md5=1b1649221d615d9805d5cc197a39e05a</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.02.075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.02.075%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DTebben%26aufirst%3DA.%26aulast%3DDyckman%26aufirst%3DA.%2BJ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DSpergel%26aufirst%3DS.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DOlini%26aufirst%3DG.%2BC.%26aulast%3DStrnad%26aufirst%3DJ.%26aulast%3DSurti%26aufirst%3DN.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DAn%26aufirst%3DY.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DRuan%26aufirst%3DQ.%26aulast%3DLeftheris%26aufirst%3DK.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26aulast%3DDe%2BLucca%26aufirst%3DG.%2BV.%26atitle%3DPurine%2520derivatives%2520as%2520potent%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520inhibitors%2520for%2520autoimmune%2520diseases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D2206%26epage%3D2211%26doi%3D10.1016%2Fj.bmcl.2014.02.075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippy, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surti, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pokross, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton’s tyrosine kinase (BTK) and Janus kinase 2 (JAK2)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">4265</span>– <span class="NLM_lpage">4269</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.07.102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1016%2Fj.bmcl.2015.07.102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=26320619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlSlsLvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=4265-4269&author=Q.+Liuauthor=D.+G.+Battauthor=J.+S.+Lippyauthor=N.+Surtiauthor=A.+J.+Tebbenauthor=J.+K.+Muckelbauerauthor=L.+Chenauthor=Y.+Anauthor=C.+Changauthor=M.+Pokrossauthor=Z.+Yangauthor=H.+Wangauthor=J.+R.+Burkeauthor=P.+H.+Carterauthor=J.+A.+Tino&title=Design+and+synthesis+of+carbazole+carboxamides+as+promising+inhibitors+of+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+and+Janus+kinase+2+%28JAK2%29&doi=10.1016%2Fj.bmcl.2015.07.102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19aR"><div class="casContent"><span class="casTitleNuber">19a</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton's tyrosine kinase (BTK) and Janus kinase 2 (JAK2)</span></div><div class="casAuthors">Liu, Qingjie; Batt, Douglas G.; Lippy, Jonathan S.; Surti, Neha; Tebben, Andrew J.; Muckelbauer, Jodi K.; Chen, Lin; An, Yongmi; Chang, Chiehying; Pokross, Matt; Yang, Zheng; Wang, Haiqing; Burke, James R.; Carter, Percy H.; Tino, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4265-4269</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Four series of disubstituted carbazole-1-carboxamides, e.g. I [R = 2-F, 3-MeO, 2-Me, etc.] were designed and synthesized as inhibitors of Bruton's tyrosine kinase.  4,7- And 4,6-Disubstituted carbazole-1-carboxamides were potent and selective inhibitors of BTK, while 3,7- and 3,6-disubstituted carbazole-1-carboxamides were potent and selective inhibitors of Janus kinase 2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD3SZfBfD4ZbVg90H21EOLACvtfcHk0ljV5aB_qlAHuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlSlsLvF&md5=3558c8ca9a9c29bb38ef98936f61200a</span></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.07.102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.07.102%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DLippy%26aufirst%3DJ.%2BS.%26aulast%3DSurti%26aufirst%3DN.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DAn%26aufirst%3DY.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DPokross%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520carbazole%2520carboxamides%2520as%2520promising%2520inhibitors%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520and%2520Janus%2520kinase%25202%2520%2528JAK2%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D4265%26epage%3D4269%26doi%3D10.1016%2Fj.bmcl.2015.07.102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit19b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">De Lucca, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudoin Bertrand, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampulla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickery, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marathe, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattoli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukral, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Small molecule reversible inhibitors of Bruton’s tyrosine kinase (BTK): Structure-activity relationships leading to the identification of 7-(2-hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7915</span>– <span class="NLM_lpage">7935</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00722</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00722" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlCrsL3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7915-7935&author=G.+B.+De+Luccaauthor=Q.+Shiauthor=Q.+Liuauthor=D.+G.+Battauthor=M.+Beaudoin+Bertrandauthor=R.+Rampullaauthor=A.+Mathurauthor=L.+Discenzaauthor=C.+D%E2%80%99Arienzoauthor=J.+Daiauthor=M.+T.+Obermeierauthor=R.+Vickeryauthor=Y.+Zhangauthor=Z.+Yangauthor=P.+H.+Maratheauthor=A.+J.+Tebbenauthor=J.+K.+Muckelbauerauthor=C.+Y.+Changauthor=H.+Zhangauthor=K.+Gilloolyauthor=T.+L.+Taylorauthor=M.+A.+Pattoliauthor=S.+Skalaauthor=D.+W.+Kukralauthor=K.+W.+McIntyreauthor=L.+Salter-Cidauthor=A.+Furaauthor=J.+R.+Burkeauthor=J.+C.+Barrishauthor=P.+H.+Carterauthor=J.+A.+Tino&title=Small+molecule+reversible+inhibitors+of+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29%3A+Structure-activity+relationships+leading+to+the+identification+of+7-%282-hydroxypropan-2-yl%29-4-%5B2-methyl-3-%284-oxo-3%2C4-dihydroquinazolin-3-yl%29phenyl%5D-9H-carbazole-1-carboxamide+%28BMS-935177%29&doi=10.1021%2Facs.jmedchem.6b00722"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19bR"><div class="casContent"><span class="casTitleNuber">19b</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Reversible Inhibitors of Bruton's Tyrosine Kinase (BTK): Structure-Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177)</span></div><div class="casAuthors">De Lucca, George V.; Shi, Qing; Liu, Qingjie; Batt, Douglas G.; Beaudoin Bertrand, Myra; Rampulla, Rick; Mathur, Arvind; Discenza, Lorell; D'Arienzo, Celia; Dai, Jun; Obermeier, Mary; Vickery, Rodney; Zhang, Yingru; Yang, Zheng; Marathe, Punit; Tebben, Andrew J.; Muckelbauer, Jodi K.; Chang, ChiehYing J.; Zhang, Huiping; Gillooly, Kathleen; Taylor, Tracy; Pattoli, Mark A.; Skala, Stacey; Kukral, Daniel W.; McIntyre, Kim W.; Salter-Cid, Luisa; Fura, Aberra; Burke, James R.; Barrish, Joel C.; Carter, Percy H.; Tino, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7915-7935</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) belongs to the TEC family of nonreceptor tyrosine kinases and plays a crit. role in multiple cell types responsible for numerous autoimmune diseases.  This article will detail the structure-activity relationships (SARs) leading to a novel second generation series of potent and selective reversible carbazole inhibitors of BTK.  With an excellent pharmacokinetic profile as well as demonstrated in vivo activity and an acceptable safety profile, 7-(2-hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide 6 (BMS-935177) was selected to advance into clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1HUwZaRn_w7Vg90H21EOLACvtfcHk0ljV5aB_qlAHuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlCrsL3M&md5=7c7ec1a52121c541753c045c1cbf758b</span></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00722%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BLucca%26aufirst%3DG.%2BB.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DBeaudoin%2BBertrand%26aufirst%3DM.%26aulast%3DRampulla%26aufirst%3DR.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DDiscenza%26aufirst%3DL.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DObermeier%26aufirst%3DM.%2BT.%26aulast%3DVickery%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DMarathe%26aufirst%3DP.%2BH.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DGillooly%26aufirst%3DK.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DPattoli%26aufirst%3DM.%2BA.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DKukral%26aufirst%3DD.%2BW.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DSmall%2520molecule%2520reversible%2520inhibitors%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%253A%2520Structure-activity%2520relationships%2520leading%2520to%2520the%2520identification%2520of%25207-%25282-hydroxypropan-2-yl%2529-4-%255B2-methyl-3-%25284-oxo-3%252C4-dihydroquinazolin-3-yl%2529phenyl%255D-9H-carbazole-1-carboxamide%2520%2528BMS-935177%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7915%26epage%3D7935%26doi%3D10.1021%2Facs.jmedchem.6b00722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span>; <span class="NLM_string-name">Bertrand, M. B.</span>; <span class="NLM_string-name">Delucca, G. V.</span>; <span class="NLM_string-name">Galella, M. A.</span>; <span class="NLM_string-name">Ko, S. S.</span>; <span class="NLM_string-name">Langevine, C. M.</span>; <span class="NLM_string-name">Liu, Q.</span>; <span class="NLM_string-name">Shi, Q.</span>; <span class="NLM_string-name">Srivastava, A. S.</span>; <span class="NLM_string-name">Tino, J. A.</span>; <span class="NLM_string-name">Watterson, S. H.</span></span> <span> </span><span class="NLM_article-title">Substituted Carbazolecarboxamide Derivatives as BTK Inhibitors and Their Preparation and Use for the Treatment of Diseases</span>. <span class="NLM_patent">WO 2014210085</span>, <span class="NLM_year">2014</span>;</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=D.+G.+Batt&author=M.+B.+Bertrand&author=G.+V.+Delucca&author=M.+A.+Galella&author=S.+S.+Ko&author=C.+M.+Langevine&author=Q.+Liu&author=Q.+Shi&author=A.+S.+Srivastava&author=J.+A.+Tino&author=S.+H.+Watterson&title=Substituted+Carbazolecarboxamide+Derivatives+as+BTK+Inhibitors+and+Their+Preparation+and+Use+for+the+Treatment+of+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBatt%26aufirst%3DD.%2BG.%26atitle%3DSubstituted%2520Carbazolecarboxamide%2520Derivatives%2520as%2520BTK%2520Inhibitors%2520and%2520Their%2520Preparation%2520and%2520Use%2520for%2520the%2520Treatment%2520of%2520Diseases%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit20a.1"><span> <i>Chem. Abstr.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume">162</span>,  <span class="NLM_fpage">161072</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Chem.+Abstr.+2014%2C+162%2C+161072."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20a.1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26jtitle%3DChem.%2520Abstr.%26date%3D2014%26volume%3D162%26spage%3D161072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit20b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Ko, S. S.</span>; <span class="NLM_string-name">Batt, D. A.</span>; <span class="NLM_string-name">Bertrand, M. B.</span>; <span class="NLM_string-name">Delucca, G. V.</span>; <span class="NLM_string-name">Langevine, C. M.</span>; <span class="NLM_string-name">Liu, Q.</span>; <span class="NLM_string-name">Srivastava, A. S.</span>; <span class="NLM_string-name">Watterson, S. H.</span></span> <span> </span><span class="NLM_article-title">Preparation of 4-Phenylcarbazole-1-carboxamide Compounds Useful as Bruton’s Tyrosine Kinase (BTK) Inhibitors</span>. <span class="NLM_patent">WO 2014210087</span>, <span class="NLM_year">2014</span>;</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=S.+S.+Ko&author=D.+A.+Batt&author=M.+B.+Bertrand&author=G.+V.+Delucca&author=C.+M.+Langevine&author=Q.+Liu&author=A.+S.+Srivastava&author=S.+H.+Watterson&title=Preparation+of+4-Phenylcarbazole-1-carboxamide+Compounds+Useful+as+Bruton%E2%80%99s+Tyrosine+Kinase+%28BTK%29+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKo%26aufirst%3DS.%2BS.%26atitle%3DPreparation%2520of%25204-Phenylcarbazole-1-carboxamide%2520Compounds%2520Useful%2520as%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520%2528BTK%2529%2520Inhibitors%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit20b.2"><span> <i>Chem. Abstr.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume">162</span>,  <span class="NLM_fpage">150740</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Chem.+Abstr.+2014%2C+162%2C+150740."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20b.2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26jtitle%3DChem.%2520Abstr.%26date%3D2014%26volume%3D162%26spage%3D150740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippy, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattoli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surti, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Conversion of carbazole carboxamide based reversible inhibitors of Bruton’s tyrosine kinase (BTK) into potent, selective irreversible inhibitors in the carbazole, tetrahydrocarbazole, and a new 2,3-dimethylindole series</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">3080</span>– <span class="NLM_lpage">3084</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.07.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1016%2Fj.bmcl.2018.07.041" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=3080-3084&author=Q.+Liuauthor=D.+G.+Battauthor=C.+Chaudhryauthor=J.+S.+Lippyauthor=M.+A.+Pattoliauthor=N.+Surtiauthor=S.+Xuauthor=P.+H.+Carterauthor=J.+R.+Burkeauthor=J.+A.+Tino&title=Conversion+of+carbazole+carboxamide+based+reversible+inhibitors+of+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+into+potent%2C+selective+irreversible+inhibitors+in+the+carbazole%2C+tetrahydrocarbazole%2C+and+a+new+2%2C3-dimethylindole+series&doi=10.1016%2Fj.bmcl.2018.07.041"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.07.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.07.041%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DChaudhry%26aufirst%3DC.%26aulast%3DLippy%26aufirst%3DJ.%2BS.%26aulast%3DPattoli%26aufirst%3DM.%2BA.%26aulast%3DSurti%26aufirst%3DN.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DConversion%2520of%2520carbazole%2520carboxamide%2520based%2520reversible%2520inhibitors%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520into%2520potent%252C%2520selective%2520irreversible%2520inhibitors%2520in%2520the%2520carbazole%252C%2520tetrahydrocarbazole%252C%2520and%2520a%2520new%25202%252C3-dimethylindole%2520series%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D3080%26epage%3D3084%26doi%3D10.1016%2Fj.bmcl.2018.07.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, S.</span>; <span class="NLM_string-name">Batt, D.
G.</span>; <span class="NLM_string-name">Liu, Q.</span>; <span class="NLM_string-name">Macor, J. E.</span>; <span class="NLM_string-name">Tino, J. A.</span>; <span class="NLM_string-name">Watterson, S. H.</span></span> <span> </span><span class="NLM_article-title">Carbazole Inhibitors</span>. <span class="NLM_patent">WO 2016065236</span>, <span class="NLM_year">2016</span>;</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=S.+Ahmad&author=D.%0AG.+Batt&author=Q.+Liu&author=J.+E.+Macor&author=J.+A.+Tino&author=S.+H.+Watterson&title=Carbazole+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAhmad%26aufirst%3DS.%26atitle%3DCarbazole%2520Inhibitors%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit22a.1"><span> <i>Chem. Abstr.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume">164</span>,  <span class="NLM_fpage">556167</span> (example 88).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Chem.+Abstr.+2016%2C+164%2C+556167+%28example+88%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22a.1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26jtitle%3DChem.%2520Abstr.%26date%3D2016%26volume%3D164%26spage%3D556167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span>; <span class="NLM_string-name">Pattoli, M. A.</span>; <span class="NLM_string-name">Cheng, L.</span>; <span class="NLM_string-name">Skala, S.</span>; <span class="NLM_string-name">Heimrich, E. M.</span>; <span class="NLM_string-name">Taylor, T. L.</span>; <span class="NLM_string-name">Pulicicchio, C.</span>; <span class="NLM_string-name">Kukral, D. W.</span>; <span class="NLM_string-name">Petrone, T.</span>; <span class="NLM_string-name">Catlett, I. M.</span>; <span class="NLM_string-name">Zheng, N.</span>; <span class="NLM_string-name">Li, W.</span>; <span class="NLM_string-name">Watterson, S. H.</span>; <span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">BMS-986195 is a highly selective and rapidly acting covalent inhibitor of Bruton’s tyrosine kinsase with robust efficacy at low doses in preclinical models of RA and lupus nephritis</span>.  <i>Arthritis Rhematol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume">69</span> (<span class="NLM_issue">Suppl. 10</span>), <a href="https://acrabstracts.org/abstract/bms-986195-is-a-highly-selective-and-rapidly-acting-covalent-inhibitor-of-brutons-tyrosine-kinase-with-robust-efficacy-at-low-doses-in-preclinical-models-of-ra-and-lupus-nephritis/" class="extLink">https://acrabstracts.org/abstract/bms-986195-is-a-highly-selective-and-rapidly-acting-covalent-inhibitor-of-brutons-tyrosine-kinase-with-robust-efficacy-at-low-doses-in-preclinical-models-of-ra-and-lupus-nephritis/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2017&issue=Suppl.+10&author=J.+R.+Burke&author=M.+A.+Pattoli&author=L.+Cheng&author=S.+Skala&author=E.+M.+Heimrich&author=T.+L.+Taylor&author=C.+Pulicicchio&author=D.+W.+Kukral&author=T.+Petrone&author=I.+M.+Catlett&author=N.+Zheng&author=W.+Li&author=S.+H.+Watterson&author=J.+A.+Tino&title=BMS-986195+is+a+highly+selective+and+rapidly+acting+covalent+inhibitor+of+Bruton%E2%80%99s+tyrosine+kinsase+with+robust+efficacy+at+low+doses+in+preclinical+models+of+RA+and+lupus+nephritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26atitle%3DBMS-986195%2520is%2520a%2520highly%2520selective%2520and%2520rapidly%2520acting%2520covalent%2520inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinsase%2520with%2520robust%2520efficacy%2520at%2520low%2520doses%2520in%2520preclinical%2520models%2520of%2520RA%2520and%2520lupus%2520nephritis%26jtitle%3DArthritis%2520Rhematol.%26date%3D2017%26volume%3D69%26issue%3DSuppl.%252010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dahal, U. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, A. M.</span></span> <span> </span><span class="NLM_article-title">Benchmarking in vitro covalent binding burden as a tool to assess potential toxicity caused by nonspecific covalent binding of covalent drugs</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1739</span>– <span class="NLM_lpage">1745</span>, <span class="refDoi"> DOI: 10.1021/tx400301q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx400301q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Sis7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2013&pages=1739-1745&author=U.+P.+Dahalauthor=R.+S.+Obachauthor=A.+M.+Gilbert&title=Benchmarking+in+vitro+covalent+binding+burden+as+a+tool+to+assess+potential+toxicity+caused+by+nonspecific+covalent+binding+of+covalent+drugs&doi=10.1021%2Ftx400301q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Benchmarking in Vitro Covalent Binding Burden As a Tool To Assess Potential Toxicity Caused by Nonspecific Covalent Binding of Covalent Drugs</span></div><div class="casAuthors">Dahal, Upendra P.; Obach, R. Scott; Gilbert, Adam M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1739-1745</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Despite several advantages of covalent inhibitors (such as increased biochem. efficiency, longer duration of action on the target, and lower efficacious doses) over their reversible binding counterparts, there is a reluctance to use covalent inhibitors as a drug design strategy in pharmaceutical research.  This reluctance is due to their anticipated reactions with nontargeted macromols.  We hypothesized that there may be a threshold limit for nonspecific covalent binding, below which a covalent binding drug may be less likely to cause toxicity due to irreversible binding to off-target macromols.  Estn. of in vivo covalent binding burden from in vitro data has previously been used as an approach to distinguish those agents more likely to cause toxicity (e.g., hepatotoxicity) via metabolic activation to reactive metabolites.  We have extended this approach to nine covalent binding drugs to det. in vitro covalent binding burden.  In vitro covalent binding burden was detd. by incubating radiolabeled drugs with pooled human hepatocytes.  These data were scaled to an est. of in vivo covalent binding burden by combining the in vitro data with daily dose.  Scaled in vivo daily covalent binding burden of marketed covalent drugs was found to be under 10 mg/day, which is in agreement with previously reported threshold value for metabolically activated reversible drugs.  Covalent binding was also compared to the intrinsic reactivities of the covalent inhibitors assessed using nucleophiles glutathione and N-α-acetyl lysine.  The intrinsic reactivity did not correlate with obsd. in vitro covalent binding, which demonstrated that the intrinsic reactivity of the electrophilic groups of covalent drugs does not exclusively account for the extent of covalent binding.  The ramifications of these findings for consideration of using a covalent strategy in drug design are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr23ygNWkgm7bVg90H21EOLACvtfcHk0lhuCrVAR-vVBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Sis7%252FJ&md5=08384c595edf0b5e8ae939f75d9a5e97</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Ftx400301q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx400301q%26sid%3Dliteratum%253Aachs%26aulast%3DDahal%26aufirst%3DU.%2BP.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DGilbert%26aufirst%3DA.%2BM.%26atitle%3DBenchmarking%2520in%2520vitro%2520covalent%2520binding%2520burden%2520as%2520a%2520tool%2520to%2520assess%2520potential%2520toxicity%2520caused%2520by%2520nonspecific%2520covalent%2520binding%2520of%2520covalent%2520drugs%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2013%26volume%3D26%26spage%3D1739%26epage%3D1745%26doi%3D10.1021%2Ftx400301q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Catlett, I.</span>; <span class="NLM_string-name">Wei, L.</span>; <span class="NLM_string-name">Zheng, N.</span>; <span class="NLM_string-name">Liu, A.</span>; <span class="NLM_string-name">He, B.</span>; <span class="NLM_string-name">Girgis, I.</span>; <span class="NLM_string-name">Nowak, M.</span></span> <span> </span><span class="NLM_article-title">BMS-986195, a novel, rapidly acting, covalent inhibitor of Bruton’s tyrosine kinase: safety, pharmacokinetic and pharmacodynamic profiles in healthy participants</span>.  <i>Arthritis Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume">69</span> (<span class="NLM_issue">Suppl. 10</span>), <a href="https://acrabstracts.org/abstract/bms-986195-a-novel-rapidly-acting-covalent-inhibitor-of-brutons-tyrosine-kinase-safety-pharmacokinetic-and-pharmacodynamic-profiles-in-healthy-participants/" class="extLink">https://acrabstracts.org/abstract/bms-986195-a-novel-rapidly-acting-covalent-inhibitor-of-brutons-tyrosine-kinase-safety-pharmacokinetic-and-pharmacodynamic-profiles-in-healthy-participants/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2017&issue=Suppl.+10&author=I.+Catlett&author=L.+Wei&author=N.+Zheng&author=A.+Liu&author=B.+He&author=I.+Girgis&author=M.+Nowak&title=BMS-986195%2C+a+novel%2C+rapidly+acting%2C+covalent+inhibitor+of+Bruton%E2%80%99s+tyrosine+kinase%3A+safety%2C+pharmacokinetic+and+pharmacodynamic+profiles+in+healthy+participants"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCatlett%26aufirst%3DI.%26atitle%3DBMS-986195%252C%2520a%2520novel%252C%2520rapidly%2520acting%252C%2520covalent%2520inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%253A%2520safety%252C%2520pharmacokinetic%2520and%2520pharmacodynamic%2520profiles%2520in%2520healthy%2520participants%26jtitle%3DArthritis%2520Rheumatol.%26date%3D2017%26volume%3D69%26issue%3DSuppl.%252010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit25b"><span><span class="NLM_label">(b) </span> ClinicalTrials.gov
identifiers: NCT02705989, NCT03245515, NCT03262740, NCT03131973.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+ClinicalTrials.gov%0Aidentifiers%3A+NCT02705989%2C+NCT03245515%2C+NCT03262740%2C+NCT03131973."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span>; <span class="NLM_string-name">Watterson, S. H.</span>; <span class="NLM_string-name">Ahmad, S.</span></span> <span> </span><span class="NLM_article-title">Indole Carboxamide Compounds</span>. <span class="NLM_patent">US 9,688,629</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=Q.+Liu&author=S.+H.+Watterson&author=S.+Ahmad&title=Indole+Carboxamide+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DIndole%2520Carboxamide%2520Compounds%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit26b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span>; <span class="NLM_string-name">Watterson, S. H.</span>; <span class="NLM_string-name">Batt, D. G.</span>; <span class="NLM_string-name">Ahmad, S.</span>; <span class="NLM_string-name">Beaudoin Bertrand, M.</span>; <span class="NLM_string-name">Gong, H.</span>; <span class="NLM_string-name">Guo, W.</span>; <span class="NLM_string-name">Macor, J. E.</span>; <span class="NLM_string-name">Ngu, K.</span>; <span class="NLM_string-name">Tebben, A.</span>; <span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Indole Carboxamide Compounds</span>. <span class="NLM_patent">US 2016/0115126</span>, <span class="NLM_year">2016</span>;</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=Q.+Liu&author=S.+H.+Watterson&author=D.+G.+Batt&author=S.+Ahmad&author=M.+Beaudoin+Bertrand&author=H.+Gong&author=W.+Guo&author=J.+E.+Macor&author=K.+Ngu&author=A.+Tebben&author=J.+A.+Tino&title=Indole+Carboxamide+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DIndole%2520Carboxamide%2520Compounds%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit26b.1"><span> <i>Chem. Abstr.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume">164</span>,  <span class="NLM_fpage">556179</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Chem.+Abstr.+2016%2C+164%2C+556179."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26b.1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26jtitle%3DChem.%2520Abstr.%26date%3D2016%26volume%3D164%26spage%3D556179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Castillo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, S. L.</span></span> <span> </span><span class="NLM_article-title">Applications of palladium-catalyzed C–N cross-coupling reactions</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">12564</span>– <span class="NLM_lpage">12649</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.6b00512</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.6b00512" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFymu7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2016&pages=12564-12649&author=P.+Ruiz-Castilloauthor=S.+L.+Buchwald&title=Applications+of+palladium-catalyzed+C%E2%80%93N+cross-coupling+reactions&doi=10.1021%2Facs.chemrev.6b00512"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Applications of Palladium-Catalyzed C-N Cross-Coupling Reactions</span></div><div class="casAuthors">Ruiz-Castillo, Paula; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">12564-12649</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Pd-catalyzed cross-coupling reactions that form C-N bonds have become useful methods to synthesize anilines and aniline derivs., an important class of compds. throughout chem. research.  A key factor in the widespread adoption of these methods has been the continued development of reliable and versatile catalysts that function under operationally simple, user-friendly conditions.  This review provides an overview of Pd-catalyzed N-arylation reactions found in both basic and applied chem. research from 2008 to the present.  Selected examples of C-N cross-coupling reactions between nine classes of nitrogen-based coupling partners and (pseudo)aryl halides are described for the synthesis of heterocycles, medicinally relevant compds., natural products, org. materials, and catalysts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraGxaaZq3Pa7Vg90H21EOLACvtfcHk0lgRAXTdtRCG6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFymu7bJ&md5=09edd584bbb4bd3ba6f0d422749fc6c3</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.6b00512&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.6b00512%26sid%3Dliteratum%253Aachs%26aulast%3DRuiz-Castillo%26aufirst%3DP.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DApplications%2520of%2520palladium-catalyzed%2520C%25E2%2580%2593N%2520cross-coupling%2520reactions%26jtitle%3DChem.%2520Rev.%26date%3D2016%26volume%3D116%26spage%3D12564%26epage%3D12649%26doi%3D10.1021%2Facs.chemrev.6b00512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1a','cit1b'],'ref2':['cit2a','cit2b','cit2c'],'ref3':['cit3'],'ref4':['cit4a','cit4b','cit4c'],'ref5':['cit5a','cit5b','cit5c'],'ref6':['cit6'],'ref7':['cit7a','cit7b'],'ref8':['cit8'],'ref9':['cit9a','cit9b'],'ref10':['cit10a','cit10b','cit10c'],'ref11':['cit11'],'ref12':['cit12a','cit12b','cit12c','cit12d','cit12e'],'ref13':['cit13a','cit13b','cit13c'],'ref14':['cit14'],'ref15':['cit15a','cit15b','cit15c','cit15d'],'ref16':['cit16a','cit16b'],'ref17':['cit17a','cit17b','cit17c'],'ref18':['cit18'],'ref19':['cit19a','cit19b'],'ref20':['cit20a','cit20a.1','cit20b','cit20b.2'],'ref21':['cit21'],'ref22':['cit22','cit22a.1'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25a','cit25b'],'ref26':['cit26a','cit26b','cit26b.1'],'ref27':['cit27']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 33 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Mark S. Tichenor, John J. M. Wiener, Navin L. Rao, Charlotte Pooley Deckhut, J. Kent Barbay, Kevin D. Kreutter, Genesis M. Bacani, Jianmei Wei, Leon Chang, Heather E. Murrey, Weixue Wang, Kay Ahn, Michael Huber, Elizabeth Rex, Kevin J. Coe, JieJun Wu, Mark Seierstad, Scott D. Bembenek, Kristi A. Leonard, Alec D. Lebsack, Jennifer D. Venable, <span class="NLM_string-name hlFld-ContribAuthor">James P. Edwards</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Potent and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase with Oral Anti-Inflammatory Activity. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>12 </em>
                                    (5)
                                     , 782-790. <a href="https://doi.org/10.1021/acsmedchemlett.1c00044" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.1c00044</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.1c00044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.1c00044%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Ba%252BPotent%252Band%252BSelective%252BCovalent%252BInhibitor%252Bof%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252Bwith%252BOral%252BAnti-Inflammatory%252BActivity%26aulast%3DTichenor%26aufirst%3DMark%2BS.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D27012021%26date%3D28032021%26date%3D05042021%26volume%3D12%26issue%3D5%26spage%3D782%26epage%3D790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Elma Mons, Robbert Q. Kim, Bjorn R. van Doodewaerd, Peter A. van Veelen, Monique P. C. Mulder, <span class="NLM_string-name hlFld-ContribAuthor">Huib Ovaa</span>. </span><span class="cited-content_cbyCitation_article-title">Exploring the Versatility of the Covalent Thiol–Alkyne Reaction with Substituted Propargyl Warheads: A Deciding Role for the Cysteine Protease. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2021,</strong> <em>143 </em>
                                    (17)
                                     , 6423-6433. <a href="https://doi.org/10.1021/jacs.0c10513" title="DOI URL">https://doi.org/10.1021/jacs.0c10513</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.0c10513&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.0c10513%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DExploring%252Bthe%252BVersatility%252Bof%252Bthe%252BCovalent%252BThiol%2525E2%252580%252593Alkyne%252BReaction%252Bwith%252BSubstituted%252BPropargyl%252BWarheads%25253A%252BA%252BDeciding%252BRole%252Bfor%252Bthe%252BCysteine%252BProtease%26aulast%3DMons%26aufirst%3DElma%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D02102020%26date%3D22042021%26volume%3D143%26issue%3D17%26spage%3D6423%26epage%3D6433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zhijie Wang, Jiongheng Cai, Jie Cheng, Wenqianzi Yang, Yifan Zhu, Hongmei Li, Tao Lu, Yadong Chen, <span class="NLM_string-name hlFld-ContribAuthor">Shuai Lu</span>. </span><span class="cited-content_cbyCitation_article-title">FLT3 Inhibitors in Acute Myeloid Leukemia: Challenges and Recent Developments in Overcoming Resistance. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (6)
                                     , 2878-2900. <a href="https://doi.org/10.1021/acs.jmedchem.0c01851" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01851</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01851%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFLT3%252BInhibitors%252Bin%252BAcute%252BMyeloid%252BLeukemia%25253A%252BChallenges%252Band%252BRecent%252BDevelopments%252Bin%252BOvercoming%252BResistance%26aulast%3DWang%26aufirst%3DZhijie%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D23102020%26date%3D10032021%26volume%3D64%26issue%3D6%26spage%3D2878%26epage%3D2900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zhouling Xie, Xiaoxiao Yang, Yajun Duan, Jihong Han, <span class="NLM_string-name hlFld-ContribAuthor">Chenzhong Liao</span>. </span><span class="cited-content_cbyCitation_article-title">Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (3)
                                     , 1283-1345. <a href="https://doi.org/10.1021/acs.jmedchem.0c01511" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01511</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01511%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall-Molecule%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BNononcologic%252BDiseases%26aulast%3DXie%26aufirst%3DZhouling%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D29082020%26date%3D22012021%26volume%3D64%26issue%3D3%26spage%3D1283%26epage%3D1345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Bin Ma, Tonika Bohnert, Kevin L. Otipoby, Eric Tien, Million Arefayene, Judy Bai, Bekim Bajrami, Eris Bame, Timothy R. Chan, Michael Humora, J. Michael MacPhee, Douglas Marcotte, Devangi Mehta, Claire M. Metrick, George Moniz, Evelyne Polack, Urjana Poreci, Annick Prefontaine, Sarah Sheikh, Patricia Schroeder, Karen Smirnakis, Lei Zhang, Fengmei Zheng, <span class="NLM_string-name hlFld-ContribAuthor">Brian T. Hopkins</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of BIIB068: A Selective, Potent, Reversible Bruton’s Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (21)
                                     , 12526-12541. <a href="https://doi.org/10.1021/acs.jmedchem.0c00702" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00702</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00702%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BBIIB068%25253A%252BA%252BSelective%25252C%252BPotent%25252C%252BReversible%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252BInhibitor%252Bas%252Ban%252BOrally%252BEfficacious%252BAgent%252Bfor%252BAutoimmune%252BDiseases%26aulast%3DMa%26aufirst%3DBin%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D27042020%26date%3D06082020%26date%3D22072020%26volume%3D63%26issue%3D21%26spage%3D12526%26epage%3D12541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Anurag S. Srivastava, Soo Ko, Scott H. Watterson, Mark A. Pattoli, Stacey Skala, Lihong Cheng, Mary T. Obermeier, Rodney Vickery, Lorell N. Discenza, Celia J. D’Arienzo, Kathleen M. Gillooly, Tracy L. Taylor, Claudine Pulicicchio, Kim W. McIntyre, Shiuhang Yip, Peng Li, Dawn Sun, Dauh-Rurng Wu, Jun Dai, Chunlei Wang, Yingru Zhang, Bei Wang, Joseph Pawluczyk, James Kempson, Rulin Zhao, Xiaoping Hou, Richard Rampulla, Arvind Mathur, Michael A. Galella, Luisa Salter-Cid, Joel C. Barrish, Percy H. Carter, Aberra Fura, James R. Burke, <span class="NLM_string-name hlFld-ContribAuthor">Joseph A. Tino</span>. </span><span class="cited-content_cbyCitation_article-title">Driving Potency with Rotationally Stable Atropisomers: Discovery of Pyridopyrimidinedione-Carbazole Inhibitors of BTK. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (11)
                                     , 2195-2203. <a href="https://doi.org/10.1021/acsmedchemlett.0c00335" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00335</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00335%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDriving%252BPotency%252Bwith%252BRotationally%252BStable%252BAtropisomers%25253A%252BDiscovery%252Bof%252BPyridopyrimidinedione-Carbazole%252BInhibitors%252Bof%252BBTK%26aulast%3DSrivastava%26aufirst%3DAnurag%2BS.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D16062020%26date%3D16092020%26date%3D22092020%26date%3D16092020%26volume%3D11%26issue%3D11%26spage%3D2195%26epage%3D2203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Thomas J. Struble, Juan C. Alvarez, Scott P. Brown, Milan Chytil, Justin Cisar, Renee L. DesJarlais, Ola Engkvist, Scott A. Frank, Daniel R. Greve, Daniel J. Griffin, Xinjun Hou, Jeffrey W. Johannes, Constantine Kreatsoulas, Brian Lahue, Miriam Mathea, Georg Mogk, Christos A. Nicolaou, Andrew D. Palmer, Daniel J. Price, Richard I. Robinson, Sebastian Salentin, Li Xing, Tommi Jaakkola, William. H. Green, Regina Barzilay, Connor W. Coley, <span class="NLM_string-name hlFld-ContribAuthor">Klavs F. Jensen</span>. </span><span class="cited-content_cbyCitation_article-title">Current and Future Roles of Artificial Intelligence in Medicinal Chemistry Synthesis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (16)
                                     , 8667-8682. <a href="https://doi.org/10.1021/acs.jmedchem.9b02120" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b02120</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b02120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b02120%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCurrent%252Band%252BFuture%252BRoles%252Bof%252BArtificial%252BIntelligence%252Bin%252BMedicinal%252BChemistry%252BSynthesis%26aulast%3DStruble%26aufirst%3DThomas%2BJ.%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D19122019%26date%3D14042020%26date%3D03042020%26volume%3D63%26issue%3D16%26spage%3D8667%26epage%3D8682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="NLM_string-name hlFld-ContribAuthor">Tanaji T. Talele</span>. </span><span class="cited-content_cbyCitation_article-title">Acetylene Group, Friend or Foe in Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (11)
                                     , 5625-5663. <a href="https://doi.org/10.1021/acs.jmedchem.9b01617" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01617</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01617%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAcetylene%252BGroup%25252C%252BFriend%252Bor%252BFoe%252Bin%252BMedicinal%252BChemistry%26aulast%3DTalele%26aufirst%3DTanaji%2BT.%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D29092019%26date%3D19022020%26date%3D07022020%26volume%3D63%26issue%3D11%26spage%3D5625%26epage%3D5663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Daniela Angst, François Gessier, Philipp Janser, Anna Vulpetti, Rudolf Wälchli, Christian Beerli, Amanda Littlewood-Evans, Janet Dawson, Barbara Nuesslein-Hildesheim, Grazyna Wieczorek, Sascha Gutmann, Clemens Scheufler, Alexandra Hinniger, Alfred Zimmerlin, Enrico G. Funhoff, Robert Pulz, <span class="NLM_string-name hlFld-ContribAuthor">Bruno Cenni</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (10)
                                     , 5102-5118. <a href="https://doi.org/10.1021/acs.jmedchem.9b01916" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01916</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01916&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01916%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BLOU064%252B%252528Remibrutinib%252529%25252C%252Ba%252BPotent%252Band%252BHighly%252BSelective%252BCovalent%252BInhibitor%252Bof%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%26aulast%3DAngst%26aufirst%3DDaniela%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D19112019%26date%3D04032020%26date%3D21022020%26volume%3D63%26issue%3D10%26spage%3D5102%26epage%3D5118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yunhang Guo, Ye Liu, Nan Hu, Desheng Yu, Changyou Zhou, Gongyin Shi, Bo Zhang, Min Wei, Junhua Liu, Lusong Luo, Zhiyu Tang, Huipeng Song, Yin Guo, Xuesong Liu, Dan Su, Shuo Zhang, Xiaomin Song, Xing Zhou, Yuan Hong, Shuaishuai Chen, Zhenzhen Cheng, Steve Young, Qiang Wei, Haisheng Wang, Qiuwen Wang, Lei Lv, Fan Wang, Haipeng Xu, Hanzi Sun, Haimei Xing, Na Li, Wei Zhang, Zhongbo Wang, Guodong Liu, Zhijian Sun, Dongping Zhou, Wei Li, Libin Liu, Lai Wang, <span class="NLM_string-name hlFld-ContribAuthor">Zhiwei Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (17)
                                     , 7923-7940. <a href="https://doi.org/10.1021/acs.jmedchem.9b00687" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00687</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00687&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00687%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BZanubrutinib%252B%252528BGB-3111%252529%25252C%252Ba%252BNovel%25252C%252BPotent%25252C%252Band%252BSelective%252BCovalent%252BInhibitor%252Bof%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%26aulast%3DGuo%26aufirst%3DYunhang%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D27042019%26date%3D19082019%26date%3D05082019%26volume%3D62%26issue%3D17%26spage%3D7923%26epage%3D7940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Naiyu Zheng, Ian M. Catlett, Kristin Taylor, Huidong Gu, Mark A. Pattoli, Robert J. Neely, Wenying Li, Alban Allentoff, Xiling Yuan, Eugene Ciccimaro, Ming Yao, Bethanne M. Warrack, James R. Burke, Yan J. Zhang, Renuka Pillutla, <span class="NLM_string-name hlFld-ContribAuthor">Jianing Zeng</span>. </span><span class="cited-content_cbyCitation_article-title">Determination of Real Time in Vivo Drug Receptor Occupancy for a Covalent Binding Drug as a Clinical Pharmacodynamic Biomarker by Immunocapture-LC-MS/MS. </span><span class="cited-content_cbyCitation_journal-name">Analytical Chemistry</span><span> <strong>2019,</strong> <em>91 </em>
                                    (13)
                                     , 8443-8452. <a href="https://doi.org/10.1021/acs.analchem.9b01462" title="DOI URL">https://doi.org/10.1021/acs.analchem.9b01462</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.analchem.9b01462&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.analchem.9b01462%26sid%3Dliteratum%253Aachs%26jtitle%3DAnalytical%2520Chemistry%26atitle%3DDetermination%252Bof%252BReal%252BTime%252Bin%252BVivo%252BDrug%252BReceptor%252BOccupancy%252Bfor%252Ba%252BCovalent%252BBinding%252BDrug%252Bas%252Ba%252BClinical%252BPharmacodynamic%252BBiomarker%252Bby%252BImmunocapture-LC-MS%25252FMS%26aulast%3DZheng%26aufirst%3DNaiyu%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D22032019%26date%3D05062019%26date%3D19062019%26date%3D05062019%26volume%3D91%26issue%3D13%26spage%3D8443%26epage%3D8452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lei  Zhong</span>, <span class="hlFld-ContribAuthor ">Yueshan  Li</span>, <span class="hlFld-ContribAuthor ">Liang  Xiong</span>, <span class="hlFld-ContribAuthor ">Wenjing  Wang</span>, <span class="hlFld-ContribAuthor ">Ming  Wu</span>, <span class="hlFld-ContribAuthor ">Ting  Yuan</span>, <span class="hlFld-ContribAuthor ">Wei  Yang</span>, <span class="hlFld-ContribAuthor ">Chenyu  Tian</span>, <span class="hlFld-ContribAuthor ">Zhuang  Miao</span>, <span class="hlFld-ContribAuthor ">Tianqi  Wang</span>, <span class="hlFld-ContribAuthor ">Shengyong  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. </span><span class="cited-content_cbyCitation_journal-name">Signal Transduction and Targeted Therapy</span><span> <strong>2021,</strong> <em>6 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41392-021-00572-w" title="DOI URL">https://doi.org/10.1038/s41392-021-00572-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41392-021-00572-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41392-021-00572-w%26sid%3Dliteratum%253Aachs%26jtitle%3DSignal%2520Transduction%2520and%2520Targeted%2520Therapy%26atitle%3DSmall%252Bmolecules%252Bin%252Btargeted%252Bcancer%252Btherapy%25253A%252Badvances%25252C%252Bchallenges%25252C%252Band%252Bfuture%252Bperspectives%26aulast%3DZhong%26aufirst%3DLei%26date%3D2021%26date%3D2021%26volume%3D6%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chung-Pu  Wu</span>, <span class="hlFld-ContribAuthor ">Megumi  Murakami</span>, <span class="hlFld-ContribAuthor ">Yu-Shan  Wu</span>, <span class="hlFld-ContribAuthor ">Ya-Chen  Chi</span>, <span class="hlFld-ContribAuthor ">Sung-Han  Hsiao</span>, <span class="hlFld-ContribAuthor ">Yang-Hui  Huang</span>, <span class="hlFld-ContribAuthor ">Tai-Ho  Hung</span>, <span class="hlFld-ContribAuthor ">Suresh V.  Ambudkar</span>. </span><span class="cited-content_cbyCitation_article-title">Branebrutinib (BMS-986195), a Bruton’s Tyrosine Kinase Inhibitor, Resensitizes P-Glycoprotein-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Agents. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Cell and Developmental Biology</span><span> <strong>2021,</strong> <em>9 </em><a href="https://doi.org/10.3389/fcell.2021.699571" title="DOI URL">https://doi.org/10.3389/fcell.2021.699571</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fcell.2021.699571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffcell.2021.699571%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Cell%2520and%2520Developmental%2520Biology%26atitle%3DBranebrutinib%252B%252528BMS-986195%252529%25252C%252Ba%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252BInhibitor%25252C%252BResensitizes%252BP-Glycoprotein-Overexpressing%252BMultidrug-Resistant%252BCancer%252BCells%252Bto%252BChemotherapeutic%252BAgents%26aulast%3DWu%26aufirst%3DChung-Pu%26date%3D2021%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dandan  Zhang</span>, <span class="hlFld-ContribAuthor ">Guiqing  Xu</span>, <span class="hlFld-ContribAuthor ">Jie  Zhao</span>, <span class="hlFld-ContribAuthor ">Yue  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaofang  Wu</span>, <span class="hlFld-ContribAuthor ">Xing  He</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>, <span class="hlFld-ContribAuthor ">Shuting  Zhang</span>, <span class="hlFld-ContribAuthor ">Shouning  Yang</span>, <span class="hlFld-ContribAuthor ">Chunhua  Ma</span>, <span class="hlFld-ContribAuthor ">Yuqin  Jiang</span>, <span class="hlFld-ContribAuthor ">Qingjie  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-activity relationship investigation for imidazopyrazole-3-carboxamide derivatives as novel selective inhibitors of Bruton's tyrosine kinase. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>4 </em>, 113724. <a href="https://doi.org/10.1016/j.ejmech.2021.113724" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113724</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113724&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113724%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-activity%252Brelationship%252Binvestigation%252Bfor%252Bimidazopyrazole-3-carboxamide%252Bderivatives%252Bas%252Bnovel%252Bselective%252Binhibitors%252Bof%252BBruton%252527s%252Btyrosine%252Bkinase%26aulast%3DZhang%26aufirst%3DDandan%26date%3D2021%26volume%3D4%26spage%3D113724" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Charu  Chaudhry</span>, <span class="hlFld-ContribAuthor ">Andrew  Tebben</span>, <span class="hlFld-ContribAuthor ">John S.  Tokarski</span>, <span class="hlFld-ContribAuthor ">Robert  Borzilleri</span>, <span class="hlFld-ContribAuthor ">William J.  Pitts</span>, <span class="hlFld-ContribAuthor ">Jonathan  Lippy</span>, <span class="hlFld-ContribAuthor ">Litao  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">An innovative kinome platform to accelerate small-molecule inhibitor discovery and optimization from hits to leads. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2021,</strong> <em>26 </em>
                                    (5)
                                     , 1115-1125. <a href="https://doi.org/10.1016/j.drudis.2021.01.018" title="DOI URL">https://doi.org/10.1016/j.drudis.2021.01.018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2021.01.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2021.01.018%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DAn%252Binnovative%252Bkinome%252Bplatform%252Bto%252Baccelerate%252Bsmall-molecule%252Binhibitor%252Bdiscovery%252Band%252Boptimization%252Bfrom%252Bhits%252Bto%252Bleads%26aulast%3DChaudhry%26aufirst%3DCharu%26date%3D2021%26volume%3D26%26issue%3D5%26spage%3D1115%26epage%3D1125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Martin  Kaul</span>, <span class="hlFld-ContribAuthor ">Peter  End</span>, <span class="hlFld-ContribAuthor ">Maciej  Cabanski</span>, <span class="hlFld-ContribAuthor ">Carole  Schuhler</span>, <span class="hlFld-ContribAuthor ">Annamaria  Jakab</span>, <span class="hlFld-ContribAuthor ">Magdalena  Kistowska</span>, <span class="hlFld-ContribAuthor ">Arvind  Kinhikar</span>, <span class="hlFld-ContribAuthor ">Alessio  Maiolica</span>, <span class="hlFld-ContribAuthor ">Angela  Sinn</span>, <span class="hlFld-ContribAuthor ">Rainard  Fuhr</span>, <span class="hlFld-ContribAuthor ">Bruno  Cenni</span>. </span><span class="cited-content_cbyCitation_article-title">Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial. </span><span class="cited-content_cbyCitation_journal-name">Clinical and Translational Science</span><span> <strong>2021,</strong> <em>151 </em><a href="https://doi.org/10.1111/cts.13005" title="DOI URL">https://doi.org/10.1111/cts.13005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cts.13005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcts.13005%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520and%2520Translational%2520Science%26atitle%3DRemibrutinib%252B%252528LOU064%252529%25253A%252BA%252Bselective%252Bpotent%252Boral%252BBTK%252Binhibitor%252Bwith%252Bpromising%252Bclinical%252Bsafety%252Band%252Bpharmacodynamics%252Bin%252Ba%252Brandomized%252Bphase%252BI%252Btrial%26aulast%3DKaul%26aufirst%3DMartin%26date%3D2021%26date%3D2021%26volume%3D151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiamin  Zheng</span>, <span class="hlFld-ContribAuthor ">Jun  Wu</span>, <span class="hlFld-ContribAuthor ">Xiao  Ding</span>, <span class="hlFld-ContribAuthor ">Hong C.  Shen</span>, <span class="hlFld-ContribAuthor ">Ge  Zou</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecule approaches to treat autoimmune and inflammatory diseases (Part I): Kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>38 </em>, 127862. <a href="https://doi.org/10.1016/j.bmcl.2021.127862" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.127862</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.127862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.127862%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSmall%252Bmolecule%252Bapproaches%252Bto%252Btreat%252Bautoimmune%252Band%252Binflammatory%252Bdiseases%252B%252528Part%252BI%252529%25253A%252BKinase%252Binhibitors%26aulast%3DZheng%26aufirst%3DJiamin%26date%3D2021%26volume%3D38%26spage%3D127862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zheng  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Achieving a low human dose for targeted covalent drugs: Pharmacokinetic and pharmacodynamic considerations on target characteristics and drug attributes. </span><span class="cited-content_cbyCitation_journal-name">Biopharmaceutics & Drug Disposition</span><span> <strong>2021,</strong> <em>42 </em>
                                    (4)
                                     , 150-159. <a href="https://doi.org/10.1002/bdd.2263" title="DOI URL">https://doi.org/10.1002/bdd.2263</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/bdd.2263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fbdd.2263%26sid%3Dliteratum%253Aachs%26jtitle%3DBiopharmaceutics%2520%2526%2520Drug%2520Disposition%26atitle%3DAchieving%252Ba%252Blow%252Bhuman%252Bdose%252Bfor%252Btargeted%252Bcovalent%252Bdrugs%25253A%252BPharmacokinetic%252Band%252Bpharmacodynamic%252Bconsiderations%252Bon%252Btarget%252Bcharacteristics%252Band%252Bdrug%252Battributes%26aulast%3DYang%26aufirst%3DZheng%26date%3D2021%26date%3D2021%26volume%3D42%26issue%3D4%26spage%3D150%26epage%3D159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">H. Yesid  Estupiñán</span>, <span class="hlFld-ContribAuthor ">Anna  Berglöf</span>, <span class="hlFld-ContribAuthor ">Rula  Zain</span>, <span class="hlFld-ContribAuthor ">C. I. Edvard  Smith</span>. </span><span class="cited-content_cbyCitation_article-title">Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Cell and Developmental Biology</span><span> <strong>2021,</strong> <em>9 </em><a href="https://doi.org/10.3389/fcell.2021.630942" title="DOI URL">https://doi.org/10.3389/fcell.2021.630942</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fcell.2021.630942&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffcell.2021.630942%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Cell%2520and%2520Developmental%2520Biology%26atitle%3DComparative%252BAnalysis%252Bof%252BBTK%252BInhibitors%252Band%252BMechanisms%252BUnderlying%252BAdverse%252BEffects%26aulast%3DEstupi%25C3%25B1%25C3%25A1n%26aufirst%3DH.%2BYesid%26date%3D2021%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Philipp  von Hundelshausen</span>, <span class="hlFld-ContribAuthor ">Wolfgang  Siess</span>. </span><span class="cited-content_cbyCitation_article-title">Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (5)
                                     , 1103. <a href="https://doi.org/10.3390/cancers13051103" title="DOI URL">https://doi.org/10.3390/cancers13051103</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13051103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13051103%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DBleeding%252Bby%252BBruton%252BTyrosine%252BKinase-Inhibitors%25253A%252BDependency%252Bon%252BDrug%252BType%252Band%252BDisease%26aulast%3Dvon%2BHundelshausen%26aufirst%3DPhilipp%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D5%26spage%3D1103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jinsha  Liu</span>, <span class="hlFld-ContribAuthor ">Joey Paolo  Ting</span>, <span class="hlFld-ContribAuthor ">Shams  Al-Azzam</span>, <span class="hlFld-ContribAuthor ">Yun  Ding</span>, <span class="hlFld-ContribAuthor ">Sepideh  Afshar</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2021,</strong> <em>22 </em>
                                    (6)
                                     , 2805. <a href="https://doi.org/10.3390/ijms22062805" title="DOI URL">https://doi.org/10.3390/ijms22062805</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms22062805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms22062805%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DTherapeutic%252BAdvances%252Bin%252BDiabetes%25252C%252BAutoimmune%25252C%252Band%252BNeurological%252BDiseases%26aulast%3DLiu%26aufirst%3DJinsha%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D6%26spage%3D2805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fandi  Sutanto</span>, <span class="hlFld-ContribAuthor ">Shabnam  Shaabani</span>, <span class="hlFld-ContribAuthor ">Constantinos G.  Neochoritis</span>, <span class="hlFld-ContribAuthor ">Tryfon  Zarganes-Tzitzikas</span>, <span class="hlFld-ContribAuthor ">Pravin  Patil</span>, <span class="hlFld-ContribAuthor ">Ehsan  Ghonchepour</span>, <span class="hlFld-ContribAuthor ">Alexander  Dömling</span>. </span><span class="cited-content_cbyCitation_article-title">Multicomponent reaction–derived covalent inhibitor space. </span><span class="cited-content_cbyCitation_journal-name">Science Advances</span><span> <strong>2021,</strong> <em>7 </em>
                                    (6)
                                     , eabd9307. <a href="https://doi.org/10.1126/sciadv.abd9307" title="DOI URL">https://doi.org/10.1126/sciadv.abd9307</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1126/sciadv.abd9307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1126%2Fsciadv.abd9307%26sid%3Dliteratum%253Aachs%26jtitle%3DScience%2520Advances%26atitle%3DMulticomponent%252Breaction%2525E2%252580%252593derived%252Bcovalent%252Binhibitor%252Bspace%26aulast%3DSutanto%26aufirst%3DFandi%26date%3D2021%26date%3D2021%26volume%3D7%26issue%3D6%26spage%3Deabd9307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Soňa  Krajčovičová</span>, <span class="hlFld-ContribAuthor ">Radek  Jorda</span>, <span class="hlFld-ContribAuthor ">David  Vanda</span>, <span class="hlFld-ContribAuthor ">Miroslav  Soural</span>, <span class="hlFld-ContribAuthor ">Vladimír  Kryštof</span>. </span><span class="cited-content_cbyCitation_article-title">1,4,6-Trisubstituted imidazo[4,5-c]pyridines as inhibitors of Bruton’s tyrosine kinase. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>211 </em>, 113094. <a href="https://doi.org/10.1016/j.ejmech.2020.113094" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.113094</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.113094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.113094%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3D1%25252C4%25252C6-Trisubstituted%252Bimidazo%25255B4%25252C5-c%25255Dpyridines%252Bas%252Binhibitors%252Bof%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%26aulast%3DKraj%25C4%258Dovi%25C4%258Dov%25C3%25A1%26aufirst%3DSo%25C5%2588a%26date%3D2021%26volume%3D211%26spage%3D113094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maan H.  Harbi</span>, <span class="hlFld-ContribAuthor ">Christopher W.  Smith</span>, <span class="hlFld-ContribAuthor ">Phillip L. R.  Nicolson</span>, <span class="hlFld-ContribAuthor ">Steve P.  Watson</span>, <span class="hlFld-ContribAuthor ">Mark R.  Thomas</span>. </span><span class="cited-content_cbyCitation_article-title">Novel antiplatelet strategies targeting GPVI, CLEC-2 and tyrosine kinases. </span><span class="cited-content_cbyCitation_journal-name">Platelets</span><span> <strong>2021,</strong> <em>32 </em>
                                    (1)
                                     , 29-41. <a href="https://doi.org/10.1080/09537104.2020.1849600" title="DOI URL">https://doi.org/10.1080/09537104.2020.1849600</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/09537104.2020.1849600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F09537104.2020.1849600%26sid%3Dliteratum%253Aachs%26jtitle%3DPlatelets%26atitle%3DNovel%252Bantiplatelet%252Bstrategies%252Btargeting%252BGPVI%25252C%252BCLEC-2%252Band%252Btyrosine%252Bkinases%26aulast%3DHarbi%26aufirst%3DMaan%2BH.%26date%3D2021%26date%3D2020%26volume%3D32%26issue%3D1%26spage%3D29%26epage%3D41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ali A.  Zarrin</span>, <span class="hlFld-ContribAuthor ">Katherine  Bao</span>, <span class="hlFld-ContribAuthor ">Patrick  Lupardus</span>, <span class="hlFld-ContribAuthor ">Domagoj  Vucic</span>. </span><span class="cited-content_cbyCitation_article-title">Kinase inhibition in autoimmunity and inflammation. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Drug Discovery</span><span> <strong>2021,</strong> <em>20 </em>
                                    (1)
                                     , 39-63. <a href="https://doi.org/10.1038/s41573-020-0082-8" title="DOI URL">https://doi.org/10.1038/s41573-020-0082-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41573-020-0082-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41573-020-0082-8%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Drug%2520Discovery%26atitle%3DKinase%252Binhibition%252Bin%252Bautoimmunity%252Band%252Binflammation%26aulast%3DZarrin%26aufirst%3DAli%2BA.%26date%3D2021%26date%3D2020%26volume%3D20%26issue%3D1%26spage%3D39%26epage%3D63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Leonard  Sung</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent drugs in development for immune-mediated diseases. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 33-74. <a href="https://doi.org/10.1016/bs.armc.2021.03.001" title="DOI URL">https://doi.org/10.1016/bs.armc.2021.03.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.armc.2021.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.armc.2021.03.001%26sid%3Dliteratum%253Aachs%26atitle%3DCovalent%252Bdrugs%252Bin%252Bdevelopment%252Bfor%252Bimmune-mediated%252Bdiseases%26aulast%3DSung%26aufirst%3DLeonard%26date%3D2021%26spage%3D33%26epage%3D74%26pub%3DElsevier%26atitle%3DThe%252BDesign%252Bof%252BCovalent-Based%252BInhibitors%26date%3D2021%26volume%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zizhen  Yin</span>, <span class="hlFld-ContribAuthor ">Wenfei  Hu</span>, <span class="hlFld-ContribAuthor ">Wei  Zhang</span>, <span class="hlFld-ContribAuthor ">Hiroyuki  Konno</span>, <span class="hlFld-ContribAuthor ">Hiroki  Moriwaki</span>, <span class="hlFld-ContribAuthor ">Kunisuke  Izawa</span>, <span class="hlFld-ContribAuthor ">Jianlin  Han</span>, <span class="hlFld-ContribAuthor ">Vadim A.  Soloshonok</span>. </span><span class="cited-content_cbyCitation_article-title">Tailor-made amino acid-derived pharmaceuticals approved by the FDA in 2019. </span><span class="cited-content_cbyCitation_journal-name">Amino Acids</span><span> <strong>2020,</strong> <em>52 </em>
                                    (9)
                                     , 1227-1261. <a href="https://doi.org/10.1007/s00726-020-02887-4" title="DOI URL">https://doi.org/10.1007/s00726-020-02887-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00726-020-02887-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00726-020-02887-4%26sid%3Dliteratum%253Aachs%26jtitle%3DAmino%2520Acids%26atitle%3DTailor-made%252Bamino%252Bacid-derived%252Bpharmaceuticals%252Bapproved%252Bby%252Bthe%252BFDA%252Bin%252B2019%26aulast%3DYin%26aufirst%3DZizhen%26date%3D2020%26date%3D2020%26volume%3D52%26issue%3D9%26spage%3D1227%26epage%3D1261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ian M.  Catlett</span>, <span class="hlFld-ContribAuthor ">Miroslawa  Nowak</span>, <span class="hlFld-ContribAuthor ">Sudeep  Kundu</span>, <span class="hlFld-ContribAuthor ">Naiyu  Zheng</span>, <span class="hlFld-ContribAuthor ">Ang  Liu</span>, <span class="hlFld-ContribAuthor ">Bing  He</span>, <span class="hlFld-ContribAuthor ">Ihab G.  Girgis</span>, <span class="hlFld-ContribAuthor ">Dennis M.  Grasela</span>. </span><span class="cited-content_cbyCitation_article-title">Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS‐986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo‐controlled trial in healthy participants. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Clinical Pharmacology</span><span> <strong>2020,</strong> <em>86 </em>
                                    (9)
                                     , 1849-1859. <a href="https://doi.org/10.1111/bcp.14290" title="DOI URL">https://doi.org/10.1111/bcp.14290</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bcp.14290&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbcp.14290%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Clinical%2520Pharmacology%26atitle%3DSafety%25252C%252Bpharmacokinetics%252Band%252Bpharmacodynamics%252Bof%252Bbranebrutinib%252B%252528BMS%2525E2%252580%252590986195%252529%25252C%252Ba%252Bcovalent%25252C%252Birreversible%252Binhibitor%252Bof%252BBruton%252527s%252Btyrosine%252Bkinase%25253A%252BRandomised%252Bphase%252BI%25252C%252Bplacebo%2525E2%252580%252590controlled%252Btrial%252Bin%252Bhealthy%252Bparticipants%26aulast%3DCatlett%26aufirst%3DIan%2BM.%26date%3D2020%26date%3D2020%26volume%3D86%26issue%3D9%26spage%3D1849%26epage%3D1859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">L. L.  Ong</span>, <span class="hlFld-ContribAuthor ">J. D.  Vasta</span>, <span class="hlFld-ContribAuthor ">L.  Monereau</span>, <span class="hlFld-ContribAuthor ">G.  Locke</span>, <span class="hlFld-ContribAuthor ">H.  Ribeiro</span>, <span class="hlFld-ContribAuthor ">M. A.  Pattoli</span>, <span class="hlFld-ContribAuthor ">S.  Skala</span>, <span class="hlFld-ContribAuthor ">J. R.  Burke</span>, <span class="hlFld-ContribAuthor ">S. H.  Watterson</span>, <span class="hlFld-ContribAuthor ">J. A.  Tino</span>, <span class="hlFld-ContribAuthor ">P. L.  Meisenheimer</span>, <span class="hlFld-ContribAuthor ">B.  Arey</span>, <span class="hlFld-ContribAuthor ">J.  Lippy</span>, <span class="hlFld-ContribAuthor ">L.  Zhang</span>, <span class="hlFld-ContribAuthor ">M. B.  Robers</span>, <span class="hlFld-ContribAuthor ">A.  Tebben</span>, <span class="hlFld-ContribAuthor ">C.  Chaudhry</span>. </span><span class="cited-content_cbyCitation_article-title">A High-Throughput BRET Cellular Target Engagement Assay Links Biochemical to Cellular Activity for Bruton’s Tyrosine Kinase. </span><span class="cited-content_cbyCitation_journal-name">SLAS DISCOVERY: Advancing the Science of Drug Discovery</span><span> <strong>2020,</strong> <em>25 </em>
                                    (2)
                                     , 176-185. <a href="https://doi.org/10.1177/2472555219884881" title="DOI URL">https://doi.org/10.1177/2472555219884881</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/2472555219884881&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F2472555219884881%26sid%3Dliteratum%253Aachs%26jtitle%3DSLAS%2520DISCOVERY%253A%2520Advancing%2520the%2520Science%2520of%2520Drug%2520Discovery%26atitle%3DA%252BHigh-Throughput%252BBRET%252BCellular%252BTarget%252BEngagement%252BAssay%252BLinks%252BBiochemical%252Bto%252BCellular%252BActivity%252Bfor%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%26aulast%3DOng%26aufirst%3DL.%2BL.%26date%3D2020%26date%3D2019%26volume%3D25%26issue%3D2%26spage%3D176%26epage%3D185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matthias  Gehringer</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent Kinase Inhibitors: An Overview. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 43-94. <a href="https://doi.org/10.1007/7355_2020_103" title="DOI URL">https://doi.org/10.1007/7355_2020_103</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2020_103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2020_103%26sid%3Dliteratum%253Aachs%26atitle%3DCovalent%252BKinase%252BInhibitors%25253A%252BAn%252BOverview%26aulast%3DGehringer%26aufirst%3DMatthias%26date%3D2020%26date%3D2020%26spage%3D43%26epage%3D94%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DProteinkinase%252BInhibitors%26aulast%3DLaufer%26aufirst%3DStefan%26date%3D2021%26volume%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Quanpeng  Wei</span>, <span class="hlFld-ContribAuthor ">Yunhan  Wang</span>, <span class="hlFld-ContribAuthor ">Jinlong  Zhao</span>, <span class="hlFld-ContribAuthor ">Xiaojing  Zhang</span>, <span class="hlFld-ContribAuthor ">Dawei  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Assembly of 7-carboxylate indoles via the Cu-catalyzed coupling of substituted 2-iodobenzoic acids and substituted hydrazines. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2020,</strong> <em>76 </em>
                                    (1)
                                     , 130794. <a href="https://doi.org/10.1016/j.tet.2019.130794" title="DOI URL">https://doi.org/10.1016/j.tet.2019.130794</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2019.130794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2019.130794%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DAssembly%252Bof%252B7-carboxylate%252Bindoles%252Bvia%252Bthe%252BCu-catalyzed%252Bcoupling%252Bof%252Bsubstituted%252B2-iodobenzoic%252Bacids%252Band%252Bsubstituted%252Bhydrazines%26aulast%3DWei%26aufirst%3DQuanpeng%26date%3D2020%26volume%3D76%26issue%3D1%26spage%3D130794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Saqib A.  Iqbal</span>, <span class="hlFld-ContribAuthor ">Jessica  Cid</span>, <span class="hlFld-ContribAuthor ">Richard J.  Procter</span>, <span class="hlFld-ContribAuthor ">Marina  Uzelac</span>, <span class="hlFld-ContribAuthor ">Kang  Yuan</span>, <span class="hlFld-ContribAuthor ">Michael J.  Ingleson</span>. </span><span class="cited-content_cbyCitation_article-title">Acyl‐Directed
              ortho
              ‐Borylation of Anilines and C7 Borylation of Indoles using just BBr
              3. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2019,</strong> <em>131 </em>
                                    (43)
                                     , 15525-15529. <a href="https://doi.org/10.1002/ange.201909786" title="DOI URL">https://doi.org/10.1002/ange.201909786</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.201909786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.201909786%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DAcyl%2525E2%252580%252590Directed%252Bortho%252B%2525E2%252580%252590Borylation%252Bof%252BAnilines%252Band%252BC7%252BBorylation%252Bof%252BIndoles%252Busing%252Bjust%252BBBr%252B3%26aulast%3DIqbal%26aufirst%3DSaqib%2BA.%26date%3D2019%26date%3D2019%26volume%3D131%26issue%3D43%26spage%3D15525%26epage%3D15529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Saqib A.  Iqbal</span>, <span class="hlFld-ContribAuthor ">Jessica  Cid</span>, <span class="hlFld-ContribAuthor ">Richard J.  Procter</span>, <span class="hlFld-ContribAuthor ">Marina  Uzelac</span>, <span class="hlFld-ContribAuthor ">Kang  Yuan</span>, <span class="hlFld-ContribAuthor ">Michael J.  Ingleson</span>. </span><span class="cited-content_cbyCitation_article-title">Acyl‐Directed
              ortho
              ‐Borylation of Anilines and C7 Borylation of Indoles using just BBr
              3. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2019,</strong> <em>58 </em>
                                    (43)
                                     , 15381-15385. <a href="https://doi.org/10.1002/anie.201909786" title="DOI URL">https://doi.org/10.1002/anie.201909786</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.201909786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.201909786%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DAcyl%2525E2%252580%252590Directed%252Bortho%252B%2525E2%252580%252590Borylation%252Bof%252BAnilines%252Band%252BC7%252BBorylation%252Bof%252BIndoles%252Busing%252Bjust%252BBBr%252B3%26aulast%3DIqbal%26aufirst%3DSaqib%2BA.%26date%3D2019%26volume%3D58%26issue%3D43%26spage%3D15381%26epage%3D15385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0027.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00167&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0001.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Approved covalent, irreversible inhibitors of BTK.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00167&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0002.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Compound <b>2</b> is a potent reversible BTK inhibitor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00167&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0003.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00167&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0004.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. The rate of target inactivation must be faster than the rate of drug elimination.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00167&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0005.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. X-ray crystal structure of <b>2</b> bound to the kinase domain of BTK (1.5 Å structure) (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5T18">5T18</a>).<a onclick="showRef(event, 'cit15d'); return false;" href="javascript:void(0);" class="ref cit15d">(15d)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00167&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0006.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Initial design strategy for covalent, irreversible inhibition.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00167&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0007.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. BTK inactivation rate comparison between <b>4d</b> and <b>1a</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00167&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0008.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Optimizing linker and acceptor geometry to improve intrinsic covalent potency.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00167&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0009.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Time- and dose-dependent inactivation of BTK with <b>5a</b> (A) vs <b>1a</b> (B). Either <b>5a</b> or <b>1a</b> at various concentrations was added to human whole blood, and the kinetics of BTK inactivation were measured. The solid line represents the fit of the data to a second order rate constant of 3.5 × 10<sup>–4</sup> nM<sup>–1</sup>·min<sup>–1</sup> (<b>5a</b>) vs 1.2 × 10<sup>–4</sup> nM<sup>–1</sup>·min<sup>–1</sup> (<b>1a</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00167&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0010.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Compound <b>5a</b> is highly selective for BTK. Illustration reproduced courtesy of Cell Signaling Technology, Inc.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00167&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0011.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. X-ray crystal structure of <b>5a</b> covalently bound to the kinase domain of BTK (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O8I">6O8I</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00167&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0012.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Overlay of the single crystal X-ray structure (pink) with the X-ray crystal structure of <b>5a</b> bound to the active site of BTK (gold).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00167&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0013.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. A single, low dose of <b>5a</b> (0.5 mg/kg orally, once daily) resulted in >90% BTK inactivation in mice (A) and 100% inactivation in cynomolgus monkey (B). (c) Compound <b>5a</b> inactivated BTK in mice significantly faster than <b>1a</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00167&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0014.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Potent and robust activity against collagen-induced arthritis in vivo was observed with <b>5a</b> (fully preventative dosing). Error bars represent the mean ± SEM: *<i>P</i> < 0.05, **<i>P</i> < 0.01 versus vehicle control group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00167&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0015.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Protection against lupus nephritis by <b>5a</b> in NZB/W mice vs vehicle and prednisolone. Error bars represent the mean ± SEM: *<i>P</i> < 0.05, **<i>P</i> < 0.01 versus vehicle control group. ds-DNA = double-stranded DNA; Ig = I mmunoglobulin; Pred = prednisolone.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00167&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0016.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of Dimethylindoles <b>4</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00167&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) R<sup>1</sup>R<sup>2</sup>NH, Pd<sub>2</sub>(dba)<sub>3</sub>, BINAP, Cs<sub>2</sub>CO<sub>3</sub>; (b) H<sub>2</sub>SO<sub>4</sub>, 60 °C; (c) chloroethanesulfonyl chloride, THF/CH<sub>2</sub>Cl<sub>2</sub>; (d) acryloyl chloride, Hunig’s base, THF/CH<sub>2</sub>Cl<sub>2</sub>; (e) propiolic acid or but-2-ynoic acid, HATU, Hunig’s base.</p></p></figure><figure data-id="sch2" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0017.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of Dimethylindoles <b>5a</b> and <b>5b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00167&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (<i>S</i>)-<i>tert</i>-butyl piperidin-3-ylcarbamate, Pd<sub>2</sub>(dba)<sub>3</sub>, BINAP, Cs<sub>2</sub>CO<sub>3</sub>, 86%; (b) H<sub>2</sub>SO<sub>4</sub>, 60 °C, 82–95%; (c) but-2-ynoic acid, HATU, Hunig’s base, 75–85%; (d) propiolic acid, HATU, Hunig’s base, 45%.</p></p></figure><figure data-id="sch3" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0018.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of Dimethylindoles <b>3b</b> and <b>3c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00167&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (Ph<sub>3</sub>P)<sub>4</sub>Pd, 2 M Na<sub>2</sub>CO<sub>3</sub>, toluene/EtOH, 90 °C, 16 h.</p></p></figure><figure data-id="sch4" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/medium/jm-2019-001678_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0019.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Preparation of Intermediates <b>6</b> and <b>9</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00167/20190404/images/large/jm-2019-001678_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00167&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 2-butanone, AcOH, toluene, 50–90%; (b) NH<sub>4</sub>OH, EDC, HOBt, THF, CH<sub>2</sub>Cl<sub>2</sub>, 75–90%; (c) POCl<sub>3</sub>, THF, 89%; (d) POCl<sub>3</sub>, pyridine, CH<sub>2</sub>Cl<sub>2</sub>, 92%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i67">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52018" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52018" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 27 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Jansson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmdahl, R.</span></span> <span> </span><span class="NLM_article-title">Genes on the X chromosome affect development of collagen-induced arthritis in mice</span>. <i>Clin. Exp. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">465</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2249.1993.tb08218.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1111%2Fj.1365-2249.1993.tb08218.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=8252807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADyaK2cXhtVCksL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1993&pages=459-465&author=L.+Janssonauthor=R.+Holmdahl&title=Genes+on+the+X+chromosome+affect+development+of+collagen-induced+arthritis+in+mice&doi=10.1111%2Fj.1365-2249.1993.tb08218.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">Genes on the X chromosome affect development of collagen-induced arthritis in mice</span></div><div class="casAuthors">Jansson, Liselotte; Holmdahl, R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Experimental Immunology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">459-65</span>CODEN:
                <span class="NLM_cas:coden">CEXIAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-9104</span>.
    </div><div class="casAbstract">Susceptibility to collagen-induced arthritis (CIA) in mice is assocd. with a class II gene in MHC (Aq) but also with unknown genes outside MHC.  Investigated here is the influence of genes on the X chromosome as well as the role of the X-linked immunodeficiency (xid) mutation.  Reciprocal male F1 hybrids, bred to be heterozygous or homozygous for Aq, showed a genetic influence in their susceptibility to develop CIA.  Crosses were made between B10.G, B10.Q, DBA/1, SWR/J, C3H.Q and CBA/Ca, and all F1 mice were castrated to avoid sex hormone modulation of the susceptibility.  A differential timing of arthritis onset and severity were seen in the reciprocal F1 males.  An exception was the reciprocal F1 male offspring from SWR/J and DBA/1 crosses which differed only in disease severity late in the course of the disease.  The female F1 crosses did not show the same pattern of differential susceptibility to CIA as the F1 males.  To exclude the possible influence of the Y chromosome, F1 males of reciprocal crosses were back-crossed to the parental strains creating offspring with equal X chromosomes but divergent Y chromosomes.  No difference in development of arthritis was obsd. in these.  The influence of the xid mutation was investigated next.  The xid loci from the CBA/N mouse was bred into DBA/1 strain which is highly susceptible to CIA.  The resulting congenic DBA/1-xid strain was resistant to induction of CIA and did not develop an antibody response to type II collagen.  The authors concluded that polymorphic genes on the X chromosome modulate susceptibility to CIA.  The results from the expts. with mice carrying xid mutations confirm that such immune modulating genes exist on the sex chromosomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXuu6ocKN6h7Vg90H21EOLACvtfcHk0litDzjZJg9vmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhtVCksL0%253D&md5=77777b6215fb6c1e839b5a68d555df3c</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2249.1993.tb08218.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2249.1993.tb08218.x%26sid%3Dliteratum%253Aachs%26aulast%3DJansson%26aufirst%3DL.%26aulast%3DHolmdahl%26aufirst%3DR.%26atitle%3DGenes%2520on%2520the%2520X%2520chromosome%2520affect%2520development%2520of%2520collagen-induced%2520arthritis%2520in%2520mice%26jtitle%3DClin.%2520Exp.%2520Immunol.%26date%3D1993%26volume%3D94%26spage%3D459%26epage%3D465%26doi%3D10.1111%2Fj.1365-2249.1993.tb08218.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Steinberg, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smathers, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederiksen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinberg, A. D.</span></span> <span> </span><span class="NLM_article-title">Ability of the <i>xid</i> gene to prevent autoimmunity in (NZBXNZW)F1 mice during the course of their natural history, after polyclonal stimulation, or following immunization with DNA</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">587</span>– <span class="NLM_lpage">597</span>, <span class="refDoi"> DOI: 10.1172/JCI110651</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1172%2FJCI110651" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=6980900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A280%3ADyaL383ms1ejtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=1982&pages=587-597&author=B.+J.+Steinbergauthor=P.+A.+Smathersauthor=K.+Frederiksenauthor=A.+D.+Steinberg&title=Ability+of+the+xid+gene+to+prevent+autoimmunity+in+%28NZBXNZW%29F1+mice+during+the+course+of+their+natural+history%2C+after+polyclonal+stimulation%2C+or+following+immunization+with+DNA&doi=10.1172%2FJCI110651"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">Ability of the xid gene to prevent autoimmunity in (NZB X NZW)F1 mice during the course of their natural history, after polyclonal stimulation, or following immunization with DNA</span></div><div class="casAuthors">Steinberg B J; Smathers P A; Frederiksen K; Steinberg A D</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">587-97</span>
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    </div><div class="casAbstract">F1 hybrid offspring of New Zealand Black mothers and New Zealand White fathers [(NZB X NZW)F1] female mice develop antibodies to single-stranded (ss) and native DNA, immune complex glomerulonephritis, massive proteinuria, and premature death with renal failure.  By a series of matings, congenic (NZB X NZW)F1 . xid/xid mice were prepared.  These mice were different from (NZB X NZW)F1 mice in having the X chromosome-linked immune deficiency gene, xid, in homozygous form.  Such congenic (NZB X NZW)F1 . xid/xid females failed to develop antibodies to single-stranded or native DNA.  They also failed to develop fatal renal disease as measured by proteinuria, glomerular histology, glomerular immunofluorescence, and survival.  To control for unknown genetic factors, studies were performed with littermates that were derived by mating NZB . xid/+ females with NZW . xid/Y males such that the resulting offspring were either (NZB X NZW)F1 . xid/xid (and therefore "defective") or (NZB X NZW)F1 . xid/+ [phenotypically like (NZB X NZW)F1].  In these and in additional studies, mice were housed in the same cages and identified by ear tagging so as to avoid possible environmental variations from cage to cage.  In these studies, xid/xid mice failed to develop the characteristic signs of autoimmunity, whereas the controls did.  Similar results were also obtained with (NZW X NZB)F1 xid/xid mice compared with (NZW X NZB)F1 xid/+ mice.  The effect of xid/xid upon (NZB X NZW)F1 mice was further investigated by assessing responses to immunization and polyclonal B cell activation in vivo.  The xid/xid mice failed to produce anti-ssDNA following immunization with ssDNA complexed to a protein carrier in fluid form or even emulsified in adjuvant.  Finally, the xid/xid mice failed to produce antiDNA in response to multiple injections of the polyclonal activator, bacterial lipopolysaccharide (LPS), or the polyclonal activator, polyribose inosinic acid . polyribose cytidylic acid.  However, the xid/xid mice were neither generally hyporesponsive nor unable to recognize LPS because they made normal antibody responses following immunization with LPS to which multiple trinitrophenyl groups were chemically attached.  We conclude from these studies that xid/xid, which is known to cause the deletion of a B cell subset, has a profound affect upon (NZB X NZW)F1 mice, rendering them insusceptible to the naturally occurring autoimmune disease characteristic of (NZB X NZW)F1 mice, and preventing them from producing antibodies to DNA despite purposeful immunization and polyclonal B cell activation.  These results force a reevaluation of previous concepts regarding the mechanisms by which xid/xid might interfere with the development of autoimmunity, and a consideration of therapeutic implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcThDLn7032pYRBrI9DTGjC0fW6udTcc2eaQkTwhtGunO7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL383ms1ejtg%253D%253D&md5=8608a4617f65a1c46ef46a6e5388f7a6</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1172%2FJCI110651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI110651%26sid%3Dliteratum%253Aachs%26aulast%3DSteinberg%26aufirst%3DB.%2BJ.%26aulast%3DSmathers%26aufirst%3DP.%2BA.%26aulast%3DFrederiksen%26aufirst%3DK.%26aulast%3DSteinberg%26aufirst%3DA.%2BD.%26atitle%3DAbility%2520of%2520the%2520xid%2520gene%2520to%2520prevent%2520autoimmunity%2520in%2520%2528NZBXNZW%2529F1%2520mice%2520during%2520the%2520course%2520of%2520their%2520natural%2520history%252C%2520after%2520polyclonal%2520stimulation%252C%2520or%2520following%2520immunization%2520with%2520DNA%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1982%26volume%3D70%26spage%3D587%26epage%3D597%26doi%3D10.1172%2FJCI110651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postelnek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vu, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, D.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pashine, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Mahony, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narula, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMartino, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fine, J. S.</span></span> <span> </span><span class="NLM_article-title">RN486, a selective Bruton’s tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>341</i></span>,  <span class="NLM_fpage">90</span>– <span class="NLM_lpage">103</span>, <span class="refDoi"> DOI: 10.1124/jpet.111.187740</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1124%2Fjpet.111.187740" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=22228807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC38XltVagt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=2012&pages=90-103&author=D.+Xuauthor=Y.+Kimauthor=J.+Postelnekauthor=M.+D.+Vuauthor=D.-Q.+Huauthor=C.+Liaoauthor=M.+Bradshawauthor=J.+Hsuauthor=J.+Zhangauthor=A.+Pashineauthor=D.+Srinivasanauthor=J.+Woodsauthor=A.+Levinauthor=A.+O%E2%80%99Mahonyauthor=T.+D.+Owensauthor=Y.+Louauthor=R.+J.+Hillauthor=S.+Narulaauthor=J.+DeMartinoauthor=J.+S.+Fine&title=RN486%2C+a+selective+Bruton%E2%80%99s+tyrosine+kinase+inhibitor%2C+abrogates+immune+hypersensitivity+responses+and+arthritis+in+rodents&doi=10.1124%2Fjpet.111.187740"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents</span></div><div class="casAuthors">Xu, Daigen; Kim, Yong; Postelnek, Jennifer; Vu, Minh Diem; Hu, Dong-Qing; Liao, Cheng; Bradshaw, Mike; Hsu, Jonathan; Zhang, Jun; Pashine, Achal; Srinivasan, Dinesh; Woods, John; Levin, Anita; O'Mahony, Alison; Owens, Timothy D.; Lou, Yan; Hill, Ronald J.; Narula, Satwant; DeMartino, Julie; Fine, Jay S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">90-103</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Genetic mutation and pharmacol. inhibition of Bruton's tyrosine kinase (Btk) both have been shown to prevent the development of collagen-induced arthritis (CIA) in mice, providing a rationale for the development of Btk inhibitors for treating rheumatoid arthritis (RA).  In the present study, we characterized a novel Btk inhibitor, 6-cyclopropyl-8-fluoro-2-(2-hydroxymethyl-3-{1-methyl-5-[5-(4-methyl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-2H-isoquinolin-1-one (RN486), in vitro and in rodent models of immune hypersensitivity and arthritis.  We demonstrated that RN486 not only potently and selectively inhibited the Btk enzyme, but also displayed functional activities in human cell-based assays in multiple cell types, blocking Fcε receptor crosslinking-induced degranulation in mast cells (IC50 = 2.9 nM), Fcγ receptor engagement-mediated tumor necrosis factor α prodn. in monocytes (IC50 = 7.0 nM), and B cell antigen receptor-induced expression of an activation marker, CD69, in B cells in whole blood (IC50 = 21.0 nM).  RN486 displayed similar functional activities in rodent models, effectively preventing type I and type III hypersensitivity responses.  More importantly, RN486 produced robust anti-inflammatory and bone-protective effects in mouse CIA and rat adjuvant-induced arthritis (AIA) models.  In the AIA model, RN486 inhibited both joint and systemic inflammation either alone or in combination with methotrexate, reducing both paw swelling and inflammatory markers in the blood.  Together, our findings not only demonstrate that Btk plays an essential and conserved role in regulating immunoreceptor-mediated immune responses in both humans and rodents, but also provide evidence and mechanistic insights to support the development of selective Btk inhibitors as small-mol. disease-modifying drugs for RA and potentially other autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXBTQENfl5RbVg90H21EOLACvtfcHk0lgPnA2Q4A_S-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltVagt7g%253D&md5=06be56a47afd2eb09e0871710c1d2b47</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.187740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.187740%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DPostelnek%26aufirst%3DJ.%26aulast%3DVu%26aufirst%3DM.%2BD.%26aulast%3DHu%26aufirst%3DD.-Q.%26aulast%3DLiao%26aufirst%3DC.%26aulast%3DBradshaw%26aufirst%3DM.%26aulast%3DHsu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DPashine%26aufirst%3DA.%26aulast%3DSrinivasan%26aufirst%3DD.%26aulast%3DWoods%26aufirst%3DJ.%26aulast%3DLevin%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Mahony%26aufirst%3DA.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DLou%26aufirst%3DY.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DNarula%26aufirst%3DS.%26aulast%3DDeMartino%26aufirst%3DJ.%26aulast%3DFine%26aufirst%3DJ.%2BS.%26atitle%3DRN486%252C%2520a%2520selective%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitor%252C%2520abrogates%2520immune%2520hypersensitivity%2520responses%2520and%2520arthritis%2520in%2520rodents%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D341%26spage%3D90%26epage%3D103%26doi%3D10.1124%2Fjpet.111.187740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balazs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barck, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carano, R. A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darrow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeForge, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrando, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallion, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannetti, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gribling, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropf, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciejewski, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staker, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span> <span> </span><span class="NLM_article-title">Specific Btk inhibition suppresses B cell and myeloid cell-mediated arthritis</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1038/nchembio.481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1038%2Fnchembio.481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=21113169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=41-50&author=J.+A.+Di+Paoloauthor=T.+Huangauthor=M.+Balazsauthor=J.+Barbosaauthor=K.+H.+Barckauthor=B.+J.+Bravoauthor=R.+A.+D.+Caranoauthor=J.+Darrowauthor=D.+R.+Daviesauthor=L.+E.+DeForgeauthor=L.+Diehlauthor=R.+Ferrandoauthor=S.+L.+Gallionauthor=A.+M.+Giannettiauthor=P.+P.+Griblingauthor=V.+Hurezauthor=S.+G.+Hymowitzauthor=R.+Jonesauthor=J.+E.+Kropfauthor=W.+P.+Leeauthor=P.+M.+Maciejewskiauthor=S.+A.+Mitchellauthor=H.+Rongauthor=B.+L.+Stakerauthor=J.+A.+Whitneyauthor=S.+Yehauthor=W.+B.+Youngauthor=C.+Yuauthor=J.+Zhangauthor=K.+Reifauthor=K.+S.+Currie&title=Specific+Btk+inhibition+suppresses+B+cell+and+myeloid+cell-mediated+arthritis&doi=10.1038%2Fnchembio.481"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis</span></div><div class="casAuthors">Di Paolo, Julie A.; Huang, Tao; Balazs, Mercedesz; Barbosa, James; Barck, Kai H.; Bravo, Brandon J.; Carano, Richard A. D.; Darrow, James; Davies, Douglas R.; DeForge, Laura E.; Diehl, Lauri; Ferrando, Ronald; Gallion, Steven L.; Giannetti, Anthony M.; Gribling, Peter; Hurez, Vincent; Hymowitz, Sarah G.; Jones, Randall; Kropf, Jeffrey E.; Lee, Wyne P.; Maciejewski, Patricia M.; Mitchell, Scott A.; Rong, Hong; Staker, Bart L.; Whitney, J. Andrew; Yeh, Sherry; Young, Wendy B.; Yu, Christine; Zhang, Juan; Reif, Karin; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-50</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a therapeutic target for rheumatoid arthritis, but the cellular and mol. mechanisms by which Btk mediates inflammation are poorly understood.  Here we describe the discovery of CGI1746, a small-mol. Btk inhibitor chemotype with a new binding mode that stabilizes an inactive nonphosphorylated enzyme conformation.  CGI1746 has exquisite selectivity for Btk and inhibits both auto- and transphosphorylation steps necessary for enzyme activation.  Using CGI1746, we demonstrate that Btk regulates inflammatory arthritis by two distinct mechanisms.  CGI1746 blocks B cell receptor-dependent B cell proliferation and in prophylactic regimens reduces autoantibody levels in collagen-induced arthritis.  In macrophages, Btk inhibition abolishes FcγRIII-induced TNFα, IL-1β and IL-6 prodn.  Accordingly, in myeloid- and FcγR-dependent autoantibody-induced arthritis, CGI1746 decreases cytokine levels within joints and ameliorates disease.  These results provide new understanding of the function of Btk in both B cell- or myeloid cell-driven disease processes and provide a compelling rationale for targeting Btk in rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoegiZYoitP57Vg90H21EOLACvtfcHk0liFdlmDR_ZLCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP&md5=99d925c71bc1b201191ebde0f1c0b50f</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.481%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%2BA.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBarck%26aufirst%3DK.%2BH.%26aulast%3DBravo%26aufirst%3DB.%2BJ.%26aulast%3DCarano%26aufirst%3DR.%2BA.%2BD.%26aulast%3DDarrow%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DD.%2BR.%26aulast%3DDeForge%26aufirst%3DL.%2BE.%26aulast%3DDiehl%26aufirst%3DL.%26aulast%3DFerrando%26aufirst%3DR.%26aulast%3DGallion%26aufirst%3DS.%2BL.%26aulast%3DGiannetti%26aufirst%3DA.%2BM.%26aulast%3DGribling%26aufirst%3DP.%2BP.%26aulast%3DHurez%26aufirst%3DV.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DMaciejewski%26aufirst%3DP.%2BM.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DStaker%26aufirst%3DB.%2BL.%26aulast%3DWhitney%26aufirst%3DJ.%2BA.%26aulast%3DYeh%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DSpecific%2520Btk%2520inhibition%2520suppresses%2520B%2520cell%2520and%2520myeloid%2520cell-mediated%2520arthritis%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D41%26epage%3D50%26doi%3D10.1038%2Fnchembio.481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rankin, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seth, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreyeva, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmonds, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathialagan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benoit, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyashiro, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peeva, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramaiah, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messing, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homer, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunussi-Joannopoulos, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickerson-Nutter, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnute, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douhan, J.,  III.</span></span> <span> </span><span class="NLM_article-title">Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>191</i></span>,  <span class="NLM_fpage">4540</span>– <span class="NLM_lpage">4550</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1301553</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.4049%2Fjimmunol.1301553" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=24068666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1eqs7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2013&pages=4540-4550&author=A.+L.+Rankinauthor=N.+Sethauthor=S.+Keeganauthor=T.+Andreyevaauthor=T.+A.+Cookauthor=J.+Edmondsauthor=N.+Mathialaganauthor=M.+J.+Bensonauthor=J.+Syedauthor=Y.+Zhanauthor=S.+E.+Benoitauthor=J.+S.+Miyashiroauthor=N.+Woodauthor=S.+Mohanauthor=E.+Peevaauthor=S.+K.+Ramaiahauthor=D.+Messingauthor=B.+L.+Homerauthor=K.+Dunussi-Joannopoulosauthor=C.+L.+Nickerson-Nutterauthor=M.+E.+Schnuteauthor=J.+Douhan&title=Selective+inhibition+of+BTK+prevents+murine+lupus+and+antibody-mediated+glomerulonephritis&doi=10.4049%2Fjimmunol.1301553"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2cR"><div class="casContent"><span class="casTitleNuber">2c</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of BTK Prevents Murine Lupus and Antibody-Mediated Glomerulonephritis</span></div><div class="casAuthors">Rankin, Andrew L.; Seth, Nilufer; Keegan, Sean; Andreyeva, Tatyana; Cook, Tim A.; Edmonds, Jason; Mathialagan, Nagappan; Benson, Micah J.; Syed, Jameel; Zhan, Yutian; Benoit, Stephen E.; Miyashiro, Joy S.; Wood, Nancy; Mohan, Shashi; Peeva, Elena; Ramaiah, Shashi K.; Messing, Dean; Homer, Bruce L.; Dunussi-Joannopoulos, Kyri; Nickerson-Nutter, Cheryl L.; Schnute, Mark E.; Douhan, John, III</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4540-4550</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Autoantibody prodn. and immune complex deposition within the kidney promote renal disease in patients with lupus nephritis.  Thus, therapeutics that inhibit these pathways may be efficacious in the treatment of systemic lupus erythematosus.  Bruton's tyrosine kinase (BTK) is a crit. signaling component of both BCR and FcR signaling.  We sought to assess the efficacy of inhibiting BTK in the development of lupus-like disease, and in this article describe (R)-5-amino-1-(1-cyanopiperidin-3-yl)-3-(4-[2,4-difluorophenoxy]phenyl)-1H-pyrazole-4-carboxamide (PF-06250112), a novel highly selective and potent BTK inhibitor.  We demonstrate in vitro that PF-06250112 inhibits both BCR-mediated signaling and proliferation, as well as FcR-mediated activation.  To assess the therapeutic impact of BTK inhibition, we treated aged NZBxWF1 mice with PF-06250112 and demonstrate that PF-06250112 significantly limits the spontaneous accumulation of splenic germinal center B cells and plasma cells.  Correspondingly, anti-dsDNA and autoantibody levels were reduced in a dose-dependent manner.  Moreover, administration of PF-06250112 prevented the development of proteinuria and improved glomerular pathol. scores in all treatment groups.  Strikingly, this therapeutic effect could occur with only a modest redn. obsd. in anti-dsDNA titers, implying a crit. role for BTK signaling in disease pathogenesis beyond inhibition of autoantibody prodn.  We subsequently demonstrate that PF-06250112 prevents proteinuria in an FcR-dependent, Ab-mediated model of glomerulonephritis.  Importantly, these results highlight that BTK inhibition potently limits the development of glomerulonephritis by impacting both cell- and effector mol.-mediated pathways.  These data provide support for evaluating the efficacy of BTK inhibition in systemic lupus erythematosus patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBldekay4INLVg90H21EOLACvtfcHk0liFdlmDR_ZLCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1eqs7zE&md5=7abfb074bf422aa3fb63aa0bc3d8cf58</span></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1301553&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1301553%26sid%3Dliteratum%253Aachs%26aulast%3DRankin%26aufirst%3DA.%2BL.%26aulast%3DSeth%26aufirst%3DN.%26aulast%3DKeegan%26aufirst%3DS.%26aulast%3DAndreyeva%26aufirst%3DT.%26aulast%3DCook%26aufirst%3DT.%2BA.%26aulast%3DEdmonds%26aufirst%3DJ.%26aulast%3DMathialagan%26aufirst%3DN.%26aulast%3DBenson%26aufirst%3DM.%2BJ.%26aulast%3DSyed%26aufirst%3DJ.%26aulast%3DZhan%26aufirst%3DY.%26aulast%3DBenoit%26aufirst%3DS.%2BE.%26aulast%3DMiyashiro%26aufirst%3DJ.%2BS.%26aulast%3DWood%26aufirst%3DN.%26aulast%3DMohan%26aufirst%3DS.%26aulast%3DPeeva%26aufirst%3DE.%26aulast%3DRamaiah%26aufirst%3DS.%2BK.%26aulast%3DMessing%26aufirst%3DD.%26aulast%3DHomer%26aufirst%3DB.%2BL.%26aulast%3DDunussi-Joannopoulos%26aufirst%3DK.%26aulast%3DNickerson-Nutter%26aufirst%3DC.%2BL.%26aulast%3DSchnute%26aufirst%3DM.%2BE.%26aulast%3DDouhan%26aufirst%3DJ.%26atitle%3DSelective%2520inhibition%2520of%2520BTK%2520prevents%2520murine%2520lupus%2520and%2520antibody-mediated%2520glomerulonephritis%26jtitle%3DJ.%2520Immunol.%26date%3D2013%26volume%3D191%26spage%3D4540%26epage%3D4550%26doi%3D10.4049%2Fjimmunol.1301553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mease, P. J.</span></span> <span> </span><span class="NLM_article-title">B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application</span>. <i>J. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">1245</span>– <span class="NLM_lpage">1255</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=18609733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpslajtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2008&pages=1245-1255&author=P.+J.+Mease&title=B+cell-targeted+therapy+in+autoimmune+disease%3A+rationale%2C+mechanisms%2C+and+clinical+application"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application</span></div><div class="casAuthors">Mease, Philip J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Rheumatology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1245-1255</span>CODEN:
                <span class="NLM_cas:coden">JRHUA9</span>;
        ISSN:<span class="NLM_cas:issn">0315-162X</span>.
    
            (<span class="NLM_cas:orgname">Journal of Rheumatology Publishing Co. Ltd.</span>)
        </div><div class="casAbstract">A review.  B cells play a crit. role in the pathogenesis of rheumatoid arthritis (RA) and other autoimmune diseases.  Recently, a no. of biol. agents that target B cells have been tested as therapies for these conditions.  These agents either deplete B cells, by targeting cell-surface antigens such as CD20, or block B cell function, for example by inhibiting the activity of B cell survival factors such as BLyS.  Of this group of agents, the first in clin. use has been rituximab, a chimeric monoclonal antibody that depletes B cells by binding to the CD20 cell-surface antigen.  Initially introduced as a treatment for non-Hodgkin's lymphoma, rituximab is now approved for the treatment of RA.  In this review we explore the rationale behind B cell-targeted therapy, highlight the results of clin. trials with rituximab in RA and other autoimmune diseases, and describe other emerging therapies directed at B cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEpprn0Fq_lLVg90H21EOLACvtfcHk0lgT5OInIWR2cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpslajtro%253D&md5=1e31bd50b6afae7e8273a1da7a06f828</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMease%26aufirst%3DP.%2BJ.%26atitle%3DB%2520cell-targeted%2520therapy%2520in%2520autoimmune%2520disease%253A%2520rationale%252C%2520mechanisms%252C%2520and%2520clinical%2520application%26jtitle%3DJ.%2520Rheumatol.%26date%3D2008%26volume%3D35%26spage%3D1245%26epage%3D1255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Mohamed, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bäckesjö, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vargas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faryal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aints, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berglöf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vihinen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nore, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. I. E.</span></span> <span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain</span>. <i>Immunol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>228</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.1111/j.1600-065X.2008.00741.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1111%2Fj.1600-065X.2008.00741.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=19290921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=2009&pages=58-73&author=A.+J.+Mohamedauthor=L.+Yuauthor=C.-M.+B%C3%A4ckesj%C3%B6author=L.+Vargasauthor=R.+Faryalauthor=A.+Aintsauthor=B.+Christenssonauthor=A.+Bergl%C3%B6fauthor=M.+Vihinenauthor=B.+F.+Noreauthor=C.+I.+E.+Smith&title=Bruton%E2%80%99s+tyrosine+kinase+%28Btk%29%3A+function%2C+regulation%2C+and+transformation+with+special+emphasis+on+the+PH+domain&doi=10.1111%2Fj.1600-065X.2008.00741.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain</span></div><div class="casAuthors">Mohamed, Abdalla J.; Yu, Liang; Backesjo, Carl-Magnus; Vargas, Leonardo; Faryal, Rani; Aints, Alar; Christensson, Birger; Berglof, Anna; Vihinen, Mauno; Nore, Beston F.; Smith, C. I. Edvard</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">228</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-73</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Bruton's agammaglobulinemia tyrosine kinase (Btk) is a cytoplasmic tyrosine kinase important in B-lymphocyte development, differentiation, and signaling.  Btk is a member of the Tec family of kinases.  Mutations in the Elk gene lead to X-linked agammaglobulinemia (XLA) in humans and X-linked immunodeficiency (Xid) in mice.  Activation of Btk triggers a cascade of signaling events that culminates in the generation of calcium mobilization and fluxes, cytoskeletal rearrangements, and transcriptional regulation involving nuclear factor-κB (NF-κB) and nuclear factor of activated T cells (NFAT).  In B cells, NF-κB was shown to bind to the Btk promoter and induce transcription, whereas the B-cell receptor-dependent NF-κB signaling pathway requires functional Btk.  Moreover, Btk activation is tightly regulated by a plethora of other signaling proteins including protein kinase C (PKC), Sab/SH3BP5, and caveolin-1.  For example, the prolyl isomerase Pin1 neg. regulates Btk by decreasing tyrosine phosphorylation and steady state levels of Btk.  It is intriguing that PKC and Pin1, both of which are neg. regulators, bind to the pleckstrin homol. domain of Btk.  To this end, we describe here novel mutations in the pleckstrin homol. domain investigated for their transforming capacity.  In particular, we show that the mutant D43R behaves similar to E41K, already known to possess such activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpo1L-Ch4HjNLVg90H21EOLACvtfcHk0lgT5OInIWR2cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7rO&md5=7a84f2b3604d67bcc1490fadcbfea234</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00741.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00741.x%26sid%3Dliteratum%253Aachs%26aulast%3DMohamed%26aufirst%3DA.%2BJ.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DB%25C3%25A4ckesj%25C3%25B6%26aufirst%3DC.-M.%26aulast%3DVargas%26aufirst%3DL.%26aulast%3DFaryal%26aufirst%3DR.%26aulast%3DAints%26aufirst%3DA.%26aulast%3DChristensson%26aufirst%3DB.%26aulast%3DBergl%25C3%25B6f%26aufirst%3DA.%26aulast%3DVihinen%26aufirst%3DM.%26aulast%3DNore%26aufirst%3DB.%2BF.%26aulast%3DSmith%26aufirst%3DC.%2BI.%2BE.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528Btk%2529%253A%2520function%252C%2520regulation%252C%2520and%2520transformation%2520with%2520special%2520emphasis%2520on%2520the%2520PH%2520domain%26jtitle%3DImmunol.%2520Rev.%26date%3D2009%26volume%3D228%26spage%3D58%26epage%3D73%26doi%3D10.1111%2Fj.1600-065X.2008.00741.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit4b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Mohamed, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nore, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. I. E.</span></span> <span> </span><span class="NLM_article-title">Signaling of Bruton’s tyrosine kinase, Btk</span>. <i>Scand. J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">118</span>, <span class="refDoi"> DOI: 10.1046/j.1365-3083.1999.00504.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1046%2Fj.1365-3083.1999.00504.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10075013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADyaK1MXhslSisr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1999&pages=113-118&author=A.+J.+Mohamedauthor=B.+F.+Noreauthor=B.+Christenssonauthor=C.+I.+E.+Smith&title=Signaling+of+Bruton%E2%80%99s+tyrosine+kinase%2C+Btk&doi=10.1046%2Fj.1365-3083.1999.00504.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">Signalling of Bruton's tyrosine kinase, Btk</span></div><div class="casAuthors">Mohamed, A. J.; Nore, B. F.; Christensson, B.; Smith, C. I. E.</div><div class="citationInfo"><span class="NLM_cas:title">Scandinavian Journal of Immunology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">113-118</span>CODEN:
                <span class="NLM_cas:coden">SJIMAX</span>;
        ISSN:<span class="NLM_cas:issn">0300-9475</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">A review with 63 refs.  Bruton's tyrosine kinase, which is encoded by the BTK gene, is a cytoplasmic protein tyrosine kinase (PTK) crucial for B-cell development and differentiation.  It belongs to the Tec family of PTKs contg. several domains that are characteristic of signalling mols.  In humans, mutations that disrupt the function of this gene lead to the classical XLA syndrome (X-linked agammaglobulinemia), a primary immunodeficiency mainly characterized by lack of mature B cells as well as low levels of Igs.  In contrast, animal models of this disease such as the xid mice display profoundly milder XLA phenotype.  BTK phosphorylation and activation in response to engagement of the B-cell receptor (BCR) by antigen is a dynamic process whereby a variety of proteins interact with each other and recruit signalling mols. resulting in a physiol. response such as B-cell proliferation and antibody prodn.  The main players, however, that participate in the intracellular downstream cascade have not yet been identified and are therefore under intense scrutiny in several labs.  This review discusses certain aspects of BTK activation following receptor stimulation by agonists and how this event is translated into the biochem. signals within the cell that eventually lead to nuclear responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphmZBDkpS1ubVg90H21EOLACvtfcHk0lgT5OInIWR2cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhslSisr0%253D&md5=a3842c00d3cd4e45458c050941026476</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1046%2Fj.1365-3083.1999.00504.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1365-3083.1999.00504.x%26sid%3Dliteratum%253Aachs%26aulast%3DMohamed%26aufirst%3DA.%2BJ.%26aulast%3DNore%26aufirst%3DB.%2BF.%26aulast%3DChristensson%26aufirst%3DB.%26aulast%3DSmith%26aufirst%3DC.%2BI.%2BE.%26atitle%3DSignaling%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%252C%2520Btk%26jtitle%3DScand.%2520J.%2520Immunol.%26date%3D1999%26volume%3D49%26spage%3D113%26epage%3D118%26doi%3D10.1046%2Fj.1365-3083.1999.00504.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit4c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Takata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurosaki, T.</span></span> <span> </span><span class="NLM_article-title">A role for Bruton’s tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-γ2</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>184</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">40</span>, <span class="refDoi"> DOI: 10.1084/jem.184.1.31</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1084%2Fjem.184.1.31" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=8691147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADyaK28Xkt1ajs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=1996&pages=31-40&author=M.+Takataauthor=T.+Kurosaki&title=A+role+for+Bruton%E2%80%99s+tyrosine+kinase+in+B+cell+antigen+receptor-mediated+activation+of+phospholipase+C-%CE%B32&doi=10.1084%2Fjem.184.1.31"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4cR"><div class="casContent"><span class="casTitleNuber">4c</span><div class="casTitle"><span class="NLM_cas:atitle">A role for Bruton's tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-γ2</span></div><div class="casAuthors">Takata, Minoru; Kurosaki, Tomohiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-40</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Defects in the gene encoding Bruton's tyrosine kinase (Btk) result in a disease called X-linked agammaglobulinemia, in which there is a profound decrease of mature B cells due to a block in B cell development.  Recent studies have shown that Btk is tyrosine phosphorylated and activated upon B cell antigen receptor (BCR) stimulation.  To elucidate the functions of this kinase, we examd. BCR signaling of DT40 B cells deficient in Btk.  Tyrosine phosphorylation of phospholipase C (PLC)-γ2 upon receptor stimulation was significantly reduced in the mutant cells, leading to the loss of both BCR-coupled phosphatidylinositol hydrolysis and calcium mobilization.  Pleckstrin homol. and Src-homol. 2 domains of Btk were required for PLC-γ2 activation.  Since Syk is also required for the BCR-induced PLC-γ2 activation, our findings indicate that PLC-γ2 activation is regulated by Btk and Syk through their concerted actions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrvJR6GCfI7rVg90H21EOLACvtfcHk0lgT5OInIWR2cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xkt1ajs74%253D&md5=7244a36ac8298ccde274e05016ec68ba</span></div><a href="/servlet/linkout?suffix=cit4c&amp;dbid=16384&amp;doi=10.1084%2Fjem.184.1.31&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.184.1.31%26sid%3Dliteratum%253Aachs%26aulast%3DTakata%26aufirst%3DM.%26aulast%3DKurosaki%26aufirst%3DT.%26atitle%3DA%2520role%2520for%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520in%2520B%2520cell%2520antigen%2520receptor-mediated%2520activation%2520of%2520phospholipase%2520C-%25CE%25B32%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D1996%26volume%3D184%26spage%3D31%26epage%3D40%26doi%3D10.1084%2Fjem.184.1.31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Jongstra-Bilen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puig Cano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasija, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cybulsky, M. I.</span></span> <span> </span><span class="NLM_article-title">Dual functions of Bruton’s tyrosine kinase and Tec kinase during Fcγ receptor-induced signaling and phagocytosis</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">288</span>– <span class="NLM_lpage">298</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.181.1.288</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.4049%2Fjimmunol.181.1.288" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2008&pages=288-298&author=J.+Jongstra-Bilenauthor=A.+Puig+Canoauthor=M.+Hasijaauthor=H.+Xiaoauthor=C.+I.+Smithauthor=M.+I.+Cybulsky&title=Dual+functions+of+Bruton%E2%80%99s+tyrosine+kinase+and+Tec+kinase+during+Fc%CE%B3+receptor-induced+signaling+and+phagocytosis&doi=10.4049%2Fjimmunol.181.1.288"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.181.1.288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.181.1.288%26sid%3Dliteratum%253Aachs%26aulast%3DJongstra-Bilen%26aufirst%3DJ.%26aulast%3DPuig%2BCano%26aufirst%3DA.%26aulast%3DHasija%26aufirst%3DM.%26aulast%3DXiao%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DC.%2BI.%26aulast%3DCybulsky%26aufirst%3DM.%2BI.%26atitle%3DDual%2520functions%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520and%2520Tec%2520kinase%2520during%2520Fc%25CE%25B3%2520receptor-induced%2520signaling%2520and%2520phagocytosis%26jtitle%3DJ.%2520Immunol.%26date%3D2008%26volume%3D181%26spage%3D288%26epage%3D298%26doi%3D10.4049%2Fjimmunol.181.1.288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit5b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kuehn, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radinger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanhaesebroeck, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaven, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalfe, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilfillan, A. M.</span></span> <span> </span><span class="NLM_article-title">Btk-dependent Rac activation and actin rearrangement following FcεRI aggregation promotes enhanced chemotactic responses of mast cells</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">2576</span>– <span class="NLM_lpage">2585</span>, <span class="refDoi"> DOI: 10.1242/jcs.071043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1242%2Fjcs.071043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=20587594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtF2mtL7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2010&pages=2576-2585&author=H.+S.+Kuehnauthor=M.+Radingerauthor=J.+M.+Brownauthor=K.+Aliauthor=B.+Vanhaesebroeckauthor=M.+A.+Beavenauthor=D.+D.+Metcalfeauthor=A.+M.+Gilfillan&title=Btk-dependent+Rac+activation+and+actin+rearrangement+following+Fc%CE%B5RI+aggregation+promotes+enhanced+chemotactic+responses+of+mast+cells&doi=10.1242%2Fjcs.071043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">Btk-dependent Rac activation and actin rearrangement following FcεRI aggregation promotes enhanced chemotactic responses of mast cells</span></div><div class="casAuthors">Kuehn, Hye Sun; Radinger, Madeleine; Brown, Jared M.; Ali, Khaled; Vanhaesebroeck, Bart; Beaven, Michael A.; Metcalfe, Dean D.; Gilfillan, Alasdair M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2576-2585</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">Mast cells infiltrate the sites of inflammation assocd. with chronic atopic disease and during helminth and bacterial infection.  This process requires receptor-mediated cell chemotaxis across a concn. gradient of their chemotactic ligands.  In vivo, mast cells are likely to be exposed to several such agents, which can cooperate in a synergistic manner to regulate mast cell homing.  Here, we report that chemotaxis of mouse bone-marrow-derived mast cells (BMMCs) in response to the chemoattractants stem-cell factor (SCF) and prostaglandin (PG)E2, is substantially enhanced following antigen-dependent ligation of the high-affinity receptor for IgE (FcεRI).  These responses were assocd. with enhanced activation of phosphoinositide 3-kinase (PI3K), and downstream activation of the tyrosine protein kinase Btk, with subsequent enhanced phospholipase (PL)Cγ-mediated Ca2+ mobilization, Rac activation and F-actin rearrangement.  Antigen-induced chemotaxis, and the ability of antigen to amplify responses mediated by SCF, adenosine and PGE2 were suppressed following inhibition of PI3K, and were impaired in BMMCs derived from Btk-/- mice.  There were corresponding decreases in the PLCγ-mediated Ca2+ signal, Rac activation and F-actin rearrangement, which, as they are essential for BMMC chemotaxis, accounts for the impaired migration of Btk-deficient cells.  Taken together, these data demonstrate that, by regulating signaling pathways that control F-actin rearrangement, Btk is crucial for the ability of antigen to amplify mast-cell chemotactic responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx05z-3Sv-D7Vg90H21EOLACvtfcHk0lhFNRrZvM1SQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtF2mtL7O&md5=2a02fc66a2b3994eb6c983a8c3b91f63</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1242%2Fjcs.071043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.071043%26sid%3Dliteratum%253Aachs%26aulast%3DKuehn%26aufirst%3DH.%2BS.%26aulast%3DRadinger%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DJ.%2BM.%26aulast%3DAli%26aufirst%3DK.%26aulast%3DVanhaesebroeck%26aufirst%3DB.%26aulast%3DBeaven%26aufirst%3DM.%2BA.%26aulast%3DMetcalfe%26aufirst%3DD.%2BD.%26aulast%3DGilfillan%26aufirst%3DA.%2BM.%26atitle%3DBtk-dependent%2520Rac%2520activation%2520and%2520actin%2520rearrangement%2520following%2520Fc%25CE%25B5RI%2520aggregation%2520promotes%2520enhanced%2520chemotactic%2520responses%2520of%2520mast%2520cells%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2010%26volume%3D123%26spage%3D2576%26epage%3D2585%26doi%3D10.1242%2Fjcs.071043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit5c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawlings, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, O. N.</span></span> <span> </span><span class="NLM_article-title">Role of Bruton’s tyrosine kinase in immunodeficiency</span>. <i>Curr. Opin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">623</span>– <span class="NLM_lpage">630</span>, <span class="refDoi"> DOI: 10.1016/0952-7915(94)90151-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1016%2F0952-7915%2894%2990151-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=7946052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADyaK2cXlsFCqur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1994&pages=623-630&author=S.+Tsukadaauthor=D.+J.+Rawlingsauthor=O.+N.+Witte&title=Role+of+Bruton%E2%80%99s+tyrosine+kinase+in+immunodeficiency&doi=10.1016%2F0952-7915%2894%2990151-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5cR"><div class="casContent"><span class="casTitleNuber">5c</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Bruton's tyrosine kinase in immunodeficiency</span></div><div class="casAuthors">Tsukada, Satoshi; Rawlings, David J.; Witte, Owen N.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Immunology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">623-30</span>CODEN:
                <span class="NLM_cas:coden">COPIEL</span>;
        ISSN:<span class="NLM_cas:issn">0952-7915</span>.
    </div><div class="casAbstract">A review, with 71 refs.  The genetic defect assocd. with human X-linked agammaglobulinemia and murine X-linked immunodeficiency was recently shown to result from lack of function of a new cytoplasmic tyrosine kinase, called Bruton's tyrosine kinase (Btk).  The phenotypes assocd. with these immunodeficiencies indicate that Btk plays a crit. role in B lymphocyte development.  The distinctive protein structure of Btk and preliminary functional studies suggest that Btk may act in a novel manner in a variety of signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAyW0bZjSS3rVg90H21EOLACvtfcHk0lhFNRrZvM1SQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXlsFCqur8%253D&md5=d9932cf5d56f7a77723a46cae519cbeb</span></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=10.1016%2F0952-7915%2894%2990151-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0952-7915%252894%252990151-1%26sid%3Dliteratum%253Aachs%26aulast%3DTsukada%26aufirst%3DS.%26aulast%3DRawlings%26aufirst%3DD.%2BJ.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26atitle%3DRole%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520in%2520immunodeficiency%26jtitle%3DCurr.%2520Opin.%2520Immunol.%26date%3D1994%26volume%3D6%26spage%3D623%26epage%3D630%26doi%3D10.1016%2F0952-7915%2894%2990151-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y.</span></span> <span> </span><span class="NLM_article-title">The Tec family tyrosine kinase Btk regulates RANKL-induced osteoclast maturation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">11526</span>– <span class="NLM_lpage">11534</span>, <span class="refDoi"> DOI: 10.1074/jbc.M708935200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1074%2Fjbc.M708935200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=11526-11534&author=S.+H.+Leeauthor=T.+Kimauthor=D.+Jeongauthor=N.+Kimauthor=Y.+Choi&title=The+Tec+family+tyrosine+kinase+Btk+regulates+RANKL-induced+osteoclast+maturation&doi=10.1074%2Fjbc.M708935200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M708935200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M708935200%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DT.%26aulast%3DJeong%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DN.%26aulast%3DChoi%26aufirst%3DY.%26atitle%3DThe%2520Tec%2520family%2520tyrosine%2520kinase%2520Btk%2520regulates%2520RANKL-induced%2520osteoclast%2520maturation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26spage%3D11526%26epage%3D11534%26doi%3D10.1074%2Fjbc.M708935200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Middendorp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dingjan, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlenborg, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendriks, R. W.</span></span> <span> </span><span class="NLM_article-title">Function of Bruton’s tyrosine kinase during B cell development is partially independent of its catalytic activity</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>171</i></span>,  <span class="NLM_fpage">5988</span>– <span class="NLM_lpage">5996</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.171.11.5988</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.4049%2Fjimmunol.171.11.5988" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2003&pages=5988-5996&author=S.+Middendorpauthor=G.+M.+Dingjanauthor=A.+Maasauthor=K.+Dahlenborgauthor=R.+W.+Hendriks&title=Function+of+Bruton%E2%80%99s+tyrosine+kinase+during+B+cell+development+is+partially+independent+of+its+catalytic+activity&doi=10.4049%2Fjimmunol.171.11.5988"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.171.11.5988&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.171.11.5988%26sid%3Dliteratum%253Aachs%26aulast%3DMiddendorp%26aufirst%3DS.%26aulast%3DDingjan%26aufirst%3DG.%2BM.%26aulast%3DMaas%26aufirst%3DA.%26aulast%3DDahlenborg%26aufirst%3DK.%26aulast%3DHendriks%26aufirst%3DR.%2BW.%26atitle%3DFunction%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520during%2520B%2520cell%2520development%2520is%2520partially%2520independent%2520of%2520its%2520catalytic%2520activity%26jtitle%3DJ.%2520Immunol.%26date%3D2003%26volume%3D171%26spage%3D5988%26epage%3D5996%26doi%3D10.4049%2Fjimmunol.171.11.5988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Petro, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, S. M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, W. N.</span></span> <span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase is required for activation of IκB kinase and nuclear factor κB in response to B cell receptor engagement</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>191</i></span>,  <span class="NLM_fpage">1745</span>– <span class="NLM_lpage">1753</span>, <span class="refDoi"> DOI: 10.1084/jem.191.10.1745</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1084%2Fjem.191.10.1745" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2000&pages=1745-1753&author=J.+B.+Petroauthor=S.+M.+J.+Rahmanauthor=D.+W.+Ballardauthor=W.+N.+Khan&title=Bruton%E2%80%99s+tyrosine+kinase+is+required+for+activation+of+I%CE%BAB+kinase+and+nuclear+factor+%CE%BAB+in+response+to+B+cell+receptor+engagement&doi=10.1084%2Fjem.191.10.1745"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1084%2Fjem.191.10.1745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.191.10.1745%26sid%3Dliteratum%253Aachs%26aulast%3DPetro%26aufirst%3DJ.%2BB.%26aulast%3DRahman%26aufirst%3DS.%2BM.%2BJ.%26aulast%3DBallard%26aufirst%3DD.%2BW.%26aulast%3DKhan%26aufirst%3DW.%2BN.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520is%2520required%2520for%2520activation%2520of%2520I%25CE%25BAB%2520kinase%2520and%2520nuclear%2520factor%2520%25CE%25BAB%2520in%2520response%2520to%2520B%2520cell%2520receptor%2520engagement%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2000%26volume%3D191%26spage%3D1745%26epage%3D1753%26doi%3D10.1084%2Fjem.191.10.1745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whyburn, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halcomb, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contreras, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, O. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satterthwaite, A. B.</span></span> <span> </span><span class="NLM_article-title">Haploinsufficiency of B cell linker protein enhanced B cell signaling defects in mice expressing a limiting dosage of Bruton’s tyrosine kinase</span>. <i>Int. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">383</span>– <span class="NLM_lpage">392</span>, <span class="refDoi"> DOI: 10.1093/intimm/dxg034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1093%2Fintimm%2Fdxg034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=12618482" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitFKlsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2003&pages=383-392&author=L.+R.+Whyburnauthor=K.+E.+Halcombauthor=C.+M.+Contrerasauthor=R.+Pappuauthor=O.+N.+Witteauthor=A.+C.+Chanauthor=A.+B.+Satterthwaite&title=Haploinsufficiency+of+B+cell+linker+protein+enhanced+B+cell+signaling+defects+in+mice+expressing+a+limiting+dosage+of+Bruton%E2%80%99s+tyrosine+kinase&doi=10.1093%2Fintimm%2Fdxg034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Haploinsufficiency of B cell linker protein enhances B cell signaling defects in mice expressing a limiting dosage of Bruton's tyrosine kinase</span></div><div class="casAuthors">Whyburn, Lindsey R.; Halcomb, Kristina E.; Contreras, Cristina M.; Pappu, Rajita; Witte, Owen N.; Chan, Andrew C.; Satterthwaite, Anne B.</div><div class="citationInfo"><span class="NLM_cas:title">International Immunology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">383-392</span>CODEN:
                <span class="NLM_cas:coden">INIMEN</span>;
        ISSN:<span class="NLM_cas:issn">0953-8178</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Current models of lymphocyte activation suggest that formation of a signaling complex, or signalosome', composed of Syk, Bruton's tyrosine kinase (Btk), phospholipase γ2 and the adaptor protein B cell linker protein (BLNK) is crit. for transmission of signals from the BCR.  However, impaired B cell development in mice lacking each individual signalosome component has made it difficult to study the functional consequences of the formation of this complex in mature B cells.  Sensitized genetic systems, commonly used in Drosophila, define signaling pathways by combining partial loss of function mutations in the components of interest.  This allows genetic interactions to be obsd. in the absence of pleiotropic or lethal effects of complete deficiency of either gene.  We used this approach to demonstrate that Btk and BLNK are limiting components of a common signaling pathway that mediates the mitogenic response of mature B cells to antigen.  B cells from transgenic mice expressing a limiting dosage of Btk (Btklo) have normal nos. of mature B cells that have reduced, but measurable, responses to BCR crosslinking.  Haploinsufficiency of BLNK did not affect the development of Btklo B cells.  However, it exacerbated their defects in BCR-induced Ca2+ flux, IκB degrdn., and up-regulation of cyclin D2, bcl-xL and A1 leading to dramatic impairment of B cell mitogenic responses.  In contrast, no effect of reduced Btk and BLNK dosage was obsd. on extracellular signal-regulated kinase activation.  These results suggest that the signals regulating the maintenance and activation of mature B cells are differentially sensitive to the strength of the signal emanating from the signalosome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrowqlQ3xDitLVg90H21EOLACvtfcHk0limn8mqWeEpHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitFKlsL4%253D&md5=8d56f66c8b68159d61a86322e174c81f</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1093%2Fintimm%2Fdxg034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fintimm%252Fdxg034%26sid%3Dliteratum%253Aachs%26aulast%3DWhyburn%26aufirst%3DL.%2BR.%26aulast%3DHalcomb%26aufirst%3DK.%2BE.%26aulast%3DContreras%26aufirst%3DC.%2BM.%26aulast%3DPappu%26aufirst%3DR.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26aulast%3DChan%26aufirst%3DA.%2BC.%26aulast%3DSatterthwaite%26aufirst%3DA.%2BB.%26atitle%3DHaploinsufficiency%2520of%2520B%2520cell%2520linker%2520protein%2520enhanced%2520B%2520cell%2520signaling%2520defects%2520in%2520mice%2520expressing%2520a%2520limiting%2520dosage%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DInt.%2520Immunol.%26date%3D2003%26volume%3D15%26spage%3D383%26epage%3D392%26doi%3D10.1093%2Fintimm%2Fdxg034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taunton, J.</span></span> <span> </span><span class="NLM_article-title">Structural bioinformatics-based design of selective, irreversible kinase inhibitors</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>308</i></span>,  <span class="NLM_fpage">1318</span>– <span class="NLM_lpage">1321</span>, <span class="refDoi"> DOI: 10.1126/science1108367</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1126%2Fscience1108367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=15919995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1Ciurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=308&publication_year=2005&pages=1318-1321&author=M.+S.+Cohenauthor=C.+Zhangauthor=K.+M.+Shokatauthor=J.+Taunton&title=Structural+bioinformatics-based+design+of+selective%2C+irreversible+kinase+inhibitors&doi=10.1126%2Fscience1108367"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9a</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors</span></div><div class="casAuthors">Cohen, Michael S.; Zhang, Chao; Shokat, Kevan M.; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">308</span>
        (<span class="NLM_cas:issue">5726</span>),
    <span class="NLM_cas:pages">1318-1321</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The active sites of 491 human protein kinase domains are highly conserved, which makes the design of selective inhibitors a formidable challenge.  We used a structural bioinformatics approach to identify two selectivity filters, a threonine and a cysteine, at defined positions in the active site of p90 ribosomal protein S6 kinase (RSK).  A fluoromethylketone inhibitor, designed to exploit both selectivity filters, potently and selectively inactivated RSK1 and RSK2 in mammalian cells.  Kinases with only one selectivity filter were resistant to the inhibitor, yet they became sensitized after genetic introduction of the second selectivity filter.  Thus, two amino acids that distinguish RSK from other protein kinases are sufficient to confer inhibitor sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovfUrzVFth_bVg90H21EOLACvtfcHk0limn8mqWeEpHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1Ciurs%253D&md5=1364444dada4d1d46510aa0212428952</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1126%2Fscience1108367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience1108367%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DM.%2BS.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DStructural%2520bioinformatics-based%2520design%2520of%2520selective%252C%2520irreversible%2520kinase%2520inhibitors%26jtitle%3DScience%26date%3D2005%26volume%3D308%26spage%3D1318%26epage%3D1321%26doi%3D10.1126%2Fscience1108367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit9b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Leproult, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barluenga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moras, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurtz, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winssinger, N.</span></span> <span> </span><span class="NLM_article-title">Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1347</span>– <span class="NLM_lpage">1355</span>, <span class="refDoi"> DOI: 10.1021/jm101396q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101396q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvFeis70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1347-1355&author=E.+Leproultauthor=S.+Barluengaauthor=D.+Morasauthor=J.-M.+Wurtzauthor=N.+Winssinger&title=Cysteine+mapping+in+conformationally+distinct+kinase+nucleotide+binding+sites%3A+application+to+the+design+of+selective+covalent+inhibitors&doi=10.1021%2Fjm101396q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors</span></div><div class="casAuthors">Leproult, Emeline; Barluenga, Sofia; Moras, Dino; Wurtz, Jean-Marie; Winssinger, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1347-1355</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Kinases have emerged as one of the most prolific therapeutic targets.  An important criterion in the therapeutic success of inhibitors targeting the nucleotide binding pocket of kinases is the inhibitor residence time.  Recently, covalent kinase inhibitors have attracted attention since they confer terminal inhibition and should thus be more effective than reversible inhibitors with transient inhibition.  The most robust approach to design irreversible inhibitors is to capitalize on the nucleophilicity of a cysteine thiol group present in the target protein.  Herein, the authors report a systematic anal. of cysteine residues present in the nucleotide binding site of kinases, which could be harnessed for irreversible inhibition, taking into consideration the different kinase conformations.  The authors demonstrate the predictive power of this anal. with the design and validation of an irreversible inhibitor of KIT/PDGFR kinases.  This is the first example of a covalent kinase inhibitor that combines a pharmacophore addressing the DFG-out conformation with a covalent trap.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkzqt0gMrz3rVg90H21EOLACvtfcHk0lierWzjNzOoMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvFeis70%253D&md5=329ae5eaa6102b6dd34a0d1274631247</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1021%2Fjm101396q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101396q%26sid%3Dliteratum%253Aachs%26aulast%3DLeproult%26aufirst%3DE.%26aulast%3DBarluenga%26aufirst%3DS.%26aulast%3DMoras%26aufirst%3DD.%26aulast%3DWurtz%26aufirst%3DJ.-M.%26aulast%3DWinssinger%26aufirst%3DN.%26atitle%3DCysteine%2520mapping%2520in%2520conformationally%2520distinct%2520kinase%2520nucleotide%2520binding%2520sites%253A%2520application%2520to%2520the%2520design%2520of%2520selective%2520covalent%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1347%26epage%3D1355%26doi%3D10.1021%2Fjm101396q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulligan, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaeger, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devereux, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barr, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kipps, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cymbalista, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pocock, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thornton, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caligaris-Cappio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robak, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delgado, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuster, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montillo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dearden, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fardis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGreivy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clow, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmen, P.</span></span> <span> </span><span class="NLM_article-title">Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>371</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1400376</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1056%2FNEJMoa1400376" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=24881631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1egsbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=213-223&author=J.+C.+Byrdauthor=J.+R.+Brownauthor=S.+O%E2%80%99Brienauthor=J.+C.+Barrientosauthor=N.+E.+Kayauthor=N.+M.+Reddyauthor=S.+Coutreauthor=C.+S.+Tamauthor=S.+P.+Mulliganauthor=U.+Jaegerauthor=S.+Devereuxauthor=P.+M.+Barrauthor=R.+R.+Furmanauthor=T.+J.+Kippsauthor=F.+Cymbalistaauthor=C.+Pocockauthor=P.+Thorntonauthor=F.+Caligaris-Cappioauthor=T.+Robakauthor=J.+Delgadoauthor=S.+J.+Schusterauthor=M.+Montilloauthor=A.+Schuhauthor=S.+de+Vosauthor=D.+Gillauthor=A.+Bloorauthor=C.+Deardenauthor=C.+Morenoauthor=J.+J.+Jonesauthor=A.+D.+Chuauthor=M.+Fardisauthor=J.+McGreivyauthor=F.+Clowauthor=D.+F.+Jamesauthor=P.+Hillmen&title=Ibrutinib+versus+ofatumumab+in+previously+treated+chronic+lymphoid+leukemia&doi=10.1056%2FNEJMoa1400376"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia</span></div><div class="casAuthors">Byrd, J. C.; Brown, J. R.; O'Brien, S.; Barrientos, J. C.; Kay, N. E.; Reddy, N. M.; Coutre, S.; Tam, C. S.; Mulligan, S. P.; Jaeger, U.; Devereux, S.; Barr, P. M.; Furman, R. R.; Kipps, T. J.; Cymbalista, F.; Pocock, C.; Thornton, P.; Caligaris-Cappio, F.; Robak, T.; Delgado, J.; Schuster, S. J.; Montillo, M.; Schuh, A.; de Vos, S.; Gill, D.; Bloor, A.; Dearden, C.; Moreno, C.; Jones, J. J.; Chu, A. D.; Fardis, M.; McGreivy, J.; Clow, F.; James, D. F.; Hillmen, P.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">213-223, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: In patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response to therapy or adverse cytogenetic abnormalities are assocd. with a poor outcome.  We evaluated the efficacy of ibrutinib, a covalent inhibitor of Bruton's tyrosine kinase, in patients at risk for a poor outcome.  Methods: In this multicenter, open-label, phase 3 study, we randomly assigned 391 patients with relapsed or refractory CLL or SLL to receive daily ibrutinib or the anti-CD20 antibody ofatumumab.  The primary end point was the duration of progression-free survival, with the duration of overall survival and the overall response rate as secondary end points.  Results: At a median follow-up of 9.4 mo, ibrutinib significantly improved progression-free survival; the median duration was not reached in the ibrutinib group (with a rate of progression-free survival of 88% at 6 mo), as compared with a median of 8.1 mo in the ofatumumab group (hazard ratio for progression or death in the ibrutinib group, 0.22; P < 0.001).  Ibrutinib also significantly improved overall survival (hazard ratio for death, 0.43; P = 0.005).  At 12 mo, the overall survival rate was 90% in the ibrutinib group and 81% in the ofatumumab group.  The overall response rate was significantly higher in the ibrutinib group than in the ofatumumab group (42.6% vs. 4.1%, P < 0.001).  An addnl. 20% of ibrutinib-treated patients had a partial response with lymphocytosis.  Similar effects were obsd. regardless of whether patients had a chromosome 17p13.1 deletion or resistance to purine analogs.  The most frequent nonhematol. adverse events were diarrhea, fatigue, pyrexia, and nausea in the ibrutinib group and fatigue, infusion-related reactions, and cough in the ofatumumab group.  Conclusions: Ibrutinib, as compared with ofatumumab, significantly improved progression-free survival, overall survival, and response rate among patients with previously treated CLL or SLL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCuX1vrLZxQLVg90H21EOLACvtfcHk0lierWzjNzOoMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1egsbrN&md5=87b692d35faa0fb8666bb945746fb9b0</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1400376&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1400376%26sid%3Dliteratum%253Aachs%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DKay%26aufirst%3DN.%2BE.%26aulast%3DReddy%26aufirst%3DN.%2BM.%26aulast%3DCoutre%26aufirst%3DS.%26aulast%3DTam%26aufirst%3DC.%2BS.%26aulast%3DMulligan%26aufirst%3DS.%2BP.%26aulast%3DJaeger%26aufirst%3DU.%26aulast%3DDevereux%26aufirst%3DS.%26aulast%3DBarr%26aufirst%3DP.%2BM.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DKipps%26aufirst%3DT.%2BJ.%26aulast%3DCymbalista%26aufirst%3DF.%26aulast%3DPocock%26aufirst%3DC.%26aulast%3DThornton%26aufirst%3DP.%26aulast%3DCaligaris-Cappio%26aufirst%3DF.%26aulast%3DRobak%26aufirst%3DT.%26aulast%3DDelgado%26aufirst%3DJ.%26aulast%3DSchuster%26aufirst%3DS.%2BJ.%26aulast%3DMontillo%26aufirst%3DM.%26aulast%3DSchuh%26aufirst%3DA.%26aulast%3Dde%2BVos%26aufirst%3DS.%26aulast%3DGill%26aufirst%3DD.%26aulast%3DBloor%26aufirst%3DA.%26aulast%3DDearden%26aufirst%3DC.%26aulast%3DMoreno%26aufirst%3DC.%26aulast%3DJones%26aufirst%3DJ.%2BJ.%26aulast%3DChu%26aufirst%3DA.%2BD.%26aulast%3DFardis%26aufirst%3DM.%26aulast%3DMcGreivy%26aufirst%3DJ.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DJames%26aufirst%3DD.%2BF.%26aulast%3DHillmen%26aufirst%3DP.%26atitle%3DIbrutinib%2520versus%2520ofatumumab%2520in%2520previously%2520treated%2520chronic%2520lymphoid%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26spage%3D213%26epage%3D223%26doi%3D10.1056%2FNEJMoa1400376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit10b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rule, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahl, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurczak, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Advani, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romaguera, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielowska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stilgenbauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreyling, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jedrzejczak, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spurgeon, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newberry, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGreivy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clow, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaupre, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunkel, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, K. A.</span></span> <span> </span><span class="NLM_article-title">Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>369</i></span>,  <span class="NLM_fpage">507</span>– <span class="NLM_lpage">516</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1306220</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1056%2FNEJMoa1306220" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=23782157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1OgtL%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=507-516&author=M.+L.+Wangauthor=S.+Ruleauthor=P.+Martinauthor=A.+Goyauthor=R.+Auerauthor=B.+S.+Kahlauthor=W.+Jurczakauthor=R.+H.+Advaniauthor=J.+E.+Romagueraauthor=M.+E.+Williamsauthor=J.+C.+Barrientosauthor=E.+Chmielowskaauthor=J.+Radfordauthor=S.+Stilgenbauerauthor=M.+Dreylingauthor=W.+W.+Jedrzejczakauthor=P.+Johnsonauthor=S.+E.+Spurgeonauthor=L.+Liauthor=L.+Zhangauthor=K.+Newberryauthor=Z.+Ouauthor=N.+Chengauthor=B.+Fangauthor=J.+McGreivyauthor=F.+Clowauthor=J.+J.+Buggyauthor=B.+Y.+Changauthor=D.+M.+Beaupreauthor=L.+A.+Kunkelauthor=K.+A.+Blum&title=Targeting+BTK+with+ibrutinib+in+relapsed+or+refractory+mantle-cell+lymphoma&doi=10.1056%2FNEJMoa1306220"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma</span></div><div class="casAuthors">Wang, Michael L.; Rule, Simon; Martin, Peter; Goy, Andre; Auer, Rebecca; Kahl, Brad S.; Jurczak, Wojciech; Advani, Ranjana H.; Romaguera, Jorge E.; Williams, Michael E.; Barrientos, Jacqueline C.; Chmielowska, Ewa; Radford, John; Stilgenbauer, Stephan; Dreyling, Martin; Jedrzejczak, Wieslaw Wiktor; Johnson, Peter; Spurgeon, Stephen E.; Li, Lei; Zhang, Liang; Newberry, Kate; Ou, Zhishuo; Cheng, Nancy; Fang, Bingliang; McGreivy, Jesse; Clow, Fong; Buggy, Joseph J.; Chang, Betty Y.; Beaupre, Darrin M.; Kunkel, Lori A.; Blum, Kristie A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">507-516</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Bruton's tyrosine kinase (BTK) is a mediator of the B-cell-receptor signaling pathway implicated in the pathogenesis of B-cell cancers.  In a phase 1 study, ibrutinib, a BTK inhibitor, showed antitumor activity in several types of non-Hodgkin's lymphoma, including mantle-cell lymphoma.  METHODS: In this phase 2 study, we investigated oral ibrutinib, at a daily dose of 560 mg, in 111 patients with relapsed or refractory mantle-cell lymphoma.  Patients were enrolled into two groups: those who had previously received at least 2 cycles of bortezomib therapy and those who had received less than 2 complete cycles of bortezomib or had received no prior bortezomib therapy.  The primary end point was the overall response rate.  Secondary end points were duration of response, progression-free survival, overall survival, and safety.  RESULTS: The median age was 68 years, and 86% of patients had intermediate-risk or high-risk mantle-cell lymphoma according to clin. prognostic factors.  Patients had received a median of three prior therapies.  The most common treatment-related adverse events were mild or moderate diarrhea, fatigue, and nausea.  Grade 3 or higher hematol. events were infrequent and included neutropenia (in 16% of patients), thrombocytopenia (in 11%), and anemia (in 10%).  A response rate of 68% (75 patients) was obsd., with a complete response rate of 21% and a partial response rate of 47%; prior treatment with bortezomib had no effect on the response rate.  With an estd. median follow-up of 15.3 mo, the estd. median response duration was 17.5 mo (95% confidence interval [CI], 15.8 to not reached), the estd. median progression-free survival was 13.9 mo (95% CI, 7.0 to not reached), and the median overall survival was not reached.  The estd. rate of overall survival was 58% at 18 mo.  CONCLUSIONS: Ibrutinib shows durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovUuOKvHS0NrVg90H21EOLACvtfcHk0liSwx29ra6syA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1OgtL%252FF&md5=7a92bbd5acf86e614cea96f44503e12b</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1306220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1306220%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DM.%2BL.%26aulast%3DRule%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DP.%26aulast%3DGoy%26aufirst%3DA.%26aulast%3DAuer%26aufirst%3DR.%26aulast%3DKahl%26aufirst%3DB.%2BS.%26aulast%3DJurczak%26aufirst%3DW.%26aulast%3DAdvani%26aufirst%3DR.%2BH.%26aulast%3DRomaguera%26aufirst%3DJ.%2BE.%26aulast%3DWilliams%26aufirst%3DM.%2BE.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DChmielowska%26aufirst%3DE.%26aulast%3DRadford%26aufirst%3DJ.%26aulast%3DStilgenbauer%26aufirst%3DS.%26aulast%3DDreyling%26aufirst%3DM.%26aulast%3DJedrzejczak%26aufirst%3DW.%2BW.%26aulast%3DJohnson%26aufirst%3DP.%26aulast%3DSpurgeon%26aufirst%3DS.%2BE.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DNewberry%26aufirst%3DK.%26aulast%3DOu%26aufirst%3DZ.%26aulast%3DCheng%26aufirst%3DN.%26aulast%3DFang%26aufirst%3DB.%26aulast%3DMcGreivy%26aufirst%3DJ.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DBeaupre%26aufirst%3DD.%2BM.%26aulast%3DKunkel%26aufirst%3DL.%2BA.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26atitle%3DTargeting%2520BTK%2520with%2520ibrutinib%2520in%2520relapsed%2520or%2520refractory%2520mantle-cell%2520lymphoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D507%26epage%3D516%26doi%3D10.1056%2FNEJMoa1306220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit10c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Treon, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripsas, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meid, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varma, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argyropoulos, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zehnder, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aster, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghobrial, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castillo, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laubach, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, Z. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salman, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clow, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graef, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palomba, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Advani, R. H.</span></span> <span> </span><span class="NLM_article-title">Ibrutinib in previously treated waldenstrom’s macroglobulinemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">1430</span>– <span class="NLM_lpage">1440</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1501548</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1056%2FNEJMoa1501548" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=25853747" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC2MXns1Wrt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=1430-1440&author=S.+P.+Treonauthor=C.+K.+Tripsasauthor=K.+Meidauthor=D.+Warrenauthor=G.+Varmaauthor=R.+Greenauthor=K.+V.+Argyropoulosauthor=G.+Yangauthor=+Caoauthor=L.+Xuauthor=C.+J.+Pattersonauthor=S.+Rodigauthor=J.+L.+Zehnderauthor=J.+C.+Asterauthor=N.+L.+Harrisauthor=S.+Kananauthor=I.+Ghobrialauthor=J.+J.+Castilloauthor=J.+P.+Laubachauthor=Z.+R.+Hunterauthor=Z.+Salmanauthor=J.+Liauthor=M.+Chengauthor=F.+Clowauthor=T.+Graefauthor=M.+L.+Palombaauthor=R.+H.+Advani&title=Ibrutinib+in+previously+treated+waldenstrom%E2%80%99s+macroglobulinemia&doi=10.1056%2FNEJMoa1501548"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10cR"><div class="casContent"><span class="casTitleNuber">10c</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib in previously treated waldenstrom's macroglobulinemia</span></div><div class="casAuthors">Treon, Steven P.; Tripsas, Christina K.; Meid, Kirsten; Warren, Diane; Varma, Gaurav; Green, Rebecca; Argyropoulos, Kimon V.; Yang, Guang; Cao, Yang; Xu, Lian; Patterson, Christopher J.; Rodig, Scott; Zehnder, James L.; Aster, Jon C.; Harris, Nancy Lee; Kanan, Sandra; Ghobrial, Irene; Castillo, Jorge J.; Laubach, Jacob P.; Hunter, Zachary R.; Salman, Zeena; Li, Jianling; Cheng, Mei; Clow, Fong; Graef, Thorsten; Palomba, M. Lia; Advani, Ranjana H.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1430-1440</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">MYD88L265P and CXCR4WHIM mutations are highly prevalent in Waldenstrom's macroglobulinemia.  MYD88L265P triggers tumor-cell growth through Bruton's tyrosine kinase, a target of ibrutinib.  CXCR4WHIM mutations confer in vitro resistance to ibrutinib.  We performed a prospective study of ibrutinib in 63 symptomatic patients with Waldenstrom's macroglobulinemia who had received at least one previous treatment, and we investigated the effect of MYD88 and CXCR4 mutations on outcomes.  Ibrutinib at a daily dose of 420 mg was administered orally until disease progression or the development of unacceptable toxic effects.  After the patients received ibrutinib, median serum IgM levels decreased from 3520 mg per dL to 880 mg per dL, median Hb levels increased from 10.5 g per dL to 13.8 g per dL, and bone marrow involvement decreased from 60% to 25% (P<0.01 for all comparisons).  The median time to at least a minor response was 4 wk.  The overall response rate was 90.5%, and the major response rate was 73.0%; these rates were highest among patients with MYD88L265PCXCR4WT (with WT indicating wild-type) (100% overall response rate and 91.2% major response rate), followed by patients with MYD88L265PCXCR4WHIM (85.7% and 61.9%, resp.) and patients with MYD88WTCXCR4WT (71.4% and 28.6%).  The estd. 2-yr progression-free and overall survival rates among all patients were 69.1% and 95.2%, resp.  Treatment-related toxic effects of grade 2 or higher included neutropenia (in 22% of the patients) and thrombocytopenia (in 14%), which were more common in heavily pretreated patients; postprocedural bleeding (in 3%); epistaxis assocd. with the use of fish-oil supplements (in 3%); and atrial fibrillation assocd. with a history of arrhythmia (5%).  Ibrutinib was highly active, assocd. with durable responses, and safe in pretreated patients with Waldenstrom's macroglobulinemia.  MYD88 and CXCR4 mutation status affected responses to this drug. (Funded by Pharmacyclics and others; ClinicalTrials.gov no., NCT01614821.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoifbEcGkxnFrVg90H21EOLACvtfcHk0liSwx29ra6syA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXns1Wrt7w%253D&md5=00d1d3dd9be87801725d8c161afa899c</span></div><a href="/servlet/linkout?suffix=cit10c&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1501548&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1501548%26sid%3Dliteratum%253Aachs%26aulast%3DTreon%26aufirst%3DS.%2BP.%26aulast%3DTripsas%26aufirst%3DC.%2BK.%26aulast%3DMeid%26aufirst%3DK.%26aulast%3DWarren%26aufirst%3DD.%26aulast%3DVarma%26aufirst%3DG.%26aulast%3DGreen%26aufirst%3DR.%26aulast%3DArgyropoulos%26aufirst%3DK.%2BV.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DCao%26aulast%3DXu%26aufirst%3DL.%26aulast%3DPatterson%26aufirst%3DC.%2BJ.%26aulast%3DRodig%26aufirst%3DS.%26aulast%3DZehnder%26aufirst%3DJ.%2BL.%26aulast%3DAster%26aufirst%3DJ.%2BC.%26aulast%3DHarris%26aufirst%3DN.%2BL.%26aulast%3DKanan%26aufirst%3DS.%26aulast%3DGhobrial%26aufirst%3DI.%26aulast%3DCastillo%26aufirst%3DJ.%2BJ.%26aulast%3DLaubach%26aufirst%3DJ.%2BP.%26aulast%3DHunter%26aufirst%3DZ.%2BR.%26aulast%3DSalman%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DGraef%26aufirst%3DT.%26aulast%3DPalomba%26aufirst%3DM.%2BL.%26aulast%3DAdvani%26aufirst%3DR.%2BH.%26atitle%3DIbrutinib%2520in%2520previously%2520treated%2520waldenstrom%25E2%2580%2599s%2520macroglobulinemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D1430%26epage%3D1440%26doi%3D10.1056%2FNEJMoa1501548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mauro, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caputo, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosati, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pepe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Benedittis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Luca, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foa, R.</span></span> <span> </span><span class="NLM_article-title">Balancing efficacy and toxicity of targeted agents currently used for the treatment of patients with chronic lymphocytic leukemia</span>. <i>Expert Rev. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">601</span>– <span class="NLM_lpage">611</span>, <span class="refDoi"> DOI: 10.1080/17474086.2018.1495557</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1080%2F17474086.2018.1495557" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=29969322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlClt73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=601-611&author=F.+R.+Mauroauthor=M.+D.+Caputoauthor=S.+Rosatiauthor=S.+Pepeauthor=D.+De+Benedittisauthor=M.+L.+De+Lucaauthor=R.+Foa&title=Balancing+efficacy+and+toxicity+of+targeted+agents+currently+used+for+the+treatment+of+patients+with+chronic+lymphocytic+leukemia&doi=10.1080%2F17474086.2018.1495557"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Balancing efficacy and toxicity of targeted agents currently used for the treatment of patients with chronic lymphocytic leukemia</span></div><div class="casAuthors">Mauro, Francesca R.; Caputo, Maria D.; Rosati, Serena; Pepe, Sara; De Benedittis, Daniela; De Luca, Maria L.; Foa, Robin</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Hematology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">601-611</span>CODEN:
                <span class="NLM_cas:coden">ERHXAV</span>;
        ISSN:<span class="NLM_cas:issn">1747-4094</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: In recent years, innovative mechanism-based drugs have enriched the therapeutic armamentarium for patients with chronic lymphocytic leukemia (CLL) and are widely used in the clin. practice.  These small mols. targeting the B-cell receptor signaling pathway and the BCL-2 anti-apoptotic protein offer new chemo-free options to both unfit patients and high-risk patients who show a poor response to chemoimmunotherapy.  Nonetheless, treatment with ibrutinib, idelalisib and venetoclax is assocd. with unique side effects.  Awareness, prevention and the appropriate management of these specific toxicities are of crucial importance for a successful treatment.: The purpose of this review is to discuss the most relevant studies on small mols. in CLL, with particular attention to the emerging toxicity profile of these agents and to the factors that should be considered to address the most appropriate treatment approach for each patient.: The increased knowledge on the biol. of CLL has translated into the development of targeted agents that are highly effective and produce deep responses.  Toxicities potentially assocd. with these agents should be known for an optimal management of CLL patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOEVNTkF_oYLVg90H21EOLACvtfcHk0liSwx29ra6syA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlClt73O&md5=44f85d32375f1ac41227a37d75aebe9c</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1080%2F17474086.2018.1495557&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17474086.2018.1495557%26sid%3Dliteratum%253Aachs%26aulast%3DMauro%26aufirst%3DF.%2BR.%26aulast%3DCaputo%26aufirst%3DM.%2BD.%26aulast%3DRosati%26aufirst%3DS.%26aulast%3DPepe%26aufirst%3DS.%26aulast%3DDe%2BBenedittis%26aufirst%3DD.%26aulast%3DDe%2BLuca%26aufirst%3DM.%2BL.%26aulast%3DFoa%26aufirst%3DR.%26atitle%3DBalancing%2520efficacy%2520and%2520toxicity%2520of%2520targeted%2520agents%2520currently%2520used%2520for%2520the%2520treatment%2520of%2520patients%2520with%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DExpert%2520Rev.%2520Hematol.%26date%3D2018%26volume%3D11%26spage%3D601%26epage%3D611%26doi%3D10.1080%2F17474086.2018.1495557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, P.</span></span> <span> </span><span class="NLM_article-title">Investigational Bruton’s tyrosine kinase inhibitors for the treatment of rheumatoid arthritis</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">891</span>– <span class="NLM_lpage">899</span>, <span class="refDoi"> DOI: 10.1080/13543784.2016.1182499</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1080%2F13543784.2016.1182499" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=27148767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC28Xnslentb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2016&pages=891-899&author=P.+Norman&title=Investigational+Bruton%E2%80%99s+tyrosine+kinase+inhibitors+for+the+treatment+of+rheumatoid+arthritis&doi=10.1080%2F13543784.2016.1182499"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">Investigational Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis</span></div><div class="casAuthors">Norman, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">891-899</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The Tec family of non-receptor tyrosine kinases comprises five members.  The cellular expression and function of these kinases has implicated them as potential drug targets for the treatment of both malignant and autoimmune diseases.  Most attention has focused on inhibitors of BTK kinase with ibrutinib already approved for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia.  Multiple BTK inhibitors are being developed for both oncol. and autoimmune disease indications.  BTK inhibitors being evaluated in rheumatoid arthritis are considered.  Both inhibitors which have progressed to early clin. development, and those demonstrating activity in rodent models of arthritis are reviewed.  These include both reversible and irreversible inhibitors of the kinase, most of which target the cysteine-481 residue of BTK.  The selectivity of these inhibitors for Tec family kinases is considered.  Developing inhibitors of any kinase to treat of rheumatoid arthritis has proved problematic with regard to both efficacy and selectivity.  It is anticipated that the more selective BTK inhibitors may prove more useful in treating arthritis, with the use of reversible inhibitors possibly offering a better strategy.  Chronic dosing may exacerbate the emergence of drug resistance, with resistant mutations already obsd. in ibrutinib-treated patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQsRSjuYxYa7Vg90H21EOLACvtfcHk0ljrW8GdHCNh3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xnslentb0%253D&md5=037f60be680ad282725fe8f7619f1212</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1080%2F13543784.2016.1182499&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2016.1182499%26sid%3Dliteratum%253Aachs%26aulast%3DNorman%26aufirst%3DP.%26atitle%3DInvestigational%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2016%26volume%3D25%26spage%3D891%26epage%3D899%26doi%3D10.1080%2F13543784.2016.1182499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit12b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, J. A.</span></span> <span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase inhibitors: first and second generation agents for patients with chronic lymphocytic leukemia (CLL)</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1080/13543784.2018.1404027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1080%2F13543784.2018.1404027" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2018&pages=31-42&author=P.+A.+Thompsonauthor=J.+A.+Burger&title=Bruton%E2%80%99s+tyrosine+kinase+inhibitors%3A+first+and+second+generation+agents+for+patients+with+chronic+lymphocytic+leukemia+%28CLL%29&doi=10.1080%2F13543784.2018.1404027"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1080%2F13543784.2018.1404027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2018.1404027%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DP.%2BA.%26aulast%3DBurger%26aufirst%3DJ.%2BA.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitors%253A%2520first%2520and%2520second%2520generation%2520agents%2520for%2520patients%2520with%2520chronic%2520lymphocytic%2520leukemia%2520%2528CLL%2529%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2018%26volume%3D27%26spage%3D31%26epage%3D42%26doi%3D10.1080%2F13543784.2018.1404027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit12c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnarajah, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunn, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karr, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masjedizadeh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gourlay, S. G.</span></span> <span> </span><span class="NLM_article-title">A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton’s tyrosine kinase in healthy volunteers</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">2367</span>– <span class="NLM_lpage">2376</span>, <span class="refDoi"> DOI: 10.1111/bcp.13351</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1111%2Fbcp.13351" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=28636208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslWrsLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2017&pages=2367-2376&author=P.+F.+Smithauthor=J.+Krishnarajahauthor=P.+A.+Nunnauthor=R.+J.+Hillauthor=D.+Karrauthor=D.+Tamauthor=M.+Masjedizadehauthor=J.+O.+Funkauthor=S.+G.+Gourlay&title=A+phase+I+trial+of+PRN1008%2C+a+novel+reversible+covalent+inhibitor+of+Bruton%E2%80%99s+tyrosine+kinase+in+healthy+volunteers&doi=10.1111%2Fbcp.13351"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12cR"><div class="casContent"><span class="casTitleNuber">12c</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers</span></div><div class="casAuthors">Smith, Patrick F.; Krishnarajah, Janakan; Nunn, Philip A.; Hill, Ron J.; Karr, Dane; Tam, D.; Masjedizadeh, Mohammad; Funk, Jens O.; Gourlay, Steve G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2367-2376</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">To evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics of PRN1008, a novel Bruton's tyrosine kinase (BTK) inhibitor, in healthy volunteers, and thus det. the dose range for future clin. studies.  This was a two-part randomized, placebo controlled study in healthy volunteers using a liq. formulation.  Part I was a single ascending dose design with dose levels of 50-1200 mg (n = 6 active, two placebos per cohort); Part II was a multiple ascending dose design, with dose regimens ranging from 300 to 900 mg daily, either four times or twice daily for 10 days.  Plasma pharmacokinetics, adverse events, vital signs, electrocardiograms and lab. parameters were assessed.  BTK occupancy in peripheral blood mononuclear cells was evaluated as a marker of target engagement.  PRN1008 was rapidly absorbed following oral administration, and was safe and well tolerated in all dose regimens evaluated in both single and multiple doses.  PRN1008 demonstrated a large vol. of distribution, and a half-life of approx. 3-4 h.  BTK occupancy of >90% was obsd. within 4 h after dosing in both single and multiple dose regimens, and was closely linked to max. plasma concn.  BTK occupancy decay was slow (-1.6% h-1), and occupancy was sustained despite drug concns. being undetectable.  No severe or serious adverse events occurred, and the most common adverse events were gastrointestinal in nature.  PRN1008 was safe and well-tolerated following oral administration, and achieved high, sustained levels of BTK occupancy in peripheral blood mononuclear cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDCmAr26_VXLVg90H21EOLACvtfcHk0ljrW8GdHCNh3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslWrsLnE&md5=8da03545b8beec4c50cdd95854bcad8f</span></div><a href="/servlet/linkout?suffix=cit12c&amp;dbid=16384&amp;doi=10.1111%2Fbcp.13351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.13351%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DP.%2BF.%26aulast%3DKrishnarajah%26aufirst%3DJ.%26aulast%3DNunn%26aufirst%3DP.%2BA.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DKarr%26aufirst%3DD.%26aulast%3DTam%26aufirst%3DD.%26aulast%3DMasjedizadeh%26aufirst%3DM.%26aulast%3DFunk%26aufirst%3DJ.%2BO.%26aulast%3DGourlay%26aufirst%3DS.%2BG.%26atitle%3DA%2520phase%2520I%2520trial%2520of%2520PRN1008%252C%2520a%2520novel%2520reversible%2520covalent%2520inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520in%2520healthy%2520volunteers%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2017%26volume%3D83%26spage%3D2367%26epage%3D2376%26doi%3D10.1111%2Fbcp.13351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit12d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harb, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabrilove, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreeder, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barr, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foran, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahadevan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnett, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marine, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miranda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azaryan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nava-Parada, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kipps, T. J.</span></span> <span> </span><span class="NLM_article-title">Phase I study of single-agent CC-292, a highly selective Bruton’s tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">e295</span>– <span class="NLM_lpage">e298</span>, <span class="refDoi"> DOI: 10.3324/haematol.2015.140806</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.3324%2Fhaematol.2015.140806" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=27151992" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2016&pages=e295-e298&author=J.+R.+Brownauthor=W.+A.+Harbauthor=B.+T.+Hillauthor=J.+Gabriloveauthor=J.+P.+Sharmanauthor=M.+T.+Schreederauthor=P.+M.+Barrauthor=J.+M.+Foranauthor=T.+P.+Millerauthor=J.+A.+Burgerauthor=K.+R.+Kellyauthor=D.+Mahadevanauthor=S.+Maauthor=Y.+Liauthor=D.+W.+Pierceauthor=E.+Barnettauthor=J.+Marineauthor=M.+Mirandaauthor=A.+Azaryanauthor=X.+Yuauthor=P.+Nava-Paradaauthor=J.+Meiauthor=T.+J.+Kipps&title=Phase+I+study+of+single-agent+CC-292%2C+a+highly+selective+Bruton%E2%80%99s+tyrosine+kinase+inhibitor%2C+in+relapsed%2Frefractory+chronic+lymphocytic+leukemia&doi=10.3324%2Fhaematol.2015.140806"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12d&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2015.140806&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2015.140806%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DHarb%26aufirst%3DW.%2BA.%26aulast%3DHill%26aufirst%3DB.%2BT.%26aulast%3DGabrilove%26aufirst%3DJ.%26aulast%3DSharman%26aufirst%3DJ.%2BP.%26aulast%3DSchreeder%26aufirst%3DM.%2BT.%26aulast%3DBarr%26aufirst%3DP.%2BM.%26aulast%3DForan%26aufirst%3DJ.%2BM.%26aulast%3DMiller%26aufirst%3DT.%2BP.%26aulast%3DBurger%26aufirst%3DJ.%2BA.%26aulast%3DKelly%26aufirst%3DK.%2BR.%26aulast%3DMahadevan%26aufirst%3DD.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DPierce%26aufirst%3DD.%2BW.%26aulast%3DBarnett%26aufirst%3DE.%26aulast%3DMarine%26aufirst%3DJ.%26aulast%3DMiranda%26aufirst%3DM.%26aulast%3DAzaryan%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DNava-Parada%26aufirst%3DP.%26aulast%3DMei%26aufirst%3DJ.%26aulast%3DKipps%26aufirst%3DT.%2BJ.%26atitle%3DPhase%2520I%2520study%2520of%2520single-agent%2520CC-292%252C%2520a%2520highly%2520selective%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitor%252C%2520in%2520relapsed%252Frefractory%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DHaematologica%26date%3D2016%26volume%3D101%26spage%3De295%26epage%3De298%26doi%3D10.3324%2Fhaematol.2015.140806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit12e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Kivitz, A. J.</span>; <span class="NLM_string-name">Gupta, R.</span>; <span class="NLM_string-name">Valenzuela, G.</span>; <span class="NLM_string-name">Smith, E.</span>; <span class="NLM_string-name">Rehman, Q.</span>; <span class="NLM_string-name">El Kadi, H.</span>; <span class="NLM_string-name">Bretton, E.</span>; <span class="NLM_string-name">Aelion, J. A.</span>; <span class="NLM_string-name">Chadha, A.</span>; <span class="NLM_string-name">Tesser, J.</span>; <span class="NLM_string-name">Hough, D.</span>; <span class="NLM_string-name">Korish, S.</span>; <span class="NLM_string-name">Schafer, P. H.</span>; <span class="NLM_string-name">Ringheim, G.</span>; <span class="NLM_string-name">Sutherland, D.</span>; <span class="NLM_string-name">Li, L.</span></span> <span> </span><span class="NLM_article-title">A phase 2a, 4-week double-blind, proof of concept efficacy and safety study of CC-292 versus placebo as co-therapy with methotrexate in active rheumatoid arthritis (RA)</span>.  <i>Arthritis Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume">68</span>, (<span class="NLM_issue">Suppl. 10</span>), <a href="https://acrabstracts.org/abstract/a-phase-2a-4-week-double-blind-proof-of-concept-efficacy-and-safety-study-of-cc-292-versus-placebo-as-co-therapy-with-methotrexate-in-active-rheumatoid-arthritis-ra/." class="extLink">https://acrabstracts.org/abstract/a-phase-2a-4-week-double-blind-proof-of-concept-efficacy-and-safety-study-of-cc-292-versus-placebo-as-co-therapy-with-methotrexate-in-active-rheumatoid-arthritis-ra</a>/.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2016&issue=Suppl.+10&author=A.+J.+Kivitz&author=R.+Gupta&author=G.+Valenzuela&author=E.+Smith&author=Q.+Rehman&author=H.+El+Kadi&author=E.+Bretton&author=J.+A.+Aelion&author=A.+Chadha&author=J.+Tesser&author=D.+Hough&author=S.+Korish&author=P.+H.+Schafer&author=G.+Ringheim&author=D.+Sutherland&author=L.+Li&title=A+phase+2a%2C+4-week+double-blind%2C+proof+of+concept+efficacy+and+safety+study+of+CC-292+versus+placebo+as+co-therapy+with+methotrexate+in+active+rheumatoid+arthritis+%28RA%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKivitz%26aufirst%3DA.%2BJ.%26atitle%3DA%2520phase%25202a%252C%25204-week%2520double-blind%252C%2520proof%2520of%2520concept%2520efficacy%2520and%2520safety%2520study%2520of%2520CC-292%2520versus%2520placebo%2520as%2520co-therapy%2520with%2520methotrexate%2520in%2520active%2520rheumatoid%2520arthritis%2520%2528RA%2529%26jtitle%3DArthritis%2520Rheumatol.%26date%3D2016%26volume%3D68%26issue%3DSuppl.%252010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rule, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R. W.</span></span> <span> </span><span class="NLM_article-title">New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma – where do they fit in?</span>. <i>Expert Rev. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">749</span>– <span class="NLM_lpage">756</span>, <span class="refDoi"> DOI: 10.1080/17474086.2018.1506327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1080%2F17474086.2018.1506327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=30052472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVGjtrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=749-756&author=S.+Ruleauthor=R.+W.+Chen&title=New+and+emerging+Bruton+tyrosine+kinase+inhibitors+for+treating+mantle+cell+lymphoma+%E2%80%93+where+do+they+fit+in%3F&doi=10.1080%2F17474086.2018.1506327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?</span></div><div class="casAuthors">Rule, Simon; Chen, Robert W.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Hematology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">749-756</span>CODEN:
                <span class="NLM_cas:coden">ERHXAV</span>;
        ISSN:<span class="NLM_cas:issn">1747-4094</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: Despite recent prognostic improvements, mantle cell lymphoma (MCL) remains incurable.  Bruton tyrosine kinase (BTK) is a key receptor in B-cell tumorigenesis, and the benefits of the first BTK inhibitor, ibrutinib, are becoming clear in MCL.  However, off-target activities, which contribute to ibrutinib-related adverse events, suggest potential for further improvement of this drug class.: The authors systematically interrogated ClinicalTrials.gov for trials contg. keywords for BTK and MCL.  Published literature for new and emerging BTK inhibitors being investigated in MCL was then identified (PubMed and Embase), summarized, and placed in the context of treatment guidelines.: Reduced off-target effects of new and emerging covalent, irreversible BTK inhibitors under investigation in patients with MCL offer the potential of improved safety compared with ibrutinib.  Efficacy may also be favorable based on trial data for acalabrutinib, which has just been approved in the USA as second-line therapy for MCL.  The role of BTK inhibitors in treating MCL will evolve substantially over the coming years as results from a no. of trials become available, particularly in relation to potential upfront use and possible synergy with other targeted therapies such as B-cell lymphoma 2, phosphoinositide 3-kinase and checkpoint inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjnXtQxShPybVg90H21EOLACvtfcHk0ljvAGgiTEZUPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVGjtrrI&md5=59bf858c7cffaceff538b87366042739</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1080%2F17474086.2018.1506327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17474086.2018.1506327%26sid%3Dliteratum%253Aachs%26aulast%3DRule%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DR.%2BW.%26atitle%3DNew%2520and%2520emerging%2520Bruton%2520tyrosine%2520kinase%2520inhibitors%2520for%2520treating%2520mantle%2520cell%2520lymphoma%2520%25E2%2580%2593%2520where%2520do%2520they%2520fit%2520in%253F%26jtitle%3DExpert%2520Rev.%2520Hematol.%26date%3D2018%26volume%3D11%26spage%3D749%26epage%3D756%26doi%3D10.1080%2F17474086.2018.1506327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rule, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinzani, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casasnovas, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damaj, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doorduijn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamy, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morschhauser, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panizo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupuis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kater, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Gouill, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oberic, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robak, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dua, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamdy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothbaum, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slatter, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurczak, W.</span></span> <span> </span><span class="NLM_article-title">Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>391</i></span>,  <span class="NLM_fpage">659</span>– <span class="NLM_lpage">667</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(17)33108-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1016%2FS0140-6736%2817%2933108-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=29241979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFOhsb%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=391&publication_year=2018&pages=659-667&author=M.+Wangauthor=S.+Ruleauthor=P.+L.+Zinzaniauthor=A.+Goyauthor=O.+Casasnovasauthor=S.+D.+Smithauthor=G.+Damajauthor=J.+Doorduijnauthor=T.+Lamyauthor=F.+Morschhauserauthor=C.+Panizoauthor=B.+Shahauthor=A.+Daviesauthor=R.+Eekauthor=J.+Dupuisauthor=E.+Jacobsenauthor=A.+P.+Katerauthor=S.+Le+Gouillauthor=L.+Obericauthor=T.+Robakauthor=T.+Coveyauthor=R.+Duaauthor=A.+Hamdyauthor=X.+Huangauthor=R.+Izumiauthor=P.+Patelauthor=W.+Rothbaumauthor=J.+G.+Slatterauthor=W.+Jurczak&title=Acalabrutinib+in+relapsed+or+refractory+mantle+cell+lymphoma+%28ACE-LY-004%29%3A+a+single-arm%2C+multicentre%2C+phase+2+trial&doi=10.1016%2FS0140-6736%2817%2933108-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicenter, phase 2 trial</span></div><div class="casAuthors">Wang, Michael; Rule, Simon; Zinzani, Pier Luigi; Goy, Andre; Casasnovas, Olivier; Smith, Stephen D.; Damaj, Gandhi; Doorduijn, Jeanette; Lamy, Thierry; Morschhauser, Franck; Panizo, Carlos; Shah, Bijal; Davies, Andrew; Eek, Richard; Dupuis, Jehan; Jacobsen, Eric; Kater, Arnon P.; Le Gouill, Steven; Oberic, Lucie; Robak, Taduesz; Covey, Todd; Dua, Richa; Hamdy, Ahmed; Huang, Xin; Izumi, Raquel; Patel, Priti; Rothbaum, Wayne; Slatter, J. Greg; Jurczak, Wojciech</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">391</span>
        (<span class="NLM_cas:issue">10121</span>),
    <span class="NLM_cas:pages">659-667</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Bruton tyrosine kinase is a clin. validated target in mantle cell lymphoma.  Acalabrutinib (ACP-196) is a highly selective, potent Bruton tyrosine kinase inhibitor developed to minimize off-target activity.  In this open-label, phase 2 study, oral acalabrutinib (100 mg twice per day) was given to patients with relapsed or refractory mantle cell lymphoma, until disease progression or unacceptable toxicity.  The primary endpoint was overall response assessed according to the Lugano classification, and safety analyses were done in all participants.  This trial is registered with ClinicalTrials.gov, no. NCT02213926.  From March 12, 2015, to Jan 5, 2016, 124 patients with relapsed or refractory mantle cell lymphoma were enrolled and all patients received treatment; median age 68 years.  Patients received a median of two (IQR 1-2) previous therapies.  At a median follow-up of 15·2 mo, 100 (81%) patients achieved an overall response and 49 (40%) patients achieved a complete response.  The Kaplan-Meier estd. medians for duration of response, progression-free survival, and overall survival were not reached; the 12-mo rates were 72% (95% CI 62-80), 67% (58-75), and 87% (79-92%), resp.  The most common adverse events were primarily grade 1 or 2 and were headache (47 [38%]), diarrhea (38 [31%]), fatigue (34 [27%]), and myalgia (26 [21%]).  The most common grade 3 or worse adverse events were neutropenia (13 [10%]), anemia (11 [9%]), and pneumonia (six [5%]).  There were no cases of atrial fibrillation and one case of grade 3 or worse hemorrhage.  The median duration of treatment was 13·8 mo.  Treatment was discontinued in 54 (44%) patients, primarily due to progressive disease (39 [31%]) and adverse events (seven [6%]).  Acalabrutinib treatment provided a high rate of durable responses and a favorable safety profile in patients with relapsed or refractory mantle cell lymphoma.  These findings suggest an important role for acalabrutinib in the treatment of this disease population.  Acerta Pharma, a member of the AstraZeneca Group.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpM5ii2D3nt7rVg90H21EOLACvtfcHk0lhNIb3kodiWyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFOhsb%252FN&md5=5631617d6830e4f1f062a0531d8d36a0</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2817%2933108-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252817%252933108-2%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DM.%26aulast%3DRule%26aufirst%3DS.%26aulast%3DZinzani%26aufirst%3DP.%2BL.%26aulast%3DGoy%26aufirst%3DA.%26aulast%3DCasasnovas%26aufirst%3DO.%26aulast%3DSmith%26aufirst%3DS.%2BD.%26aulast%3DDamaj%26aufirst%3DG.%26aulast%3DDoorduijn%26aufirst%3DJ.%26aulast%3DLamy%26aufirst%3DT.%26aulast%3DMorschhauser%26aufirst%3DF.%26aulast%3DPanizo%26aufirst%3DC.%26aulast%3DShah%26aufirst%3DB.%26aulast%3DDavies%26aufirst%3DA.%26aulast%3DEek%26aufirst%3DR.%26aulast%3DDupuis%26aufirst%3DJ.%26aulast%3DJacobsen%26aufirst%3DE.%26aulast%3DKater%26aufirst%3DA.%2BP.%26aulast%3DLe%2BGouill%26aufirst%3DS.%26aulast%3DOberic%26aufirst%3DL.%26aulast%3DRobak%26aufirst%3DT.%26aulast%3DCovey%26aufirst%3DT.%26aulast%3DDua%26aufirst%3DR.%26aulast%3DHamdy%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DIzumi%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DP.%26aulast%3DRothbaum%26aufirst%3DW.%26aulast%3DSlatter%26aufirst%3DJ.%2BG.%26aulast%3DJurczak%26aufirst%3DW.%26atitle%3DAcalabrutinib%2520in%2520relapsed%2520or%2520refractory%2520mantle%2520cell%2520lymphoma%2520%2528ACE-LY-004%2529%253A%2520a%2520single-arm%252C%2520multicentre%252C%2520phase%25202%2520trial%26jtitle%3DLancet%26date%3D2018%26volume%3D391%26spage%3D659%26epage%3D667%26doi%3D10.1016%2FS0140-6736%2817%2933108-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit13c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Barf, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Kar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulrajani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Lith, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Hoek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Zwart, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittag, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demont, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verkaik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krantz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulrich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaptein, A.</span></span> <span> </span><span class="NLM_article-title">Acalabrutinib (ACP-196): a covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>363</i></span>,  <span class="NLM_fpage">240</span>– <span class="NLM_lpage">252</span>, <span class="refDoi"> DOI: 10.1124/jpet.117.242909</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1124%2Fjpet.117.242909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=28882879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtleltrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2017&pages=240-252&author=T.+Barfauthor=T.+Coveyauthor=R.+Izumiauthor=B.+van+de+Karauthor=M.+Gulrajaniauthor=B.+van+Lithauthor=M.+van+Hoekauthor=E.+de+Zwartauthor=D.+Mittagauthor=D.+Demontauthor=S.+Verkaikauthor=F.+Krantzauthor=P.+G.+Pearsonauthor=R.+Ulrichauthor=A.+Kaptein&title=Acalabrutinib+%28ACP-196%29%3A+a+covalent+Bruton+tyrosine+kinase+inhibitor+with+a+differentiated+selectivity+and+in+vivo+potency+profile&doi=10.1124%2Fjpet.117.242909"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13cR"><div class="casContent"><span class="casTitleNuber">13c</span><div class="casTitle"><span class="NLM_cas:atitle">Acalabrutinib (ACP-196): a covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile</span></div><div class="casAuthors">Barf, Tjeerd; Covey, Todd; Izumi, Raquel; van de Kar, Bas; Gulrajani, Michael; van Lith, Bart; van Hoek, Maaike; de Zwart, Edwin; Mittag, Diana; Demont, Dennis; Verkaik, Saskia; Krantz, Fanny; Pearson, Paul G.; Ulrich, Roger; Kaptein, Allard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">240-252</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Several small-mol. Bruton tyrosine kinase (BTK) inhibitors are in development for B cell malignancies and autoimmune disorders, each characterized by distinct potency and selectivity patterns.  Herein we describe the pharmacol. characterization of BTK inhibitor acalabrutinib [compd. 1, ACP-196 (4-[8- amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin1-yl]-N-(2-pyridyl)benzamide)].  Acalabrutinib possesses a reactive butynamide group that binds covalently to Cys481 in BTK.  Relative to the other BTK inhibitors described here, the reduced intrinsic reactivity of acalabrutinib helps to limit inhibition of off-target kinases having cysteine-mediated covalent binding potential.  Acalabrutinib demonstrated higher biochem. and cellular selectivity than ibrutinib and spebrutinib (compds. 2 and 3, resp.).  Importantly, off-target kinases, such as epidermal growth factor receptor (EGFR) and interleukin 2-inducible T cell kinase (ITK), were not inhibited.  Detn. of the inhibitory potential of anti-IgM-induced CD69 expression in human peripheral blood mononuclear cells and whole blood demonstrated that acalabrutinib is a potent functional BTK inhibitor.  In vivo evaluation in mice revealed that acalabrutinib is more potent than ibrutinib and spebrutinib.  Preclin. and clin. studies showed that the level and duration of BTK occupancy correlates with in vivo efficacy.  Evaluation of the pharmacokinetic properties of acalabrutinib in healthy adult volunteers demonstrated rapid absorption and fast elimination.  In these healthy individuals, a single oral dose of 100 mg showed approx. 99% median target coverage at 3 and 12 h and around 90% at 24 h in peripheral B cells.  In conclusion, acalabrutinib is a BTK inhibitor with key pharmacol. differentiators vs. ibrutinib and spebrutinib and is currently being evaluated in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol9xhDmwvup7Vg90H21EOLACvtfcHk0lhNIb3kodiWyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtleltrnO&md5=73cbd3a87396abbf8cb20e4361f96f64</span></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=10.1124%2Fjpet.117.242909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.117.242909%26sid%3Dliteratum%253Aachs%26aulast%3DBarf%26aufirst%3DT.%26aulast%3DCovey%26aufirst%3DT.%26aulast%3DIzumi%26aufirst%3DR.%26aulast%3Dvan%2Bde%2BKar%26aufirst%3DB.%26aulast%3DGulrajani%26aufirst%3DM.%26aulast%3Dvan%2BLith%26aufirst%3DB.%26aulast%3Dvan%2BHoek%26aufirst%3DM.%26aulast%3Dde%2BZwart%26aufirst%3DE.%26aulast%3DMittag%26aufirst%3DD.%26aulast%3DDemont%26aufirst%3DD.%26aulast%3DVerkaik%26aufirst%3DS.%26aulast%3DKrantz%26aufirst%3DF.%26aulast%3DPearson%26aufirst%3DP.%2BG.%26aulast%3DUlrich%26aufirst%3DR.%26aulast%3DKaptein%26aufirst%3DA.%26atitle%3DAcalabrutinib%2520%2528ACP-196%2529%253A%2520a%2520covalent%2520Bruton%2520tyrosine%2520kinase%2520inhibitor%2520with%2520a%2520differentiated%2520selectivity%2520and%2520in%2520vivo%2520potency%2520profile%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2017%26volume%3D363%26spage%3D240%26epage%3D252%26doi%3D10.1124%2Fjpet.117.242909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belmont, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanedo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coraggio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katewa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohli, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span> <span> </span><span class="NLM_article-title">Discovery of GDC-0853: A potent, selective, and noncovalent Bruton’s tyrosine kinase inhibitor in early clinical development</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2227</span>– <span class="NLM_lpage">2245</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01712</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01712" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFCnt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2227-2245&author=J.+J.+Crawfordauthor=A.+R.+Johnsonauthor=D.+L.+Misnerauthor=L.+D.+Belmontauthor=G.+Castanedoauthor=R.+Choyauthor=M.+Coraggioauthor=L.+Dongauthor=C.+Eigenbrotauthor=R.+Ericksonauthor=N.+Ghilardiauthor=J.+Hauauthor=A.+Katewaauthor=P.+B.+Kohliauthor=W.+Leeauthor=J.+W.+Lubachauthor=B.+S.+McKenzieauthor=D.+F.+Ortwineauthor=L.+Schuttauthor=S.+Tayauthor=B.+Weiauthor=K.+Reifauthor=L.+Liuauthor=H.+Wongauthor=W.+B.+Young&title=Discovery+of+GDC-0853%3A+A+potent%2C+selective%2C+and+noncovalent+Bruton%E2%80%99s+tyrosine+kinase+inhibitor+in+early+clinical+development&doi=10.1021%2Facs.jmedchem.7b01712"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development</span></div><div class="casAuthors">Crawford, James J.; Johnson, Adam R.; Misner, Dinah L.; Belmont, Lisa D.; Castanedo, Georgette; Choy, Regina; Coraggio, Melis; Dong, Liming; Eigenbrot, Charles; Erickson, Rebecca; Ghilardi, Nico; Hau, Jonathan; Katewa, Arna; Kohli, Pawan Bir; Lee, Wendy; Lubach, Joseph W.; McKenzie, Brent S.; Ortwine, Daniel F.; Schutt, Leah; Tay, Suzanne; Wei, BinQing; Reif, Karin; Liu, Lichuan; Wong, Harvey; Young, Wendy B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2227-2245</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a nonreceptor cytoplasmic tyrosine kinase involved in B-cell and myeloid cell activation, downstream of B-cell and Fcγ receptors, resp.  Preclin. studies have indicated that inhibition of Btk activity might offer a potential therapy in autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus.  Here we disclose the discovery and preclin. characterization of a potent, selective, and noncovalent Btk inhibitor currently in clin. development.  GDC-0853 (29) suppresses B cell- and myeloid cell-mediated components of disease and demonstrates dose-dependent activity in an in vivo rat model of inflammatory arthritis.  It demonstrates highly favorable safety, pharmacokinetic (PK), and pharmacodynamic (PD) profiles in preclin. and Phase 2 studies ongoing in patients with rheumatoid arthritis, lupus, and chronic spontaneous urticaria.  On the basis of its potency, selectivity, long target residence time, and noncovalent mode of inhibition, 29 has the potential to be a best-in-class Btk inhibitor for a wide range of immunol. indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOUJgTOFJ-o7Vg90H21EOLACvtfcHk0lgbZ0S10qZfAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFCnt7c%253D&md5=eddbd31f387fe86827a7469e8be45430</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01712%26sid%3Dliteratum%253Aachs%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DMisner%26aufirst%3DD.%2BL.%26aulast%3DBelmont%26aufirst%3DL.%2BD.%26aulast%3DCastanedo%26aufirst%3DG.%26aulast%3DChoy%26aufirst%3DR.%26aulast%3DCoraggio%26aufirst%3DM.%26aulast%3DDong%26aufirst%3DL.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DErickson%26aufirst%3DR.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DHau%26aufirst%3DJ.%26aulast%3DKatewa%26aufirst%3DA.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DMcKenzie%26aufirst%3DB.%2BS.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DSchutt%26aufirst%3DL.%26aulast%3DTay%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26atitle%3DDiscovery%2520of%2520GDC-0853%253A%2520A%2520potent%252C%2520selective%252C%2520and%2520noncovalent%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitor%2520in%2520early%2520clinical%2520development%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D2227%26epage%3D2245%26doi%3D10.1021%2Facs.jmedchem.7b01712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15a"><span><span class="NLM_label">(a) </span> ClinicalTrials.gov
identifiers: phase II, NCT02638948; phase I, NCT02257151, NCT02880670,
NCT02762123, NCT02456844, NCT02832180..</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+ClinicalTrials.gov%0Aidentifiers%3A+phase+II%2C+NCT02638948%3B+phase+I%2C+NCT02257151%2C+NCT02880670%2C%0ANCT02762123%2C+NCT02456844%2C+NCT02832180.."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catlett, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamczyk, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffies, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murthy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, M.</span></span> <span> </span><span class="NLM_article-title">Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants</span>. <i>Eur. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">689</span>– <span class="NLM_lpage">698</span>, <span class="refDoi"> DOI: 10.1007/s00228-017-2226-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1007%2Fs00228-017-2226-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=28265691" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjvVahs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2017&pages=689-698&author=S.+K.+Leeauthor=J.+Xingauthor=I.+M.+Catlettauthor=R.+Adamczykauthor=A.+Griffiesauthor=A.+Liuauthor=B.+Murthyauthor=M.+Nowak&title=Safety%2C+pharmacokinetics%2C+and+pharmacodynamics+of+BMS-986142%2C+a+novel+reversible+BTK+inhibitor%2C+in+healthy+participants&doi=10.1007%2Fs00228-017-2226-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15bR"><div class="casContent"><span class="casTitleNuber">15b</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants</span></div><div class="casAuthors">Lee, Sun Ku; Xing, Jun; Catlett, Ian M.; Adamczyk, Robert; Griffies, Amber; Liu, Ang; Murthy, Bindu; Nowak, Miroslawa</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">689-698</span>CODEN:
                <span class="NLM_cas:coden">EJCPAS</span>;
        ISSN:<span class="NLM_cas:issn">0031-6970</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">BMS-986142 is an oral, small-mol. reversible inhibitor of Bruton's tyrosine kinase.  The main objectives of our phase I studies were to characterize the safety and tolerability, pharmacokinetics, and pharmacodynamics of BMS-986142 in healthy participants, and to investigate the potential for the effect of BMS-986142 on the PK of methotrexate (MTX) in combination.  In a combined single ascending dose and multiple ascending dose study, the safety, pharmacokinetics, and pharmacodynamics of BMS-986142 were assessed in healthy non-Japanese participants following administration of a single dose (5-900 mg) or multiple doses (25-350 mg, once daily for 14 days).  In a drug-drug interaction study, the effect of BMS-986142 (350 mg, once daily for 5 days) on the single-dose pharmacokinetics of MTX (7.5 mg) was assessed in healthy participants.  Results: BMS-986142 was generally well tolerated, alone and in combination with MTX.  BMS-986142 was rapidly absorbed with peak concns. occurring within 2 h, and was eliminated with a mean half-life ranging from 7 to 11 h.  Exposure of BMS-986142 appeared dose proportional within the dose ranges tested.  A dose- and concn.-dependent inhibition of CD69 expression was obsd. following administration of BMS-986142.  BMS-986142 did not affect the pharmacokinetics of MTX.  BMS-986142 was well tolerated at the doses tested, had pharmacokinetic and pharmacodynamic profiles which support once-daily dosing, and can be coadministered with MTX without the pharmacokinetic interaction of BMS-986142 on MTX.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkY5ZXpICJWrVg90H21EOLACvtfcHk0lgbZ0S10qZfAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjvVahs70%253D&md5=d1435ec2479d5a50d0a5b863cc98d803</span></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=10.1007%2Fs00228-017-2226-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00228-017-2226-2%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%2BK.%26aulast%3DXing%26aufirst%3DJ.%26aulast%3DCatlett%26aufirst%3DI.%2BM.%26aulast%3DAdamczyk%26aufirst%3DR.%26aulast%3DGriffies%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DA.%26aulast%3DMurthy%26aufirst%3DB.%26aulast%3DNowak%26aufirst%3DM.%26atitle%3DSafety%252C%2520pharmacokinetics%252C%2520and%2520pharmacodynamics%2520of%2520BMS-986142%252C%2520a%2520novel%2520reversible%2520BTK%2520inhibitor%252C%2520in%2520healthy%2520participants%26jtitle%3DEur.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2017%26volume%3D73%26spage%3D689%26epage%3D698%26doi%3D10.1007%2Fs00228-017-2226-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit15c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulicicchio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattoli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukral, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudhgaonkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span> <span> </span><span class="NLM_article-title">Bruton’s Tyrosine Kinase Inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">e0181782</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0181782</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1371%2Fjournal.pone.0181782" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=28742141" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVSntbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=e0181782&author=K.+M.+Gilloolyauthor=C.+Pulicicchioauthor=M.+A.+Pattoliauthor=L.+Chengauthor=S.+Skalaauthor=E.+M.+Heimrichauthor=K.+W.+McIntyreauthor=T.+L.+Taylorauthor=D.+W.+Kukralauthor=S.+Dudhgaonkarauthor=J.+Nagarauthor=D.+Banasauthor=S.+H.+Wattersonauthor=J.+A.+Tinoauthor=A.+Furaauthor=J.+R.+Burke&title=Bruton%E2%80%99s+Tyrosine+Kinase+Inhibitor+BMS-986142+in+experimental+models+of+rheumatoid+arthritis+enhances+efficacy+of+agents+representing+clinical+standard-of-care&doi=10.1371%2Fjournal.pone.0181782"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15cR"><div class="casContent"><span class="casTitleNuber">15c</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care</span></div><div class="casAuthors">Gillooly, Kathleen M.; Pulicicchio, Claudine; Pattoli, Mark A.; Cheng, Lihong; Skala, Stacey; Heimrich, Elizabeth M.; McIntyre, Kim W.; Taylor, Tracy L.; Kukral, Daniel W.; Dudhgaonkar, Shailesh; Nagar, Jignesh; Banas, Dana; Watterson, Scott H.; Tino, Joseph A.; Fura, Aberra; Burke, James R.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e0181782/1-e0181782/20</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) regulates crit. signal transduction pathways involved in the pathobiol. of rheumatoid arthritis (RA) and other autoimmune disorders.  BMS-986142 is a potent and highly selective reversible small mol. inhibitor of BTK currently being investigated in clin. trials for the treatment of both RA and primary Sj.ovrddot.ogren's syndrome.  In the present report, we detail the in vitro and in vivo pharmacol. of BMS-986142 and show this agent provides potent and selective inhibition of BTK (IC50 = 0.5 nM), blocks antigen receptor-dependent signaling and functional endpoints (cytokine prodn., co-stimulatory mol. expression, and proliferation) in human B cells (IC50 ≤ 5 nM), inhibits Fcγ receptor-dependent cytokine prodn. from peripheral blood mononuclear cells, and blocks RANK-L-induced osteoclastogenesis.  Through the benefits of impacting these important drivers of autoimmunity, BMS-986142 demonstrated robust efficacy in murine models of rheumatoid arthritis (RA), including collagen-induced arthritis (CIA) and collagen antibody-induced arthritis (CAIA).  In both models, robust efficacy was obsd. without continuous, complete inhibition of BTK.  When a suboptimal dose of BMS-986142 was combined with other agents representing the current std. of care for RA (e.g., methotrexate, the TNFα antagonist etanercept, or the murine form of CTLA4-Ig) in the CIA model, improved efficacy compared to either agent alone was obsd.  The results suggest BMS-986142 represents a potential therapeutic for clin. investigation in RA, as monotherapy or co-administered with agents with complementary mechanisms of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg22LhZ5lc9rVg90H21EOLACvtfcHk0li05QrlKrsPIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVSntbs%253D&md5=144039a2425c898869da3d9c263d7321</span></div><a href="/servlet/linkout?suffix=cit15c&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0181782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0181782%26sid%3Dliteratum%253Aachs%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DPulicicchio%26aufirst%3DC.%26aulast%3DPattoli%26aufirst%3DM.%2BA.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DHeimrich%26aufirst%3DE.%2BM.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DKukral%26aufirst%3DD.%2BW.%26aulast%3DDudhgaonkar%26aufirst%3DS.%26aulast%3DNagar%26aufirst%3DJ.%26aulast%3DBanas%26aufirst%3DD.%26aulast%3DWatterson%26aufirst%3DS.%2BH.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26atitle%3DBruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Inhibitor%2520BMS-986142%2520in%2520experimental%2520models%2520of%2520rheumatoid%2520arthritis%2520enhances%2520efficacy%2520of%2520agents%2520representing%2520clinical%2520standard-of-care%26jtitle%3DPLoS%2520One%26date%3D2017%26volume%3D12%26spage%3De0181782%26doi%3D10.1371%2Fjournal.pone.0181782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit15d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lucca, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langevine, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudoin
Bertrand, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traeger, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattoli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickery, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulicchio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampulla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of 6-fluoro-5-(<i>R</i>)-(3-(<i>S</i>)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-2-(<i>S</i>)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide (BMS-986142): A reversible inhibitor of bruton’s tyrosine kinase conformationally constrained by two locked atropisomers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9173</span>– <span class="NLM_lpage">9200</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01088</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01088" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9173-9200&author=S.+H.+Wattersonauthor=G.+V.+De+Luccaauthor=Q.+Shiauthor=C.+M.+Langevineauthor=Q.+Liuauthor=D.+G.+Battauthor=M.+Beaudoin%0ABertrandauthor=H.+Gongauthor=J.+Daiauthor=S.+Yipauthor=P.+Liauthor=D.+Sunauthor=D.-R.+Wuauthor=C.+Wangauthor=Y.+Zhangauthor=S.+C.+Traegerauthor=M.+A.+Pattoliauthor=S.+Skalaauthor=L.+Chengauthor=M.+T.+Obermeierauthor=R.+Vickeryauthor=L.+Discenzaauthor=C.+D%E2%80%99Arienzoauthor=Y.+Zhangauthor=E.+Heimrichauthor=K.+Gilloolyauthor=T.+L.+Taylorauthor=C.+Pulicchioauthor=K.+W.+McIntyreauthor=A.+J.+Tebbenauthor=J.+K.+Muckelbauerauthor=C.+Y.+Changauthor=R.+Rampullaauthor=A.+Mathurauthor=L.+Salter-Cidauthor=J.+C.+Barrishauthor=P.+H.+Carterauthor=A.+Furaauthor=J.+R.+Burkeauthor=J.+A.+Tino&title=Discovery+of+6-fluoro-5-%28R%29-%283-%28S%29-%288-fluoro-1-methyl-2%2C4-dioxo-1%2C2-dihydroquinazolin-3%284H%29-yl%29-2-methylphenyl%29-2-%28S%29-%282-hydroxypropan-2-yl%29-2%2C3%2C4%2C9-tetrahydro-1H-carbazole-8-carboxamide+%28BMS-986142%29%3A+A+reversible+inhibitor+of+bruton%E2%80%99s+tyrosine+kinase+conformationally+constrained+by+two+locked+atropisomers&doi=10.1021%2Facs.jmedchem.6b01088"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15d&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01088%26sid%3Dliteratum%253Aachs%26aulast%3DWatterson%26aufirst%3DS.%2BH.%26aulast%3DDe%2BLucca%26aufirst%3DG.%2BV.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DLangevine%26aufirst%3DC.%2BM.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DBeaudoin%2BBertrand%26aufirst%3DM.%26aulast%3DGong%26aufirst%3DH.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DYip%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DD.-R.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DTraeger%26aufirst%3DS.%2BC.%26aulast%3DPattoli%26aufirst%3DM.%2BA.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DObermeier%26aufirst%3DM.%2BT.%26aulast%3DVickery%26aufirst%3DR.%26aulast%3DDiscenza%26aufirst%3DL.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHeimrich%26aufirst%3DE.%26aulast%3DGillooly%26aufirst%3DK.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DPulicchio%26aufirst%3DC.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DRampulla%26aufirst%3DR.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%25206-fluoro-5-%2528R%2529-%25283-%2528S%2529-%25288-fluoro-1-methyl-2%252C4-dioxo-1%252C2-dihydroquinazolin-3%25284H%2529-yl%2529-2-methylphenyl%2529-2-%2528S%2529-%25282-hydroxypropan-2-yl%2529-2%252C3%252C4%252C9-tetrahydro-1H-carbazole-8-carboxamide%2520%2528BMS-986142%2529%253A%2520A%2520reversible%2520inhibitor%2520of%2520bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520conformationally%2520constrained%2520by%2520two%2520locked%2520atropisomers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9173%26epage%3D9200%26doi%3D10.1021%2Facs.jmedchem.6b01088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lonsdale, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. S.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of targeted covalent inhibitors</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">3816</span>– <span class="NLM_lpage">3830</span>, <span class="refDoi"> DOI: 10.1039/C7CS00220C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1039%2FC7CS00220C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=29620097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVGiurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2018&pages=3816-3830&author=R.+Lonsdaleauthor=R.+S.+Ward&title=Structure-based+design+of+targeted+covalent+inhibitors&doi=10.1039%2FC7CS00220C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16aR"><div class="casContent"><span class="casTitleNuber">16a</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design of targeted covalent inhibitors</span></div><div class="casAuthors">Lonsdale, Richard; Ward, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3816-3830</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Covalent inhibition is a rapidly growing discipline within drug discovery.  Many historical covalent inhibitors were discovered by serendipity, with such a mechanism of action often regarded as undesirable due to potential toxicity issues.  Recent progress has seen a major shift in this outlook, as covalent inhibition shows promise for targets where previous efforts to identify non-covalent small mol. inhibitors have failed.  Targeted covalent inhibitors (TCIs) can offer drug discovery scientists the ability to increase the potency and/or selectivity of small mol. inhibitors, by attachment of reactive functional groups designed to covalently bind to specific sites in a target.  In this tutorial review we introduce the broader concept of covalent inhibition, discuss the potential benefits and challenges of such an approach, and provide an overview of the current status of the field.  We also describe some strategies and computational tools to enable successful covalent drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnSIGMuS3vm7Vg90H21EOLACvtfcHk0li05QrlKrsPIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVGiurs%253D&md5=a7e31b23cf8ecfcad1397ad10ea10b7b</span></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1039%2FC7CS00220C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7CS00220C%26sid%3Dliteratum%253Aachs%26aulast%3DLonsdale%26aufirst%3DR.%26aulast%3DWard%26aufirst%3DR.%2BS.%26atitle%3DStructure-based%2520design%2520of%2520targeted%2520covalent%2520inhibitors%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2018%26volume%3D47%26spage%3D3816%26epage%3D3830%26doi%3D10.1039%2FC7CS00220C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit16b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Bello, C.</span></span> <span> </span><span class="NLM_article-title">Designing irreversible inhibitors—Worth the effort?</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">22</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500469</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1002%2Fcmdc.201500469" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=26593241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVyhtLnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=22-30&author=C.+Gonzalez-Bello&title=Designing+irreversible+inhibitors%E2%80%94Worth+the+effort%3F&doi=10.1002%2Fcmdc.201500469"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16b</span><div class="casTitle"><span class="NLM_cas:atitle">Designing Irreversible Inhibitors-Worth the Effort?</span></div><div class="casAuthors">Gonzalez-Bello, Concepcion</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">22-30</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Despite the unquestionable success of numerous irreversible drugs that are currently in clin. use, such as acetylsalicylic acid (Aspirin) and penicillin, the no. of such approved drugs is much lower than that of noncovalent drugs.  Over the years, the potential off-target effects of these types of compds. have been the primary concern that has hampered their development.  However, their remarkable advantages over noncovalent drugs and a better anal. of the risks have decreased the widespread skepticism surrounding them.  The design of irreversible inhibitors is a challenge, particularly considering that in some cases their efficacy is due to complex and unexpected mechanisms of action.  In this review the main advantages of irreversible inhibition are summarized, and the complexity of certain covalent modification mechanisms is highlighted with selected examples.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpER985BdGxe7Vg90H21EOLACvtfcHk0lh9B3dxtd2VWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVyhtLnK&md5=a4686a10be608f23a1131023ff1594ad</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500469%26sid%3Dliteratum%253Aachs%26aulast%3DGonzalez-Bello%26aufirst%3DC.%26atitle%3DDesigning%2520irreversible%2520inhibitors%25E2%2580%2594Worth%2520the%2520effort%253F%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D22%26epage%3D30%26doi%3D10.1002%2Fcmdc.201500469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D.
S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weerapana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">Strategies for discovering and derisking covalent, irreversible enzyme inhibitors</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">949</span>– <span class="NLM_lpage">964</span>, <span class="refDoi"> DOI: 10.4155/fmc.10.21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.4155%2Ffmc.10.21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=20640225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsFakur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=949-964&author=D.%0AS.+Johnsonauthor=E.+Weerapanaauthor=B.+F.+Cravatt&title=Strategies+for+discovering+and+derisking+covalent%2C+irreversible+enzyme+inhibitors&doi=10.4155%2Ffmc.10.21"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies for discovering and derisking covalent, irreversible enzyme inhibitors</span></div><div class="casAuthors">Johnson, Douglas S.; Weerapana, Eranthie; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">949-964</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  This article presents several covalent inhibitors, including examples of successful drugs, as well as highly selective, irreversible inhibitors of emerging therapeutic targets, such as fatty acid amide hydolase.  Covalent inhibitors have many desirable features, including increased biochem. efficiency of target disruption, less sensitivity toward pharmacokinetic parameters and increased duration of action that outlasts the pharmacokinetics of the compd.  Safety concerns that must be mitigated include lack of specificity and the potential immunogenicity of protein-inhibitor adduct(s).  Particular attention will be given to recent technologies, such as activity-based protein profiling, which allow one to define the proteome-wide selectivity patterns for covalent inhibitors in vitro and in vivo.  For instance, any covalent inhibitor can, in principle, be modified with a 'clickable' tag to generate an activity probe that is almost indistinguishable from the original agent.  These probes can be applied to any living system across a broad dose range to fully inventory their on and off targets.  The substantial no. of drugs on the market today that act by a covalent mechanism belies historical prejudices against the development of irreversibly acting therapeutic small mols.  Emerging proteomic technologies offer a means to systematically discriminate safe (selective) vs. deleterious (nonselective) covalent inhibitors and thus should inspire their future design and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqm0whEybB-LVg90H21EOLACvtfcHk0lh9B3dxtd2VWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsFakur4%253D&md5=07e1f89418b168798ae5c1a9fa43e9c1</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.4155%2Ffmc.10.21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.10.21%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DD.%2BS.%26aulast%3DWeerapana%26aufirst%3DE.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DStrategies%2520for%2520discovering%2520and%2520derisking%2520covalent%252C%2520irreversible%2520enzyme%2520inhibitors%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2010%26volume%3D2%26spage%3D949%26epage%3D964%26doi%3D10.4155%2Ffmc.10.21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit17b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Uetrecht, J.
P.</span></span> <span> </span><span class="NLM_article-title">New concepts in immunology relevant to idiosyncratic drug reactions: The “danger hypothesis” and innate immue system</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">395</span>, <span class="refDoi"> DOI: 10.1021/tx980249i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx980249i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1999&pages=387-395&author=J.%0AP.+Uetrecht&title=New+concepts+in+immunology+relevant+to+idiosyncratic+drug+reactions%3A+The+%E2%80%9Cdanger+hypothesis%E2%80%9D+and+innate+immue+system&doi=10.1021%2Ftx980249i"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1021%2Ftx980249i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx980249i%26sid%3Dliteratum%253Aachs%26aulast%3DUetrecht%26aufirst%3DJ.%2BP.%26atitle%3DNew%2520concepts%2520in%2520immunology%2520relevant%2520to%2520idiosyncratic%2520drug%2520reactions%253A%2520The%2520%25E2%2580%259Cdanger%2520hypothesis%25E2%2580%259D%2520and%2520innate%2520immue%2520system%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D1999%26volume%3D12%26spage%3D387%26epage%3D395%26doi%3D10.1021%2Ftx980249i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit17c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atsumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takakusa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurihara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okazaki, O.</span></span> <span> </span><span class="NLM_article-title">A zone classification system for risk assessemnt of idiosyncratic drug toxicity using daily dose and covalent binding</span>. <i>Drug Met. Distrib.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1970</span>– <span class="NLM_lpage">1977</span>, <span class="refDoi"> DOI: 10.1124/dmd.109.027797</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1124%2Fdmd.109.027797" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=19487250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVOrsrfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=1970-1977&author=S.+Nakayamaauthor=R.+Atsumiauthor=H.+Takakusaauthor=Y.+Kobayashiauthor=A.+Kuriharaauthor=Y.+Nagaiauthor=D.+Nakaiauthor=O.+Okazaki&title=A+zone+classification+system+for+risk+assessemnt+of+idiosyncratic+drug+toxicity+using+daily+dose+and+covalent+binding&doi=10.1124%2Fdmd.109.027797"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17cR"><div class="casContent"><span class="casTitleNuber">17c</span><div class="casTitle"><span class="NLM_cas:atitle">A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding</span></div><div class="casAuthors">Nakayama, Shintaro; Atsumi, Ryo; Takakusa, Hideo; Kobayashi, Yoshimasa; Kurihara, Atsushi; Nagai, Yoko; Nakai, Daisuke; Okazaki, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1970-1977</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The risk of idiosyncratic drug toxicity (IDT) is of great concern to the pharmaceutical industry.  Current hypotheses based on retrospective studies suggest that the occurrence of IDT is related to covalent binding and daily dose.  The authors detd. the covalent binding of 42 radiolabeled drugs in three test systems (human liver microsomes and hepatocytes in vitro and rat liver in vivo) to assess the risk of IDT.  On the basis of safety profiles given in official documentation, tested drugs were classified into the safety categories of safe, warning, black box warning, and withdrawn.  The covalent binding in each of the three test systems did not distinguish the safety categories clearly.  However, when the log-normalized covalent binding was plotted against the log-normalized daily dose, the distribution of the plot in the safety categories became clear.  An ordinal logistic regression anal. indicated that both covalent binding and daily dose were significantly correlated with safety category and that covalent binding in hepatocytes was the best predictor among the three systems.  When two sepn. lines were drawn on the correlation graph between covalent binding in human hepatocytes and daily dose by a regression anal. to create three zones, 30 of 37 tested drugs were located in zones corresponding to their resp. classified safety categories.  In conclusion, the authors established a zone classification system using covalent binding in human hepatocytes and daily dose for the risk assessment of IDTs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtahZPkNJ3JbVg90H21EOLACvtfcHk0lh9B3dxtd2VWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVOrsrfO&md5=425119e0451fc50ec6ca95d5e3fe5fd3</span></div><a href="/servlet/linkout?suffix=cit17c&amp;dbid=16384&amp;doi=10.1124%2Fdmd.109.027797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.109.027797%26sid%3Dliteratum%253Aachs%26aulast%3DNakayama%26aufirst%3DS.%26aulast%3DAtsumi%26aufirst%3DR.%26aulast%3DTakakusa%26aufirst%3DH.%26aulast%3DKobayashi%26aufirst%3DY.%26aulast%3DKurihara%26aufirst%3DA.%26aulast%3DNagai%26aufirst%3DY.%26aulast%3DNakai%26aufirst%3DD.%26aulast%3DOkazaki%26aufirst%3DO.%26atitle%3DA%2520zone%2520classification%2520system%2520for%2520risk%2520assessemnt%2520of%2520idiosyncratic%2520drug%2520toxicity%2520using%2520daily%2520dose%2520and%2520covalent%2520binding%26jtitle%3DDrug%2520Met.%2520Distrib.%26date%3D2009%26volume%3D37%26spage%3D1970%26epage%3D1977%26doi%3D10.1124%2Fdmd.109.027797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyckman, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spergel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olini, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strnad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surti, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leftheris, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lucca, G. V.</span></span> <span> </span><span class="NLM_article-title">Purine derivatives as potent Bruton’s tyrosine kinase (BTK) inhibitors for autoimmune diseases</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">2206</span>– <span class="NLM_lpage">2211</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.02.075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1016%2Fj.bmcl.2014.02.075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=24685542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFOgsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=2206-2211&author=Q.+Shiauthor=A.+Tebbenauthor=A.+J.+Dyckmanauthor=H.+Liauthor=C.+Liuauthor=J.+Linauthor=S.+Spergelauthor=J.+R.+Burkeauthor=K.+W.+McIntyreauthor=G.+C.+Oliniauthor=J.+Strnadauthor=N.+Surtiauthor=J.+K.+Muckelbauerauthor=C.+Changauthor=Y.+Anauthor=L.+Chengauthor=Q.+Ruanauthor=K.+Leftherisauthor=P.+H.+Carterauthor=J.+A.+Tinoauthor=G.+V.+De+Lucca&title=Purine+derivatives+as+potent+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+inhibitors+for+autoimmune+diseases&doi=10.1016%2Fj.bmcl.2014.02.075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases</span></div><div class="casAuthors">Shi, Qing; Tebben, Andrew; Dyckman, Alaric J.; Li, Hedy; Liu, Chunjian; Lin, James; Spergel, Steve; Burke, James R.; McIntyre, Kim W.; Olini, Gilbert C.; Strnad, Joann; Surti, Neha; Muckelbauer, Jodi K.; Chang, Chiehying; An, Yongmi; Cheng, Lin; Ruan, Qian; Leftheris, Katerina; Carter, Percy H.; Tino, Joseph; De Lucca, George V.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2206-2211</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Investigation of various heterocyclic core isosteres of imidazopyrazines 1 & 2 yielded purine derivs. 3 & 8 as potent and selective BTK inhibitors.  Subsequent SAR studies of the purine series led to the discovery of 20 as a leading compd.  Compd. 20 is very selective when screened against a panel of 400 kinases and is a potent inhibitor in cellular assays of human B cell function including B-Cell proliferation and CD86 cell surface expression and exhibited in vivo efficacy in a mouse PCA model.  Its X-ray co-crystal structure with BTK shows that the high selectivity is gained from filling a BTK specific lipophilic pocket.  However, phys. and ADME properties leading to low oral exposure hindered further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobsHsC5Hi6lbVg90H21EOLACvtfcHk0lj2ouBR1lwCFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFOgsL8%253D&md5=1b1649221d615d9805d5cc197a39e05a</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.02.075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.02.075%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DTebben%26aufirst%3DA.%26aulast%3DDyckman%26aufirst%3DA.%2BJ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DSpergel%26aufirst%3DS.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DOlini%26aufirst%3DG.%2BC.%26aulast%3DStrnad%26aufirst%3DJ.%26aulast%3DSurti%26aufirst%3DN.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DAn%26aufirst%3DY.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DRuan%26aufirst%3DQ.%26aulast%3DLeftheris%26aufirst%3DK.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26aulast%3DDe%2BLucca%26aufirst%3DG.%2BV.%26atitle%3DPurine%2520derivatives%2520as%2520potent%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520inhibitors%2520for%2520autoimmune%2520diseases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D2206%26epage%3D2211%26doi%3D10.1016%2Fj.bmcl.2014.02.075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippy, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surti, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pokross, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton’s tyrosine kinase (BTK) and Janus kinase 2 (JAK2)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">4265</span>– <span class="NLM_lpage">4269</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.07.102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1016%2Fj.bmcl.2015.07.102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=26320619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlSlsLvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=4265-4269&author=Q.+Liuauthor=D.+G.+Battauthor=J.+S.+Lippyauthor=N.+Surtiauthor=A.+J.+Tebbenauthor=J.+K.+Muckelbauerauthor=L.+Chenauthor=Y.+Anauthor=C.+Changauthor=M.+Pokrossauthor=Z.+Yangauthor=H.+Wangauthor=J.+R.+Burkeauthor=P.+H.+Carterauthor=J.+A.+Tino&title=Design+and+synthesis+of+carbazole+carboxamides+as+promising+inhibitors+of+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+and+Janus+kinase+2+%28JAK2%29&doi=10.1016%2Fj.bmcl.2015.07.102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19aR"><div class="casContent"><span class="casTitleNuber">19a</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton's tyrosine kinase (BTK) and Janus kinase 2 (JAK2)</span></div><div class="casAuthors">Liu, Qingjie; Batt, Douglas G.; Lippy, Jonathan S.; Surti, Neha; Tebben, Andrew J.; Muckelbauer, Jodi K.; Chen, Lin; An, Yongmi; Chang, Chiehying; Pokross, Matt; Yang, Zheng; Wang, Haiqing; Burke, James R.; Carter, Percy H.; Tino, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4265-4269</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Four series of disubstituted carbazole-1-carboxamides, e.g. I [R = 2-F, 3-MeO, 2-Me, etc.] were designed and synthesized as inhibitors of Bruton's tyrosine kinase.  4,7- And 4,6-Disubstituted carbazole-1-carboxamides were potent and selective inhibitors of BTK, while 3,7- and 3,6-disubstituted carbazole-1-carboxamides were potent and selective inhibitors of Janus kinase 2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD3SZfBfD4ZbVg90H21EOLACvtfcHk0lj2ouBR1lwCFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlSlsLvF&md5=3558c8ca9a9c29bb38ef98936f61200a</span></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.07.102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.07.102%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DLippy%26aufirst%3DJ.%2BS.%26aulast%3DSurti%26aufirst%3DN.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DAn%26aufirst%3DY.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DPokross%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520carbazole%2520carboxamides%2520as%2520promising%2520inhibitors%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520and%2520Janus%2520kinase%25202%2520%2528JAK2%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D4265%26epage%3D4269%26doi%3D10.1016%2Fj.bmcl.2015.07.102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit19b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">De Lucca, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudoin Bertrand, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampulla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickery, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marathe, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattoli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukral, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Small molecule reversible inhibitors of Bruton’s tyrosine kinase (BTK): Structure-activity relationships leading to the identification of 7-(2-hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7915</span>– <span class="NLM_lpage">7935</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00722</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00722" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlCrsL3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7915-7935&author=G.+B.+De+Luccaauthor=Q.+Shiauthor=Q.+Liuauthor=D.+G.+Battauthor=M.+Beaudoin+Bertrandauthor=R.+Rampullaauthor=A.+Mathurauthor=L.+Discenzaauthor=C.+D%E2%80%99Arienzoauthor=J.+Daiauthor=M.+T.+Obermeierauthor=R.+Vickeryauthor=Y.+Zhangauthor=Z.+Yangauthor=P.+H.+Maratheauthor=A.+J.+Tebbenauthor=J.+K.+Muckelbauerauthor=C.+Y.+Changauthor=H.+Zhangauthor=K.+Gilloolyauthor=T.+L.+Taylorauthor=M.+A.+Pattoliauthor=S.+Skalaauthor=D.+W.+Kukralauthor=K.+W.+McIntyreauthor=L.+Salter-Cidauthor=A.+Furaauthor=J.+R.+Burkeauthor=J.+C.+Barrishauthor=P.+H.+Carterauthor=J.+A.+Tino&title=Small+molecule+reversible+inhibitors+of+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29%3A+Structure-activity+relationships+leading+to+the+identification+of+7-%282-hydroxypropan-2-yl%29-4-%5B2-methyl-3-%284-oxo-3%2C4-dihydroquinazolin-3-yl%29phenyl%5D-9H-carbazole-1-carboxamide+%28BMS-935177%29&doi=10.1021%2Facs.jmedchem.6b00722"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19bR"><div class="casContent"><span class="casTitleNuber">19b</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Reversible Inhibitors of Bruton's Tyrosine Kinase (BTK): Structure-Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177)</span></div><div class="casAuthors">De Lucca, George V.; Shi, Qing; Liu, Qingjie; Batt, Douglas G.; Beaudoin Bertrand, Myra; Rampulla, Rick; Mathur, Arvind; Discenza, Lorell; D'Arienzo, Celia; Dai, Jun; Obermeier, Mary; Vickery, Rodney; Zhang, Yingru; Yang, Zheng; Marathe, Punit; Tebben, Andrew J.; Muckelbauer, Jodi K.; Chang, ChiehYing J.; Zhang, Huiping; Gillooly, Kathleen; Taylor, Tracy; Pattoli, Mark A.; Skala, Stacey; Kukral, Daniel W.; McIntyre, Kim W.; Salter-Cid, Luisa; Fura, Aberra; Burke, James R.; Barrish, Joel C.; Carter, Percy H.; Tino, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7915-7935</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) belongs to the TEC family of nonreceptor tyrosine kinases and plays a crit. role in multiple cell types responsible for numerous autoimmune diseases.  This article will detail the structure-activity relationships (SARs) leading to a novel second generation series of potent and selective reversible carbazole inhibitors of BTK.  With an excellent pharmacokinetic profile as well as demonstrated in vivo activity and an acceptable safety profile, 7-(2-hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide 6 (BMS-935177) was selected to advance into clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1HUwZaRn_w7Vg90H21EOLACvtfcHk0lhrGDHpGFn17A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlCrsL3M&md5=7c7ec1a52121c541753c045c1cbf758b</span></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00722%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BLucca%26aufirst%3DG.%2BB.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DBeaudoin%2BBertrand%26aufirst%3DM.%26aulast%3DRampulla%26aufirst%3DR.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DDiscenza%26aufirst%3DL.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DObermeier%26aufirst%3DM.%2BT.%26aulast%3DVickery%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DMarathe%26aufirst%3DP.%2BH.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DGillooly%26aufirst%3DK.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DPattoli%26aufirst%3DM.%2BA.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DKukral%26aufirst%3DD.%2BW.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DSmall%2520molecule%2520reversible%2520inhibitors%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%253A%2520Structure-activity%2520relationships%2520leading%2520to%2520the%2520identification%2520of%25207-%25282-hydroxypropan-2-yl%2529-4-%255B2-methyl-3-%25284-oxo-3%252C4-dihydroquinazolin-3-yl%2529phenyl%255D-9H-carbazole-1-carboxamide%2520%2528BMS-935177%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7915%26epage%3D7935%26doi%3D10.1021%2Facs.jmedchem.6b00722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span>; <span class="NLM_string-name">Bertrand, M. B.</span>; <span class="NLM_string-name">Delucca, G. V.</span>; <span class="NLM_string-name">Galella, M. A.</span>; <span class="NLM_string-name">Ko, S. S.</span>; <span class="NLM_string-name">Langevine, C. M.</span>; <span class="NLM_string-name">Liu, Q.</span>; <span class="NLM_string-name">Shi, Q.</span>; <span class="NLM_string-name">Srivastava, A. S.</span>; <span class="NLM_string-name">Tino, J. A.</span>; <span class="NLM_string-name">Watterson, S. H.</span></span> <span> </span><span class="NLM_article-title">Substituted Carbazolecarboxamide Derivatives as BTK Inhibitors and Their Preparation and Use for the Treatment of Diseases</span>. <span class="NLM_patent">WO 2014210085</span>, <span class="NLM_year">2014</span>;</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=D.+G.+Batt&author=M.+B.+Bertrand&author=G.+V.+Delucca&author=M.+A.+Galella&author=S.+S.+Ko&author=C.+M.+Langevine&author=Q.+Liu&author=Q.+Shi&author=A.+S.+Srivastava&author=J.+A.+Tino&author=S.+H.+Watterson&title=Substituted+Carbazolecarboxamide+Derivatives+as+BTK+Inhibitors+and+Their+Preparation+and+Use+for+the+Treatment+of+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBatt%26aufirst%3DD.%2BG.%26atitle%3DSubstituted%2520Carbazolecarboxamide%2520Derivatives%2520as%2520BTK%2520Inhibitors%2520and%2520Their%2520Preparation%2520and%2520Use%2520for%2520the%2520Treatment%2520of%2520Diseases%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit20a.1"><span> <i>Chem. Abstr.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume">162</span>,  <span class="NLM_fpage">161072</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Chem.+Abstr.+2014%2C+162%2C+161072."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20a.1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26jtitle%3DChem.%2520Abstr.%26date%3D2014%26volume%3D162%26spage%3D161072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit20b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Ko, S. S.</span>; <span class="NLM_string-name">Batt, D. A.</span>; <span class="NLM_string-name">Bertrand, M. B.</span>; <span class="NLM_string-name">Delucca, G. V.</span>; <span class="NLM_string-name">Langevine, C. M.</span>; <span class="NLM_string-name">Liu, Q.</span>; <span class="NLM_string-name">Srivastava, A. S.</span>; <span class="NLM_string-name">Watterson, S. H.</span></span> <span> </span><span class="NLM_article-title">Preparation of 4-Phenylcarbazole-1-carboxamide Compounds Useful as Bruton’s Tyrosine Kinase (BTK) Inhibitors</span>. <span class="NLM_patent">WO 2014210087</span>, <span class="NLM_year">2014</span>;</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=S.+S.+Ko&author=D.+A.+Batt&author=M.+B.+Bertrand&author=G.+V.+Delucca&author=C.+M.+Langevine&author=Q.+Liu&author=A.+S.+Srivastava&author=S.+H.+Watterson&title=Preparation+of+4-Phenylcarbazole-1-carboxamide+Compounds+Useful+as+Bruton%E2%80%99s+Tyrosine+Kinase+%28BTK%29+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKo%26aufirst%3DS.%2BS.%26atitle%3DPreparation%2520of%25204-Phenylcarbazole-1-carboxamide%2520Compounds%2520Useful%2520as%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520%2528BTK%2529%2520Inhibitors%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit20b.2"><span> <i>Chem. Abstr.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume">162</span>,  <span class="NLM_fpage">150740</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Chem.+Abstr.+2014%2C+162%2C+150740."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20b.2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26jtitle%3DChem.%2520Abstr.%26date%3D2014%26volume%3D162%26spage%3D150740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippy, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattoli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surti, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Conversion of carbazole carboxamide based reversible inhibitors of Bruton’s tyrosine kinase (BTK) into potent, selective irreversible inhibitors in the carbazole, tetrahydrocarbazole, and a new 2,3-dimethylindole series</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">3080</span>– <span class="NLM_lpage">3084</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.07.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=10.1016%2Fj.bmcl.2018.07.041" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=3080-3084&author=Q.+Liuauthor=D.+G.+Battauthor=C.+Chaudhryauthor=J.+S.+Lippyauthor=M.+A.+Pattoliauthor=N.+Surtiauthor=S.+Xuauthor=P.+H.+Carterauthor=J.+R.+Burkeauthor=J.+A.+Tino&title=Conversion+of+carbazole+carboxamide+based+reversible+inhibitors+of+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+into+potent%2C+selective+irreversible+inhibitors+in+the+carbazole%2C+tetrahydrocarbazole%2C+and+a+new+2%2C3-dimethylindole+series&doi=10.1016%2Fj.bmcl.2018.07.041"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.07.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.07.041%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DChaudhry%26aufirst%3DC.%26aulast%3DLippy%26aufirst%3DJ.%2BS.%26aulast%3DPattoli%26aufirst%3DM.%2BA.%26aulast%3DSurti%26aufirst%3DN.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DConversion%2520of%2520carbazole%2520carboxamide%2520based%2520reversible%2520inhibitors%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520into%2520potent%252C%2520selective%2520irreversible%2520inhibitors%2520in%2520the%2520carbazole%252C%2520tetrahydrocarbazole%252C%2520and%2520a%2520new%25202%252C3-dimethylindole%2520series%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D3080%26epage%3D3084%26doi%3D10.1016%2Fj.bmcl.2018.07.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, S.</span>; <span class="NLM_string-name">Batt, D.
G.</span>; <span class="NLM_string-name">Liu, Q.</span>; <span class="NLM_string-name">Macor, J. E.</span>; <span class="NLM_string-name">Tino, J. A.</span>; <span class="NLM_string-name">Watterson, S. H.</span></span> <span> </span><span class="NLM_article-title">Carbazole Inhibitors</span>. <span class="NLM_patent">WO 2016065236</span>, <span class="NLM_year">2016</span>;</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=S.+Ahmad&author=D.%0AG.+Batt&author=Q.+Liu&author=J.+E.+Macor&author=J.+A.+Tino&author=S.+H.+Watterson&title=Carbazole+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAhmad%26aufirst%3DS.%26atitle%3DCarbazole%2520Inhibitors%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit22a.1"><span> <i>Chem. Abstr.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume">164</span>,  <span class="NLM_fpage">556167</span> (example 88).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Chem.+Abstr.+2016%2C+164%2C+556167+%28example+88%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22a.1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26jtitle%3DChem.%2520Abstr.%26date%3D2016%26volume%3D164%26spage%3D556167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span>; <span class="NLM_string-name">Pattoli, M. A.</span>; <span class="NLM_string-name">Cheng, L.</span>; <span class="NLM_string-name">Skala, S.</span>; <span class="NLM_string-name">Heimrich, E. M.</span>; <span class="NLM_string-name">Taylor, T. L.</span>; <span class="NLM_string-name">Pulicicchio, C.</span>; <span class="NLM_string-name">Kukral, D. W.</span>; <span class="NLM_string-name">Petrone, T.</span>; <span class="NLM_string-name">Catlett, I. M.</span>; <span class="NLM_string-name">Zheng, N.</span>; <span class="NLM_string-name">Li, W.</span>; <span class="NLM_string-name">Watterson, S. H.</span>; <span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">BMS-986195 is a highly selective and rapidly acting covalent inhibitor of Bruton’s tyrosine kinsase with robust efficacy at low doses in preclinical models of RA and lupus nephritis</span>.  <i>Arthritis Rhematol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume">69</span> (<span class="NLM_issue">Suppl. 10</span>), <a href="https://acrabstracts.org/abstract/bms-986195-is-a-highly-selective-and-rapidly-acting-covalent-inhibitor-of-brutons-tyrosine-kinase-with-robust-efficacy-at-low-doses-in-preclinical-models-of-ra-and-lupus-nephritis/" class="extLink">https://acrabstracts.org/abstract/bms-986195-is-a-highly-selective-and-rapidly-acting-covalent-inhibitor-of-brutons-tyrosine-kinase-with-robust-efficacy-at-low-doses-in-preclinical-models-of-ra-and-lupus-nephritis/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2017&issue=Suppl.+10&author=J.+R.+Burke&author=M.+A.+Pattoli&author=L.+Cheng&author=S.+Skala&author=E.+M.+Heimrich&author=T.+L.+Taylor&author=C.+Pulicicchio&author=D.+W.+Kukral&author=T.+Petrone&author=I.+M.+Catlett&author=N.+Zheng&author=W.+Li&author=S.+H.+Watterson&author=J.+A.+Tino&title=BMS-986195+is+a+highly+selective+and+rapidly+acting+covalent+inhibitor+of+Bruton%E2%80%99s+tyrosine+kinsase+with+robust+efficacy+at+low+doses+in+preclinical+models+of+RA+and+lupus+nephritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26atitle%3DBMS-986195%2520is%2520a%2520highly%2520selective%2520and%2520rapidly%2520acting%2520covalent%2520inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinsase%2520with%2520robust%2520efficacy%2520at%2520low%2520doses%2520in%2520preclinical%2520models%2520of%2520RA%2520and%2520lupus%2520nephritis%26jtitle%3DArthritis%2520Rhematol.%26date%3D2017%26volume%3D69%26issue%3DSuppl.%252010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dahal, U. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, A. M.</span></span> <span> </span><span class="NLM_article-title">Benchmarking in vitro covalent binding burden as a tool to assess potential toxicity caused by nonspecific covalent binding of covalent drugs</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1739</span>– <span class="NLM_lpage">1745</span>, <span class="refDoi"> DOI: 10.1021/tx400301q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx400301q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Sis7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2013&pages=1739-1745&author=U.+P.+Dahalauthor=R.+S.+Obachauthor=A.+M.+Gilbert&title=Benchmarking+in+vitro+covalent+binding+burden+as+a+tool+to+assess+potential+toxicity+caused+by+nonspecific+covalent+binding+of+covalent+drugs&doi=10.1021%2Ftx400301q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Benchmarking in Vitro Covalent Binding Burden As a Tool To Assess Potential Toxicity Caused by Nonspecific Covalent Binding of Covalent Drugs</span></div><div class="casAuthors">Dahal, Upendra P.; Obach, R. Scott; Gilbert, Adam M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1739-1745</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Despite several advantages of covalent inhibitors (such as increased biochem. efficiency, longer duration of action on the target, and lower efficacious doses) over their reversible binding counterparts, there is a reluctance to use covalent inhibitors as a drug design strategy in pharmaceutical research.  This reluctance is due to their anticipated reactions with nontargeted macromols.  We hypothesized that there may be a threshold limit for nonspecific covalent binding, below which a covalent binding drug may be less likely to cause toxicity due to irreversible binding to off-target macromols.  Estn. of in vivo covalent binding burden from in vitro data has previously been used as an approach to distinguish those agents more likely to cause toxicity (e.g., hepatotoxicity) via metabolic activation to reactive metabolites.  We have extended this approach to nine covalent binding drugs to det. in vitro covalent binding burden.  In vitro covalent binding burden was detd. by incubating radiolabeled drugs with pooled human hepatocytes.  These data were scaled to an est. of in vivo covalent binding burden by combining the in vitro data with daily dose.  Scaled in vivo daily covalent binding burden of marketed covalent drugs was found to be under 10 mg/day, which is in agreement with previously reported threshold value for metabolically activated reversible drugs.  Covalent binding was also compared to the intrinsic reactivities of the covalent inhibitors assessed using nucleophiles glutathione and N-α-acetyl lysine.  The intrinsic reactivity did not correlate with obsd. in vitro covalent binding, which demonstrated that the intrinsic reactivity of the electrophilic groups of covalent drugs does not exclusively account for the extent of covalent binding.  The ramifications of these findings for consideration of using a covalent strategy in drug design are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr23ygNWkgm7bVg90H21EOLACvtfcHk0lhdWJB-VE2heA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Sis7%252FJ&md5=08384c595edf0b5e8ae939f75d9a5e97</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Ftx400301q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx400301q%26sid%3Dliteratum%253Aachs%26aulast%3DDahal%26aufirst%3DU.%2BP.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DGilbert%26aufirst%3DA.%2BM.%26atitle%3DBenchmarking%2520in%2520vitro%2520covalent%2520binding%2520burden%2520as%2520a%2520tool%2520to%2520assess%2520potential%2520toxicity%2520caused%2520by%2520nonspecific%2520covalent%2520binding%2520of%2520covalent%2520drugs%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2013%26volume%3D26%26spage%3D1739%26epage%3D1745%26doi%3D10.1021%2Ftx400301q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Catlett, I.</span>; <span class="NLM_string-name">Wei, L.</span>; <span class="NLM_string-name">Zheng, N.</span>; <span class="NLM_string-name">Liu, A.</span>; <span class="NLM_string-name">He, B.</span>; <span class="NLM_string-name">Girgis, I.</span>; <span class="NLM_string-name">Nowak, M.</span></span> <span> </span><span class="NLM_article-title">BMS-986195, a novel, rapidly acting, covalent inhibitor of Bruton’s tyrosine kinase: safety, pharmacokinetic and pharmacodynamic profiles in healthy participants</span>.  <i>Arthritis Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume">69</span> (<span class="NLM_issue">Suppl. 10</span>), <a href="https://acrabstracts.org/abstract/bms-986195-a-novel-rapidly-acting-covalent-inhibitor-of-brutons-tyrosine-kinase-safety-pharmacokinetic-and-pharmacodynamic-profiles-in-healthy-participants/" class="extLink">https://acrabstracts.org/abstract/bms-986195-a-novel-rapidly-acting-covalent-inhibitor-of-brutons-tyrosine-kinase-safety-pharmacokinetic-and-pharmacodynamic-profiles-in-healthy-participants/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2017&issue=Suppl.+10&author=I.+Catlett&author=L.+Wei&author=N.+Zheng&author=A.+Liu&author=B.+He&author=I.+Girgis&author=M.+Nowak&title=BMS-986195%2C+a+novel%2C+rapidly+acting%2C+covalent+inhibitor+of+Bruton%E2%80%99s+tyrosine+kinase%3A+safety%2C+pharmacokinetic+and+pharmacodynamic+profiles+in+healthy+participants"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCatlett%26aufirst%3DI.%26atitle%3DBMS-986195%252C%2520a%2520novel%252C%2520rapidly%2520acting%252C%2520covalent%2520inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%253A%2520safety%252C%2520pharmacokinetic%2520and%2520pharmacodynamic%2520profiles%2520in%2520healthy%2520participants%26jtitle%3DArthritis%2520Rheumatol.%26date%3D2017%26volume%3D69%26issue%3DSuppl.%252010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit25b"><span><span class="NLM_label">(b) </span> ClinicalTrials.gov
identifiers: NCT02705989, NCT03245515, NCT03262740, NCT03131973.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+ClinicalTrials.gov%0Aidentifiers%3A+NCT02705989%2C+NCT03245515%2C+NCT03262740%2C+NCT03131973."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span>; <span class="NLM_string-name">Watterson, S. H.</span>; <span class="NLM_string-name">Ahmad, S.</span></span> <span> </span><span class="NLM_article-title">Indole Carboxamide Compounds</span>. <span class="NLM_patent">US 9,688,629</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=Q.+Liu&author=S.+H.+Watterson&author=S.+Ahmad&title=Indole+Carboxamide+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DIndole%2520Carboxamide%2520Compounds%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit26b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span>; <span class="NLM_string-name">Watterson, S. H.</span>; <span class="NLM_string-name">Batt, D. G.</span>; <span class="NLM_string-name">Ahmad, S.</span>; <span class="NLM_string-name">Beaudoin Bertrand, M.</span>; <span class="NLM_string-name">Gong, H.</span>; <span class="NLM_string-name">Guo, W.</span>; <span class="NLM_string-name">Macor, J. E.</span>; <span class="NLM_string-name">Ngu, K.</span>; <span class="NLM_string-name">Tebben, A.</span>; <span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Indole Carboxamide Compounds</span>. <span class="NLM_patent">US 2016/0115126</span>, <span class="NLM_year">2016</span>;</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=Q.+Liu&author=S.+H.+Watterson&author=D.+G.+Batt&author=S.+Ahmad&author=M.+Beaudoin+Bertrand&author=H.+Gong&author=W.+Guo&author=J.+E.+Macor&author=K.+Ngu&author=A.+Tebben&author=J.+A.+Tino&title=Indole+Carboxamide+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DIndole%2520Carboxamide%2520Compounds%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit26b.1"><span> <i>Chem. Abstr.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume">164</span>,  <span class="NLM_fpage">556179</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Chem.+Abstr.+2016%2C+164%2C+556179."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26b.1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26jtitle%3DChem.%2520Abstr.%26date%3D2016%26volume%3D164%26spage%3D556179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Castillo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, S. L.</span></span> <span> </span><span class="NLM_article-title">Applications of palladium-catalyzed C–N cross-coupling reactions</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">12564</span>– <span class="NLM_lpage">12649</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.6b00512</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.6b00512" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFymu7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2016&pages=12564-12649&author=P.+Ruiz-Castilloauthor=S.+L.+Buchwald&title=Applications+of+palladium-catalyzed+C%E2%80%93N+cross-coupling+reactions&doi=10.1021%2Facs.chemrev.6b00512"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Applications of Palladium-Catalyzed C-N Cross-Coupling Reactions</span></div><div class="casAuthors">Ruiz-Castillo, Paula; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">12564-12649</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Pd-catalyzed cross-coupling reactions that form C-N bonds have become useful methods to synthesize anilines and aniline derivs., an important class of compds. throughout chem. research.  A key factor in the widespread adoption of these methods has been the continued development of reliable and versatile catalysts that function under operationally simple, user-friendly conditions.  This review provides an overview of Pd-catalyzed N-arylation reactions found in both basic and applied chem. research from 2008 to the present.  Selected examples of C-N cross-coupling reactions between nine classes of nitrogen-based coupling partners and (pseudo)aryl halides are described for the synthesis of heterocycles, medicinally relevant compds., natural products, org. materials, and catalysts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraGxaaZq3Pa7Vg90H21EOLACvtfcHk0lhQQ5hxM6aUaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFymu7bJ&md5=09edd584bbb4bd3ba6f0d422749fc6c3</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.6b00512&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.6b00512%26sid%3Dliteratum%253Aachs%26aulast%3DRuiz-Castillo%26aufirst%3DP.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DApplications%2520of%2520palladium-catalyzed%2520C%25E2%2580%2593N%2520cross-coupling%2520reactions%26jtitle%3DChem.%2520Rev.%26date%3D2016%26volume%3D116%26spage%3D12564%26epage%3D12649%26doi%3D10.1021%2Facs.chemrev.6b00512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5T18" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5T18','PDB','5T18'); return false;">PDB: 5T18</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O8I" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O8I','PDB','6O8I'); return false;">PDB: 6O8I</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i63"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00167">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_70728"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.9b00167">10.1021/acs.jmedchem.9b00167</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00167/suppl_file/jm9b00167_si_001.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00167/suppl_file/jm9b00167_si_001.csv">jm9b00167_si_001.csv (1.68 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB code for <b>5a</b> is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6O8I">6O8I</a>. Authors will release the atomic coordinates upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b00167%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-7%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b00167" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679919e9ca0e3d4e","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
